No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3kfaB1, 1.0000, 0.00, 1.000, 283, 283, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2, d3kfaA1, 0.9999, 0.05, 1.000, 283, 283, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3, d3oy3B1, 0.9942, 0.51, 0.996, 283, 283, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4, d3oy3A1, 0.9940, 0.50, 0.996, 283, 283, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
5, d3ik3B1, 0.9917, 0.59, 0.993, 285, 283, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
6, d3ik3A1, 0.9728, 0.51, 0.996, 279, 277, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
7, d3k5vA1, 0.9440, 1.36, 0.996, 281, 275, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
8, d1opjB1, 0.9430, 1.53, 0.982, 284, 276, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
9, d3oxzA1, 0.9386, 0.46, 0.996, 267, 267, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
10, d1opjA1, 0.9361, 1.69, 1.000, 282, 276, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
11, d1iepA1, 0.9352, 0.98, 1.000, 270, 270, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
12, d3k5vB1, 0.9348, 1.49, 1.000, 279, 273, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
13, d2f4jA_, 0.9342, 1.45, 0.993, 287, 272, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
14, d1iepB1, 0.9338, 1.04, 1.000, 270, 270, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
15, d1fpuA1, 0.9323, 1.22, 0.993, 271, 271, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
16, d2hznA2, 0.9287, 0.96, 0.993, 268, 268, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
17, d2hiwA1, 0.9285, 1.24, 0.989, 270, 270, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
18, d3ms9B1, 0.9283, 0.86, 0.993, 267, 267, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
19, d2e2bA1, 0.9279, 0.77, 0.996, 266, 266, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
20, d3qriA1, 0.9278, 1.24, 0.989, 270, 270, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
21, d2qohB2, 0.9263, 1.30, 0.996, 280, 269, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
22, d2z60A1, 0.9256, 1.38, 0.996, 280, 269, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
23, d2hiwB1, 0.9253, 1.28, 0.996, 270, 270, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
24, d3cs9A_, 0.9244, 0.61, 0.996, 264, 264, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
25, d3kf4A_, 0.9188, 1.37, 0.996, 281, 267, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
26, d3qrkA1, 0.9182, 1.20, 0.996, 268, 268, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
27, d2hyyA_, 0.9177, 0.73, 0.989, 263, 263, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
28, d1fpuB1, 0.9174, 1.15, 1.000, 266, 266, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
29, d3ms9A1, 0.9104, 0.75, 1.000, 261, 261, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
30, d1t45A_, 0.9103, 1.88, 0.377, 331, 273, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
31, d4u0iA_, 0.9097, 1.84, 0.384, 297, 271, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
32, d3mssB1, 0.9088, 0.67, 1.000, 260, 260, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
33, d3mssD1, 0.9086, 0.68, 1.000, 260, 260, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
34, d3mssC1, 0.9086, 0.68, 1.000, 260, 260, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
35, d3mssA1, 0.9084, 0.69, 1.000, 260, 260, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
36, d1t46A_, 0.9084, 1.87, 0.384, 297, 271, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
37, d3gvuA1, 0.9077, 0.88, 0.927, 261, 261, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
38, d4ag8A_, 0.9072, 1.88, 0.380, 296, 271, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
39, d3u6jA1, 0.9069, 1.96, 0.372, 305, 274, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
40, d4asdA_, 0.9065, 1.89, 0.380, 305, 271, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
41, d3vntA_, 0.9060, 1.89, 0.380, 301, 271, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
42, d3vo3A_, 0.9055, 1.90, 0.380, 303, 271, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
43, d4aseA_, 0.9054, 1.88, 0.380, 305, 271, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
44, d3beaA_, 0.9046, 2.15, 0.387, 310, 274, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
45, d4agcA_, 0.9039, 1.91, 0.380, 304, 271, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
46, d2i1mA_, 0.9032, 2.05, 0.388, 311, 273, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
47, d5grnA_, 0.9025, 1.83, 0.383, 285, 269, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
48, d2e2bB1, 0.9022, 0.67, 0.996, 258, 258, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
49, d3cs9D_, 0.9020, 1.17, 0.996, 263, 263, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
50, d3qriB_, 0.9018, 1.25, 0.989, 262, 262, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
51, d3wzeA_, 0.9014, 1.86, 0.383, 298, 269, KDR IN COMPLEX WITH LIGAND SORAFENIB
52, d4hvsA1, 0.9013, 1.86, 0.387, 323, 269, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
53, d1m52B_, 0.9012, 1.13, 1.000, 272, 260, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
54, d4agdA_, 0.9006, 1.94, 0.380, 303, 271, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
55, d2qohA2, 0.8947, 1.28, 0.996, 270, 259, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
56, d1m52A_, 0.8945, 1.24, 1.000, 271, 259, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
57, d3g0eA1, 0.8934, 1.98, 0.383, 330, 269, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
58, d2g2hB_, 0.8927, 1.43, 0.981, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
59, d2g2hA_, 0.8924, 1.46, 0.988, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
60, d4twpB_, 0.8911, 1.45, 0.992, 271, 260, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
61, d4r7hA_, 0.8911, 1.90, 0.393, 308, 267, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
62, d4at5A1, 0.8901, 2.10, 0.375, 291, 272, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
63, d4zogB_, 0.8894, 1.13, 0.988, 268, 257, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
64, d4at3A1, 0.8886, 2.08, 0.370, 286, 270, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
65, d4hw7A_, 0.8879, 1.90, 0.391, 289, 266, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
66, d4r7iA_, 0.8878, 1.91, 0.391, 290, 266, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
67, d5kmnA1, 0.8876, 2.39, 0.367, 290, 275, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
68, d3g0fA_, 0.8872, 2.21, 0.379, 291, 269, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
69, d4f0iB_, 0.8871, 2.09, 0.370, 294, 270, CRYSTAL STRUCTURE OF APO TRKA
70, d5kmlA1, 0.8869, 2.41, 0.367, 290, 275, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
71, p5x02A_, 0.8867, 2.02, 0.397, 305, 267, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
72, d4xeyA_, 0.8856, 1.29, 0.996, 269, 257, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
73, d3kf4B_, 0.8856, 1.50, 1.000, 270, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
74, d3zosA_, 0.8853, 2.08, 0.407, 301, 268, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
75, d3g0fB_, 0.8852, 2.24, 0.379, 293, 269, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
76, d3zosB1, 0.8848, 2.13, 0.405, 301, 269, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
77, d2ogvA_, 0.8848, 2.17, 0.381, 317, 270, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
78, d3ewhA1, 0.8844, 1.97, 0.391, 295, 266, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
79, d4aszA1, 0.8843, 2.22, 0.376, 286, 271, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
80, d1lufA_, 0.8842, 1.85, 0.417, 275, 264, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
81, d2i0vA_, 0.8834, 1.93, 0.404, 303, 265, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
82, d4at4A1, 0.8828, 2.15, 0.370, 289, 270, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
83, d5kmjA_, 0.8827, 2.43, 0.366, 300, 273, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
84, d4ymjB1, 0.8822, 1.94, 0.387, 272, 266, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
85, d3dk3B_, 0.8818, 1.32, 0.984, 269, 256, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
86, d3dk7B_, 0.8817, 1.33, 0.980, 268, 256, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
87, d4zogA_, 0.8808, 1.44, 0.996, 269, 257, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
88, d3ue4A_, 0.8808, 1.51, 0.996, 270, 258, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
89, d2hyyB1, 0.8806, 0.68, 0.996, 252, 252, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
90, d3krjA_, 0.8805, 2.08, 0.392, 304, 265, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
91, d5kmiA_, 0.8801, 2.33, 0.365, 300, 271, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
92, d4twpA_, 0.8801, 1.33, 0.992, 266, 255, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
93, d5kmkA1, 0.8795, 2.37, 0.368, 302, 272, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
94, d2i0yA_, 0.8794, 1.93, 0.402, 289, 264, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
95, d5hu9A1, 0.8793, 1.78, 0.989, 262, 261, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
96, d4mxcA_, 0.8793, 2.14, 0.369, 290, 268, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
97, d2gqgB1, 0.8790, 1.64, 0.985, 270, 259, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
98, d5kmmA1, 0.8789, 2.37, 0.368, 300, 272, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
99, d2hziA_, 0.8789, 1.47, 0.996, 268, 256, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
100, d3ue4B_, 0.8785, 1.40, 0.992, 268, 256, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
101, d5nkgA_, 0.8781, 2.24, 0.384, 292, 268, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
102, d3dk3A_, 0.8777, 1.15, 0.996, 266, 254, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
103, d2gqgA1, 0.8777, 1.69, 0.996, 271, 260, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
104, d3dk7A_, 0.8776, 1.17, 0.992, 265, 254, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
105, d5htiA_, 0.8775, 2.14, 0.369, 290, 268, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
106, d5nkfA_, 0.8771, 2.27, 0.384, 291, 268, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
107, d2hyyD1, 0.8771, 0.69, 0.992, 251, 251, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
108, d5ia2A_, 0.8762, 2.42, 0.381, 287, 270, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
109, d1oplA3, 0.8762, 2.03, 0.973, 291, 261, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
110, d1opkA3, 0.8760, 2.04, 0.977, 291, 261, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
111, d1oplB2, 0.8754, 1.41, 0.992, 267, 255, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
112, d3pyyA1, 0.8751, 0.75, 0.996, 251, 251, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
113, d3zzeA_, 0.8750, 2.13, 0.366, 286, 268, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
114, d2v7aA_, 0.8749, 1.62, 0.992, 269, 258, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
115, d5wr7A_, 0.8742, 2.17, 0.369, 301, 268, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
116, d5kmoA1, 0.8741, 2.43, 0.363, 290, 270, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
117, d2hziB_, 0.8739, 1.10, 0.996, 264, 252, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
118, d4f0iA_, 0.8737, 2.16, 0.371, 284, 267, CRYSTAL STRUCTURE OF APO TRKA
119, d2wd1A_, 0.8736, 2.14, 0.366, 289, 268, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
120, d4gt5A_, 0.8731, 2.22, 0.375, 290, 269, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
121, d4pmmA1, 0.8730, 2.01, 0.381, 281, 265, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
122, d3rhkA_, 0.8729, 2.35, 0.358, 298, 271, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
123, d2wkmA_, 0.8728, 2.43, 0.367, 286, 270, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
124, d3c4fB_, 0.8727, 2.12, 0.391, 290, 266, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
125, d2wgjA_, 0.8727, 2.09, 0.372, 289, 266, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
126, d3c4fA_, 0.8726, 2.27, 0.397, 290, 267, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
127, d2hyyC1, 0.8723, 0.60, 0.996, 249, 249, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
128, d2oh4A1, 0.8722, 2.09, 0.374, 296, 265, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
129, d2fo0A3, 0.8722, 1.94, 0.992, 291, 261, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
130, d3zclA_, 0.8718, 2.13, 0.367, 289, 267, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
131, d5h3qA_, 0.8717, 2.38, 0.370, 302, 270, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
132, d4ap7A_, 0.8715, 2.14, 0.367, 289, 267, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
133, d3dk6A_, 0.8714, 1.08, 0.992, 262, 251, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
134, d5nk9A_, 0.8713, 2.28, 0.383, 285, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
135, d5nk4A_, 0.8713, 2.38, 0.384, 290, 268, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
136, d4ymjA1, 0.8713, 1.81, 0.387, 267, 261, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
137, d5nkbA_, 0.8712, 2.27, 0.383, 285, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
138, d4xeyB2, 0.8709, 1.21, 0.996, 264, 252, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
139, d4r1vA_, 0.8709, 2.20, 0.366, 289, 268, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
140, d2v7aB_, 0.8709, 1.76, 0.988, 268, 258, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
141, d3zxzA_, 0.8706, 2.16, 0.367, 289, 267, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
142, d1rjbA_, 0.8704, 2.13, 0.403, 298, 263, CRYSTAL STRUCTURE OF FLT3
143, d4aoiA_, 0.8701, 2.16, 0.367, 289, 267, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
144, d3zbxA_, 0.8700, 2.16, 0.367, 282, 267, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
145, d4rwjA1, 0.8697, 2.15, 0.390, 306, 264, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
146, d5nk6A_, 0.8694, 2.25, 0.381, 284, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
147, d5nk1A_, 0.8694, 2.25, 0.381, 284, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
148, d5eg3A_, 0.8691, 2.40, 0.386, 301, 267, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
149, d4zsaA_, 0.8690, 2.33, 0.393, 289, 267, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
150, d3zc5A_, 0.8687, 2.18, 0.367, 289, 267, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
151, d3rhkB_, 0.8687, 2.27, 0.368, 299, 269, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
152, d5nk7A_, 0.8685, 2.27, 0.381, 284, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
153, d5nk2A_, 0.8685, 2.33, 0.380, 290, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
154, d3krlA_, 0.8684, 1.95, 0.410, 281, 261, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
155, d4rwiA_, 0.8683, 2.30, 0.389, 305, 265, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
156, d5eobA_, 0.8680, 2.29, 0.366, 288, 268, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
157, d3js2A_, 0.8679, 2.34, 0.390, 295, 267, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
158, d5i9xA_, 0.8678, 2.26, 0.381, 284, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
159, d4v05A_, 0.8678, 2.37, 0.393, 287, 267, FGFR1 IN COMPLEX WITH AZD4547.
160, d4ckrA1, 0.8676, 2.19, 0.396, 294, 265, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
161, d4bkiA1, 0.8676, 2.19, 0.396, 294, 265,  
162, d2rl5A1, 0.8676, 1.60, 0.384, 290, 258, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
163, d4uwcA_, 0.8674, 2.38, 0.393, 300, 267, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
164, d4pmpA1, 0.8674, 1.95, 0.382, 276, 262, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
165, d5dg5B_, 0.8673, 2.45, 0.375, 297, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
166, d4deiA_, 0.8668, 2.33, 0.369, 287, 268, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
167, d4rwkA1, 0.8667, 2.08, 0.392, 307, 263, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
168, d3ky2A1, 0.8665, 2.18, 0.388, 305, 263, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
169, d4v05B_, 0.8661, 2.21, 0.396, 286, 265, FGFR1 IN COMPLEX WITH AZD4547.
170, d4pmsA1, 0.8657, 2.09, 0.379, 279, 264, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
171, d3f66A_, 0.8656, 2.46, 0.364, 288, 269, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
172, d4yc8B_, 0.8654, 1.31, 0.996, 264, 252, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
173, d4xyfA_, 0.8654, 2.35, 0.362, 290, 268, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
174, d2hz4A_, 0.8654, 1.31, 0.996, 262, 251, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
175, d4qrcA_, 0.8653, 2.24, 0.426, 297, 263, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
176, d5am6A1, 0.8652, 2.21, 0.394, 294, 264, NATIVE FGFR1 WITH AN INHIBITOR
177, d3qrjB1, 0.8652, 1.17, 0.988, 252, 252, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
178, d3nsvA_, 0.8652, 1.52, 0.921, 264, 253,  
179, d5nkdA_, 0.8651, 2.33, 0.381, 287, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
180, d4tyjA1, 0.8651, 1.78, 0.432, 275, 257, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
181, d2xynA_, 0.8651, 1.52, 0.921, 264, 253, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
182, d5eydA_, 0.8647, 2.38, 0.362, 289, 268, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
183, d5dg5A_, 0.8646, 2.49, 0.375, 297, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
184, d5bvkA_, 0.8644, 1.98, 0.399, 278, 263, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
185, d4uxqA_, 0.8643, 2.05, 0.427, 286, 262, FGFR4 IN COMPLEX WITH PONATINIB
186, d3tt0A_, 0.8643, 2.22, 0.386, 305, 264, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
187, d5nkcA_, 0.8642, 2.35, 0.381, 286, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
188, d4v04B_, 0.8641, 2.37, 0.396, 287, 265, FGFR1 IN COMPLEX WITH PONATINIB.
189, d4uwbB_, 0.8641, 2.52, 0.393, 299, 267, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
190, d5a46A_, 0.8636, 2.49, 0.393, 289, 267, FGFR1 IN COMPLEX WITH DOVITINIB
191, d3cs9B_, 0.8636, 0.65, 0.996, 247, 247, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
192, d1fgiA_, 0.8636, 2.24, 0.398, 283, 264, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
193, d4uwbA_, 0.8635, 2.48, 0.393, 299, 267, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
194, d4bkjB1, 0.8635, 2.20, 0.392, 296, 265, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
195, d5ew8A_, 0.8634, 2.49, 0.393, 291, 267, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
196, d4gg7A_, 0.8632, 2.31, 0.360, 278, 267, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
197, d4ypsA1, 0.8631, 1.89, 0.358, 275, 260, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
198, d4gu6A_, 0.8630, 1.80, 0.378, 271, 259, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
199, d4bkjA1, 0.8630, 2.22, 0.396, 294, 265, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
200, d4rwjB_, 0.8629, 2.33, 0.402, 282, 264, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
201, d5eycA_, 0.8628, 2.37, 0.371, 288, 267, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
202, d3clyA_, 0.8628, 2.29, 0.402, 289, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
203, d4xliA_, 0.8627, 1.61, 0.921, 264, 253, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
204, d4nkaB_, 0.8626, 2.51, 0.395, 287, 266, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
205, d4gg5A_, 0.8626, 2.08, 0.354, 274, 263, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
206, d4qqjA_, 0.8624, 2.17, 0.420, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
207, d4rwlB_, 0.8621, 2.35, 0.396, 285, 265, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
208, d3v5qB1, 0.8621, 1.59, 0.383, 262, 256, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
209, d5a46B_, 0.8620, 2.43, 0.391, 297, 266, FGFR1 IN COMPLEX WITH DOVITINIB
210, d4nk9A_, 0.8620, 2.48, 0.395, 281, 266, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
211, d5ew8B_, 0.8617, 2.43, 0.391, 290, 266, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
212, d4uwcB_, 0.8616, 2.35, 0.392, 301, 265, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
213, d3rhxA_, 0.8616, 2.41, 0.395, 289, 266, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
214, d5vndB_, 0.8615, 2.42, 0.391, 295, 266, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
215, d4xliB_, 0.8615, 1.61, 0.921, 264, 253, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
216, d4dehA_, 0.8614, 2.30, 0.368, 286, 266, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
217, d3dtwA1, 0.8614, 1.47, 0.390, 281, 254, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
218, d3b8qA1, 0.8614, 1.75, 0.387, 285, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
219, d4degA_, 0.8613, 2.24, 0.362, 286, 265, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
220, d5am7A_, 0.8612, 2.24, 0.395, 294, 263, FGFR1 MUTANT WITH AN INHIBITOR
221, d4rwkB_, 0.8612, 2.09, 0.395, 282, 261, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
222, d5i9yA_, 0.8611, 2.35, 0.383, 287, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
223, d5a4cB1, 0.8611, 2.46, 0.391, 284, 266, FGFR1 LIGAND COMPLEX
224, d2xynC_, 0.8611, 1.41, 0.920, 262, 251, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
225, d5bvnA_, 0.8610, 2.01, 0.399, 278, 263, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
226, d4nk9B_, 0.8610, 2.31, 0.390, 282, 264, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
227, d2qu5A_, 0.8608, 2.04, 0.387, 292, 261, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
228, d2xynB_, 0.8605, 1.57, 0.921, 264, 253, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
229, d4f65A_, 0.8603, 2.26, 0.388, 279, 263, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
230, d5vndA_, 0.8602, 2.52, 0.393, 302, 267, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
231, d3nsvB_, 0.8602, 1.57, 0.921, 264, 253,  
232, d3hmiA_, 0.8600, 1.73, 0.926, 268, 256, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
233, d2g15A_, 0.8599, 2.37, 0.368, 301, 266, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
234, d5bvoA_, 0.8598, 1.86, 0.395, 276, 261, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
235, d5a4cA_, 0.8597, 2.42, 0.389, 294, 265, FGFR1 LIGAND COMPLEX
236, d4v04A_, 0.8597, 2.18, 0.397, 290, 262, FGFR1 IN COMPLEX WITH PONATINIB.
237, d2p2iA2, 0.8597, 1.85, 0.385, 283, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
238, d3nsvC_, 0.8595, 1.44, 0.920, 262, 251,  
239, d4zsaB_, 0.8594, 2.14, 0.397, 282, 262, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
240, d4v01B_, 0.8593, 1.91, 0.398, 275, 259, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
241, d1u59A1, 0.8592, 1.97, 0.358, 276, 260, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
242, d4rwlA_, 0.8591, 2.29, 0.392, 282, 263, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
243, d3v5qA1, 0.8591, 1.56, 0.373, 260, 255, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
244, d4wa9B1, 0.8590, 1.42, 0.992, 263, 251, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
245, d4xmoA_, 0.8588, 2.36, 0.365, 289, 266, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
246, d2oiqA_, 0.8587, 2.39, 0.479, 265, 261, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
247, d4nkaA_, 0.8585, 2.25, 0.397, 279, 262, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
248, d4knbA_, 0.8580, 2.27, 0.377, 273, 265, C-MET IN COMPLEX WITH OSI LIGAND
249, d3vw8A_, 0.8580, 2.37, 0.390, 303, 264, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
250, d3lw0B_, 0.8580, 2.49, 0.434, 292, 267, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
251, d3lw0A_, 0.8580, 2.49, 0.434, 292, 267, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
252, d3dpkA_, 0.8580, 1.98, 0.401, 279, 257, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
253, d2etmB_, 0.8580, 1.72, 0.397, 263, 257, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
254, d4uxlA_, 0.8579, 2.08, 0.418, 288, 261, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
255, d3lw0D_, 0.8579, 2.50, 0.434, 292, 267, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
256, d3lq8A_, 0.8579, 2.11, 0.379, 278, 261, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
257, d3ky2B_, 0.8579, 2.20, 0.402, 280, 261, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
258, d3lw0C_, 0.8578, 2.50, 0.434, 292, 267, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
259, d4v01A_, 0.8576, 2.32, 0.397, 273, 262, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
260, d2j0lA_, 0.8576, 2.15, 0.404, 274, 260, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
261, d3wj6B_, 0.8575, 2.21, 0.395, 277, 261,  
262, d3gqlA_, 0.8575, 2.61, 0.400, 287, 265, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
263, d5b7vB_, 0.8573, 2.21, 0.398, 277, 261, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
264, d1p4oA_, 0.8573, 2.53, 0.428, 308, 269, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
265, d5hhwA_, 0.8569, 2.28, 0.401, 306, 267, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
266, d3l8vA_, 0.8569, 2.15, 0.383, 293, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
267, d5mo4A3, 0.8568, 1.73, 0.960, 271, 253, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
268, d4qqtA_, 0.8568, 2.15, 0.419, 283, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
269, d3gqiA_, 0.8568, 2.23, 0.397, 304, 262, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
270, d1p4oB_, 0.8568, 2.54, 0.428, 314, 269, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
271, d3js2B_, 0.8567, 2.41, 0.398, 291, 264, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
272, d4xcuA1, 0.8561, 2.12, 0.418, 287, 261, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
273, d5nk3A_, 0.8560, 2.49, 0.392, 281, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
274, d4rwiB_, 0.8558, 2.26, 0.406, 280, 261, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
275, d3wj6A_, 0.8558, 2.24, 0.391, 282, 261,  
276, d5b7vA_, 0.8557, 2.24, 0.391, 282, 261, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
277, d4j96B_, 0.8557, 2.20, 0.414, 305, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
278, d3f66B_, 0.8556, 2.05, 0.368, 269, 261, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
279, d5bvwA_, 0.8552, 1.90, 0.394, 274, 259, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
280, d5flfB_, 0.8550, 2.29, 0.405, 292, 262, DISEASE LINKED MUTATION IN FGFR
281, d3h3cA_, 0.8549, 1.91, 0.401, 263, 257, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
282, d3b8rA1, 0.8549, 1.65, 0.395, 282, 253, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
283, d3etaB_, 0.8547, 1.95, 0.404, 292, 260, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
284, d3eflA1, 0.8547, 1.59, 0.394, 279, 254, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
285, d1m7nB_, 0.8546, 2.58, 0.428, 299, 269, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
286, d4uwyA_, 0.8545, 2.09, 0.391, 296, 258, FGFR1 APO STRUCTURE
287, d3ri1A_, 0.8544, 2.13, 0.412, 285, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
288, d3dk6B_, 0.8543, 1.28, 0.984, 259, 247, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
289, d1m7nA_, 0.8542, 2.58, 0.428, 299, 269, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
290, d5ew3A_, 0.8540, 1.62, 0.395, 274, 253, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
291, d5am7B_, 0.8540, 2.17, 0.396, 287, 260, FGFR1 MUTANT WITH AN INHIBITOR
292, d4wunA_, 0.8540, 2.12, 0.411, 282, 258, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
293, d3b2tA_, 0.8540, 2.28, 0.405, 288, 262, STRUCTURE OF PHOSPHOTRANSFERASE
294, d3a4pA_, 0.8540, 2.43, 0.362, 285, 265, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
295, d3g6gA_, 0.8538, 2.38, 0.477, 264, 260, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
296, d3be2A1, 0.8535, 1.95, 0.395, 285, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
297, d3cp9A1, 0.8533, 1.40, 0.398, 281, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
298, d4tygA1, 0.8532, 2.36, 0.417, 290, 264, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
299, d5hlwA_, 0.8531, 2.41, 0.367, 284, 264, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
300, d2hz4C_, 0.8530, 1.34, 0.992, 259, 248, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
301, d3cpbA1, 0.8528, 1.35, 0.392, 278, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
302, d5ui0B_, 0.8525, 2.20, 0.408, 304, 260, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
303, d5ui0A_, 0.8525, 2.23, 0.406, 301, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
304, d3cd8A_, 0.8525, 2.25, 0.374, 278, 262, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
305, d2hz0A_, 0.8525, 1.94, 0.992, 265, 254, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
306, d2pl0A_, 0.8523, 2.35, 0.471, 268, 263, LCK BOUND TO IMATINIB
307, d2psqA_, 0.8522, 2.19, 0.412, 287, 260, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
308, d3etaA_, 0.8521, 2.11, 0.405, 293, 262, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
309, d5flfD_, 0.8520, 2.28, 0.406, 290, 261, DISEASE LINKED MUTATION IN FGFR
310, d1fgiB_, 0.8519, 2.11, 0.399, 272, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
311, d4j96A_, 0.8518, 2.24, 0.414, 302, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
312, d3ri1B_, 0.8516, 2.24, 0.406, 283, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
313, d3o23A_, 0.8511, 2.22, 0.431, 293, 262, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
314, d1qpdA_, 0.8510, 2.14, 0.477, 270, 258, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
315, d3bymA_, 0.8509, 2.15, 0.473, 271, 258, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
316, d3ad6A_, 0.8509, 2.19, 0.475, 272, 259, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
317, d2p2hA1, 0.8508, 2.00, 0.381, 289, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
318, d4cnhB_, 0.8506, 2.69, 0.408, 293, 265, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
319, d2ofuA_, 0.8505, 2.15, 0.477, 272, 258, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
320, d1irkA_, 0.8505, 2.42, 0.401, 303, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
321, d2rfsA_, 0.8504, 1.93, 0.378, 264, 259, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
322, d2psqB_, 0.8501, 2.28, 0.410, 286, 261, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
323, d4f65B_, 0.8500, 2.30, 0.398, 279, 261, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
324, d3dtwB_, 0.8500, 1.44, 0.392, 269, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
325, d3c7qA_, 0.8500, 2.32, 0.370, 286, 262, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
326, d4knbC_, 0.8497, 2.24, 0.370, 271, 262, C-MET IN COMPLEX WITH OSI LIGAND
327, d4j98B_, 0.8497, 2.20, 0.417, 304, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
328, d5am6B_, 0.8496, 2.26, 0.413, 280, 259, NATIVE FGFR1 WITH AN INHIBITOR
329, d3rhxB_, 0.8496, 2.27, 0.400, 275, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
330, d3b8qB_, 0.8496, 1.46, 0.392, 271, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
331, d2of4A_, 0.8496, 2.15, 0.477, 271, 258, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
332, d5hibA_, 0.8495, 2.47, 0.374, 314, 262, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
333, d3kmmA_, 0.8493, 2.20, 0.473, 270, 258, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
334, d2j0mB_, 0.8490, 1.55, 0.402, 257, 251, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
335, d5fdpA_, 0.8489, 2.26, 0.407, 285, 263, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
336, d4d58B_, 0.8489, 1.76, 0.388, 261, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
337, d5iuhA_, 0.8488, 2.03, 0.406, 285, 256, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
338, d4yc8A_, 0.8488, 1.31, 0.988, 259, 247, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
339, d3tz8B_, 0.8488, 2.38, 0.471, 263, 259, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
340, d3ac2A_, 0.8488, 2.17, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
341, d1qpcA_, 0.8488, 2.18, 0.473, 270, 258, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
342, d3lckA_, 0.8487, 2.18, 0.477, 270, 258, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
343, d3ac5A_, 0.8487, 2.18, 0.473, 270, 258, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
344, d4f63A_, 0.8486, 2.23, 0.394, 278, 259, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
345, d3ac1A_, 0.8486, 2.18, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
346, d1fgkA_, 0.8486, 2.23, 0.394, 278, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
347, d5fdxA_, 0.8485, 2.15, 0.410, 280, 261, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
348, d4f64A_, 0.8485, 2.25, 0.398, 278, 259, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
349, d3cpcA1, 0.8485, 1.43, 0.392, 277, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
350, d3gqlC_, 0.8484, 2.34, 0.404, 275, 260, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
351, d2zm1A_, 0.8484, 2.17, 0.477, 270, 258, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
352, d3fzpA_, 0.8483, 1.62, 0.403, 259, 253, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
353, d2of2A_, 0.8483, 2.17, 0.477, 271, 258, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
354, d3ac3A_, 0.8481, 2.19, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
355, d2ijmB_, 0.8481, 1.91, 0.418, 261, 256, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
356, d2etmA_, 0.8481, 1.86, 0.398, 262, 256, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
357, d1agwA_, 0.8481, 2.25, 0.398, 278, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
358, d5flfA_, 0.8480, 2.29, 0.408, 296, 260, DISEASE LINKED MUTATION IN FGFR
359, d4yneA1, 0.8479, 2.12, 0.380, 276, 258, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
360, d2qu6A1, 0.8479, 1.46, 0.396, 276, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
361, d5iugA_, 0.8478, 2.13, 0.409, 285, 257, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
362, d4d4sB_, 0.8478, 1.73, 0.390, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
363, d3acjA_, 0.8478, 2.19, 0.477, 270, 258, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
364, d2zybA_, 0.8478, 2.19, 0.473, 270, 258, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
365, d2zm4A_, 0.8478, 2.21, 0.473, 270, 258, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
366, d3ackA_, 0.8477, 2.19, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
367, d5i9zA_, 0.8476, 2.14, 0.398, 273, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
368, d3pyyB1, 0.8476, 0.89, 0.992, 244, 244, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
369, d3ad5A_, 0.8476, 2.20, 0.477, 270, 258, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
370, d2jkmA_, 0.8475, 1.78, 0.406, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
371, d3ccnA_, 0.8473, 2.23, 0.373, 275, 260, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
372, d3byoA_, 0.8473, 2.21, 0.477, 270, 258, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
373, d3ad4A_, 0.8473, 2.20, 0.477, 270, 258, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
374, d2pvfA_, 0.8473, 2.23, 0.405, 285, 259, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
375, d3byuA_, 0.8472, 1.90, 0.475, 256, 255, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
376, d4gmyA_, 0.8471, 2.41, 0.370, 298, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
377, d1ywnA_, 0.8471, 2.31, 0.365, 279, 260, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
378, d3ac8A_, 0.8470, 2.18, 0.477, 270, 258, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
379, d3ac4A_, 0.8469, 2.21, 0.477, 270, 258, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
380, d2pwlB_, 0.8466, 2.31, 0.412, 286, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
381, d4jiaA_, 0.8465, 2.46, 0.370, 298, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
382, d5uafA_, 0.8464, 2.30, 0.375, 291, 261, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
383, d5uadA_, 0.8464, 2.30, 0.375, 291, 261, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
384, d4fnyA_, 0.8464, 2.06, 0.404, 273, 255, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
385, d3i5nA_, 0.8464, 2.20, 0.365, 280, 260, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
386, d2pwlA_, 0.8463, 2.26, 0.413, 284, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
387, d1qpeA_, 0.8463, 2.22, 0.473, 270, 258, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
388, d3gqlB_, 0.8462, 2.36, 0.402, 276, 259, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
389, d2fgiA_, 0.8461, 2.38, 0.394, 274, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
390, d4j98A_, 0.8459, 2.22, 0.405, 304, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
391, d3lctA_, 0.8459, 2.58, 0.402, 308, 264, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
392, d5uq0A_, 0.8458, 2.01, 0.404, 266, 255, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
393, d5flfC_, 0.8457, 2.40, 0.406, 283, 261, DISEASE LINKED MUTATION IN FGFR
394, d3qrjA1, 0.8457, 1.12, 0.992, 246, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
395, d5ia5A_, 0.8456, 2.39, 0.402, 273, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
396, d4f63B_, 0.8456, 2.28, 0.399, 271, 258, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
397, d5u9dA_, 0.8454, 2.80, 0.451, 271, 268, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
398, d3ikaA_, 0.8454, 2.71, 0.383, 310, 264, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
399, d3g6gB_, 0.8452, 2.38, 0.477, 263, 258, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
400, d3dqwA_, 0.8452, 2.80, 0.471, 278, 263, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
401, d2ijmA_, 0.8452, 1.79, 0.408, 260, 255, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
402, d5ur1A_, 0.8451, 2.25, 0.405, 278, 257, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
403, d3cp9B_, 0.8451, 1.47, 0.394, 269, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
404, d5ia3A_, 0.8450, 2.47, 0.407, 275, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
405, d4ibmA_, 0.8449, 2.50, 0.407, 301, 268, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
406, d3oezA_, 0.8448, 2.40, 0.479, 261, 257, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
407, d2yjrA_, 0.8448, 2.19, 0.412, 278, 257, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
408, d4d5hB_, 0.8447, 1.77, 0.390, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
409, d1fgkB_, 0.8447, 2.28, 0.403, 272, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
410, d1agwB_, 0.8447, 2.29, 0.403, 272, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
411, d3et7A_, 0.8446, 1.78, 0.407, 261, 253, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
412, d3dqwD_, 0.8446, 2.66, 0.473, 276, 262, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
413, d2py3B_, 0.8446, 2.18, 0.409, 284, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
414, d5mjbA_, 0.8445, 2.46, 0.392, 276, 260, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
415, d4d4yB_, 0.8445, 1.77, 0.390, 260, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN
416, d4nksB_, 0.8443, 2.18, 0.405, 271, 257, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
417, d4f64B_, 0.8443, 2.30, 0.407, 272, 258, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
418, d4nksA_, 0.8441, 2.25, 0.395, 265, 258, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
419, d4cd0A_, 0.8441, 2.46, 0.406, 295, 261, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
420, d4j97A_, 0.8440, 2.10, 0.414, 282, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
421, d4j97C_, 0.8439, 2.12, 0.414, 283, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
422, d5u6bB1, 0.8438, 2.29, 0.448, 289, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
423, d5ia4A_, 0.8438, 2.36, 0.404, 269, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
424, d3dqwB_, 0.8438, 2.65, 0.475, 278, 261, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
425, d4j97B_, 0.8436, 2.09, 0.406, 283, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
426, d3zbfA_, 0.8436, 2.17, 0.424, 281, 257, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
427, d2py3A_, 0.8436, 2.23, 0.409, 282, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
428, d3lcsA_, 0.8435, 2.80, 0.402, 304, 266, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
429, d5njzA_, 0.8434, 2.31, 0.395, 273, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
430, d4r1yA_, 0.8434, 1.94, 0.363, 265, 256, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
431, d3fzrA_, 0.8434, 1.80, 0.407, 261, 253, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
432, d2fgiB_, 0.8434, 2.29, 0.403, 272, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
433, d5hznE_, 0.8433, 2.40, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
434, d5hznA_, 0.8433, 2.39, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
435, d5ftoA1, 0.8433, 2.53, 0.403, 297, 263, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
436, d3l9pA_, 0.8433, 2.58, 0.402, 303, 264, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
437, d5u6bD1, 0.8432, 2.29, 0.448, 289, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
438, d3bysA_, 0.8432, 1.86, 0.466, 255, 253, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
439, d5ugxA_, 0.8431, 2.26, 0.402, 297, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
440, d3qquB_, 0.8431, 2.50, 0.432, 288, 266, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
441, d3f3vB_, 0.8431, 2.43, 0.473, 262, 258, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
442, d3ce3A_, 0.8431, 2.43, 0.378, 293, 262, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
443, d5p9kA_, 0.8430, 2.82, 0.451, 271, 268, CRYSTAL STRUCTURE OF BTK WITH CNX 774
444, d5l6pA_, 0.8430, 2.39, 0.375, 274, 261, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
445, d5l6oA_, 0.8430, 2.33, 0.388, 267, 258, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
446, d4o2pA_, 0.8428, 2.52, 0.452, 265, 259, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
447, d5ugbA_, 0.8427, 2.58, 0.382, 307, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
448, d3f3wA_, 0.8427, 2.37, 0.471, 261, 257, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
449, d5uhnA_, 0.8426, 2.31, 0.405, 282, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
450, d5hg8A_, 0.8426, 2.89, 0.385, 300, 265, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
451, d3f3vA_, 0.8426, 2.34, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
452, d3cs9C_, 0.8426, 0.89, 0.992, 243, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
453, d5xgnA_, 0.8425, 2.65, 0.376, 302, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
454, d4ckjA1, 0.8425, 2.37, 0.415, 287, 260, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
455, d3lcdA_, 0.8425, 2.13, 0.398, 290, 254, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
456, d4aojA_, 0.8424, 1.90, 0.376, 260, 255, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
457, d5mjbB_, 0.8423, 2.47, 0.396, 278, 260, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
458, d5i8aA1, 0.8423, 1.71, 0.381, 265, 252, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
459, d2ivsA_, 0.8423, 2.38, 0.417, 284, 259, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
460, d5p9mA_, 0.8422, 2.58, 0.440, 271, 266, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
461, d5hg5A_, 0.8421, 2.90, 0.385, 302, 265, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
462, d2itxA_, 0.8421, 2.57, 0.382, 307, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
463, d1y57A3, 0.8421, 2.83, 0.464, 285, 263, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
464, d5iuiA_, 0.8420, 2.52, 0.403, 303, 263, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
465, d5em8A_, 0.8420, 2.55, 0.379, 303, 261, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
466, d4wunB_, 0.8420, 2.02, 0.408, 268, 255, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
467, d4d55A_, 0.8420, 1.66, 0.398, 260, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
468, d5p9iA_, 0.8419, 2.83, 0.451, 271, 268, BTK1 SOAKED WITH IBRUTINIB-REV
469, d3dqwC_, 0.8419, 2.63, 0.475, 275, 261, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
470, d1r0pA_, 0.8419, 2.58, 0.360, 301, 264, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
471, d3cthA_, 0.8418, 2.31, 0.369, 295, 260, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
472, d4u5jB_, 0.8417, 2.49, 0.481, 267, 258, C-SRC IN COMPLEX WITH RUXOLITINIB
473, d4c7tA_, 0.8417, 1.70, 0.381, 259, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
474, d5hznB_, 0.8416, 2.43, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
475, d3cc6A_, 0.8416, 2.24, 0.400, 269, 260, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
476, d2itqA_, 0.8416, 2.50, 0.377, 300, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
477, d5hznG_, 0.8415, 2.43, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
478, d5hznC_, 0.8415, 2.43, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
479, d4j95B_, 0.8415, 2.24, 0.411, 282, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
480, d3b8rB_, 0.8415, 1.66, 0.398, 267, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
481, d5hznF_, 0.8414, 2.43, 0.435, 296, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
482, d5ek7B_, 0.8414, 2.41, 0.398, 286, 259, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
483, d3tz8A_, 0.8414, 2.38, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
484, d3eflB_, 0.8414, 1.46, 0.387, 263, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
485, d1vr2A_, 0.8414, 2.10, 0.379, 275, 256, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
486, d5jfsA_, 0.8413, 2.16, 0.376, 277, 255, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
487, d4z3vA_, 0.8412, 2.87, 0.451, 271, 268, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
488, d3kulB_, 0.8411, 1.95, 0.387, 271, 253, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
489, d5uglA_, 0.8410, 2.30, 0.405, 285, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
490, d4fobA_, 0.8410, 2.44, 0.406, 295, 261, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
491, d4brxA_, 0.8410, 1.71, 0.381, 259, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
492, d3f3tA_, 0.8410, 2.37, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
493, d5j9yA_, 0.8408, 2.48, 0.375, 300, 261, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
494, d4eevA_, 0.8407, 2.06, 0.384, 283, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
495, d1qpjA_, 0.8407, 2.12, 0.478, 265, 255, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
496, d5ew3B_, 0.8406, 1.39, 0.393, 266, 247, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
497, d3nw6A_, 0.8406, 2.70, 0.431, 301, 269, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
498, d5uabA_, 0.8405, 2.24, 0.380, 288, 258, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
499, d4tyeA_, 0.8405, 2.49, 0.425, 292, 261, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
500, d4gt4B_, 0.8404, 2.29, 0.347, 273, 262, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
501, d4ckiA1, 0.8404, 2.53, 0.414, 288, 261, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
502, d3f3uA_, 0.8404, 2.38, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
503, d4ebwA_, 0.8402, 2.33, 0.402, 259, 256, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
504, d3wzdA_, 0.8402, 1.78, 0.390, 278, 251, KDR IN COMPLEX WITH LIGAND LENVATINIB
505, d4mkcA_, 0.8401, 2.56, 0.405, 303, 262, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
506, d5j7hA_, 0.8400, 2.44, 0.404, 291, 260, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
507, d4cljA_, 0.8400, 2.49, 0.406, 295, 261, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
508, d3bz3A_, 0.8400, 1.97, 0.410, 259, 256, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
509, d1m17A_, 0.8400, 2.54, 0.379, 312, 261, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
510, d1gjoA_, 0.8400, 2.23, 0.420, 280, 257, THE FGFR2 TYROSINE KINASE DOMAIN
511, d5ugxB_, 0.8399, 2.27, 0.403, 282, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
512, d4kaoB_, 0.8399, 1.67, 0.414, 254, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
513, d5xdkA_, 0.8398, 2.66, 0.378, 307, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
514, d4ebvA1, 0.8398, 2.32, 0.402, 261, 256, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
515, d3qquA_, 0.8398, 2.46, 0.432, 285, 264, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
516, d2pz5A_, 0.8398, 2.16, 0.412, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
517, d2jkqA_, 0.8398, 1.72, 0.409, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
518, d1oecA_, 0.8398, 2.23, 0.424, 280, 257, FGFR2 KINASE DOMAIN
519, d5mjaB_, 0.8397, 2.49, 0.400, 274, 260, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
520, d5hznD_, 0.8397, 2.45, 0.435, 304, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
521, d1m14A_, 0.8397, 2.59, 0.379, 307, 261, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
522, d4j95C_, 0.8396, 2.22, 0.409, 281, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
523, d2q0bB_, 0.8396, 2.20, 0.406, 282, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
524, d2j6mA_, 0.8396, 2.41, 0.386, 306, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
525, d5jfvA_, 0.8395, 1.95, 0.375, 277, 253, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
526, d5hznH_, 0.8395, 2.45, 0.435, 303, 260, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
527, d5i9vA_, 0.8394, 2.16, 0.404, 279, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
528, d4jq8A_, 0.8394, 2.60, 0.379, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
529, d4j99C_, 0.8394, 2.30, 0.415, 291, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
530, d4e4mA_, 0.8394, 2.58, 0.370, 296, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
531, d5jfwA_, 0.8393, 2.18, 0.376, 277, 255, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
532, d4y95D_, 0.8393, 2.63, 0.458, 265, 262, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
533, d4uwyB_, 0.8393, 1.98, 0.407, 273, 253, FGFR1 APO STRUCTURE
534, d4j99B_, 0.8393, 2.30, 0.411, 291, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
535, d3tz9A_, 0.8393, 2.37, 0.475, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
536, d4j95A_, 0.8392, 2.25, 0.415, 279, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
537, d3u6iA_, 0.8392, 2.13, 0.379, 281, 256, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
538, d3r7oA1, 0.8392, 2.46, 0.385, 295, 260, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
539, d2pzpA_, 0.8392, 2.17, 0.416, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
540, d2pz5B_, 0.8392, 2.17, 0.412, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
541, d2itpA_, 0.8392, 2.53, 0.377, 305, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
542, d5ek7A_, 0.8391, 2.56, 0.396, 286, 260, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
543, d4j95D_, 0.8391, 2.01, 0.425, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
544, d4e4mE_, 0.8391, 2.57, 0.366, 296, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
545, d2p2iB_, 0.8391, 1.41, 0.389, 263, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
546, d3dkfA1, 0.8390, 2.33, 0.367, 293, 259, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
547, d2q0bA_, 0.8390, 2.15, 0.404, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
548, d4j97D_, 0.8389, 2.08, 0.413, 285, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
549, d3w2qA1, 0.8389, 2.65, 0.374, 306, 262, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
550, d5nkhA_, 0.8388, 2.56, 0.398, 295, 259, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
551, d4y95A1, 0.8388, 2.64, 0.458, 265, 262, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
552, d3f6xB_, 0.8388, 2.51, 0.473, 267, 258, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
553, d2pzpB_, 0.8388, 2.18, 0.416, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
554, d4j99D_, 0.8387, 2.14, 0.420, 281, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
555, d3pixA_, 0.8386, 2.34, 0.444, 268, 261, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
556, d3f3wB_, 0.8386, 2.35, 0.473, 260, 256, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
557, d2itwA_, 0.8385, 2.44, 0.382, 300, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
558, d4e4mB_, 0.8384, 2.53, 0.366, 296, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
559, d4aojC_, 0.8383, 1.96, 0.376, 261, 255, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
560, d2qu6B_, 0.8382, 1.38, 0.398, 260, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
561, d4jr3A_, 0.8381, 2.62, 0.379, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
562, d4e4mD_, 0.8381, 2.53, 0.366, 296, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
563, d4cmoA_, 0.8381, 2.48, 0.408, 295, 260, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
564, d5jfxA_, 0.8380, 2.00, 0.379, 277, 253, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
565, d5cavA_, 0.8380, 2.54, 0.381, 306, 260, EGFR KINASE DOMAIN WITH COMPOUND 41A
566, d4zlzA_, 0.8380, 2.86, 0.449, 270, 267, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
567, d4jq7A_, 0.8380, 2.62, 0.379, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
568, d3qtiA_, 0.8380, 2.52, 0.360, 292, 261, C-MET KINASE IN COMPLEX WITH NVP-BVU972
569, d5nkeA_, 0.8379, 2.52, 0.399, 292, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
570, d3q6wA1, 0.8379, 2.62, 0.379, 293, 261, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
571, d3pxkB_, 0.8379, 1.86, 0.415, 258, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
572, d2jiuA_, 0.8377, 2.74, 0.390, 303, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
573, d5wevA_, 0.8376, 2.28, 0.374, 293, 257, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
574, d4i23A_, 0.8376, 2.53, 0.382, 304, 259, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
575, d3oezB_, 0.8376, 2.50, 0.475, 261, 257, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
576, d4k8aB_, 0.8375, 1.85, 0.415, 258, 253, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
577, d3tt0B_, 0.8375, 2.06, 0.407, 272, 253, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
578, d5fdxB_, 0.8374, 2.25, 0.399, 274, 258, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
579, d5aaaA_, 0.8374, 2.50, 0.412, 294, 260, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
580, d4gu6B_, 0.8374, 1.79, 0.413, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
581, d3g6hB_, 0.8374, 2.36, 0.471, 259, 255, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
582, d4qq5A1, 0.8373, 2.20, 0.434, 272, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
583, d4k33A_, 0.8373, 2.29, 0.403, 293, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
584, d4cmuA_, 0.8372, 2.49, 0.408, 294, 260, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
585, d2dq7X_, 0.8372, 2.05, 0.476, 262, 252, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
586, d4j99A_, 0.8371, 2.23, 0.416, 280, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
587, d3w2oA1, 0.8371, 2.66, 0.378, 304, 262, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
588, d5ia0B_, 0.8370, 2.51, 0.394, 266, 259, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
589, d3nw5A_, 0.8370, 2.73, 0.428, 302, 269, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
590, d2x2kA1, 0.8370, 2.37, 0.415, 284, 258, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
591, d2gs2A_, 0.8370, 2.50, 0.381, 305, 260, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
592, d4qqcA1, 0.8369, 2.09, 0.435, 271, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
593, d3f6xD_, 0.8369, 2.57, 0.477, 267, 258, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
594, d2xvdA_, 0.8369, 2.59, 0.382, 270, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
595, d5tehA_, 0.8368, 2.44, 0.467, 261, 257, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
596, d5ia0C_, 0.8368, 2.29, 0.396, 269, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
597, d3geqB1, 0.8368, 2.67, 0.471, 270, 259, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
598, d4y95C1, 0.8367, 2.53, 0.456, 265, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
599, d3u6hA_, 0.8367, 2.11, 0.380, 280, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
600, d5nkaA_, 0.8366, 2.21, 0.402, 271, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
601, d4zlyA_, 0.8366, 2.87, 0.449, 270, 267, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
602, d4y95B1, 0.8366, 2.54, 0.456, 265, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
603, d4kabB_, 0.8366, 1.92, 0.417, 258, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
604, d4gt4A_, 0.8366, 2.26, 0.331, 274, 260, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
605, d4d5kB_, 0.8366, 1.74, 0.406, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
606, d5aa9A_, 0.8365, 2.51, 0.412, 295, 260, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
607, d4li5A1, 0.8364, 2.53, 0.381, 303, 260, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
608, d4kabA_, 0.8364, 1.87, 0.401, 255, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
609, d2jkkA_, 0.8363, 1.84, 0.405, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
610, d5p9fA_, 0.8362, 2.57, 0.454, 266, 262, BTK IN COMPLEX WITH GDC-0834
611, d4jrvA_, 0.8361, 2.60, 0.381, 300, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
612, d4bb4A_, 0.8361, 2.55, 0.384, 265, 258, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
613, d4fodA_, 0.8360, 2.48, 0.404, 308, 260, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
614, d4cliA_, 0.8360, 2.50, 0.408, 294, 260, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
615, d3cjgA_, 0.8360, 1.75, 0.392, 280, 250, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
616, d4focA_, 0.8359, 2.45, 0.377, 296, 260, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
617, d4ot6A_, 0.8358, 2.53, 0.444, 265, 261, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
618, d2eb2A_, 0.8357, 2.55, 0.375, 305, 259, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
619, d5tt7A1, 0.8356, 2.02, 0.395, 270, 253, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
620, d3cpbB_, 0.8356, 1.37, 0.392, 263, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
621, d5kz0A_, 0.8355, 2.52, 0.408, 293, 260, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
622, d4u5jA_, 0.8355, 2.49, 0.482, 267, 257, C-SRC IN COMPLEX WITH RUXOLITINIB
623, d3kulA_, 0.8355, 2.19, 0.383, 267, 253, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
624, d3cpcB_, 0.8355, 1.36, 0.388, 262, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
625, d5i9wA_, 0.8354, 1.94, 0.400, 267, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
626, d2x2mA1, 0.8354, 2.29, 0.418, 281, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
627, d2pzrB_, 0.8353, 2.22, 0.404, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
628, d4fnzA_, 0.8352, 2.18, 0.402, 287, 256, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
629, d3piyA_, 0.8352, 2.42, 0.438, 262, 258, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
630, d5ia1A_, 0.8351, 2.10, 0.397, 261, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
631, d3b2wA_, 0.8350, 2.40, 0.486, 261, 255, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
632, d5i9uA_, 0.8349, 2.30, 0.400, 281, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
633, d5gtzA_, 0.8349, 2.49, 0.384, 317, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
634, d5p9gA_, 0.8348, 2.54, 0.452, 265, 261, STRUCTURE OF BTK WITH RN486
635, d4riyD_, 0.8348, 2.60, 0.396, 297, 260, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
636, d3bceB_, 0.8348, 2.75, 0.396, 286, 260, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
637, d2pzrA_, 0.8348, 2.16, 0.406, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
638, d3en4B_, 0.8347, 2.61, 0.479, 266, 259, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
639, d4dceB_, 0.8346, 2.09, 0.406, 284, 254, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
640, d3b2tB_, 0.8346, 2.29, 0.412, 287, 255, STRUCTURE OF PHOSPHOTRANSFERASE
641, d4d4vB_, 0.8345, 1.73, 0.404, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
642, d3bceC_, 0.8345, 2.62, 0.398, 286, 259, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
643, d1yomA_, 0.8344, 2.40, 0.463, 260, 255, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
644, d5cxhA1, 0.8343, 1.97, 0.395, 273, 253, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
645, d4riwD_, 0.8343, 2.68, 0.395, 297, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
646, d3g6hA_, 0.8343, 2.53, 0.475, 266, 257, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
647, d2ivtA1, 0.8343, 2.35, 0.416, 283, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
648, d2gs6A2, 0.8343, 2.44, 0.386, 308, 259, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
649, d5ftqA1, 0.8342, 2.49, 0.405, 292, 259, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
650, d4yhfA_, 0.8342, 2.75, 0.445, 268, 263, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
651, d4rixD_, 0.8342, 2.51, 0.386, 297, 259, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
652, d4e6qA_, 0.8342, 2.64, 0.370, 296, 262, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
653, d4dggA_, 0.8341, 2.48, 0.471, 261, 257, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
654, d3geqA1, 0.8341, 2.62, 0.473, 269, 258, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
655, d2pvyA_, 0.8341, 2.08, 0.407, 288, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
656, d3zfxH_, 0.8339, 2.21, 0.406, 266, 254, CRYSTAL STRUCTURE OF EPHB1
657, d3f3uB_, 0.8339, 2.41, 0.471, 259, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
658, d2ivsB1, 0.8339, 2.16, 0.421, 272, 254, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
659, d5gmpA_, 0.8338, 2.46, 0.381, 305, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
660, d4tt7A_, 0.8338, 2.42, 0.409, 291, 257, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
661, d4aojB_, 0.8338, 2.09, 0.370, 258, 254, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
662, d4z55A_, 0.8337, 2.67, 0.406, 294, 261, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
663, d4mxzB_, 0.8337, 2.51, 0.469, 264, 256, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
664, d4mxyB_, 0.8337, 2.51, 0.469, 264, 256, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
665, d4h1jA_, 0.8337, 2.01, 0.408, 263, 255, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
666, d3of0A_, 0.8337, 2.46, 0.477, 260, 256, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
667, d3f82A_, 0.8337, 2.01, 0.385, 278, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
668, d4pmtA1, 0.8336, 2.07, 0.373, 269, 255, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
669, d4iwdA1, 0.8336, 2.44, 0.382, 295, 259, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
670, d2r2pA1, 0.8336, 2.43, 0.397, 276, 257, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
671, d5nkiA_, 0.8335, 2.17, 0.401, 268, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
672, d3qlgA_, 0.8335, 2.43, 0.478, 259, 255, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
673, d3el8A_, 0.8335, 2.49, 0.477, 263, 256, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
674, d2j5eA_, 0.8335, 2.68, 0.383, 309, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
675, d2vx0A_, 0.8334, 2.62, 0.385, 273, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
676, d5aabA_, 0.8333, 2.48, 0.411, 293, 258, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
677, d3vjnA_, 0.8333, 2.48, 0.374, 297, 257, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
678, d3bceA_, 0.8333, 2.64, 0.394, 285, 259, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
679, d2ivuA1, 0.8333, 2.44, 0.419, 283, 258, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
680, d3nw7A_, 0.8332, 2.69, 0.431, 297, 267, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
681, d2xb7A_, 0.8332, 2.46, 0.411, 286, 258, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
682, d3w2pA1, 0.8331, 2.72, 0.378, 307, 262, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
683, d3vjoA_, 0.8331, 2.51, 0.376, 298, 258, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
684, d2x9fA_, 0.8331, 2.57, 0.389, 265, 257, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
685, d4mxxB_, 0.8330, 2.44, 0.471, 260, 255, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
686, d4gu9B_, 0.8329, 1.87, 0.417, 255, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
687, d2vwzA_, 0.8329, 2.63, 0.385, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
688, d4ccuA_, 0.8328, 2.43, 0.409, 292, 257, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
689, d5calA_, 0.8327, 2.42, 0.374, 300, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
690, d1k9aB3, 0.8327, 2.45, 0.447, 267, 257, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
691, d5nk5A_, 0.8326, 2.40, 0.400, 287, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
692, d5jkgA_, 0.8326, 2.25, 0.439, 266, 253, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
693, d2vwyA_, 0.8326, 2.64, 0.385, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
694, d5j87B_, 0.8324, 2.96, 0.451, 274, 266, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
695, d3dzqA_, 0.8324, 2.24, 0.390, 268, 254, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
696, d4e6qB_, 0.8323, 2.66, 0.370, 296, 262, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
697, d2vx1A_, 0.8323, 2.64, 0.385, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
698, d2vwxA_, 0.8323, 2.63, 0.385, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
699, d4ibmB_, 0.8322, 2.39, 0.414, 294, 263, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
700, d4dceA_, 0.8322, 2.29, 0.409, 288, 257, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
701, d3eqpB_, 0.8322, 2.05, 0.399, 270, 253, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
702, d1k9aA3, 0.8322, 2.53, 0.447, 267, 257, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
703, d5uhnB_, 0.8321, 2.14, 0.413, 269, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
704, d4d4vA_, 0.8321, 1.77, 0.402, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
705, d3zfxD_, 0.8321, 2.18, 0.403, 265, 253, CRYSTAL STRUCTURE OF EPHB1
706, d3c1xA_, 0.8321, 2.14, 0.374, 290, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
707, d5fxsA1, 0.8320, 2.77, 0.414, 307, 268, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
708, d3tz9B_, 0.8320, 2.32, 0.472, 259, 254, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
709, d5edpA_, 0.8319, 2.48, 0.372, 295, 258, EGFR KINASE (T790M/L858R) APO
710, d4rfyA_, 0.8319, 2.50, 0.444, 263, 259, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
711, d4r6vA1, 0.8319, 2.23, 0.435, 271, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
712, d3zfxA_, 0.8319, 2.18, 0.403, 267, 253, CRYSTAL STRUCTURE OF EPHB1
713, d3uqgA_, 0.8318, 2.49, 0.475, 263, 255, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
714, d2x2lA1, 0.8318, 2.48, 0.416, 282, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
715, d4ot5A_, 0.8317, 2.65, 0.446, 263, 260, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
716, d2pvyD_, 0.8317, 2.13, 0.411, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
717, d1xbcA1, 0.8317, 1.97, 0.394, 267, 251, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
718, d5xp7A_, 0.8316, 2.57, 0.475, 265, 257, C-SRC IN COMPLEX WITH ATP-CHCL
719, d5nk0A_, 0.8316, 2.30, 0.398, 273, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
720, d5amnA1, 0.8316, 2.45, 0.420, 282, 257, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
721, d4rfzA_, 0.8316, 2.65, 0.446, 263, 260, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
722, d4gu9A_, 0.8316, 1.68, 0.406, 252, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
723, d1k9aE3, 0.8316, 2.29, 0.449, 268, 254, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
724, d4d2rA_, 0.8315, 2.78, 0.429, 300, 268, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
725, d2pvyC_, 0.8315, 1.99, 0.414, 285, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
726, d5ia0A_, 0.8313, 2.34, 0.396, 263, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
727, d5canA_, 0.8313, 2.45, 0.374, 301, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
728, d5c8mA_, 0.8313, 2.45, 0.374, 302, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
729, d4otqA_, 0.8313, 2.52, 0.444, 263, 259, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
730, d3pxkA_, 0.8313, 1.77, 0.406, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
731, d2oj9A_, 0.8313, 2.64, 0.410, 295, 266, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
732, d1yi6B_, 0.8313, 2.72, 0.481, 274, 260, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
733, d5mjaA_, 0.8312, 2.55, 0.393, 271, 257, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
734, d5capA_, 0.8312, 2.34, 0.375, 303, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
735, d4zimB1, 0.8312, 2.43, 0.375, 292, 259, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
736, d4anqA_, 0.8312, 2.49, 0.411, 293, 258, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
737, d3eqrA_, 0.8312, 2.12, 0.403, 270, 253, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
738, d4rixB_, 0.8311, 2.64, 0.388, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
739, d5c8kA_, 0.8310, 2.45, 0.374, 300, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
740, d3ugcA_, 0.8310, 1.97, 0.381, 274, 252, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
741, d4d4sA_, 0.8309, 1.74, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
742, d2ityA1, 0.8309, 2.44, 0.385, 299, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
743, d5sysB_, 0.8308, 2.46, 0.469, 258, 254, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
744, d3qquC_, 0.8308, 2.75, 0.429, 293, 268, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
745, d3en4A_, 0.8308, 2.32, 0.474, 257, 253, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
746, d2ituA_, 0.8308, 2.45, 0.377, 304, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
747, d5c26A1, 0.8307, 2.04, 0.399, 271, 253, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
748, d4mxxA_, 0.8307, 2.49, 0.473, 266, 256, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
749, d4mxoA_, 0.8307, 2.61, 0.475, 266, 257, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
750, d4gfgA1, 0.8307, 2.03, 0.399, 273, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
751, d5tr6A1, 0.8306, 1.87, 0.394, 268, 251, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
752, d4ansA_, 0.8306, 2.50, 0.411, 293, 258, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
753, d2ittA_, 0.8306, 2.45, 0.377, 302, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
754, d5ghvB_, 0.8305, 1.91, 0.404, 265, 250, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
755, d4xg5B_, 0.8305, 1.91, 0.404, 265, 250,  
756, d3zfxI_, 0.8304, 2.25, 0.407, 263, 253, CRYSTAL STRUCTURE OF EPHB1
757, d2hz0B_, 0.8304, 1.28, 0.992, 243, 242, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
758, d5caqA_, 0.8303, 2.47, 0.374, 301, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
759, d2pvyB_, 0.8302, 1.93, 0.416, 286, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
760, d5em7A_, 0.8301, 2.42, 0.371, 300, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
761, d2bdfB_, 0.8301, 2.66, 0.479, 265, 259, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
762, d5ghvA_, 0.8300, 1.95, 0.408, 265, 250, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
763, d4xg5A_, 0.8300, 1.95, 0.408, 265, 250,  
764, d5edqA_, 0.8299, 2.47, 0.370, 298, 257, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
765, d4o2pB_, 0.8299, 2.50, 0.473, 265, 256, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
766, d4i4fA_, 0.8299, 2.19, 0.409, 255, 252, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
767, d3zfxE_, 0.8299, 2.14, 0.409, 262, 252, CRYSTAL STRUCTURE OF EPHB1
768, d2yfxA_, 0.8299, 2.50, 0.407, 292, 258, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
769, d1xbbA1, 0.8299, 1.98, 0.406, 266, 251, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
770, d5j9zA_, 0.8298, 2.59, 0.376, 291, 258, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
771, d4rg0A_, 0.8298, 2.52, 0.444, 263, 259, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
772, d5t0pB_, 0.8297, 2.52, 0.471, 263, 255, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
773, d5cxzA1, 0.8297, 1.96, 0.398, 267, 251, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
774, d4otrA_, 0.8297, 2.53, 0.444, 263, 259, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
775, d3svvA_, 0.8297, 2.43, 0.465, 261, 254, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
776, d2itvA_, 0.8297, 2.46, 0.381, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
777, d5k9iB_, 0.8296, 2.50, 0.475, 262, 255, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
778, d5hicA_, 0.8296, 2.47, 0.374, 302, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
779, d5caoA_, 0.8296, 2.42, 0.371, 300, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
780, d3uqfA_, 0.8296, 2.50, 0.475, 260, 255, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
781, d3efkA_, 0.8296, 2.19, 0.382, 276, 254, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
782, d3dqxA_, 0.8296, 2.56, 0.482, 267, 257, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
783, d1yomB_, 0.8296, 2.42, 0.467, 261, 255, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
784, d5ur1B_, 0.8295, 2.22, 0.413, 265, 254, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
785, d5cf4B_, 0.8295, 2.45, 0.375, 291, 259, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
786, d5l3aA_, 0.8294, 2.25, 0.373, 290, 255, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
787, d5a9uA_, 0.8294, 2.48, 0.409, 292, 257, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
788, d3q6uA1, 0.8294, 2.23, 0.384, 281, 255, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
789, d3i81A_, 0.8294, 2.71, 0.434, 296, 265, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
790, d5t3qA1, 0.8293, 2.05, 0.373, 277, 252, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
791, d4rx7A1, 0.8293, 2.08, 0.395, 270, 253, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
792, d4anlA_, 0.8293, 2.50, 0.411, 292, 258, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
793, d3qquD_, 0.8293, 2.80, 0.429, 292, 268, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
794, d5hcyA_, 0.8292, 2.47, 0.374, 302, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
795, d5xp7B_, 0.8290, 2.66, 0.475, 267, 257, C-SRC IN COMPLEX WITH ATP-CHCL
796, d5cf5B1, 0.8290, 2.46, 0.375, 292, 259, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
797, d4wnmA1, 0.8290, 1.98, 0.397, 269, 252, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
798, d3kxzA_, 0.8289, 2.17, 0.478, 263, 253, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
799, d3d94A_, 0.8289, 2.65, 0.438, 288, 258, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
800, d2itnA_, 0.8288, 2.48, 0.377, 304, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
801, d2hk5A2, 0.8288, 2.27, 0.478, 268, 253, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
802, d5hcxA_, 0.8287, 2.44, 0.375, 298, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
803, d4twnA1, 0.8287, 2.66, 0.394, 275, 259, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
804, d4dfnA1, 0.8287, 1.93, 0.402, 268, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
805, d3tudA1, 0.8287, 1.79, 0.394, 255, 249, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
806, d2oiqB_, 0.8287, 2.45, 0.478, 265, 255, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
807, d5swhA_, 0.8286, 2.49, 0.469, 258, 254, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
808, d4mxoB_, 0.8286, 2.46, 0.478, 264, 255, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
809, d4ctbA_, 0.8286, 2.47, 0.409, 292, 257, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
810, d4i4eA_, 0.8285, 1.78, 0.400, 254, 250, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
811, d3qtiB_, 0.8285, 2.41, 0.363, 280, 256, C-MET KINASE IN COMPLEX WITH NVP-BVU972
812, d3q32A_, 0.8285, 2.36, 0.376, 291, 258, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
813, d4rx5A1, 0.8284, 2.73, 0.456, 264, 261, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
814, d4riyB_, 0.8284, 2.57, 0.393, 293, 257, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
815, d5edrA_, 0.8283, 2.50, 0.374, 299, 257, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
816, d5aacA_, 0.8283, 2.49, 0.409, 292, 257, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
817, d4yhfB_, 0.8283, 2.79, 0.454, 269, 262, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
818, d4mxzA_, 0.8283, 2.63, 0.467, 266, 257, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
819, d4mxyA_, 0.8283, 2.63, 0.467, 266, 257, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
820, d4ivaA_, 0.8283, 2.23, 0.371, 290, 256, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
821, d3genA_, 0.8283, 2.72, 0.452, 264, 261, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
822, d5em6A_, 0.8282, 2.45, 0.375, 301, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
823, d4z16B_, 0.8282, 2.18, 0.368, 276, 253, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
824, d4d5kA_, 0.8282, 1.78, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
825, d4d58A_, 0.8282, 1.78, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
826, d2eb3A_, 0.8282, 2.46, 0.371, 294, 256, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
827, d5vgoA1, 0.8281, 2.73, 0.456, 264, 261, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
828, d5uglB_, 0.8280, 2.21, 0.413, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
829, d5kupA1, 0.8280, 2.59, 0.454, 264, 260, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
830, d5c8nA_, 0.8280, 2.45, 0.375, 300, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
831, d4rj4A_, 0.8279, 2.45, 0.371, 299, 256, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
832, d4d5hA_, 0.8279, 1.78, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
833, d3q32B1, 0.8279, 2.54, 0.373, 293, 260, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
834, d4lqmA_, 0.8278, 2.44, 0.381, 305, 257, EGFR L858R IN COMPLEX WITH PD168393
835, d4d4yA_, 0.8278, 1.79, 0.400, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN
836, d5p9jA_, 0.8277, 2.73, 0.444, 263, 261, BTK1 COCRYSTALLIZED WITH IBRUTINIB
837, d5aa8A_, 0.8277, 2.51, 0.412, 292, 257, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
838, d4k9yA_, 0.8277, 2.56, 0.408, 271, 260, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
839, d4aqcB_, 0.8277, 2.65, 0.370, 295, 262, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
840, d3dqxB_, 0.8277, 2.66, 0.481, 268, 258, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
841, d2xyuA_, 0.8277, 2.29, 0.387, 260, 253, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
842, d5c27A1, 0.8276, 2.08, 0.399, 271, 253, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
843, d4ewhA_, 0.8275, 2.20, 0.398, 274, 254, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
844, d4knbB_, 0.8274, 1.89, 0.371, 256, 251, C-MET IN COMPLEX WITH OSI LIGAND
845, d2z8cA1, 0.8272, 2.54, 0.415, 297, 258, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
846, d5p9hA_, 0.8271, 2.59, 0.454, 264, 260, BTK1 COCRYSTALLIZED WITH RN983
847, d5fedA_, 0.8270, 2.50, 0.380, 288, 255, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
848, d4fnwA_, 0.8270, 2.40, 0.406, 304, 256, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
849, d4agwA_, 0.8270, 2.42, 0.469, 258, 254, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
850, d4rj5A_, 0.8269, 2.42, 0.373, 296, 255, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
851, d3zewA_, 0.8269, 2.33, 0.389, 269, 252, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
852, d3ctjA_, 0.8268, 2.34, 0.380, 289, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
853, d5cf6B1, 0.8267, 2.40, 0.377, 288, 257, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
854, d4g5pA_, 0.8267, 2.75, 0.382, 299, 262, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
855, d4d0xA_, 0.8267, 2.44, 0.372, 291, 258, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
856, d1mqbB_, 0.8267, 2.46, 0.395, 265, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
857, d5xdlA_, 0.8266, 2.44, 0.380, 292, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
858, d5lwnA_, 0.8266, 2.38, 0.363, 290, 256, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
859, d4xg4A_, 0.8266, 1.96, 0.410, 264, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
860, d4riwB_, 0.8266, 2.59, 0.397, 293, 257, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
861, d4r5sA_, 0.8266, 2.57, 0.377, 299, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
862, d4ctcA_, 0.8266, 2.47, 0.410, 288, 256, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
863, d4ccbA_, 0.8266, 2.45, 0.410, 287, 256, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
864, d4agwB_, 0.8266, 2.40, 0.470, 257, 253, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
865, d4k8aA_, 0.8265, 1.72, 0.415, 251, 248, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
866, d3ug1A_, 0.8265, 2.44, 0.374, 296, 254, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
867, d3e64A_, 0.8265, 2.45, 0.376, 291, 258, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
868, d2y6oA_, 0.8265, 2.31, 0.383, 263, 253, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
869, d2j5fA_, 0.8265, 2.45, 0.385, 308, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
870, d5lwmA_, 0.8264, 2.39, 0.363, 290, 256, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
871, d3eqrB_, 0.8264, 2.21, 0.401, 271, 252, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
872, d2yhvA_, 0.8264, 2.50, 0.405, 291, 257, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
873, d2itzA_, 0.8264, 2.52, 0.381, 302, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
874, d5hczA_, 0.8262, 2.47, 0.375, 300, 256, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
875, d4fl1A_, 0.8262, 2.01, 0.402, 268, 251, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
876, d5fboA_, 0.8261, 2.25, 0.451, 255, 255, BTK-INHIBITOR CO-STRUCTURE
877, d5aepA_, 0.8261, 2.46, 0.370, 287, 257, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
878, d2jitA_, 0.8261, 2.76, 0.363, 299, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
879, d4rj8A_, 0.8260, 2.42, 0.376, 298, 255, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
880, d3qlfB_, 0.8260, 2.40, 0.470, 258, 253, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
881, d5cy3A1, 0.8258, 2.27, 0.396, 274, 255, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
882, d2helA_, 0.8258, 2.22, 0.403, 256, 253, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
883, d5sysA_, 0.8257, 2.33, 0.472, 258, 252, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
884, d5fxqA1, 0.8257, 2.78, 0.414, 301, 266, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
885, d4rj7A_, 0.8257, 2.39, 0.374, 295, 254, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
886, d3pjcA_, 0.8257, 2.25, 0.364, 286, 253, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
887, d1fvrB_, 0.8257, 2.79, 0.390, 300, 259, TIE2 KINASE DOMAIN
888, d4ybjA_, 0.8256, 2.19, 0.472, 255, 250, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
889, d3ug2A_, 0.8256, 2.54, 0.375, 299, 256, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
890, d3e62A_, 0.8256, 2.49, 0.376, 291, 258, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
891, d3bu6A_, 0.8256, 2.40, 0.418, 294, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
892, d3sxsA1, 0.8255, 2.08, 0.436, 261, 250, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
893, d3aoxA_, 0.8255, 2.36, 0.408, 298, 255, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
894, d5j87A_, 0.8254, 2.73, 0.454, 263, 260, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
895, d4ybjB_, 0.8254, 2.20, 0.470, 253, 249, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
896, d2jkoA_, 0.8254, 1.91, 0.402, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
897, d1mqbA_, 0.8254, 2.39, 0.396, 263, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
898, d4xg6A1, 0.8253, 2.00, 0.398, 270, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
899, d3efjA_, 0.8251, 2.24, 0.378, 276, 254, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
900, d3e63A_, 0.8251, 2.45, 0.377, 290, 257, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
901, d2reiA1, 0.8251, 2.19, 0.385, 274, 252, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
902, d5swhB_, 0.8250, 2.56, 0.467, 261, 255, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
903, d4xlvA_, 0.8250, 2.48, 0.413, 307, 259, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
904, d4gk4A_, 0.8250, 2.58, 0.393, 275, 257, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
905, d4bbeC_, 0.8250, 2.20, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
906, d3vf8A_, 0.8250, 1.92, 0.396, 265, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
907, d3qlgB_, 0.8250, 2.51, 0.470, 260, 253, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
908, d3g5dB_, 0.8250, 2.27, 0.480, 257, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
909, d3cjfA_, 0.8250, 2.33, 0.381, 276, 252, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
910, d5casA_, 0.8249, 2.45, 0.376, 299, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
911, d4nwmB_, 0.8249, 2.67, 0.461, 261, 258, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
912, d4bbeD_, 0.8249, 2.18, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
913, d4aw5A_, 0.8249, 2.27, 0.387, 261, 253, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
914, d3fqsA1, 0.8248, 1.99, 0.410, 264, 249, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
915, d3efkB_, 0.8248, 2.17, 0.385, 272, 252, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
916, d2og8B2, 0.8247, 1.94, 0.474, 247, 247, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
917, d5t0pA_, 0.8245, 2.57, 0.471, 264, 255, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
918, d4bbeB_, 0.8244, 2.21, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
919, d4gk3A_, 0.8242, 2.55, 0.391, 275, 256, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
920, d4d0wA_, 0.8242, 2.37, 0.371, 289, 256, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
921, d4bbfB_, 0.8242, 2.23, 0.375, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
922, d3krrA1, 0.8241, 2.34, 0.375, 290, 256, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
923, d3eqpA_, 0.8241, 2.07, 0.398, 268, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
924, d3eknA_, 0.8241, 2.57, 0.409, 297, 259, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
925, d2vwvA_, 0.8241, 2.24, 0.385, 255, 252, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
926, d5xgmA_, 0.8240, 2.45, 0.384, 288, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
927, d4rj6A_, 0.8240, 2.46, 0.373, 297, 255, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
928, d5fxrA1, 0.8239, 2.80, 0.414, 299, 266, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
929, d4bbfC_, 0.8239, 2.26, 0.375, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
930, d5cauA_, 0.8238, 2.46, 0.376, 297, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
931, d4bbeA_, 0.8238, 2.21, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
932, d1xbaA1, 0.8238, 1.95, 0.396, 265, 250, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
933, d5uq0B_, 0.8237, 1.88, 0.415, 256, 248, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
934, d4fnxA_, 0.8237, 2.61, 0.399, 292, 258, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
935, d4ewhB_, 0.8237, 2.22, 0.399, 273, 253, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
936, d1jpaA_, 0.8236, 2.54, 0.390, 273, 254, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
937, d5cf5A1, 0.8235, 2.30, 0.376, 286, 255, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
938, d4i0tA1, 0.8235, 1.83, 0.405, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
939, d5fm3A_, 0.8234, 2.27, 0.421, 276, 252, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
940, d4dflA1, 0.8233, 1.82, 0.399, 262, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
941, d3f6xA_, 0.8233, 2.44, 0.474, 264, 253, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
942, d5em5A_, 0.8232, 2.47, 0.369, 298, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
943, d4xi2A2, 0.8232, 2.93, 0.452, 274, 263, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
944, d2x2mB1, 0.8232, 2.09, 0.422, 274, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
945, d5lmaA_, 0.8231, 2.06, 0.400, 267, 250, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
946, d3ocsA1, 0.8231, 2.56, 0.453, 262, 258, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
947, d1yolB_, 0.8231, 2.21, 0.462, 253, 249, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
948, d4p5qA_, 0.8230, 2.55, 0.391, 275, 256, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
949, d3efjB_, 0.8230, 2.22, 0.375, 275, 253, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
950, d1yvjA_, 0.8230, 2.28, 0.369, 288, 255, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
951, d5tehB_, 0.8229, 2.73, 0.465, 262, 258, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
952, d4rssA_, 0.8228, 2.13, 0.397, 269, 252, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
953, d4nwmA_, 0.8228, 2.70, 0.461, 261, 258, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
954, d4i0sA1, 0.8228, 1.92, 0.403, 263, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
955, d4fynA1, 0.8228, 1.94, 0.407, 263, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
956, d3pj2A_, 0.8228, 1.80, 0.460, 248, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
957, d3kckA_, 0.8228, 2.12, 0.377, 285, 252, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
958, d1yolA_, 0.8228, 2.34, 0.462, 256, 251, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
959, d5cf6A_, 0.8227, 2.24, 0.378, 285, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
960, d4ji9B_, 0.8227, 2.46, 0.377, 288, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
961, d4c3fA_, 0.8227, 2.12, 0.450, 257, 251, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
962, d2y6mA_, 0.8227, 2.31, 0.393, 262, 252, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
963, d4f09A_, 0.8226, 2.32, 0.376, 288, 255, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
964, d5nk8A_, 0.8225, 1.98, 0.403, 266, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
965, d4pv0A1, 0.8225, 1.98, 0.400, 266, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
966, d4hctA_, 0.8225, 2.87, 0.416, 265, 262, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
967, d1fvrA_, 0.8225, 2.78, 0.391, 299, 258, TIE2 KINASE DOMAIN
968, d3f6xC_, 0.8224, 2.56, 0.465, 265, 254, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
969, d5j5sA_, 0.8223, 2.47, 0.472, 258, 254, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
970, d4ythA_, 0.8223, 2.19, 0.375, 287, 253, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
971, d2bdfA_, 0.8223, 2.61, 0.477, 261, 256, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
972, d5feeA_, 0.8222, 2.51, 0.374, 287, 254, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
973, d5bpyA1, 0.8222, 2.72, 0.456, 262, 259, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
974, d2bdjA_, 0.8222, 2.08, 0.490, 254, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
975, d5usyB_, 0.8221, 2.33, 0.378, 287, 254, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
976, d5cf8B1, 0.8221, 2.43, 0.379, 287, 256, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
977, d4hvgA_, 0.8221, 2.22, 0.364, 281, 253, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
978, d4d1sA_, 0.8221, 2.13, 0.380, 280, 250, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
979, d5d12A_, 0.8220, 2.42, 0.464, 260, 252, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
980, d4gfmA_, 0.8220, 2.44, 0.379, 289, 256, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
981, d4fyoA1, 0.8220, 1.96, 0.407, 263, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
982, d3zzwA_, 0.8220, 2.56, 0.328, 269, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
983, d2og8A_, 0.8220, 1.89, 0.472, 246, 246, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
984, d5usyA_, 0.8219, 2.35, 0.378, 287, 254, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
985, d4xg3B_, 0.8218, 2.02, 0.414, 267, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
986, d4g2fA_, 0.8218, 2.64, 0.391, 275, 256, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
987, d3mpmA_, 0.8218, 2.22, 0.450, 257, 251, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
988, d1mp8A_, 0.8218, 1.82, 0.406, 252, 249, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
989, d4rx9A1, 0.8217, 1.97, 0.402, 264, 249, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
990, d4mcvB_, 0.8217, 2.56, 0.457, 265, 256, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
991, d3zfyA_, 0.8217, 2.53, 0.378, 260, 254, CRYSTAL STRUCTURE OF EPHB3
992, d3tjcB_, 0.8217, 2.40, 0.379, 287, 256, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
993, d3fztA_, 0.8216, 1.99, 0.414, 259, 251, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
994, d2xp2A_, 0.8216, 2.43, 0.409, 285, 254, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
995, d4ytfA_, 0.8215, 2.16, 0.377, 283, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
996, d1yi6A_, 0.8215, 2.75, 0.479, 274, 259, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
997, d5t68A1, 0.8214, 2.02, 0.410, 264, 249, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
998, d3rvgA_, 0.8214, 2.37, 0.378, 285, 254, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
999, d3fzoA_, 0.8214, 2.34, 0.378, 262, 254, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
1000, d2qo9A_, 0.8214, 2.60, 0.393, 277, 257, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
1001, d2ivvA1, 0.8214, 2.42, 0.427, 277, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
1002, d3bu3A_, 0.8213, 2.34, 0.420, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
1003, d2zvaA1, 0.8213, 2.18, 0.482, 260, 251, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
1004, d4rx8A1, 0.8211, 2.03, 0.400, 266, 250, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
1005, d4cmtA_, 0.8211, 2.36, 0.411, 284, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
1006, d3zewB_, 0.8211, 2.11, 0.387, 252, 248, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
1007, d5t68B_, 0.8208, 2.01, 0.406, 264, 249, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
1008, d4p5zA_, 0.8208, 2.55, 0.386, 267, 254, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
1009, d3t9tA_, 0.8208, 2.82, 0.396, 263, 260, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
1010, d3d7tB_, 0.8207, 2.55, 0.453, 265, 256, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1011, d2yn8B_, 0.8207, 2.30, 0.386, 260, 251, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1012, d4bbfD_, 0.8206, 2.25, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1013, d4py1A_, 0.8205, 2.35, 0.341, 289, 255, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
1014, d3vf9A_, 0.8205, 1.97, 0.402, 265, 249, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
1015, d5d11A_, 0.8204, 2.33, 0.460, 254, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
1016, d4ytcA_, 0.8203, 2.18, 0.377, 284, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
1017, d4bbfA_, 0.8203, 2.28, 0.372, 288, 253, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1018, d4trlA_, 0.8202, 2.18, 0.414, 268, 251, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1019, d3jy9A_, 0.8202, 2.10, 0.378, 282, 251, JANUS KINASE 2 INHIBITORS
1020, d5flfE_, 0.8201, 1.97, 0.403, 258, 248, DISEASE LINKED MUTATION IN FGFR
1021, d3iokA_, 0.8201, 2.19, 0.377, 285, 252, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
1022, d1rqqB_, 0.8200, 2.46, 0.418, 294, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
1023, d5h0gA3, 0.8199, 2.67, 0.453, 281, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
1024, d3g5dA_, 0.8197, 2.20, 0.476, 256, 248, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1025, d3dkoA1, 0.8197, 2.13, 0.388, 272, 250, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
1026, d4mcvA_, 0.8196, 2.68, 0.451, 267, 257, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1027, d2w1iA_, 0.8196, 2.31, 0.379, 284, 253, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
1028, d4wkqA1, 0.8195, 2.52, 0.383, 294, 253, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
1029, d4px6A1, 0.8195, 1.97, 0.407, 261, 248, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
1030, d5j5sB_, 0.8194, 2.47, 0.470, 258, 253, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
1031, d4yjoA_, 0.8194, 2.07, 0.402, 267, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
1032, d2w1iB_, 0.8194, 2.33, 0.379, 284, 253, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
1033, d3f3tB_, 0.8191, 2.39, 0.474, 259, 251, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
1034, d4z16D_, 0.8190, 2.34, 0.371, 271, 251, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
1035, d4z16C_, 0.8190, 2.24, 0.372, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
1036, d4z16A_, 0.8189, 2.24, 0.372, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
1037, d4ytiA_, 0.8189, 2.20, 0.377, 284, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
1038, d4aqcA_, 0.8189, 2.33, 0.373, 289, 255, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
1039, d1k3aA_, 0.8189, 2.48, 0.441, 288, 256, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
1040, d4id7A_, 0.8188, 2.13, 0.406, 268, 251, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
1041, d5lmbA_, 0.8187, 1.93, 0.403, 264, 248, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
1042, d4q9sA_, 0.8187, 1.87, 0.402, 252, 249, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
1043, d2qokA_, 0.8187, 2.72, 0.389, 281, 257, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
1044, d2qocA_, 0.8187, 2.44, 0.396, 283, 255, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
1045, d5j87D_, 0.8186, 2.67, 0.452, 263, 259, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1046, d4otfA1, 0.8186, 2.58, 0.455, 261, 257, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
1047, d5h0eA3, 0.8185, 2.68, 0.453, 281, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
1048, d4xg7A1, 0.8185, 2.02, 0.398, 265, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1049, d3lxnA_, 0.8185, 2.38, 0.335, 287, 254, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1050, d2b7aB_, 0.8185, 2.45, 0.379, 287, 256, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
1051, d4zimA_, 0.8184, 2.30, 0.378, 285, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
1052, d3fqeA1, 0.8184, 2.16, 0.404, 265, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
1053, d3el7A_, 0.8184, 2.34, 0.468, 254, 250, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
1054, d2yjsA_, 0.8184, 2.40, 0.411, 286, 253, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
1055, d2qoqA_, 0.8184, 2.51, 0.388, 284, 255, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
1056, d5tq3B_, 0.8183, 2.39, 0.376, 285, 255, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1057, d5j87C_, 0.8183, 2.72, 0.453, 261, 258, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1058, d4xg3A_, 0.8183, 1.77, 0.402, 262, 246, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1059, d1k9aF3, 0.8183, 2.40, 0.439, 264, 253, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1060, d3svvB_, 0.8182, 2.50, 0.468, 257, 252, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1061, d3d7uC1, 0.8182, 2.17, 0.470, 255, 249, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1062, d3d7uA1, 0.8182, 2.17, 0.470, 255, 249, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1063, d3d7tA_, 0.8181, 1.96, 0.460, 249, 248, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1064, d4hcuA_, 0.8180, 2.84, 0.415, 263, 260, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
1065, d4xg9B_, 0.8179, 2.03, 0.406, 265, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1066, d4hgeB_, 0.8179, 2.53, 0.377, 288, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
1067, d4dggB_, 0.8179, 2.50, 0.458, 259, 253, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1068, d3mj2A_, 0.8179, 2.71, 0.418, 259, 256, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
1069, d3el8B_, 0.8179, 2.54, 0.468, 259, 252, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1070, d5h09A3, 0.8178, 2.68, 0.453, 281, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
1071, d4p7eB_, 0.8176, 2.45, 0.379, 285, 256, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
1072, d3bu5A_, 0.8176, 2.34, 0.419, 291, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
1073, d3io7A_, 0.8175, 2.16, 0.378, 282, 251, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
1074, d1pkgA_, 0.8175, 2.39, 0.391, 290, 253, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
1075, d5k9iA_, 0.8174, 2.44, 0.474, 258, 253, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1076, d4hcvA_, 0.8172, 2.80, 0.417, 263, 259, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
1077, d1pkgB_, 0.8172, 2.59, 0.388, 277, 255, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
1078, d5fbnC_, 0.8171, 2.40, 0.455, 256, 253, BTK KINASE DOMAIN WITH INHIBITOR 1
1079, d3pp0B_, 0.8171, 2.78, 0.386, 296, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
1080, d5h0hA3, 0.8170, 2.69, 0.453, 281, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
1081, d5h0bA3, 0.8170, 2.70, 0.453, 281, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
1082, d5cf8A1, 0.8170, 2.21, 0.377, 284, 252, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1083, d4m0zA_, 0.8170, 2.89, 0.418, 264, 261, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
1084, d4ji9A_, 0.8170, 2.19, 0.377, 284, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
1085, d3lpbB1, 0.8170, 2.45, 0.382, 283, 254, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
1086, d4i0rA1, 0.8169, 1.89, 0.411, 260, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
1087, d5tq3A_, 0.8168, 2.35, 0.378, 282, 254, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1088, d4m12A_, 0.8168, 2.89, 0.418, 264, 261, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1089, d4m13A_, 0.8167, 2.85, 0.419, 264, 260, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1090, d4e6dA_, 0.8167, 2.30, 0.378, 286, 254, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
1091, d5tq5A_, 0.8166, 2.47, 0.375, 291, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1092, d4cnhA_, 0.8165, 2.43, 0.405, 285, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
1093, d5tobA_, 0.8164, 1.51, 0.405, 245, 242, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
1094, d3tjdB_, 0.8164, 2.46, 0.379, 287, 256, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
1095, d2qobA_, 0.8164, 2.63, 0.375, 279, 256, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
1096, d5tq8A_, 0.8163, 2.36, 0.376, 291, 255, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1097, d4fz6A1, 0.8163, 1.97, 0.409, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
1098, d3en5B_, 0.8163, 2.67, 0.473, 261, 256, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
1099, d5tiuA1, 0.8162, 1.82, 0.398, 262, 246, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
1100, d4kaoA_, 0.8162, 2.03, 0.412, 252, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
1101, d4xg2A1, 0.8161, 1.77, 0.410, 258, 244, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
1102, d5t18A1, 0.8160, 2.63, 0.457, 259, 256, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
1103, d4zauA_, 0.8160, 2.53, 0.385, 283, 252, AZD9291 COMPLEX WITH WILD TYPE EGFR
1104, d4twoA_, 0.8160, 2.60, 0.392, 278, 255, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
1105, d4hvhA_, 0.8160, 2.16, 0.368, 278, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
1106, d3w2sA_, 0.8159, 3.00, 0.382, 307, 262, EGFR KINASE DOMAIN WITH COMPOUND4
1107, d3eyhA_, 0.8158, 2.58, 0.362, 285, 254, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1108, d5d12B_, 0.8157, 2.37, 0.466, 253, 249, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1109, d2qonA_, 0.8157, 2.62, 0.392, 281, 255, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
1110, d2gsfA_, 0.8157, 2.71, 0.391, 281, 256, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
1111, d3tubA_, 0.8156, 1.98, 0.405, 253, 247, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
1112, d5walA1, 0.8155, 2.20, 0.335, 285, 251, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
1113, d4h1mA_, 0.8155, 1.92, 0.357, 256, 249, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
1114, d3fupB_, 0.8155, 2.50, 0.379, 287, 256, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1115, d3dkgA_, 0.8155, 2.38, 0.377, 281, 252, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
1116, d4gvjA1, 0.8154, 2.32, 0.344, 288, 253, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
1117, d1gagA_, 0.8154, 2.49, 0.415, 300, 258, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
1118, d1rqqA_, 0.8153, 2.65, 0.412, 294, 257, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
1119, d1ir3A_, 0.8152, 2.50, 0.415, 300, 258, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
1120, d5xy1A1, 0.8150, 2.11, 0.482, 252, 249, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
1121, d4m15A_, 0.8149, 2.87, 0.419, 263, 260, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
1122, d4m0yA_, 0.8148, 2.85, 0.417, 263, 259, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
1123, d3zfyB_, 0.8148, 2.47, 0.378, 255, 251, CRYSTAL STRUCTURE OF EPHB3
1124, d3pp0A_, 0.8148, 2.84, 0.386, 286, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
1125, d2zv8A1, 0.8148, 2.24, 0.484, 256, 250, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
1126, d4pdoB_, 0.8147, 1.81, 0.400, 261, 245, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1127, d4f08A_, 0.8147, 2.43, 0.376, 288, 255, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1128, d4qt1A_, 0.8146, 2.19, 0.368, 277, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
1129, d4pdoA_, 0.8145, 1.82, 0.396, 261, 245, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1130, d4gk2A_, 0.8145, 2.47, 0.389, 265, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
1131, d4e20A_, 0.8144, 2.36, 0.352, 282, 253, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
1132, d3vs3B3, 0.8144, 2.58, 0.461, 271, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
1133, d4puzB_, 0.8143, 2.21, 0.404, 265, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
1134, d2qo2A_, 0.8143, 2.68, 0.388, 282, 255, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
1135, d2b7aA_, 0.8143, 2.37, 0.379, 284, 253, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
1136, d1uwhA_, 0.8143, 2.19, 0.313, 264, 252, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
1137, d5cf4A_, 0.8141, 2.20, 0.378, 283, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1138, d4m14A_, 0.8141, 2.83, 0.421, 263, 259, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
1139, d1jpaB_, 0.8141, 2.55, 0.394, 269, 251, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
1140, d4i6qA_, 0.8140, 2.15, 0.369, 277, 249, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
1141, d3fqhA_, 0.8140, 1.87, 0.398, 262, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
1142, d2zm3A2, 0.8140, 2.50, 0.441, 299, 256, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1143, d2xbaA_, 0.8139, 2.36, 0.406, 283, 251, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
1144, d5ar7B_, 0.8138, 2.48, 0.231, 278, 255, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
1145, d3srvB_, 0.8138, 2.02, 0.401, 263, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
1146, d2qo7A_, 0.8138, 2.62, 0.390, 278, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
1147, d3u4wA_, 0.8137, 3.24, 0.449, 275, 265, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
1148, d3lxpA_, 0.8137, 2.51, 0.339, 285, 254, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1149, d4f08B_, 0.8136, 2.51, 0.376, 288, 255, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1150, d3lvpA_, 0.8136, 2.70, 0.438, 289, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1151, d5fbnD_, 0.8135, 2.54, 0.449, 255, 254, BTK KINASE DOMAIN WITH INHIBITOR 1
1152, d4fz7A1, 0.8135, 2.01, 0.405, 261, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
1153, d5tozA_, 0.8134, 2.16, 0.365, 278, 249, JAK3 WITH COVALENT INHIBITOR PF-06651600
1154, d3zfxB_, 0.8133, 2.10, 0.411, 254, 246, CRYSTAL STRUCTURE OF EPHB1
1155, d3pizA_, 0.8133, 1.84, 0.461, 245, 245, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
1156, d4puzA_, 0.8132, 2.13, 0.403, 263, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
1157, d3lxlA_, 0.8131, 2.24, 0.364, 281, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1158, d3lpbA_, 0.8129, 2.22, 0.378, 278, 251, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
1159, d4gihA1, 0.8128, 2.25, 0.335, 287, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
1160, d4p4cA_, 0.8127, 2.34, 0.386, 266, 251, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
1161, d3sxrA1, 0.8127, 2.06, 0.431, 257, 246, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
1162, d3zfxF_, 0.8126, 2.03, 0.412, 254, 245, CRYSTAL STRUCTURE OF EPHB1
1163, d1r1wA_, 0.8126, 2.33, 0.377, 287, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
1164, d5e1sA_, 0.8125, 2.14, 0.420, 284, 250, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
1165, d4hgeA_, 0.8125, 2.39, 0.379, 284, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
1166, d4h58C_, 0.8125, 2.59, 0.298, 272, 258, BRAF IN COMPLEX WITH COMPOUND 3
1167, d2zm3B2, 0.8125, 2.75, 0.440, 295, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1168, d5to8A_, 0.8124, 1.80, 0.406, 250, 244, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
1169, d2rfnB_, 0.8124, 2.25, 0.372, 269, 250, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
1170, d3srvA_, 0.8123, 2.01, 0.405, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
1171, d2yn8A_, 0.8122, 2.19, 0.397, 253, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1172, d2zm3D2, 0.8121, 2.59, 0.443, 292, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1173, d3uqgB_, 0.8120, 2.37, 0.472, 257, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1174, d3fzsA_, 0.8120, 1.84, 0.352, 254, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
1175, d5imxA_, 0.8119, 2.21, 0.415, 266, 248, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
1176, d1sm2A_, 0.8118, 1.99, 0.416, 245, 245, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1177, d4hvdA_, 0.8117, 2.11, 0.367, 276, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
1178, d2qodA_, 0.8116, 2.57, 0.383, 274, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
1179, d1uwhB_, 0.8116, 2.22, 0.317, 264, 252, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
1180, d4gj2A1, 0.8115, 2.26, 0.339, 287, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
1181, d4e6dB_, 0.8115, 2.53, 0.380, 286, 255, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
1182, d4gj3A1, 0.8114, 2.26, 0.335, 287, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
1183, d3tjcA_, 0.8114, 2.30, 0.377, 284, 252, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
1184, d3nz0A1, 0.8113, 2.45, 0.340, 283, 253, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
1185, d2rfnA_, 0.8113, 2.26, 0.372, 268, 250, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
1186, d2qoiA_, 0.8113, 2.57, 0.383, 274, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
1187, d4c8bB_, 0.8112, 2.40, 0.233, 281, 253, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
1188, d3fupA_, 0.8112, 2.42, 0.379, 284, 253, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1189, d1snuA_, 0.8112, 1.98, 0.416, 245, 245, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1190, d2qofA_, 0.8111, 2.55, 0.383, 280, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
1191, d2henB1, 0.8111, 2.27, 0.392, 258, 250, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
1192, d4p7eA_, 0.8110, 2.39, 0.379, 281, 253, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
1193, d2qooA_, 0.8108, 2.57, 0.387, 273, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
1194, d4giiA1, 0.8107, 2.28, 0.339, 287, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
1195, d3fqhB_, 0.8107, 1.87, 0.410, 258, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
1196, d3w2rA_, 0.8106, 2.63, 0.376, 297, 255, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
1197, d3ekkA_, 0.8106, 2.11, 0.408, 285, 250, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
1198, d2henD1, 0.8106, 2.28, 0.392, 258, 250, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
1199, d3zepC_, 0.8105, 2.08, 0.368, 276, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
1200, d3vs3A3, 0.8105, 2.63, 0.458, 269, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
1201, d3qgyA1, 0.8105, 1.96, 0.426, 244, 244, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1202, d2zv9A1, 0.8105, 2.29, 0.488, 255, 250, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
1203, d3u51A_, 0.8103, 2.48, 0.470, 256, 251, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1204, d4g5jA_, 0.8102, 2.52, 0.392, 307, 250, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
1205, d3zfxG_, 0.8101, 2.10, 0.412, 253, 245, CRYSTAL STRUCTURE OF EPHB1
1206, d3eygA_, 0.8101, 2.47, 0.371, 280, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1207, d4rioA_, 0.8100, 2.29, 0.364, 285, 250, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
1208, d3dkcA1, 0.8100, 3.17, 0.363, 310, 267, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
1209, d5jrsA1, 0.8098, 2.69, 0.461, 257, 254, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1210, d5u6bA_, 0.8097, 2.57, 0.440, 270, 257, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1211, d4hzrA_, 0.8097, 1.90, 0.406, 261, 244, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
1212, d5ar4B_, 0.8096, 2.74, 0.242, 279, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
1213, d2zm3C2, 0.8096, 2.69, 0.440, 295, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1214, d2vwwA_, 0.8095, 2.26, 0.383, 253, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1215, d2hz4B1, 0.8095, 1.48, 0.996, 248, 237, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
1216, d3vs4A3, 0.8093, 2.70, 0.461, 270, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1217, d1qcfA3, 0.8093, 3.07, 0.450, 281, 262, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
1218, d5p9lA_, 0.8091, 2.43, 0.454, 252, 251, BTK1 IN COMPLEX WITH CC 292
1219, d3nyxA1, 0.8091, 2.40, 0.340, 285, 253, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
1220, d5ng0B_, 0.8090, 2.59, 0.250, 282, 256, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1221, d3tucA_, 0.8090, 2.09, 0.401, 257, 247, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1222, d2vwuA_, 0.8090, 2.25, 0.383, 253, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1223, d2r4bA_, 0.8089, 3.14, 0.378, 292, 262, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
1224, d5ttvA_, 0.8087, 2.30, 0.364, 280, 250, JAK3 WITH COVALENT INHIBITOR 6
1225, d5ar5A_, 0.8086, 2.75, 0.241, 284, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1226, d5ar2B_, 0.8086, 2.77, 0.245, 285, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1227, d3vs2A3, 0.8086, 2.61, 0.460, 268, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1228, d5j7bB_, 0.8085, 2.68, 0.239, 281, 255, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1229, d3vs1A3, 0.8085, 2.58, 0.458, 268, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
1230, d3qgwA_, 0.8085, 1.87, 0.424, 244, 243, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1231, d3plsA_, 0.8085, 2.98, 0.357, 298, 263, RON IN COMPLEX WITH LIGAND AMP-PNP
1232, d1i44A_, 0.8085, 2.41, 0.421, 282, 252, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
1233, d4hviA_, 0.8084, 2.13, 0.368, 274, 247, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
1234, d5tq7A_, 0.8083, 2.46, 0.375, 275, 253, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1235, d3pj3A_, 0.8083, 1.52, 0.458, 240, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
1236, d2zv7A1, 0.8083, 2.32, 0.484, 256, 250, LYN TYROSINE KINASE DOMAIN APO FORM
1237, d3tjdA_, 0.8081, 2.42, 0.379, 284, 253, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
1238, d3sxrB1, 0.8081, 2.03, 0.430, 255, 244, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
1239, d1snxB_, 0.8081, 2.00, 0.416, 245, 245, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1240, d1snxA_, 0.8080, 2.00, 0.416, 245, 245, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1241, d2qi8B_, 0.8079, 2.32, 0.453, 249, 245, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
1242, d5u6bC_, 0.8078, 2.59, 0.440, 270, 257, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
1243, d2henA1, 0.8078, 2.41, 0.390, 258, 251, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
1244, d2r4bB_, 0.8077, 3.09, 0.375, 291, 261, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
1245, d3vs0B3, 0.8076, 2.55, 0.462, 268, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
1246, d1u4dB_, 0.8075, 2.12, 0.408, 262, 245, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
1247, d3vrzB3, 0.8073, 2.70, 0.470, 269, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
1248, d3u51B_, 0.8073, 2.48, 0.472, 255, 250, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1249, d1p14A_, 0.8073, 2.14, 0.418, 287, 249, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
1250, d3vs6A3, 0.8072, 2.67, 0.458, 269, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
1251, d5tq6A_, 0.8071, 2.47, 0.381, 274, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1252, d2henC1, 0.8070, 2.42, 0.390, 258, 251, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
1253, d4xg9A_, 0.8068, 1.97, 0.414, 259, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1254, d3vs7A3, 0.8068, 2.52, 0.460, 267, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1255, d3vs4B3, 0.8068, 2.76, 0.457, 269, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1256, d5ar7A_, 0.8067, 2.74, 0.246, 278, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
1257, d4p2wB_, 0.8067, 1.95, 0.414, 253, 244,  
1258, d4f4pA1, 0.8067, 1.98, 0.412, 260, 245, SYK IN COMPLEX WITH LIGAND LASW836
1259, d3vryA3, 0.8067, 2.66, 0.458, 269, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
1260, d3lxkA_, 0.8066, 2.40, 0.368, 279, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1261, d5ng2B_, 0.8065, 2.38, 0.238, 278, 252, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1262, d5d11B_, 0.8065, 2.48, 0.464, 255, 248, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
1263, d3vs7B3, 0.8065, 2.68, 0.468, 266, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1264, d2c0tB3, 0.8065, 2.76, 0.458, 268, 253, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
1265, d5e1eA_, 0.8063, 2.27, 0.373, 279, 249, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
1266, d2hckA3, 0.8063, 2.78, 0.457, 271, 256, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
1267, d3lvpC_, 0.8062, 2.82, 0.438, 293, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1268, d5j7bA_, 0.8061, 2.70, 0.239, 277, 255, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1269, d5hx8A_, 0.8061, 2.54, 0.370, 291, 254, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
1270, d4d4rA_, 0.8061, 2.10, 0.387, 251, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1271, d5wo4A_, 0.8060, 2.56, 0.366, 292, 254, JAK1 COMPLEXED WITH COMPOUND 28
1272, d3lvpB_, 0.8060, 2.63, 0.441, 295, 256, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1273, d2b4sD_, 0.8060, 2.75, 0.418, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
1274, d3vs6B3, 0.8059, 2.66, 0.458, 269, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
1275, d2xa4A_, 0.8059, 2.20, 0.385, 276, 247, INHIBITORS OF JAK2 KINASE DOMAIN
1276, d1k9aD3, 0.8058, 2.74, 0.433, 268, 254, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1277, d3zzwB_, 0.8057, 2.68, 0.333, 265, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
1278, d3l8pA_, 0.8057, 2.39, 0.407, 292, 248, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
1279, d3ii5A_, 0.8057, 2.24, 0.316, 262, 250, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
1280, d2c0tA3, 0.8057, 2.70, 0.468, 268, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
1281, d1ad5A3, 0.8057, 2.81, 0.453, 271, 256, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
1282, d4yjpA_, 0.8056, 2.24, 0.411, 263, 248, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
1283, d2c0iA3, 0.8056, 2.68, 0.468, 268, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
1284, d3vs2B3, 0.8055, 2.57, 0.442, 268, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1285, d4kioC1, 0.8054, 2.41, 0.411, 249, 248, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1286, d4qpsC_, 0.8053, 2.27, 0.376, 276, 250, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
1287, d5ttsA_, 0.8052, 2.19, 0.368, 274, 247, JAK3 WITH COVALENT INHIBITOR 4
1288, d3qlfA_, 0.8052, 2.20, 0.475, 249, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
1289, d3f5pM1, 0.8052, 2.73, 0.440, 294, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1290, d3octA_, 0.8051, 1.66, 0.465, 244, 241, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
1291, d2qi8A_, 0.8050, 2.36, 0.457, 255, 247, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
1292, d1uwjA_, 0.8050, 2.22, 0.316, 264, 250, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
1293, d1u54B_, 0.8050, 2.00, 0.406, 261, 244, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
1294, d1kswA3, 0.8050, 3.21, 0.455, 284, 264, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
1295, d5tq4A_, 0.8049, 2.53, 0.375, 290, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1296, d3f5pT1, 0.8048, 2.62, 0.443, 294, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1297, d3f5pS1, 0.8046, 2.70, 0.441, 294, 256, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1298, d5lmbB_, 0.8045, 2.01, 0.414, 261, 244, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
1299, d3zepD_, 0.8045, 2.33, 0.371, 272, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
1300, d3vs1B3, 0.8045, 2.64, 0.458, 268, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
1301, d1k9aC3, 0.8045, 2.58, 0.448, 266, 252, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1302, d4xg8A_, 0.8044, 2.03, 0.404, 258, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1303, d3vs0A3, 0.8044, 2.66, 0.468, 268, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
1304, d3vrzA3, 0.8042, 2.65, 0.458, 268, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
1305, d3f5pI1, 0.8042, 2.70, 0.441, 293, 256, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1306, d2c0oA3, 0.8042, 2.71, 0.468, 268, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
1307, d3f5pD1, 0.8041, 2.82, 0.440, 296, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1308, d2c0iB3, 0.8041, 2.71, 0.468, 268, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
1309, d2b4sB_, 0.8041, 2.78, 0.418, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
1310, d3k54A_, 0.8040, 1.81, 0.449, 243, 243, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
1311, d3f5pB1, 0.8040, 2.83, 0.440, 297, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1312, d3zepA_, 0.8039, 2.39, 0.371, 274, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
1313, d3vryB3, 0.8039, 2.66, 0.458, 269, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
1314, d1bygA_, 0.8039, 2.09, 0.465, 246, 245, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
1315, d1ad5B3, 0.8039, 2.95, 0.479, 271, 257, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
1316, d3vs5A3, 0.8038, 2.66, 0.468, 268, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1317, d1uwjB_, 0.8038, 2.23, 0.316, 263, 250, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
1318, d4wrgA1, 0.8037, 2.34, 0.386, 287, 246, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
1319, d3f5pH1, 0.8037, 2.83, 0.440, 298, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1320, d3f5pG1, 0.8037, 2.82, 0.440, 298, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1321, d3f5pC1, 0.8037, 2.82, 0.440, 300, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1322, d4yjuA_, 0.8036, 2.13, 0.407, 262, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
1323, d3zepB_, 0.8036, 2.18, 0.371, 268, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
1324, d3f5pA1, 0.8036, 2.83, 0.440, 298, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1325, d3f5pK1, 0.8034, 2.68, 0.443, 292, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1326, d5ttuA_, 0.8033, 2.02, 0.373, 271, 244, JAK3 WITH COVALENT INHIBITOR 7
1327, d3zmmA_, 0.8033, 2.07, 0.389, 273, 244, INHIBITORS OF JAK2 KINASE DOMAIN
1328, d4p2kA_, 0.8032, 2.23, 0.386, 259, 249, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1329, d4h58B_, 0.8032, 2.10, 0.316, 262, 247, BRAF IN COMPLEX WITH COMPOUND 3
1330, d4k77A_, 0.8031, 2.57, 0.375, 282, 253, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
1331, d4d4rB_, 0.8030, 2.98, 0.383, 270, 261, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1332, d2rfeD_, 0.8030, 2.93, 0.381, 278, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1333, d3f5pL1, 0.8029, 2.68, 0.443, 292, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1334, d4ludB3, 0.8028, 2.53, 0.468, 264, 250, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1335, d2c0oB3, 0.8026, 2.72, 0.468, 268, 252, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
1336, d3zfxC_, 0.8025, 2.03, 0.413, 248, 242, CRYSTAL STRUCTURE OF EPHB1
1337, d3vs5B3, 0.8025, 2.68, 0.440, 268, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
1338, d3pj1A_, 0.8025, 1.79, 0.465, 241, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1339, d4rfmA1, 0.8024, 2.27, 0.417, 248, 247, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
1340, d3f5pE1, 0.8024, 2.83, 0.440, 298, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1341, d3f5pF1, 0.8023, 2.84, 0.440, 298, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1342, d4c62A_, 0.8021, 2.11, 0.389, 273, 244, INHIBITORS OF JAK2 KINASE DOMAIN
1343, d4e5wA1, 0.8020, 2.76, 0.350, 291, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
1344, d5e1eB_, 0.8019, 2.41, 0.372, 280, 250, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
1345, d4yjtA_, 0.8019, 2.17, 0.405, 268, 247, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
1346, d4pp9B1, 0.8019, 2.23, 0.416, 246, 245, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1347, d4e1zA_, 0.8019, 2.66, 0.349, 288, 255, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
1348, d3f5pR1, 0.8019, 2.73, 0.441, 293, 256, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1349, d2qolA_, 0.8019, 2.63, 0.363, 271, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
1350, d5w86C_, 0.8018, 2.25, 0.376, 273, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1351, d4i5cA_, 0.8018, 2.50, 0.375, 279, 251, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1352, d1k2pA_, 0.8018, 2.33, 0.466, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1353, d5ng0A_, 0.8017, 2.30, 0.240, 274, 250, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1354, d1u54A_, 0.8017, 2.11, 0.400, 262, 245, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
1355, d5ar5B_, 0.8016, 2.66, 0.245, 279, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1356, d4ivdB_, 0.8016, 2.49, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
1357, d3of0B_, 0.8016, 2.39, 0.472, 251, 246, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
1358, d2hckB3, 0.8016, 2.85, 0.457, 271, 256, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
1359, d4e4nB_, 0.8015, 2.46, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
1360, d4e4nA1, 0.8015, 2.60, 0.372, 290, 253, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
1361, d5d10A_, 0.8014, 2.20, 0.461, 248, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
1362, d3f5pJ1, 0.8014, 2.70, 0.443, 292, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1363, d4pp9A1, 0.8013, 2.23, 0.416, 245, 245, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1364, d4l7sA1, 0.8013, 2.42, 0.413, 248, 247, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1365, d3p08B_, 0.8013, 2.55, 0.438, 258, 251, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
1366, d2jitB_, 0.8013, 2.88, 0.341, 312, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
1367, d2srcA3, 0.8012, 3.18, 0.460, 284, 263, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
1368, d5f1zA1, 0.8011, 2.36, 0.341, 280, 249, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
1369, d4l7sB1, 0.8010, 2.43, 0.413, 248, 247, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1370, d4fk6A_, 0.8010, 2.73, 0.354, 285, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
1371, d5gnkA_, 0.8009, 3.12, 0.378, 277, 259, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
1372, d5hx8B_, 0.8008, 2.41, 0.372, 279, 250, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
1373, d4fk6B_, 0.8008, 2.68, 0.354, 284, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
1374, d3uqfB_, 0.8008, 2.52, 0.464, 253, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1375, d5w86D_, 0.8007, 2.21, 0.380, 272, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1376, d4c8bA_, 0.8007, 2.39, 0.236, 279, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
1377, d4c61B_, 0.8007, 1.99, 0.387, 274, 243, INHIBITORS OF JAK2 KINASE DOMAIN
1378, d5ar2A_, 0.8006, 2.50, 0.240, 277, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1379, d4pqnA_, 0.8006, 1.95, 0.421, 240, 240, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
1380, d4mf1B1, 0.8006, 1.87, 0.415, 244, 241, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1381, d5vamA_, 0.8005, 2.48, 0.307, 269, 251, BRAF IN COMPLEX WITH RAF709
1382, d4ehzA_, 0.8005, 2.79, 0.353, 290, 255, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1383, d1k2pB_, 0.8005, 2.30, 0.462, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1384, d5ng2A_, 0.8002, 2.32, 0.233, 274, 249, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1385, d5gtyH_, 0.8002, 3.12, 0.383, 300, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1386, d4ybkA_, 0.8000, 3.06, 0.463, 266, 259, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1387, d4p2wA_, 0.8000, 1.85, 0.419, 250, 241,  
1388, d4zseA_, 0.7999, 3.16, 0.380, 297, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1389, d4zseC_, 0.7998, 3.10, 0.378, 301, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1390, d4ficA_, 0.7998, 2.36, 0.457, 251, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
1391, d5tq7B_, 0.7997, 2.39, 0.382, 269, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1392, d4zseB_, 0.7996, 3.23, 0.385, 313, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1393, d4k77B_, 0.7996, 2.52, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
1394, d4c61A_, 0.7995, 2.06, 0.391, 272, 243, INHIBITORS OF JAK2 KINASE DOMAIN
1395, d3ppzA_, 0.7994, 2.29, 0.363, 264, 248, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1396, d2xa4B_, 0.7994, 2.24, 0.386, 275, 246, INHIBITORS OF JAK2 KINASE DOMAIN
1397, d5wo4B_, 0.7993, 2.44, 0.372, 280, 250, JAK1 COMPLEXED WITH COMPOUND 28
1398, d4ivbA1, 0.7993, 2.59, 0.373, 290, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
1399, d1xkkA_, 0.7993, 3.27, 0.373, 289, 263, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
1400, d4ivcA1, 0.7992, 2.69, 0.375, 290, 253, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
1401, d4i24B_, 0.7992, 3.39, 0.374, 304, 265, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
1402, d4ivdA1, 0.7991, 2.63, 0.373, 289, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
1403, d4i5cB1, 0.7991, 2.57, 0.373, 290, 252, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1404, d4e5wB_, 0.7991, 2.46, 0.372, 278, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
1405, d2h8hA3, 0.7991, 3.03, 0.464, 280, 261, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
1406, d3zmmB_, 0.7990, 2.01, 0.387, 274, 243, INHIBITORS OF JAK2 KINASE DOMAIN
1407, d3qgyB1, 0.7990, 2.10, 0.412, 244, 243, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1408, d1u4dA_, 0.7990, 2.18, 0.402, 258, 244, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
1409, d4k11A3, 0.7989, 3.07, 0.460, 282, 261, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
1410, d3d4qA_, 0.7989, 2.22, 0.310, 264, 248, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1411, d2rgpA_, 0.7988, 3.24, 0.370, 284, 262, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
1412, d4ivbB_, 0.7987, 2.56, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
1413, d3pozA_, 0.7985, 3.09, 0.381, 293, 260, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
1414, d4qpsA_, 0.7984, 1.82, 0.375, 270, 240, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
1415, d3w33A_, 0.7984, 3.06, 0.386, 297, 259, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
1416, d4hzrB_, 0.7983, 1.89, 0.402, 258, 241, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
1417, d4ivcB_, 0.7982, 2.57, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
1418, d5bpyB1, 0.7981, 2.29, 0.453, 246, 245, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1419, d4fc0B_, 0.7979, 2.48, 0.316, 263, 250, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
1420, d3p08A_, 0.7978, 2.61, 0.466, 252, 249, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
1421, d4lghB_, 0.7976, 2.36, 0.461, 247, 243, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
1422, d4hjoA_, 0.7976, 3.37, 0.379, 278, 264, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
1423, d2wqbA_, 0.7975, 2.40, 0.397, 289, 247, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
1424, d5tq6B_, 0.7974, 2.48, 0.386, 271, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
1425, d4dbnB_, 0.7974, 2.36, 0.305, 263, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
1426, d2jiuB_, 0.7974, 3.07, 0.335, 309, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
1427, d5khwA_, 0.7973, 2.19, 0.378, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
1428, d3belA_, 0.7973, 3.13, 0.373, 280, 260, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
1429, d4c62B_, 0.7972, 1.90, 0.390, 271, 241, INHIBITORS OF JAK2 KINASE DOMAIN
1430, d2qq7A_, 0.7972, 2.32, 0.469, 251, 243, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
1431, d5vamB_, 0.7971, 2.06, 0.318, 260, 245, BRAF IN COMPLEX WITH RAF709
1432, d3miyB1, 0.7970, 1.72, 0.412, 238, 238, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
1433, d4ei4B_, 0.7969, 2.56, 0.375, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
1434, d5ar4A_, 0.7963, 2.76, 0.242, 274, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
1435, d5e8xA_, 0.7962, 2.52, 0.266, 304, 248, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
1436, d4fc0A_, 0.7961, 2.09, 0.318, 254, 245, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
1437, d1sm2B_, 0.7961, 1.97, 0.423, 241, 241, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1438, d5d7vB1, 0.7960, 2.58, 0.406, 262, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1439, d4v0gB_, 0.7960, 2.44, 0.380, 272, 245, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
1440, d3ppzB_, 0.7960, 2.22, 0.364, 264, 247, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1441, d3d4qB_, 0.7960, 2.28, 0.306, 264, 248, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1442, d5h2uB1, 0.7959, 2.66, 0.409, 261, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1443, d5gtyG_, 0.7957, 3.12, 0.381, 299, 260, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1444, d3ppkB_, 0.7956, 2.28, 0.310, 264, 248, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1445, d5cnnB_, 0.7954, 3.27, 0.375, 304, 264, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
1446, d3h10A_, 0.7953, 2.92, 0.234, 268, 261, AURORA A INHIBITOR COMPLEX
1447, d3c4dB1, 0.7953, 2.04, 0.328, 256, 244,  
1448, d1iasB_, 0.7953, 2.56, 0.247, 324, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1449, d4k6zA_, 0.7952, 2.54, 0.376, 279, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
1450, d3emgA_, 0.7952, 2.02, 0.419, 255, 241, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
1451, d5ct7A_, 0.7951, 2.08, 0.314, 257, 245, BRAF IN COMPLEX WITH RAF265
1452, d4dbnA_, 0.7950, 2.12, 0.318, 257, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
1453, d4e4lD_, 0.7948, 2.60, 0.367, 281, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1454, d4e26A_, 0.7948, 2.44, 0.304, 270, 250, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1455, d3ii5B_, 0.7948, 2.11, 0.322, 257, 245, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
1456, d1u46B_, 0.7948, 1.96, 0.408, 257, 240, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
1457, d3v5lD1, 0.7947, 2.19, 0.407, 244, 243, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1458, d4kspA_, 0.7946, 2.13, 0.314, 257, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
1459, d1snuB_, 0.7946, 2.00, 0.423, 241, 241, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1460, d5f20A_, 0.7945, 2.12, 0.348, 274, 244, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
1461, d3kcfB_, 0.7945, 2.46, 0.244, 324, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1462, d5gtyA_, 0.7943, 3.31, 0.373, 300, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1463, d3c4cB1, 0.7943, 1.94, 0.325, 256, 243, B-RAF KINASE IN COMPLEX WITH PLX4720
1464, d1u46A_, 0.7941, 1.92, 0.404, 255, 240, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
1465, d4v0gA_, 0.7940, 2.21, 0.383, 267, 243, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
1466, d3q96B_, 0.7940, 2.45, 0.317, 262, 249, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
1467, d4ehzB_, 0.7939, 2.56, 0.360, 280, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1468, d4e26B_, 0.7939, 2.20, 0.317, 264, 246, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1469, d5gtyD_, 0.7938, 3.25, 0.379, 297, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1470, d3prfA_, 0.7938, 2.11, 0.314, 262, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1471, d4g5pB_, 0.7937, 2.81, 0.337, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
1472, d2qq7B_, 0.7936, 2.27, 0.467, 244, 240, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
1473, d2hwoA_, 0.7935, 2.46, 0.457, 251, 245, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
1474, d5j79A_, 0.7933, 2.83, 0.245, 283, 253, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1475, d5d41B_, 0.7932, 3.32, 0.371, 302, 264, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
1476, d3ppkA_, 0.7932, 2.22, 0.317, 262, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1477, d2j4zA_, 0.7932, 2.91, 0.239, 263, 259, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
1478, d5vo6A_, 0.7931, 2.06, 0.376, 271, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
1479, d5gtyE_, 0.7931, 3.25, 0.379, 297, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1480, d4zseD_, 0.7931, 3.26, 0.370, 297, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1481, d5h2uD1, 0.7930, 2.60, 0.407, 261, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1482, d4ei4A1, 0.7930, 2.68, 0.359, 288, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
1483, d2auhA1, 0.7930, 2.73, 0.412, 294, 255, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
1484, d5csxA_, 0.7929, 2.32, 0.323, 261, 248, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
1485, d3lzbB_, 0.7929, 3.02, 0.387, 265, 256, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1486, d4xg8C_, 0.7928, 2.02, 0.412, 254, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1487, d4e4lE_, 0.7924, 2.61, 0.360, 280, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1488, d3lzbA_, 0.7924, 2.94, 0.392, 265, 255, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1489, d4yjqA_, 0.7923, 2.15, 0.410, 264, 244, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
1490, d5w86A_, 0.7922, 2.12, 0.382, 269, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1491, d5gtyF_, 0.7922, 3.15, 0.377, 297, 260, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1492, d5d7vC1, 0.7922, 2.73, 0.408, 262, 255, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1493, d4ehzD_, 0.7922, 2.60, 0.360, 280, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1494, d5j79B_, 0.7921, 2.74, 0.243, 277, 251, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1495, d1jqhA_, 0.7920, 2.80, 0.443, 291, 255, IGF-1 RECEPTOR KINASE DOMAIN
1496, d3qgwB_, 0.7919, 1.87, 0.414, 240, 239, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1497, d2qlqB_, 0.7919, 2.41, 0.467, 248, 242, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
1498, d4mf1A1, 0.7917, 1.96, 0.412, 241, 240, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1499, d3kcfE_, 0.7917, 2.55, 0.240, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1500, d3v5lC1, 0.7916, 2.21, 0.415, 242, 241, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1501, d3kexA_, 0.7915, 3.32, 0.326, 292, 261, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
1502, d2j4zB_, 0.7915, 2.93, 0.239, 269, 259, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
1503, d5khxA_, 0.7914, 2.35, 0.354, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
1504, d5e8wA1, 0.7914, 2.41, 0.252, 302, 246, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
1505, d5d7vD1, 0.7914, 2.74, 0.404, 262, 255, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1506, d5xgnB_, 0.7912, 3.13, 0.340, 308, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
1507, d5w86B_, 0.7911, 2.04, 0.381, 267, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1508, d3zfmA_, 0.7911, 2.28, 0.391, 248, 243, CRYSTAL STRUCTURE OF EPHB2
1509, d2wotA_, 0.7911, 2.54, 0.243, 303, 247, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
1510, d5h2uC1, 0.7910, 2.72, 0.409, 261, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1511, d4lueA3, 0.7910, 2.55, 0.463, 261, 246, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
1512, d4kioD1, 0.7910, 2.05, 0.425, 240, 240, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1513, d3lzbD_, 0.7910, 2.94, 0.386, 261, 254, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1514, d5e8uA1, 0.7909, 2.58, 0.266, 303, 248, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
1515, d3v8wB1, 0.7909, 1.98, 0.412, 240, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1516, d5khwB_, 0.7908, 2.40, 0.377, 276, 247, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
1517, d1jqhC_, 0.7908, 2.72, 0.445, 291, 254, IGF-1 RECEPTOR KINASE DOMAIN
1518, d3kexB_, 0.7907, 3.21, 0.328, 283, 259, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
1519, d5da3A1, 0.7906, 2.66, 0.402, 261, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
1520, d5cnnA_, 0.7906, 3.22, 0.387, 300, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
1521, d5gtyC_, 0.7905, 3.20, 0.382, 295, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1522, d4ficB_, 0.7905, 2.23, 0.471, 245, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
1523, d3v8tB1, 0.7904, 2.16, 0.411, 242, 241, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
1524, d2ptkA3, 0.7904, 2.49, 0.478, 259, 247, CHICKEN SRC TYROSINE KINASE
1525, d2gs7A_, 0.7904, 3.38, 0.380, 281, 263, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1526, d4yjvA_, 0.7901, 2.14, 0.407, 263, 243, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
1527, d4ludA3, 0.7901, 2.51, 0.473, 261, 245, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1528, d4h58A_, 0.7901, 2.24, 0.313, 263, 246, BRAF IN COMPLEX WITH COMPOUND 3
1529, d5gtyB_, 0.7900, 3.23, 0.372, 299, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1530, d3kcfC_, 0.7900, 2.58, 0.244, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1531, d3h10B_, 0.7899, 2.92, 0.235, 267, 260, AURORA A INHIBITOR COMPLEX
1532, d3en7A_, 0.7899, 2.38, 0.471, 247, 242, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
1533, d5h2uA1, 0.7898, 2.75, 0.409, 261, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1534, d1iasE_, 0.7898, 2.71, 0.243, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1535, d1iasC_, 0.7898, 2.69, 0.243, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1536, d5wfjA_, 0.7897, 2.02, 0.379, 265, 240, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
1537, d2wtvB_, 0.7896, 2.75, 0.238, 261, 256, AURORA-A INHIBITOR STRUCTURE
1538, d2gs7B_, 0.7896, 3.38, 0.384, 288, 263, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1539, d3ikaB_, 0.7895, 3.15, 0.340, 310, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
1540, d2wtvC_, 0.7895, 2.75, 0.238, 261, 256, AURORA-A INHIBITOR STRUCTURE
1541, d5w5oE_, 0.7894, 2.56, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1542, d5d7vA1, 0.7892, 2.78, 0.408, 262, 255, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1543, d3miyA1, 0.7892, 1.71, 0.409, 237, 237, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
1544, d3bbtB_, 0.7891, 2.98, 0.398, 274, 254, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
1545, d3prfB_, 0.7890, 2.07, 0.317, 262, 243, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1546, d1iasD_, 0.7890, 2.69, 0.243, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1547, d3q96A_, 0.7888, 2.14, 0.316, 253, 244, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
1548, d2wotA1, 0.7888, 2.40, 0.245, 301, 245, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
1549, d4x2nA1, 0.7887, 2.45, 0.248, 302, 246, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1550, d3kcfA_, 0.7887, 2.62, 0.244, 328, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1551, d5w5oA_, 0.7886, 2.57, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1552, d5cnoA_, 0.7885, 3.33, 0.374, 300, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
1553, d4x2gA1, 0.7885, 2.49, 0.248, 302, 246, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1554, d3v8wA1, 0.7885, 2.15, 0.411, 241, 241, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1555, d5d41A_, 0.7883, 3.17, 0.377, 300, 260, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
1556, d4yjrA_, 0.7883, 2.17, 0.407, 263, 243, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
1557, d4x2fA1, 0.7883, 2.56, 0.251, 302, 247, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1558, d4i24A_, 0.7882, 3.06, 0.381, 295, 257, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
1559, d1b6cD_, 0.7882, 2.57, 0.244, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1560, d4x2kA1, 0.7881, 2.57, 0.251, 302, 247, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1561, d4x2jA1, 0.7881, 2.57, 0.251, 302, 247, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1562, d1b6cF_, 0.7881, 2.57, 0.244, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1563, d5c9cA_, 0.7880, 2.16, 0.311, 254, 244, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
1564, d4ehzC_, 0.7880, 2.52, 0.363, 278, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
1565, d4e4lB_, 0.7880, 2.60, 0.361, 279, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1566, d4yjsA_, 0.7879, 1.99, 0.408, 257, 240, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
1567, d2qlqA_, 0.7878, 2.32, 0.462, 245, 240, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
1568, d2hwpA_, 0.7878, 2.29, 0.450, 245, 240, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
1569, d5d10B_, 0.7876, 2.34, 0.465, 247, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
1570, d4x0mA1, 0.7876, 2.49, 0.248, 302, 246, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1571, d3idpA_, 0.7876, 2.22, 0.322, 255, 245, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
1572, d3w32A_, 0.7875, 3.56, 0.353, 317, 266, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
1573, d3v5jB1, 0.7875, 2.01, 0.410, 239, 239, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
1574, d4lghA_, 0.7874, 2.29, 0.452, 243, 239, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
1575, d4i22A_, 0.7874, 3.17, 0.378, 297, 259, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
1576, d3bbtD_, 0.7873, 2.86, 0.394, 259, 251, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
1577, d5w5oM_, 0.7872, 2.63, 0.233, 276, 249, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1578, d3og7B_, 0.7871, 1.99, 0.336, 254, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
1579, d1iasA_, 0.7870, 2.74, 0.243, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1580, d4kspB_, 0.7869, 2.22, 0.316, 256, 244, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
1581, d3lzbC_, 0.7869, 2.87, 0.389, 259, 252, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1582, d1rw8A_, 0.7869, 2.35, 0.249, 301, 245, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
1583, d3lvpD_, 0.7868, 2.50, 0.449, 282, 247, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1584, d5w5oJ_, 0.7866, 2.58, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1585, d5w5oH_, 0.7866, 2.58, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1586, d4u42A_, 0.7866, 3.10, 0.230, 282, 257, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
1587, d3kcfD_, 0.7866, 2.68, 0.243, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1588, d5ar8B_, 0.7865, 2.69, 0.239, 274, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
1589, d2hwoB_, 0.7865, 2.20, 0.462, 242, 238, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
1590, d5valB_, 0.7864, 2.16, 0.316, 254, 244, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
1591, d5w5oD_, 0.7862, 2.60, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1592, d5cnoB_, 0.7861, 3.23, 0.385, 302, 260, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
1593, d4obpA_, 0.7861, 3.24, 0.228, 285, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1594, d4f1tA1, 0.7861, 2.59, 0.287, 267, 247, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
1595, d5w5oG_, 0.7860, 2.60, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1596, d4bchA_, 0.7860, 2.90, 0.184, 308, 255, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1597, d5w5oK_, 0.7858, 2.60, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1598, d5w5oI_, 0.7858, 2.60, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1599, d3gt8B_, 0.7858, 3.17, 0.385, 292, 260, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1600, d5w5oO_, 0.7857, 2.65, 0.237, 276, 249, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1601, d1jqhB_, 0.7855, 2.81, 0.447, 287, 253, IGF-1 RECEPTOR KINASE DOMAIN
1602, d3lokA_, 0.7853, 2.45, 0.461, 248, 241, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
1603, d4zk5A_, 0.7852, 3.10, 0.226, 286, 257, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1604, d3lokB_, 0.7852, 2.29, 0.471, 242, 238, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
1605, d5hezB_, 0.7851, 2.85, 0.361, 289, 249, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
1606, d5w5oC_, 0.7850, 2.62, 0.230, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1607, d5w5oL_, 0.7849, 2.61, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1608, d2fb8A_, 0.7849, 2.20, 0.313, 259, 243, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1609, d5d7aA_, 0.7848, 3.38, 0.231, 289, 260, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1610, d1b6cB_, 0.7848, 2.63, 0.244, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1611, d5w5oP_, 0.7847, 2.62, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1612, d4e4lA_, 0.7847, 2.57, 0.364, 277, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1613, d3mdyA_, 0.7846, 2.97, 0.277, 320, 253, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
1614, d5w5oF_, 0.7845, 2.62, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1615, d5e90A1, 0.7844, 2.50, 0.265, 300, 245, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
1616, d5w5oB_, 0.7842, 2.62, 0.234, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1617, d3v5jA1, 0.7842, 2.10, 0.423, 239, 239, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
1618, d4bciA_, 0.7841, 2.86, 0.185, 308, 254, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1619, d1py5A_, 0.7841, 2.38, 0.249, 301, 245, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
1620, d6b8uA_, 0.7839, 2.22, 0.320, 253, 244, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
1621, d4bcfA_, 0.7839, 3.02, 0.187, 307, 256, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1622, d4mneG_, 0.7838, 2.16, 0.314, 259, 242, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1623, d5j95A_, 0.7837, 3.18, 0.233, 284, 258, MAP4K4 IN COMPLEX WITH INHIBITOR
1624, d5d7aC_, 0.7837, 3.29, 0.224, 286, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1625, d3idpB_, 0.7837, 2.26, 0.320, 256, 244, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
1626, d3gt8D_, 0.7837, 3.25, 0.386, 295, 259, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1627, d2ofvA2, 0.7837, 2.26, 0.463, 243, 242, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
1628, d5itaB_, 0.7835, 1.98, 0.332, 252, 241, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
1629, d4lggB_, 0.7835, 2.47, 0.465, 245, 241, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
1630, d4bcjA_, 0.7835, 3.01, 0.187, 309, 256, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1631, d3lmgA_, 0.7834, 3.05, 0.329, 268, 255, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1632, d5cenA_, 0.7833, 3.08, 0.314, 281, 255, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
1633, d4bcgA_, 0.7833, 3.03, 0.187, 312, 256, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1634, d3gt8A_, 0.7833, 3.22, 0.385, 300, 260, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1635, d5valA_, 0.7832, 2.16, 0.314, 254, 242, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
1636, d2fb8B_, 0.7832, 2.21, 0.317, 259, 243, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1637, d1vjyA_, 0.7832, 2.52, 0.253, 299, 245, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
1638, d3mdyC_, 0.7831, 2.93, 0.278, 320, 252, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
1639, d4knbD_, 0.7828, 2.16, 0.369, 247, 241, C-MET IN COMPLEX WITH OSI LIGAND
1640, d3lmgB_, 0.7828, 3.12, 0.336, 268, 256, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1641, d5e8zA1, 0.7826, 2.51, 0.253, 300, 245, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
1642, d5ko1A_, 0.7824, 2.59, 0.250, 265, 248, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
1643, d5e8tA1, 0.7824, 2.54, 0.253, 300, 245, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
1644, d4otwA_, 0.7824, 3.09, 0.336, 272, 256, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
1645, d4yznA_, 0.7823, 2.50, 0.276, 269, 246, HUMANIZED ROCO4 BOUND TO COMPOUND 19
1646, d4imyA_, 0.7823, 3.06, 0.196, 314, 255, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1647, d5usqA_, 0.7822, 2.40, 0.247, 299, 243, ALK-5 KINASE INHIBITOR COMPLEX
1648, d3p86A_, 0.7820, 2.21, 0.358, 250, 243, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
1649, d1b6cH_, 0.7820, 2.68, 0.244, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1650, d6eixA_, 0.7819, 2.74, 0.264, 312, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
1651, d4mwiA_, 0.7819, 2.54, 0.251, 266, 247, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
1652, d2ofvB2, 0.7818, 2.21, 0.473, 243, 239, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
1653, d5d7aB_, 0.7817, 3.46, 0.230, 286, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1654, d3my1A_, 0.7817, 3.04, 0.187, 314, 256, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
1655, d5hezD_, 0.7816, 3.06, 0.363, 289, 251, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
1656, d4mneC_, 0.7816, 2.18, 0.310, 260, 242, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1657, d5hezA_, 0.7814, 2.53, 0.371, 287, 245, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
1658, d5c9cB_, 0.7814, 2.19, 0.322, 251, 242, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
1659, d4yhtB_, 0.7814, 2.19, 0.322, 258, 242, BRAF COMPLEXED WITH AN INHIBITOR
1660, d4j8mA_, 0.7814, 2.88, 0.235, 265, 255, AURORA A IN COMPLEX WITH CD532
1661, d3gt8C_, 0.7814, 3.34, 0.387, 296, 261, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1662, d5e8sA1, 0.7813, 2.41, 0.247, 299, 243, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
1663, d4mneB_, 0.7813, 2.36, 0.306, 270, 245, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1664, d4m67A_, 0.7813, 2.55, 0.251, 264, 247, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
1665, d5ct7B_, 0.7812, 2.05, 0.307, 254, 241, BRAF IN COMPLEX WITH RAF265
1666, d3v5lB1, 0.7812, 2.12, 0.408, 239, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1667, d3tn8A_, 0.7812, 2.98, 0.188, 304, 255, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1668, d4f1mA1, 0.7810, 2.70, 0.274, 274, 248, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
1669, d6aywB_, 0.7809, 3.08, 0.208, 293, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1670, d4kioA1, 0.7809, 1.99, 0.419, 238, 236, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1671, d4zy4B_, 0.7808, 3.21, 0.219, 292, 260, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1672, d4f1oA1, 0.7808, 2.61, 0.271, 274, 247, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
1673, d4mnfA_, 0.7807, 2.15, 0.324, 257, 241, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
1674, d5ng3A_, 0.7806, 2.88, 0.224, 283, 254, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1675, d5jrsB1, 0.7805, 2.19, 0.462, 239, 238, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1676, d5friA1, 0.7804, 2.41, 0.247, 299, 243, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
1677, d4mneF_, 0.7802, 2.12, 0.311, 258, 241, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1678, d3v5lA1, 0.7801, 2.06, 0.418, 238, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1679, d4riwC_, 0.7800, 3.11, 0.337, 275, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1680, d3mi9A_, 0.7800, 3.13, 0.192, 328, 255, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
1681, d3mfsA_, 0.7800, 3.18, 0.226, 303, 257, CASK-4M CAM KINASE DOMAIN AMPPNP
1682, d3c4dA1, 0.7800, 2.26, 0.324, 257, 244,  
1683, d3miaA_, 0.7798, 3.13, 0.192, 324, 255, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
1684, d5di1A_, 0.7797, 3.19, 0.233, 285, 258, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1685, d4uy9B_, 0.7797, 3.20, 0.342, 315, 257, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
1686, d4riyC_, 0.7797, 3.08, 0.335, 275, 257, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1687, d4uy9A_, 0.7795, 3.05, 0.345, 313, 255, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
1688, d2hwpB_, 0.7795, 2.14, 0.464, 239, 235, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
1689, d4or5F_, 0.7794, 3.21, 0.195, 324, 256, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1690, d4itjB_, 0.7794, 2.72, 0.285, 276, 249, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
1691, d4u45A_, 0.7793, 3.38, 0.228, 289, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1692, d4rixC_, 0.7793, 3.13, 0.337, 275, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1693, d4f0fA1, 0.7792, 2.64, 0.275, 274, 247, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
1694, d3c0hB_, 0.7792, 3.13, 0.215, 300, 256, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1695, d5ig1A_, 0.7790, 3.13, 0.242, 300, 256, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1696, d3mfuA_, 0.7789, 3.05, 0.224, 302, 255, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
1697, d6aywA_, 0.7788, 2.99, 0.209, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1698, d3lq5A_, 0.7788, 2.93, 0.186, 307, 253, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
1699, d3c4cA1, 0.7788, 2.39, 0.322, 257, 245, B-RAF KINASE IN COMPLEX WITH PLX4720
1700, d4c2vB_, 0.7787, 2.72, 0.210, 280, 252, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1701, d4zy5B_, 0.7786, 3.21, 0.219, 287, 260, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
1702, d4u44A_, 0.7786, 3.27, 0.226, 286, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1703, d4kioB1, 0.7786, 1.87, 0.413, 237, 235, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1704, d5cwzB_, 0.7783, 3.40, 0.224, 284, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1705, d4b8mB_, 0.7783, 2.73, 0.210, 279, 252, AURORA B KINASE IN COMPLEX WITH VX-680
1706, d6b16B_, 0.7782, 3.18, 0.221, 281, 258, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
1707, d4joaA_, 0.7782, 2.31, 0.423, 250, 239, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 7-AZAINDOLE BASED INHIBITOR
1708, d5hezC_, 0.7781, 2.77, 0.368, 289, 247, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
1709, d4c2wB_, 0.7781, 2.73, 0.210, 277, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
1710, d4yhtA_, 0.7779, 2.20, 0.315, 256, 241, BRAF COMPLEXED WITH AN INHIBITOR
1711, d5vloB_, 0.7777, 3.11, 0.208, 293, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1712, d4cqeB_, 0.7777, 1.96, 0.335, 248, 239, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
1713, d4imyE_, 0.7776, 2.99, 0.194, 313, 253, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1714, d2wtvD_, 0.7776, 2.95, 0.238, 262, 256, AURORA-A INHIBITOR STRUCTURE
1715, d2wtvA_, 0.7775, 2.95, 0.238, 262, 256, AURORA-A INHIBITOR STRUCTURE
1716, d4mnfB_, 0.7774, 2.22, 0.311, 257, 241, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
1717, d2c5vA_, 0.7774, 2.74, 0.238, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1718, d4zp5A_, 0.7773, 3.38, 0.231, 284, 260, MAP4K4 IN COMPLEX WITH INHIBITOR
1719, d3c0hA_, 0.7773, 3.05, 0.216, 300, 255, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1720, d2v7oA1, 0.7772, 3.15, 0.215, 297, 256, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1721, d1okuA_, 0.7772, 2.74, 0.234, 296, 248,  
1722, d2wevC_, 0.7771, 2.84, 0.241, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1723, d4or5A_, 0.7770, 3.23, 0.195, 319, 256, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1724, d2c5oC_, 0.7769, 2.76, 0.238, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1725, d2wouA_, 0.7768, 2.54, 0.243, 299, 243, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
1726, d2gcdA_, 0.7768, 3.22, 0.238, 308, 256, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1727, d5cwzA_, 0.7767, 3.30, 0.229, 284, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1728, d2c5oA_, 0.7767, 2.85, 0.241, 296, 249, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1729, d4lueB3, 0.7766, 2.51, 0.473, 256, 241, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
1730, d3c0iA_, 0.7765, 3.02, 0.217, 298, 254, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
1731, d3c0gB_, 0.7764, 3.16, 0.215, 320, 256, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1732, d3blqA_, 0.7764, 3.03, 0.190, 295, 253, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
1733, d1u5qA_, 0.7764, 3.17, 0.235, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1734, d2vn9B_, 0.7763, 3.02, 0.209, 301, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1735, d2vgpB_, 0.7763, 2.76, 0.210, 277, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
1736, d2c5xC_, 0.7763, 2.78, 0.234, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1737, d2c5xA_, 0.7763, 2.76, 0.234, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1738, d2c5pC_, 0.7763, 2.85, 0.241, 296, 249,  
1739, d1okuC_, 0.7763, 2.78, 0.234, 296, 248,  
1740, d1koaA2, 0.7763, 3.11, 0.195, 350, 256, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
1741, d4j53A_, 0.7761, 3.25, 0.209, 293, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1742, d2c5vC_, 0.7761, 2.78, 0.234, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1743, d1fvvC_, 0.7761, 2.83, 0.237, 298, 249, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1744, d2x7fB_, 0.7760, 2.98, 0.238, 288, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1745, d2vn9A_, 0.7760, 3.02, 0.209, 301, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1746, d2owbA_, 0.7760, 3.24, 0.213, 294, 258, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1747, d2lgcA1, 0.7760, 2.94, 0.217, 353, 253, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1748, d3en7B_, 0.7759, 2.12, 0.464, 237, 233, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
1749, d2whbA_, 0.7759, 2.83, 0.233, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1750, d1urcC_, 0.7759, 2.85, 0.241, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
1751, d1urcA_, 0.7759, 2.84, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
1752, d5deyB_, 0.7758, 3.16, 0.221, 281, 258, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
1753, d2x7fC_, 0.7758, 3.02, 0.238, 285, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1754, d2c5nA_, 0.7758, 2.87, 0.244, 296, 250, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1755, d1fvvA_, 0.7758, 2.88, 0.240, 298, 250, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1756, d4j52A_, 0.7757, 3.26, 0.209, 293, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1757, d2whbC_, 0.7757, 2.85, 0.241, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1758, d4c02A_, 0.7756, 2.65, 0.268, 313, 246, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
1759, d3blrA_, 0.7756, 2.97, 0.186, 300, 253, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
1760, d2gcdB_, 0.7756, 3.08, 0.244, 308, 254, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1761, d1ol2A_, 0.7756, 2.85, 0.241, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
1762, d3mfrA_, 0.7755, 3.10, 0.224, 302, 255, CASK-4M CAM KINASE DOMAIN NATIVE
1763, d2wfyA_, 0.7755, 2.83, 0.245, 295, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1764, d2c5nC_, 0.7755, 2.79, 0.234, 296, 248, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1765, d5ng3D_, 0.7754, 2.84, 0.226, 278, 252, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1766, d4zy6B_, 0.7753, 3.14, 0.222, 280, 257, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1767, d2whaC_, 0.7753, 2.87, 0.245, 296, 249,  
1768, d5ta6A_, 0.7752, 3.26, 0.209, 294, 258, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1769, d5fd2A_, 0.7752, 2.88, 0.313, 264, 249, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
1770, d3en6A_, 0.7751, 2.07, 0.461, 236, 232, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
1771, d2x1nC_, 0.7751, 2.88, 0.245, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1772, d1u5rA_, 0.7751, 3.25, 0.238, 308, 256, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1773, d4lggA_, 0.7750, 2.34, 0.447, 241, 237, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
1774, d2x1nA_, 0.7750, 2.87, 0.245, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1775, d2v22C_, 0.7750, 2.79, 0.230, 296, 248, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
1776, d1okwC_, 0.7750, 2.86, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
1777, d3qupA_, 0.7749, 2.11, 0.431, 241, 239, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
1778, d2i40C_, 0.7749, 2.85, 0.241, 296, 249, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
1779, d4gfoA1, 0.7748, 2.22, 0.351, 270, 239, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
1780, d2whaA_, 0.7748, 2.87, 0.245, 296, 249,  
1781, d2v22A_, 0.7748, 2.86, 0.241, 296, 249, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
1782, d2uueA_, 0.7748, 2.86, 0.241, 296, 249, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
1783, d2c5tC_, 0.7748, 2.88, 0.241, 296, 249,  
1784, d1ol2C_, 0.7748, 2.88, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
1785, d3uohB_, 0.7747, 3.16, 0.234, 264, 256, AURORA A IN COMPLEX WITH RPM1722
1786, d3uohA_, 0.7747, 3.16, 0.234, 264, 256, AURORA A IN COMPLEX WITH RPM1722
1787, d2uueC_, 0.7747, 2.89, 0.241, 296, 249, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
1788, d2c5tA_, 0.7747, 2.86, 0.241, 296, 249,  
1789, d1kobB_, 0.7747, 3.04, 0.191, 352, 256, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1790, d2wouA1, 0.7746, 2.40, 0.245, 297, 241, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
1791, d2wfyC_, 0.7745, 2.85, 0.245, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1792, d2c5pA_, 0.7745, 2.88, 0.241, 296, 249,  
1793, d3en5A_, 0.7744, 2.21, 0.457, 238, 234, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
1794, d4fx3C_, 0.7743, 2.94, 0.244, 298, 250, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1795, d3c0gA_, 0.7743, 3.05, 0.217, 309, 254, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1796, d2wevA_, 0.7743, 2.89, 0.241, 296, 249, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
1797, d5if1A_, 0.7742, 2.78, 0.234, 298, 248, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
1798, d3itzA1, 0.7742, 3.28, 0.219, 353, 256, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1799, d1ol1C_, 0.7742, 2.90, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
1800, d5w5oN_, 0.7741, 2.64, 0.233, 272, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1801, d3f5xC_, 0.7741, 2.87, 0.237, 298, 249, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
1802, d1kobA_, 0.7740, 3.02, 0.191, 352, 256, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1803, d5if1C_, 0.7739, 2.78, 0.242, 296, 248, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
1804, d1ol1A_, 0.7739, 2.86, 0.233, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
1805, d1okwA_, 0.7739, 2.87, 0.245, 296, 249, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
1806, d6babD_, 0.7738, 2.94, 0.210, 291, 252, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1807, d3mftA_, 0.7738, 3.03, 0.220, 302, 254, CASK-4M CAM KINASE DOMAIN MN2+
1808, d2wxvA1, 0.7738, 2.85, 0.245, 298, 249, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
1809, d2wihA1, 0.7738, 2.85, 0.245, 298, 249, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
1810, d2rkuA_, 0.7738, 3.26, 0.209, 294, 258, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1811, d3e5aA_, 0.7736, 2.74, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
1812, d2bkzA2, 0.7736, 2.85, 0.245, 298, 249, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
1813, d3unzB_, 0.7735, 3.13, 0.239, 263, 255, AURORA A IN COMPLEX WITH RPM1679
1814, d2c4gC2, 0.7735, 2.91, 0.248, 298, 250, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
1815, d3unzA_, 0.7734, 3.13, 0.239, 263, 255, AURORA A IN COMPLEX WITH RPM1679
1816, d3fc2A_, 0.7734, 3.33, 0.209, 293, 258, PLK1 IN COMPLEX WITH BI6727
1817, d1okvA_, 0.7734, 2.85, 0.241, 295, 249, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
1818, d2bkzC2, 0.7733, 2.85, 0.245, 297, 249, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
1819, d1finA_, 0.7733, 2.88, 0.241, 298, 249, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
1820, d5i4nA1, 0.7732, 2.90, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
1821, d5horA_, 0.7732, 1.99, 0.393, 247, 234, CRYSTAL STRUCTURE OF C-MET-M1250T IN COMPLEX WITH SAR125844.
1822, d3uo6B_, 0.7732, 3.07, 0.242, 264, 256, AURORA A IN COMPLEX WITH YL5-083
1823, d3uo6A_, 0.7732, 3.07, 0.242, 264, 256, AURORA A IN COMPLEX WITH YL5-083
1824, d2vgoB_, 0.7731, 2.76, 0.195, 277, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1825, d2bpmA2, 0.7731, 2.87, 0.241, 298, 249, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
1826, d1vywA1, 0.7731, 2.88, 0.245, 298, 249, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
1827, d1tkiB_, 0.7731, 2.87, 0.174, 321, 253, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
1828, d3uokB_, 0.7730, 3.22, 0.237, 265, 257, AURORA A IN COMPLEX WITH YL5-81-1
1829, d1tkiA_, 0.7730, 2.87, 0.174, 321, 253, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
1830, d3uokA_, 0.7729, 3.22, 0.237, 265, 257, AURORA A IN COMPLEX WITH YL5-81-1
1831, d1u5qB_, 0.7729, 3.13, 0.244, 308, 254, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1832, d1okvC_, 0.7729, 2.95, 0.248, 296, 250, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
1833, d4f0gA1, 0.7728, 2.20, 0.276, 260, 239, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
1834, d2ou7A_, 0.7728, 3.30, 0.214, 292, 257, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1835, d4fx3A_, 0.7727, 2.95, 0.244, 298, 250, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1836, d3tzmA_, 0.7727, 2.40, 0.250, 295, 240, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
1837, d5hesB_, 0.7726, 2.70, 0.320, 278, 247, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
1838, d4imyC_, 0.7726, 3.01, 0.191, 310, 251, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1839, d2bpmC2, 0.7724, 2.88, 0.237, 298, 249, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
1840, d5ceoA_, 0.7723, 2.69, 0.320, 269, 247, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
1841, d5ax9A_, 0.7722, 3.21, 0.236, 282, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1842, d5cepA_, 0.7721, 2.68, 0.316, 269, 247, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
1843, d5eakA_, 0.7720, 2.62, 0.256, 305, 246, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
1844, d5oneA_, 0.7719, 2.74, 0.240, 257, 250, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
1845, d2wxvC1, 0.7719, 2.87, 0.237, 298, 249, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
1846, d2y7jA_, 0.7718, 2.86, 0.210, 284, 248, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1847, d2c4gA2, 0.7718, 2.90, 0.245, 297, 249, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
1848, d1vywC1, 0.7718, 2.88, 0.237, 298, 249, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
1849, d5vloA_, 0.7717, 2.96, 0.207, 290, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1850, d4o2zA1, 0.7717, 2.83, 0.217, 357, 249, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1851, d5ajqA_, 0.7716, 3.28, 0.236, 280, 258, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
1852, d3uojB_, 0.7716, 3.12, 0.235, 263, 255, AURORA A IN COMPLEX WITH RPM1715
1853, d3f5xA_, 0.7716, 2.87, 0.246, 297, 248, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
1854, d2wihC1, 0.7716, 2.89, 0.249, 298, 249, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
1855, d5cswA_, 0.7715, 2.25, 0.320, 254, 241, B-RAF IN COMPLEX WITH DABRAFENIB
1856, d4nstA_, 0.7715, 3.12, 0.249, 322, 253, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
1857, d4cxaA_, 0.7715, 3.07, 0.237, 329, 253, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
1858, d3uojA_, 0.7715, 3.12, 0.235, 263, 255, AURORA A IN COMPLEX WITH RPM1715
1859, d3blhA1, 0.7715, 3.03, 0.190, 291, 252, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
1860, d4l3lA_, 0.7714, 3.35, 0.227, 291, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
1861, d3en6B_, 0.7714, 2.36, 0.455, 239, 235, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
1862, d1u5rB_, 0.7714, 3.21, 0.243, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1863, d2wpaA1, 0.7712, 2.88, 0.245, 298, 249, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
1864, d4nusA_, 0.7711, 3.21, 0.234, 301, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1865, d3h9rA_, 0.7711, 2.65, 0.269, 312, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
1866, d5ceqA_, 0.7710, 2.69, 0.316, 269, 247, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
1867, d4eokC1, 0.7710, 2.69, 0.248, 296, 246, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1868, d3bhuA1, 0.7710, 2.82, 0.247, 295, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
1869, d2bfxB_, 0.7710, 2.69, 0.209, 275, 249, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1870, d4ogrA_, 0.7709, 3.25, 0.192, 314, 255, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1871, d2y7jC_, 0.7709, 2.89, 0.218, 284, 248, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1872, d4o0rB_, 0.7708, 3.06, 0.224, 282, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1873, d3q53A_, 0.7708, 3.05, 0.229, 291, 253, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1874, d1h1rA1, 0.7708, 2.90, 0.238, 295, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
1875, d4rvtA_, 0.7706, 3.26, 0.228, 281, 254, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1876, d2hy81_, 0.7706, 3.24, 0.224, 293, 255, PAK1 COMPLEX WITH ST2001
1877, d1h1sA1, 0.7706, 2.78, 0.239, 295, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
1878, d5vo1A_, 0.7705, 2.70, 0.316, 269, 247, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
1879, d3uolB_, 0.7705, 3.20, 0.234, 263, 256, AURORA A IN COMPLEX WITH SO2-162
1880, d3uolA_, 0.7705, 3.20, 0.234, 263, 256, AURORA A IN COMPLEX WITH SO2-162
1881, d5imeB_, 0.7704, 3.05, 0.217, 280, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
1882, d5cswB_, 0.7704, 2.42, 0.326, 252, 242, B-RAF IN COMPLEX WITH DABRAFENIB
1883, d3wf9A_, 0.7704, 3.18, 0.230, 287, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
1884, d3wf8A_, 0.7704, 3.32, 0.224, 287, 259, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
1885, d1finC_, 0.7704, 2.93, 0.241, 298, 249, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
1886, d4nstC_, 0.7702, 3.07, 0.234, 317, 252, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
1887, d4itjA_, 0.7702, 2.55, 0.300, 261, 243, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
1888, d2wzjC_, 0.7702, 2.65, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1889, d2biyA_, 0.7702, 3.29, 0.227, 287, 256, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
1890, d5uoxA_, 0.7701, 2.75, 0.220, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
1891, d5ta8A_, 0.7700, 3.23, 0.210, 294, 257, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1892, d5cyiA1, 0.7700, 2.90, 0.230, 297, 248, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
1893, d2iw8A1, 0.7700, 2.80, 0.235, 296, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
1894, d1oi9A1, 0.7700, 2.79, 0.235, 294, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1895, d5vo2A_, 0.7699, 2.70, 0.316, 269, 247, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
1896, d5nevA1, 0.7699, 2.81, 0.235, 294, 247, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
1897, d3ddpC1, 0.7699, 2.83, 0.243, 297, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
1898, d5v24B_, 0.7698, 2.73, 0.216, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
1899, d4lg4B_, 0.7698, 3.13, 0.236, 284, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
1900, d3dogA1, 0.7698, 3.01, 0.241, 296, 249, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
1901, d3ddpA1, 0.7698, 2.82, 0.235, 296, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
1902, d2yacA_, 0.7698, 3.26, 0.211, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1903, d1h26A1, 0.7698, 2.85, 0.247, 295, 247, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1904, d3v8tA1, 0.7697, 2.10, 0.423, 236, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
1905, d3bhtA2, 0.7697, 2.82, 0.243, 295, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
1906, d1h1qA1, 0.7697, 2.80, 0.239, 295, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
1907, d5k3yB_, 0.7696, 2.77, 0.192, 277, 250, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1908, d5cyiC1, 0.7696, 2.90, 0.238, 295, 248, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
1909, d4l42A_, 0.7696, 3.39, 0.227, 299, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
1910, d3hmmA_, 0.7696, 2.38, 0.255, 293, 239, STRUCTURE OF ALK5 + GW855857
1911, d2wzjA_, 0.7696, 2.67, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1912, d1h28C1, 0.7696, 2.93, 0.238, 295, 248, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
1913, d5hieB_, 0.7695, 2.89, 0.309, 259, 249, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
1914, d4yc3A1, 0.7695, 3.06, 0.244, 294, 250, CDK1/CYCLINB1/CKS2 APO
1915, d4a4lA_, 0.7695, 3.35, 0.210, 290, 257, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1916, d3kk8A_, 0.7695, 3.06, 0.206, 283, 253, CAMKII SUBSTRATE COMPLEX A
1917, d2uzlC_, 0.7695, 2.89, 0.250, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1918, d4l46A_, 0.7693, 3.47, 0.235, 317, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
1919, d2wpaC1, 0.7693, 2.92, 0.241, 298, 249, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
1920, d5ng3B_, 0.7692, 2.71, 0.230, 275, 248, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1921, d4cfuA1, 0.7692, 2.85, 0.243, 295, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1922, d2wmaA1, 0.7692, 2.75, 0.240, 295, 246, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1923, d3zrkB_, 0.7691, 3.53, 0.177, 348, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
1924, d2bfyB_, 0.7691, 2.78, 0.192, 278, 250, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1925, d5eykB_, 0.7690, 2.78, 0.192, 275, 250, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
1926, d3ddqA1, 0.7690, 2.79, 0.240, 295, 246, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
1927, d2uzlA_, 0.7690, 2.83, 0.243, 295, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1928, d2g9xA2, 0.7690, 2.92, 0.230, 297, 248, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
1929, d2cchA2, 0.7690, 2.90, 0.246, 295, 248, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
1930, d4bcnA1, 0.7689, 2.90, 0.242, 295, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1931, d3lm0A1, 0.7689, 2.93, 0.228, 271, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
1932, d3eidA_, 0.7689, 2.98, 0.233, 292, 249, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1933, d3bhvA1, 0.7689, 2.86, 0.243, 295, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
1934, d1unlB_, 0.7689, 2.89, 0.235, 292, 247, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
1935, d1unlA_, 0.7689, 2.74, 0.233, 292, 245, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
1936, d1h28A1, 0.7689, 2.84, 0.239, 295, 247, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
1937, d4cfwA1, 0.7688, 2.82, 0.243, 297, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1938, d2cciA2, 0.7688, 2.91, 0.246, 295, 248, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
1939, d1pkdC1, 0.7688, 2.88, 0.243, 295, 247, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
1940, d5hesA_, 0.7687, 2.95, 0.320, 287, 250, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
1941, d4eosA1, 0.7687, 2.87, 0.234, 293, 248, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1942, d4eopA1, 0.7687, 2.89, 0.246, 294, 248, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1943, d4cfnA1, 0.7687, 2.88, 0.222, 293, 248, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1944, d3qhrC1, 0.7687, 2.90, 0.246, 295, 248, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1945, d3fe3B_, 0.7687, 3.14, 0.240, 317, 254, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
1946, d1okyA_, 0.7687, 3.14, 0.229, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1947, d4l3jA_, 0.7686, 3.39, 0.231, 291, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
1948, d4i5hA_, 0.7686, 3.06, 0.200, 335, 250, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
1949, d1oi9C1, 0.7686, 2.81, 0.235, 295, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1950, d1h1qC1, 0.7686, 2.74, 0.244, 295, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
1951, d4ogrE_, 0.7685, 3.13, 0.190, 310, 252, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1952, d4fvrA_, 0.7685, 2.95, 0.257, 274, 253, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
1953, d4cfmA1, 0.7685, 2.84, 0.247, 295, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1954, d2wmbA1, 0.7685, 2.90, 0.246, 295, 248, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1955, d1oguA1, 0.7685, 2.92, 0.226, 293, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1956, d4cfvA1, 0.7684, 2.76, 0.236, 297, 246, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1957, d4bcoA1, 0.7684, 2.94, 0.242, 297, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1958, d3qhrA1, 0.7684, 2.91, 0.246, 295, 248, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1959, d2wzjB_, 0.7684, 2.69, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1960, d4bcpA1, 0.7683, 2.87, 0.239, 297, 247, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1961, d2wzjF_, 0.7683, 2.70, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1962, d5m4fA_, 0.7682, 2.91, 0.169, 330, 249, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1963, d5hlnB_, 0.7682, 3.57, 0.177, 346, 260, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
1964, d5acbC_, 0.7682, 3.18, 0.228, 324, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
1965, d3qhwC1, 0.7682, 2.90, 0.246, 295, 248, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1966, d3lm5A1, 0.7682, 2.96, 0.224, 267, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
1967, d3iw4C_, 0.7682, 3.05, 0.241, 332, 253, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1968, d5ho7A_, 0.7681, 3.22, 0.228, 280, 254, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1969, d4w8eA_, 0.7681, 2.93, 0.248, 290, 250, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1970, d4ogrI_, 0.7681, 3.36, 0.195, 318, 256, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1971, d1qmzA1, 0.7681, 2.93, 0.246, 295, 248, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1972, d1oiyA1, 0.7681, 2.91, 0.226, 292, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1973, d5itaA_, 0.7680, 2.32, 0.333, 250, 240, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
1974, d3thbA_, 0.7680, 3.20, 0.216, 287, 255, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1975, d2hakF_, 0.7680, 2.98, 0.249, 318, 253, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1976, d5knjB_, 0.7679, 2.49, 0.259, 259, 243, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
1977, d5ax9C_, 0.7679, 3.42, 0.234, 282, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1978, d4bcmA1, 0.7679, 2.99, 0.233, 292, 249, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1979, d3qhwA1, 0.7679, 2.91, 0.246, 295, 248, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1980, d2uzeA_, 0.7679, 2.91, 0.246, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1981, d4cqeA_, 0.7678, 2.23, 0.321, 250, 240, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
1982, d1uvrA_, 0.7678, 3.23, 0.228, 284, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1983, d1qmzC1, 0.7678, 2.93, 0.242, 295, 248, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1984, d1pkdA1, 0.7678, 2.88, 0.247, 295, 247, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
1985, d1h1sC1, 0.7678, 2.82, 0.239, 295, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
1986, d6b8uB_, 0.7677, 2.30, 0.317, 248, 240, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
1987, d5hx6A_, 0.7677, 2.49, 0.306, 259, 242, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
1988, d2y7jB_, 0.7677, 2.81, 0.220, 281, 246, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1989, d2uzeC_, 0.7677, 2.91, 0.246, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1990, d1h1rC1, 0.7677, 2.83, 0.235, 295, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
1991, d5nevC1, 0.7676, 2.77, 0.236, 295, 246, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
1992, d5lmkA1, 0.7676, 2.86, 0.239, 295, 247, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
1993, d5ho8A_, 0.7676, 3.24, 0.228, 278, 254, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1994, d4ithB_, 0.7676, 2.67, 0.302, 270, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
1995, d4eolC1, 0.7676, 2.83, 0.243, 296, 247, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1996, d3h10D_, 0.7676, 2.83, 0.243, 255, 251, AURORA A INHIBITOR COMPLEX
1997, d1h25A1, 0.7676, 2.95, 0.246, 292, 248, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1998, d5e8yA_, 0.7675, 2.49, 0.266, 298, 241, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
1999, d4xx9A_, 0.7675, 3.21, 0.228, 288, 254, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2000, d4fvqA_, 0.7675, 3.07, 0.256, 274, 254, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
2001, d2i40A_, 0.7675, 3.03, 0.233, 291, 249, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2002, d1wbwA_, 0.7675, 3.19, 0.241, 351, 253, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
2003, d1uu8A_, 0.7675, 3.23, 0.228, 277, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2004, d1howA_, 0.7675, 3.15, 0.160, 346, 250, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
2005, d1gy3C_, 0.7675, 2.94, 0.246, 295, 248, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2006, d1fmkA3, 0.7675, 3.15, 0.480, 270, 254, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
2007, d4itiB_, 0.7674, 2.67, 0.287, 270, 244, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
2008, d4eoqC1, 0.7674, 2.83, 0.236, 271, 246, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2009, d2cjmC_, 0.7674, 2.77, 0.236, 294, 246, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2010, d1uu9A_, 0.7674, 3.24, 0.228, 276, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2011, d1oiuA1, 0.7674, 2.92, 0.234, 293, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2012, d1h27A1, 0.7674, 2.86, 0.247, 295, 247, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2013, d1e9hC1, 0.7674, 2.89, 0.238, 295, 248, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2014, d2vrxB_, 0.7673, 2.71, 0.210, 274, 248, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2015, d2iw6A1, 0.7673, 2.91, 0.234, 291, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2016, d1gy3A_, 0.7673, 2.88, 0.239, 295, 247, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2017, d5veeA_, 0.7672, 3.16, 0.189, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
2018, d4a4oA_, 0.7672, 3.29, 0.211, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
2019, d2bdwB_, 0.7672, 2.94, 0.219, 309, 251, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2020, d1h1wA_, 0.7672, 3.31, 0.227, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
2021, d5hieA_, 0.7671, 2.88, 0.310, 258, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2022, d4eqcA1, 0.7671, 3.19, 0.228, 292, 254, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2023, d3o0gA_, 0.7671, 2.77, 0.241, 289, 245, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
2024, d2xchA_, 0.7671, 3.20, 0.229, 278, 253, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2025, d1okzA_, 0.7671, 3.21, 0.229, 276, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2026, d3nunA_, 0.7670, 3.23, 0.228, 278, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2027, d1yhwA_, 0.7670, 3.26, 0.224, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2028, d4eojC1, 0.7669, 2.83, 0.240, 278, 246, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2029, d2cchC2, 0.7669, 2.94, 0.250, 295, 248, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2030, d1h24C1, 0.7669, 2.91, 0.247, 292, 247, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2031, d4rqvA_, 0.7668, 3.24, 0.228, 288, 254, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
2032, d4ii5A_, 0.7668, 2.94, 0.242, 295, 248, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2033, d4cfuC1, 0.7668, 2.92, 0.243, 269, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2034, d3zrmB_, 0.7668, 3.52, 0.178, 347, 259, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2035, d3tnwA1, 0.7668, 3.02, 0.233, 294, 249, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2036, d3rwqA_, 0.7668, 3.25, 0.228, 283, 254, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2037, d3bhvC1, 0.7668, 2.90, 0.243, 269, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2038, d1uv5A_, 0.7668, 3.60, 0.173, 348, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
2039, d1oiyC1, 0.7668, 2.92, 0.246, 295, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2040, d5nttA1, 0.7667, 2.98, 0.171, 268, 251, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
2041, d4ii5C_, 0.7667, 2.93, 0.246, 295, 248, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2042, d4eooC1, 0.7667, 2.95, 0.246, 295, 248, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2043, d3zrlB_, 0.7667, 3.55, 0.177, 347, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2044, d3we4A_, 0.7667, 3.30, 0.230, 286, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
2045, d4riyA_, 0.7666, 3.18, 0.332, 269, 253, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2046, d4qmwA_, 0.7666, 2.93, 0.259, 286, 251, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2047, d4eomA1, 0.7666, 2.81, 0.232, 294, 246, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2048, d2x7fA_, 0.7666, 3.06, 0.240, 276, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2049, d2bujA1, 0.7666, 3.09, 0.203, 283, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2050, d4qmxA_, 0.7665, 2.89, 0.248, 287, 250, MST3 IN COMPLEX WITH SARACATINIB
2051, d2uzdC_, 0.7665, 2.83, 0.240, 295, 246, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2052, d1h27C1, 0.7665, 2.88, 0.243, 290, 247, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2053, d5hlnA_, 0.7664, 3.55, 0.178, 346, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2054, d4qmsA_, 0.7664, 2.81, 0.249, 283, 249, MST3 IN COMPLEX WITH DASATINIB
2055, d3my5A1, 0.7664, 2.91, 0.235, 294, 247, CDK2/CYCLINA IN COMPLEX WITH DRB
2056, d1yhvA_, 0.7664, 3.26, 0.224, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2057, d1jstC_, 0.7664, 2.86, 0.243, 297, 247, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2058, d4eoiA1, 0.7663, 2.95, 0.242, 293, 248, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2059, d2qnjB1, 0.7663, 3.00, 0.243, 321, 251, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
2060, d2iw9A2, 0.7663, 2.91, 0.227, 292, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2061, d5ng3C_, 0.7662, 2.92, 0.233, 272, 249, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2062, d4i3zA_, 0.7662, 2.96, 0.242, 295, 248, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2063, d4cxaC_, 0.7662, 3.13, 0.242, 330, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
2064, d4bcoC1, 0.7662, 2.84, 0.236, 268, 246, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2065, d3nnwA_, 0.7662, 3.36, 0.240, 349, 254, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
2066, d3m1sA_, 0.7662, 3.60, 0.173, 348, 260, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2067, d1w82A_, 0.7662, 3.27, 0.241, 351, 253, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2068, d4i3zC_, 0.7661, 2.96, 0.242, 295, 248, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2069, d4dawA_, 0.7661, 3.13, 0.225, 293, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2070, d4bcnC1, 0.7661, 2.94, 0.246, 293, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2071, d4b4lA_, 0.7661, 3.18, 0.213, 299, 254, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2072, d3bhtC1, 0.7661, 2.92, 0.247, 269, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2073, d1fq1B_, 0.7661, 3.05, 0.240, 295, 250, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
2074, d5hngA_, 0.7660, 3.25, 0.228, 280, 254, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2075, d4o0tB_, 0.7660, 3.24, 0.214, 280, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2076, d4eomC1, 0.7660, 2.91, 0.235, 271, 247, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2077, d4bcmC1, 0.7660, 2.88, 0.247, 293, 247, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2078, d3kb7A_, 0.7660, 3.28, 0.211, 289, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2079, d2c6tC_, 0.7660, 2.91, 0.243, 295, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2080, d4aotA1, 0.7659, 3.22, 0.249, 276, 253, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2081, d3bhuC1, 0.7659, 2.99, 0.246, 269, 248, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2082, d1oguC1, 0.7659, 2.91, 0.239, 269, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2083, d5hx6B_, 0.7658, 2.43, 0.298, 264, 238, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
2084, d4riwA_, 0.7658, 3.25, 0.331, 269, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2085, d4eopC1, 0.7658, 2.96, 0.246, 295, 248, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2086, d3up2A_, 0.7658, 2.95, 0.241, 266, 253, AURORA A IN COMPLEX WITH RPM1686
2087, d3gfeA_, 0.7658, 3.37, 0.224, 352, 255, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
2088, d2wzjD_, 0.7658, 2.64, 0.241, 313, 245, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2089, d4un0C_, 0.7657, 3.12, 0.230, 308, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2090, d4rixA_, 0.7657, 3.19, 0.332, 269, 253, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2091, d4l44A_, 0.7657, 3.51, 0.231, 321, 260, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2092, d4eoqA1, 0.7657, 2.83, 0.228, 293, 246, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2093, d3zrmA_, 0.7657, 3.65, 0.176, 344, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2094, d3zrkA_, 0.7657, 3.59, 0.177, 345, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2095, d3sayA_, 0.7657, 3.70, 0.177, 347, 260, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2096, d3qd3A_, 0.7657, 3.26, 0.228, 278, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2097, d2cciC2, 0.7657, 2.98, 0.250, 295, 248, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2098, d5dfpA_, 0.7656, 3.15, 0.233, 292, 253, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2099, d5dewB_, 0.7656, 3.18, 0.219, 281, 256, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2100, d4cfnC1, 0.7656, 2.86, 0.235, 293, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2101, d1q5kA_, 0.7656, 3.55, 0.174, 345, 259, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2102, d1muoA_, 0.7656, 2.67, 0.243, 251, 247, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
2103, d3e92A_, 0.7655, 3.22, 0.234, 348, 252, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
2104, d2wipA1, 0.7655, 2.74, 0.238, 293, 244, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2105, d1q41B_, 0.7655, 3.54, 0.174, 343, 259, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2106, d4qmzA_, 0.7654, 2.98, 0.259, 286, 251, MST3 IN COMPLEX WITH SUNITINIB
2107, d3q52A_, 0.7654, 3.14, 0.225, 292, 253, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2108, d4u41A_, 0.7653, 3.30, 0.231, 275, 255, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2109, d4eonA1, 0.7653, 2.88, 0.247, 297, 247, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2110, d3zrlA_, 0.7653, 3.66, 0.176, 345, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2111, d3d7zA_, 0.7653, 3.20, 0.234, 348, 252, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
2112, d2uzbA_, 0.7653, 2.98, 0.238, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2113, d2c6tA_, 0.7653, 2.99, 0.250, 295, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2114, d1q99B_, 0.7653, 3.22, 0.155, 364, 251, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
2115, d1p5eC1, 0.7653, 2.98, 0.242, 295, 248, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2116, d5ut2A_, 0.7652, 3.04, 0.257, 273, 253, JAK2 JH2 IN COMPLEX WITH PRT062607
2117, d5uorB_, 0.7652, 2.76, 0.217, 262, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2118, d5efqA_, 0.7652, 3.31, 0.220, 321, 255, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2119, d3m1sB_, 0.7652, 3.52, 0.174, 349, 259, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2120, d3f88A_, 0.7652, 3.69, 0.180, 340, 261, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
2121, d2yabB_, 0.7652, 3.41, 0.214, 299, 257, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2122, d2oo8X_, 0.7652, 1.87, 0.432, 259, 229, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
2123, d2iw6C2, 0.7652, 2.95, 0.250, 294, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2124, d2g9xC2, 0.7652, 2.91, 0.235, 273, 247, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2125, d2uzdA_, 0.7651, 2.97, 0.246, 295, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2126, d1q97B_, 0.7651, 3.22, 0.155, 361, 251, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
2127, d4qmyA_, 0.7650, 2.92, 0.248, 287, 250, MST3 IN COMPLEX WITH STAUROSPORINE
2128, d2uzbC_, 0.7650, 2.98, 0.230, 292, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2129, d1q8zB_, 0.7650, 3.08, 0.153, 364, 249, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
2130, d1jstA_, 0.7650, 2.98, 0.246, 297, 248, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2131, d1j1bA_, 0.7650, 3.54, 0.174, 354, 259, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2132, d5ut4A_, 0.7649, 3.10, 0.260, 273, 254, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
2133, d5f94A_, 0.7649, 3.65, 0.177, 346, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2134, d3w10A_, 0.7649, 3.10, 0.223, 263, 256, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
2135, d2x4fB_, 0.7649, 3.10, 0.208, 288, 255, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2136, d2qnjA1, 0.7649, 3.05, 0.247, 317, 251, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
2137, d1h24A1, 0.7649, 2.80, 0.248, 292, 246, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2138, d5m4cA_, 0.7648, 2.98, 0.169, 329, 249, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2139, d5f94B_, 0.7648, 3.64, 0.177, 349, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2140, d4fvpA_, 0.7648, 3.15, 0.259, 274, 255, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
2141, d3juhB_, 0.7648, 3.21, 0.167, 334, 252, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2142, d3du8A_, 0.7648, 3.54, 0.174, 336, 259, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
2143, d3a7iA_, 0.7648, 2.98, 0.259, 286, 251, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2144, d1stcE_, 0.7648, 3.19, 0.237, 334, 253, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
2145, d1pyxB_, 0.7648, 3.55, 0.174, 338, 259, GSK-3 BETA COMPLEXED WITH AMP-PNP
2146, d5kbqB_, 0.7647, 3.00, 0.215, 273, 251, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2147, d4otdA_, 0.7647, 3.04, 0.251, 334, 251, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
2148, d4fzaB1, 0.7647, 2.73, 0.251, 280, 247, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2149, d4eooA1, 0.7647, 2.87, 0.236, 292, 246, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2150, d3ztxB_, 0.7647, 2.71, 0.206, 272, 247, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2151, d3sayB_, 0.7647, 3.69, 0.177, 347, 260, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2152, d3mj1A1, 0.7647, 1.48, 0.416, 226, 226, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR RO5191614
2153, d2wmbC1, 0.7647, 2.77, 0.237, 265, 245, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2154, d2wipC1, 0.7647, 2.75, 0.238, 291, 244, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2155, d4eoiC1, 0.7646, 2.89, 0.247, 295, 247, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2156, d4deaA_, 0.7646, 2.97, 0.241, 266, 253, AURORA A IN COMPLEX WITH YL1-038-18
2157, d4cfwC1, 0.7646, 2.95, 0.242, 295, 248, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2158, d3tnwC_, 0.7646, 2.82, 0.240, 291, 246, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2159, d3sc1A_, 0.7646, 3.24, 0.229, 278, 253, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2160, d3nusA_, 0.7646, 3.17, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2161, d3bw5A_, 0.7646, 3.19, 0.167, 334, 252,  
2162, d2wzjE_, 0.7646, 2.72, 0.236, 310, 246, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2163, d3eidC_, 0.7645, 2.94, 0.239, 290, 247, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2164, d2xuuA_, 0.7645, 3.44, 0.206, 301, 257, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2165, d1pyxA_, 0.7645, 3.65, 0.173, 343, 260, GSK-3 BETA COMPLEXED WITH AMP-PNP
2166, d1j1cA_, 0.7645, 3.55, 0.174, 354, 259, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2167, d4oboA_, 0.7644, 3.30, 0.231, 275, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2168, d4nm0A1, 0.7644, 3.59, 0.181, 355, 259, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
2169, d4eojA1, 0.7644, 2.94, 0.239, 293, 247, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2170, d3rwpA_, 0.7644, 3.16, 0.230, 277, 252, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2171, d3gc8A_, 0.7644, 2.81, 0.218, 347, 248, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
2172, d3bhhB1, 0.7644, 2.85, 0.214, 288, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2173, d1ymiA_, 0.7644, 3.19, 0.167, 334, 252,  
2174, d4yfiB_, 0.7643, 2.54, 0.262, 262, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
2175, d4nm5A1, 0.7643, 3.67, 0.177, 360, 260, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
2176, d3nuyA_, 0.7643, 3.18, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2177, d1e9hA_, 0.7643, 2.82, 0.244, 295, 246, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2178, d5hq0A1, 0.7642, 2.86, 0.252, 289, 246, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
2179, d4y72A1, 0.7642, 2.86, 0.252, 289, 246, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
2180, d3nuuA_, 0.7642, 3.11, 0.227, 276, 251, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2181, d1uu3A_, 0.7642, 3.17, 0.230, 276, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2182, d4nm7A1, 0.7641, 3.57, 0.178, 354, 259, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
2183, d2yaaB_, 0.7641, 3.42, 0.214, 299, 257, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2184, d5e91A_, 0.7640, 2.59, 0.266, 297, 241, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
2185, d4eolA1, 0.7640, 2.84, 0.244, 293, 246, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2186, d2ckeB_, 0.7640, 3.32, 0.207, 300, 256, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2187, d1j1cB_, 0.7640, 3.64, 0.173, 364, 260, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2188, d4eosC1, 0.7639, 2.90, 0.239, 295, 247, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2189, d3l1sB_, 0.7639, 3.58, 0.178, 330, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2190, d2y7jD_, 0.7639, 2.88, 0.220, 281, 246, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2191, d2clqA_, 0.7639, 2.77, 0.217, 263, 244, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2192, d1r0eB_, 0.7639, 3.70, 0.176, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
2193, d3gc8B_, 0.7638, 2.74, 0.211, 346, 247, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
2194, d3fxzA_, 0.7638, 3.16, 0.225, 292, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2195, d2jd5B_, 0.7638, 3.25, 0.155, 360, 251, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2196, d2ckeC_, 0.7638, 3.39, 0.210, 300, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2197, d1j1bB_, 0.7638, 3.64, 0.173, 364, 260, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2198, d5eakB_, 0.7637, 2.54, 0.260, 300, 242, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2199, d3f7zA1, 0.7637, 3.63, 0.174, 338, 259, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
2200, d1uu7A_, 0.7637, 3.18, 0.230, 280, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
2201, d5tx5A_, 0.7636, 2.55, 0.302, 259, 242, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
2202, d5ig1B_, 0.7636, 3.25, 0.243, 304, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2203, d4qnaA_, 0.7636, 2.86, 0.249, 284, 249, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2204, d3nnuA_, 0.7636, 3.33, 0.237, 348, 253, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
2205, d3i4bB_, 0.7636, 3.51, 0.171, 347, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2206, d4eorA1, 0.7635, 2.96, 0.231, 292, 247, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2207, d4eonC1, 0.7635, 3.00, 0.246, 296, 248, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2208, d4c2vA_, 0.7635, 2.76, 0.215, 270, 247, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2209, d4bcpC1, 0.7635, 2.78, 0.238, 266, 244, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2210, d4acgB_, 0.7635, 3.56, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2211, d3iecB_, 0.7635, 2.80, 0.253, 313, 245, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2212, d3gxlA_, 0.7635, 2.46, 0.261, 285, 238, ALK-5 KINASE COMPLEX WITH GW857175
2213, d3f88B_, 0.7635, 3.68, 0.172, 340, 261, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
2214, d2eufB_, 0.7635, 2.82, 0.232, 282, 246, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
2215, d1q41A_, 0.7635, 3.65, 0.173, 339, 260, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2216, d1p5eA1, 0.7635, 3.02, 0.238, 295, 248, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2217, d5ut1A_, 0.7634, 3.08, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH BI-D1870
2218, d5acbD_, 0.7634, 3.17, 0.233, 319, 253, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2219, d2jldB_, 0.7634, 3.55, 0.174, 349, 259, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
2220, d2jd5A_, 0.7634, 3.06, 0.161, 353, 248, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2221, d2bfxA_, 0.7634, 2.82, 0.214, 269, 248, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2222, d1r0eA_, 0.7634, 3.60, 0.173, 344, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
2223, d1q4lA_, 0.7634, 3.62, 0.170, 342, 259, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
2224, d1q5kB_, 0.7633, 3.67, 0.173, 344, 260, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2225, d1q3wB_, 0.7633, 3.67, 0.173, 341, 260, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2226, d5nqcA_, 0.7632, 3.11, 0.159, 331, 251, CK2ALPHA IN COMPLEX WITH NMR154
2227, d4qmuA_, 0.7632, 2.95, 0.248, 286, 250, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2228, d4qmnA_, 0.7632, 2.91, 0.260, 283, 250, MST3 IN COMPLEX WITH BOSUTINIB
2229, d4achB_, 0.7632, 3.55, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2230, d3my5C1, 0.7632, 2.79, 0.238, 265, 244, CDK2/CYCLINA IN COMPLEX WITH DRB
2231, d3du8B_, 0.7632, 3.65, 0.173, 339, 260, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
2232, d2o5kA1, 0.7632, 3.64, 0.173, 350, 260, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
2233, d5hieC_, 0.7631, 2.49, 0.320, 253, 241, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2234, d5b0xA_, 0.7631, 2.92, 0.173, 329, 248, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
2235, d3q3bB_, 0.7631, 3.57, 0.174, 341, 259, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
2236, d3orzB_, 0.7631, 3.20, 0.225, 278, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2237, d3f7zB1, 0.7631, 3.67, 0.177, 338, 260, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
2238, d2jgzA_, 0.7631, 2.68, 0.238, 288, 244, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2239, d1h26C1, 0.7631, 2.84, 0.241, 266, 245, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2240, d5l2wA1, 0.7630, 2.80, 0.241, 296, 245, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
2241, d3qcqA_, 0.7630, 3.19, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2242, d3orzD_, 0.7630, 3.20, 0.225, 278, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2243, d3o7lD_, 0.7630, 3.34, 0.240, 333, 254, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2244, d1q99A_, 0.7630, 3.07, 0.157, 354, 248, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
2245, d4eorC1, 0.7629, 2.94, 0.235, 269, 247, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2246, d4acgA_, 0.7629, 3.57, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2247, d5tx5B_, 0.7628, 2.52, 0.307, 263, 238, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
2248, d4ptgA_, 0.7628, 3.58, 0.181, 333, 259, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
2249, d4pteB_, 0.7628, 3.66, 0.177, 347, 260, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
2250, d4nw5A1, 0.7628, 3.47, 0.241, 296, 257, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
2251, d4aotB1, 0.7628, 3.34, 0.244, 277, 254, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2252, d3dt1A2, 0.7628, 3.42, 0.223, 352, 256, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
2253, d1q4lB_, 0.7628, 3.56, 0.178, 337, 258, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
2254, d1f5qA_, 0.7628, 3.02, 0.238, 296, 248, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
2255, d1bx6A_, 0.7628, 3.21, 0.241, 337, 253, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2256, d4ptgB_, 0.7627, 3.68, 0.177, 332, 260, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
2257, d4ic7A_, 0.7627, 2.81, 0.211, 355, 246, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
2258, d3qcxA_, 0.7627, 3.19, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2259, d3nnvA_, 0.7627, 3.27, 0.242, 348, 252, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
2260, d5ut3A_, 0.7626, 3.09, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
2261, d4qmmA_, 0.7626, 3.05, 0.259, 288, 251, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
2262, d4krcA_, 0.7626, 3.11, 0.245, 297, 249, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
2263, d4eokA1, 0.7626, 2.87, 0.236, 292, 246, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2264, d3q3bA_, 0.7626, 3.68, 0.173, 344, 260, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
2265, d3juhA_, 0.7626, 3.21, 0.163, 334, 252, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2266, d2oxyA_, 0.7626, 3.01, 0.169, 327, 249, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2267, d3wowA_, 0.7625, 3.01, 0.173, 334, 249, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
2268, d3wikA_, 0.7625, 3.08, 0.180, 334, 250, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
2269, d3pupB_, 0.7625, 3.56, 0.174, 347, 259, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
2270, d3iw4B_, 0.7625, 3.09, 0.243, 325, 251, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2271, d3iw4A_, 0.7625, 3.01, 0.243, 330, 251, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2272, d2welA_, 0.7625, 2.78, 0.207, 304, 246, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
2273, d2jldA_, 0.7625, 3.66, 0.173, 349, 260, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
2274, d1q8zA_, 0.7625, 3.25, 0.156, 354, 250, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
2275, d1h25C1, 0.7625, 2.93, 0.236, 277, 246, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2276, d5m56B_, 0.7624, 3.08, 0.160, 328, 250, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2277, d5efqC_, 0.7623, 3.19, 0.214, 325, 252, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2278, d4cjyC_, 0.7623, 3.13, 0.231, 303, 251,  
2279, d4afjA_, 0.7623, 3.58, 0.179, 342, 257, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
2280, d3pupA_, 0.7623, 3.57, 0.174, 346, 259, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
2281, d3og7A_, 0.7623, 2.28, 0.328, 247, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
2282, d3i4bA_, 0.7623, 3.63, 0.170, 359, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2283, d1ds5C_, 0.7623, 3.11, 0.164, 328, 250, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2284, d5es1A_, 0.7622, 2.63, 0.256, 304, 242, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2285, d5ei6A1, 0.7622, 2.97, 0.165, 261, 249, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2286, d3sd0A_, 0.7622, 3.68, 0.172, 350, 261, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
2287, d3qcsA_, 0.7622, 3.21, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2288, d1i09B_, 0.7622, 3.62, 0.178, 341, 259, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
2289, d1ds5B_, 0.7622, 3.12, 0.164, 328, 250, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2290, d5ut6A_, 0.7621, 3.10, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
2291, d5ut0A_, 0.7620, 3.10, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH AT9283
2292, d4krdA_, 0.7620, 2.97, 0.251, 294, 247, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
2293, d4acdA_, 0.7620, 3.68, 0.173, 350, 260, GSK3B IN COMPLEX WITH INHIBITOR
2294, d3uo5A_, 0.7620, 3.01, 0.241, 267, 253, AURORA A IN COMPLEX WITH YL1-038-31
2295, d3qd4A_, 0.7620, 3.23, 0.230, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2296, d2p4iB_, 0.7620, 1.82, 0.430, 258, 228, EVOLUTION OF A HIGHLY SELECTIVE AND POTENT 2-(PYRIDIN-2-YL)- 135-TRIAZINE TIE-2 KINASE INHIBITOR
2297, d2ckeD_, 0.7620, 3.33, 0.207, 300, 256, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2298, d2ckeA_, 0.7620, 3.48, 0.205, 301, 258, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2299, d1yojA_, 0.7620, 2.11, 0.454, 233, 229, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN
2300, d1ql6A_, 0.7620, 2.97, 0.214, 281, 248, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
2301, d4achA_, 0.7619, 3.58, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2302, d3ztxA_, 0.7619, 2.78, 0.215, 269, 247, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2303, d3l1sA_, 0.7619, 3.65, 0.178, 336, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2304, d2x0gA_, 0.7619, 3.40, 0.214, 318, 257, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2305, d2hakE_, 0.7619, 3.01, 0.254, 318, 252, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
2306, d1ykrA_, 0.7619, 3.07, 0.234, 298, 252, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
2307, d1h8fB_, 0.7619, 3.68, 0.173, 350, 260, GLYCOGEN SYNTHASE KINASE 3 BETA.
2308, d3uo4A_, 0.7618, 3.02, 0.241, 266, 253, AURORA A IN COMPLEX WITH RPM1680
2309, d2r7bA_, 0.7618, 3.11, 0.232, 274, 250, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2310, d1yqjA2, 0.7618, 3.39, 0.236, 351, 254, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
2311, d5hlpA_, 0.7617, 3.75, 0.177, 337, 260, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
2312, d3l9mA_, 0.7617, 3.14, 0.242, 338, 252, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2313, d1zmwA_, 0.7617, 2.70, 0.246, 302, 244, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
2314, d1h1pA1, 0.7617, 2.83, 0.244, 295, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
2315, d5lvlA_, 0.7616, 3.18, 0.231, 285, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2316, d4l00B_, 0.7616, 3.05, 0.258, 278, 252, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
2317, d4iq6B_, 0.7616, 3.58, 0.174, 332, 259, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
2318, d2ow3A_, 0.7616, 3.77, 0.179, 346, 262, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
2319, d1o9uA_, 0.7616, 3.54, 0.174, 349, 258, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
2320, d5ackA_, 0.7615, 3.19, 0.230, 286, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2321, d4nw6A1, 0.7615, 3.42, 0.242, 296, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
2322, d4md7H_, 0.7615, 3.15, 0.163, 330, 251, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2323, d4acdB_, 0.7615, 3.69, 0.173, 350, 260, GSK3B IN COMPLEX WITH INHIBITOR
2324, d4accA_, 0.7615, 3.68, 0.173, 350, 260, GSK3B IN COMPLEX WITH INHIBITOR
2325, d3qcyA_, 0.7615, 3.17, 0.231, 275, 251, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2326, d3axwA_, 0.7615, 2.93, 0.173, 329, 248, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
2327, d1wbsA_, 0.7615, 3.53, 0.238, 351, 256, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
2328, d1w83A_, 0.7615, 3.46, 0.239, 351, 255, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2329, d1h8fA_, 0.7615, 3.67, 0.173, 352, 260, GLYCOGEN SYNTHASE KINASE 3 BETA.
2330, d5uszA_, 0.7614, 3.10, 0.261, 272, 253, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
2331, d5e92A_, 0.7614, 2.65, 0.269, 298, 242, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
2332, d4rqkA_, 0.7614, 3.17, 0.231, 285, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2333, d3uodA_, 0.7614, 3.02, 0.241, 266, 253, AURORA A IN COMPLEX WITH RPM1693
2334, d3q4zB_, 0.7614, 3.13, 0.217, 279, 253, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2335, d5h9bA_, 0.7613, 2.87, 0.227, 269, 247, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2336, d3l9lA_, 0.7613, 3.14, 0.242, 338, 252, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2337, d3iopA_, 0.7613, 3.12, 0.232, 275, 250, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2338, d3gxjA_, 0.7613, 2.45, 0.256, 288, 238,  
2339, d3gb2A_, 0.7613, 3.75, 0.177, 340, 260, GSK3BETA INHIBITOR COMPLEX
2340, d3bhhA1, 0.7613, 2.84, 0.215, 287, 247, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2341, d2yaaA_, 0.7613, 3.53, 0.213, 300, 258, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2342, d2ow3B_, 0.7613, 3.70, 0.176, 351, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
2343, d1ds5D_, 0.7613, 3.12, 0.164, 328, 250, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2344, d5byyA_, 0.7612, 2.84, 0.207, 338, 246, ERK5 IN COMPLEX WITH SMALL MOLECULE
2345, d4w9wA_, 0.7612, 2.78, 0.196, 306, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2346, d4md7G_, 0.7612, 3.10, 0.164, 332, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2347, d4aw1A_, 0.7612, 3.32, 0.233, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2348, d2xckA_, 0.7612, 3.17, 0.228, 275, 250, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2349, d2clqB_, 0.7612, 2.63, 0.224, 259, 241, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2350, d5ut5A_, 0.7611, 3.04, 0.258, 272, 252, JAK2 JH2 IN COMPLEX WITH GLPG0634
2351, d5te0A_, 0.7611, 2.83, 0.176, 316, 245, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2352, d4otgA_, 0.7611, 3.09, 0.251, 322, 251, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2353, d3q9xB_, 0.7611, 3.01, 0.165, 330, 249, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
2354, d4wa9A1, 0.7610, 1.57, 0.987, 236, 224, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
2355, d4qmtA_, 0.7610, 2.98, 0.260, 284, 250, MST3 IN COMPLEX WITH HESPERADIN
2356, d4b8mA_, 0.7610, 2.80, 0.215, 270, 247, AURORA B KINASE IN COMPLEX WITH VX-680
2357, d3hrfA_, 0.7610, 3.11, 0.232, 284, 250, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2358, d3h9oA_, 0.7610, 3.12, 0.232, 275, 250, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2359, d2rkpA_, 0.7610, 3.22, 0.155, 334, 252,  
2360, d2iw9C2, 0.7610, 2.85, 0.241, 267, 245, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2361, d1wbvA_, 0.7610, 3.32, 0.245, 351, 253, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
2362, d1rejA_, 0.7610, 3.25, 0.241, 333, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
2363, d1q3wA_, 0.7610, 3.68, 0.173, 344, 260, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2364, p5xyyA_, 0.7609, 3.33, 0.233, 350, 253, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
2365, d4qmvA_, 0.7609, 3.13, 0.243, 288, 251, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2366, d4l01B_, 0.7609, 2.98, 0.256, 274, 250, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
2367, d3iecA_, 0.7609, 2.77, 0.255, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2368, d2bfyA_, 0.7609, 2.77, 0.198, 270, 247, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2369, d1z5mA_, 0.7609, 3.18, 0.231, 275, 251, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2370, d1wbtA_, 0.7609, 3.47, 0.239, 351, 255, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
2371, d1w98A2, 0.7609, 2.94, 0.244, 296, 246, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
2372, d1ds5A_, 0.7609, 3.05, 0.165, 328, 249, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2373, d5jsmA1, 0.7608, 2.70, 0.320, 262, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2374, d5hlpB_, 0.7608, 3.79, 0.176, 335, 261, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
2375, d4yfiD_, 0.7608, 2.55, 0.264, 261, 239, TNNI3K COMPLEXED WITH INHIBITOR 1
2376, d4pteA_, 0.7608, 3.52, 0.179, 341, 257, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
2377, d3p86B_, 0.7608, 1.87, 0.355, 239, 231, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
2378, d3my0M1, 0.7608, 2.76, 0.250, 297, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2379, d2pe0A_, 0.7608, 3.18, 0.231, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2380, d5oxgC1, 0.7607, 2.71, 0.276, 299, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2381, d3dbqA_, 0.7607, 2.99, 0.174, 259, 247, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
2382, d3ag9B_, 0.7607, 3.14, 0.238, 317, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2383, d2wqnA_, 0.7607, 2.85, 0.226, 259, 248, STRUCTURE OF ADP-BOUND HUMAN NEK7
2384, d5f95A_, 0.7606, 3.51, 0.174, 345, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2385, d4j7bA_, 0.7606, 3.35, 0.217, 284, 253, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2386, d4afjB_, 0.7606, 3.46, 0.180, 346, 255, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
2387, d2a27D_, 0.7606, 3.46, 0.210, 304, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2388, d1jwhA_, 0.7606, 3.04, 0.165, 336, 249, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2389, d5lvoA_, 0.7605, 3.17, 0.231, 285, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
2390, d4w8dA_, 0.7605, 3.15, 0.243, 289, 251, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
2391, d4bidB_, 0.7605, 2.71, 0.232, 258, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2392, d3iecC_, 0.7605, 2.77, 0.255, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2393, d2cjmA_, 0.7605, 2.78, 0.230, 285, 244, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2394, d5hieD_, 0.7604, 2.65, 0.313, 253, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2395, p4md9P_, 0.7604, 2.96, 0.173, 328, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2396, d4j1rB_, 0.7604, 3.71, 0.177, 346, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2397, d4accB_, 0.7604, 3.58, 0.174, 350, 259, GSK3B IN COMPLEX WITH INHIBITOR
2398, d3sd0B_, 0.7604, 3.68, 0.177, 349, 260, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
2399, d3my0B_, 0.7604, 2.69, 0.251, 295, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2400, d3fe3A_, 0.7604, 3.19, 0.241, 317, 253, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
2401, d3bhyA1, 0.7604, 2.80, 0.223, 267, 247, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2402, d2zjwA_, 0.7604, 3.01, 0.169, 332, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
2403, d1oukA_, 0.7604, 3.32, 0.229, 348, 253, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
2404, d5nhvA_, 0.7603, 2.79, 0.216, 345, 245, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2405, d5larA_, 0.7603, 3.05, 0.236, 350, 250, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
2406, d4asxA1, 0.7603, 2.65, 0.257, 295, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
2407, d3h30A_, 0.7603, 3.17, 0.159, 333, 251, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2408, d2oxyB_, 0.7603, 3.07, 0.169, 327, 249, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2409, d1szmA_, 0.7603, 3.08, 0.235, 317, 251, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2410, d1q3dB_, 0.7603, 3.77, 0.172, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
2411, d5hd7A_, 0.7602, 2.68, 0.209, 347, 244, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
2412, d4u43A_, 0.7602, 3.63, 0.227, 287, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2413, d4j1rD_, 0.7602, 3.70, 0.177, 345, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2414, d4j1rC_, 0.7602, 3.71, 0.177, 344, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2415, d4fbxA_, 0.7602, 3.16, 0.163, 333, 251, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
2416, d3a7fA_, 0.7602, 3.15, 0.247, 283, 251, HUMAN MST3 KINASE
2417, d2vgoA_, 0.7602, 2.82, 0.215, 268, 247, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2418, d1dawA_, 0.7602, 3.20, 0.171, 327, 251, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
2419, d5nhhA_, 0.7601, 2.91, 0.215, 348, 246, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2420, d4usfB1, 0.7601, 3.53, 0.233, 283, 258, HUMAN SLK WITH SB-440719
2421, d4u8zA_, 0.7601, 3.06, 0.248, 289, 250, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
2422, d4ptcB_, 0.7601, 3.51, 0.178, 347, 258, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
2423, d4ptcA_, 0.7601, 3.52, 0.178, 342, 258, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
2424, d3nayB_, 0.7601, 3.18, 0.228, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2425, d3ionA_, 0.7601, 3.09, 0.233, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
2426, d3ds6D_, 0.7601, 3.23, 0.226, 349, 252, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
2427, d2yabA_, 0.7601, 3.42, 0.215, 299, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2428, d2x4fA_, 0.7601, 3.18, 0.200, 289, 255, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2429, d2b54A_, 0.7601, 3.15, 0.233, 298, 253, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
2430, d5hniY_, 0.7600, 2.04, 0.381, 245, 231, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
2431, d4j71A_, 0.7600, 3.66, 0.178, 347, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
2432, p4ib5C_, 0.7600, 3.11, 0.168, 332, 250, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2433, d3qa0B_, 0.7600, 3.05, 0.165, 330, 249, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
2434, d3kxhA_, 0.7600, 3.05, 0.165, 326, 249, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
2435, d2vrxA_, 0.7600, 2.83, 0.215, 268, 247, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2436, d1q97A_, 0.7600, 3.00, 0.163, 351, 246, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
2437, d1phkA_, 0.7600, 2.91, 0.215, 277, 247, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
2438, d5etcA_, 0.7599, 3.40, 0.216, 355, 255, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
2439, d4md7E_, 0.7599, 3.02, 0.165, 332, 249, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2440, d4j1rA_, 0.7599, 3.74, 0.176, 343, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2441, d3wilA_, 0.7599, 3.02, 0.169, 331, 248, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
2442, d3q9wA_, 0.7599, 3.03, 0.169, 328, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
2443, d3iecD_, 0.7599, 2.78, 0.255, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2444, d2uw7A_, 0.7599, 3.27, 0.233, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
2445, d2a2aD_, 0.7599, 3.37, 0.199, 303, 256, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2446, d1oiuC1, 0.7599, 2.79, 0.243, 264, 243, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2447, d4md7F_, 0.7598, 3.08, 0.164, 332, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2448, d4m69B_, 0.7598, 2.84, 0.244, 264, 250, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
2449, p4ib5B_, 0.7598, 3.08, 0.176, 329, 250, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2450, d4bicB_, 0.7598, 2.66, 0.228, 259, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2451, d3orzC_, 0.7598, 3.15, 0.227, 276, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2452, d3orzA_, 0.7598, 3.15, 0.227, 276, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2453, d3qyiA_, 0.7597, 2.81, 0.204, 346, 245,  
2454, d3hmpA_, 0.7597, 2.84, 0.171, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
2455, d2a2aC_, 0.7597, 3.36, 0.207, 303, 256, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2456, d1q8yB_, 0.7597, 3.07, 0.154, 357, 247, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
2457, d1lp4A_, 0.7597, 3.23, 0.171, 327, 251, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
2458, d5motA_, 0.7596, 2.98, 0.170, 328, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
2459, d5knjA_, 0.7596, 2.51, 0.253, 252, 241, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
2460, d2jdvA_, 0.7596, 3.25, 0.233, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
2461, d5v19B_, 0.7595, 2.80, 0.215, 260, 242, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2462, d4j71B_, 0.7595, 3.67, 0.177, 347, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
2463, d4dedA_, 0.7595, 3.06, 0.241, 265, 253, AURORA A IN COMPLEX WITH YL1-038-21
2464, d4a06A_, 0.7595, 3.10, 0.233, 282, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2465, d3ofmA_, 0.7595, 3.02, 0.165, 325, 249, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
2466, d3l9mB_, 0.7595, 3.24, 0.241, 336, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2467, d3dogC1, 0.7595, 2.83, 0.242, 266, 244, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2468, d2jedB1, 0.7595, 3.01, 0.245, 315, 249, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2469, d1ungA_, 0.7595, 2.75, 0.236, 288, 242, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
2470, d1h1pC1, 0.7595, 2.87, 0.244, 295, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
2471, d1dayA_, 0.7595, 3.20, 0.171, 327, 251, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
2472, p6c3eA_, 0.7594, 2.77, 0.299, 258, 244, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
2473, d5jsmC1, 0.7594, 2.59, 0.324, 259, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2474, d5csvA_, 0.7594, 2.96, 0.170, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
2475, d3rinA_, 0.7594, 3.20, 0.219, 349, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2476, d3fy0A_, 0.7594, 3.16, 0.218, 292, 252, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
2477, d2zb1A_, 0.7594, 3.16, 0.240, 345, 250, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
2478, d2pe2A_, 0.7594, 3.19, 0.231, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2479, d2a27H_, 0.7594, 3.48, 0.210, 304, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2480, p5owlB_, 0.7593, 3.13, 0.164, 332, 250, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2481, d5hkmA_, 0.7593, 3.11, 0.233, 272, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2482, d4j7bD_, 0.7593, 3.31, 0.218, 281, 252, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2483, d3up7A_, 0.7593, 3.02, 0.242, 264, 252, AURORA A IN COMPLEX WITH YL1-038-09
2484, d3ddqC1, 0.7593, 2.83, 0.242, 265, 244, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2485, d2c6eA_, 0.7593, 2.83, 0.243, 251, 247, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
2486, d2a27F_, 0.7593, 3.47, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2487, d2a27B_, 0.7593, 3.48, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2488, d5t1hA_, 0.7592, 3.05, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2
2489, d5oy6D_, 0.7592, 2.58, 0.279, 292, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
2490, d5ljjA1, 0.7592, 2.95, 0.169, 260, 248, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
2491, d5uq2A_, 0.7591, 3.09, 0.245, 296, 249, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
2492, d5nhpA_, 0.7591, 2.83, 0.212, 338, 245, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2493, d5jsmB1, 0.7591, 2.73, 0.325, 259, 243, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2494, d4j8nC_, 0.7591, 3.01, 0.242, 266, 252, AURORA A KINASE APO
2495, d3rcjA_, 0.7591, 3.07, 0.234, 281, 248, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
2496, d3fwqA_, 0.7591, 3.23, 0.155, 334, 252, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2497, p2pvnA_, 0.7591, 3.17, 0.171, 327, 251, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2498, d1zmwB_, 0.7591, 2.75, 0.246, 302, 244, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
2499, d1xhaA_, 0.7591, 3.27, 0.241, 348, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2500, d5up3A_, 0.7590, 2.71, 0.216, 258, 241, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2501, d4qteA_, 0.7590, 2.74, 0.213, 348, 244, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
2502, d4qtbB_, 0.7590, 2.71, 0.217, 348, 244, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
2503, d4qmqA_, 0.7590, 3.19, 0.254, 289, 252, MST3 IN COMPLEX WITH CP-673451
2504, d2gphA_, 0.7590, 2.82, 0.208, 345, 245, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
2505, d5ke0A_, 0.7589, 2.83, 0.216, 340, 245, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
2506, d5k00A_, 0.7589, 2.44, 0.225, 311, 240, MELK IN COMPLEX WITH NVS-MELK5
2507, d4qtbA_, 0.7589, 2.80, 0.216, 351, 245, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
2508, d4qmpA_, 0.7589, 3.15, 0.243, 289, 251, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
2509, p4lopC_, 0.7589, 3.18, 0.235, 341, 251, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
2510, d3fwqB_, 0.7589, 3.26, 0.159, 334, 252, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2511, d3a7gB_, 0.7589, 2.96, 0.256, 290, 250, HUMAN MST3 KINASE
2512, d2b53A_, 0.7589, 3.06, 0.231, 294, 251, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
2513, d2a27G_, 0.7589, 3.48, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2514, d2a27C_, 0.7589, 3.48, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2515, d5u6iA_, 0.7588, 2.75, 0.209, 339, 244, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
2516, d5mz3A_, 0.7588, 3.49, 0.239, 350, 255, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
2517, d5jrqA1, 0.7588, 2.54, 0.324, 257, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
2518, d5h8bA_, 0.7588, 3.06, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
2519, d5d9kB_, 0.7588, 3.02, 0.238, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2520, d4j8nB_, 0.7588, 3.02, 0.242, 266, 252, AURORA A KINASE APO
2521, d4ic7D_, 0.7588, 2.85, 0.211, 353, 246, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
2522, d3my0N1, 0.7588, 2.76, 0.251, 299, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2523, d5hniX_, 0.7587, 2.18, 0.375, 245, 232, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
2524, d5ap6A1, 0.7587, 3.00, 0.165, 259, 249, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2525, d4qmoA_, 0.7587, 3.17, 0.243, 288, 251, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
2526, p4md8G_, 0.7587, 3.15, 0.168, 332, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
2527, d4gcjA1, 0.7587, 3.22, 0.245, 298, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
2528, d4debA_, 0.7587, 3.02, 0.242, 264, 252, AURORA A IN COMPLEX WITH RK2-17-01
2529, d2zmdA_, 0.7587, 2.88, 0.166, 259, 247, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
2530, d1ouyA_, 0.7587, 3.31, 0.234, 350, 252, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
2531, d1m7qA_, 0.7587, 3.16, 0.220, 348, 250, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
2532, d5n1vA_, 0.7586, 3.09, 0.169, 331, 249, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2533, d5h8eA_, 0.7586, 3.06, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
2534, d5f95B_, 0.7586, 3.65, 0.178, 338, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2535, d5etiA1, 0.7586, 3.37, 0.213, 352, 254, STRUCTURE OF DEAD KINASE MAPK14
2536, d4iz5D_, 0.7586, 2.84, 0.204, 347, 245, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2537, d4iz5C_, 0.7586, 2.83, 0.204, 347, 245, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2538, d4iz5B_, 0.7586, 2.83, 0.204, 347, 245, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2539, d3orxG_, 0.7586, 3.05, 0.233, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2540, d3my0V1, 0.7586, 2.69, 0.252, 281, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2541, d3h30B_, 0.7586, 3.19, 0.155, 333, 251, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2542, d2oscA_, 0.7586, 1.77, 0.429, 255, 226, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
2543, d1zogA_, 0.7586, 3.12, 0.172, 325, 250, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
2544, d1q8yA_, 0.7586, 3.03, 0.163, 351, 246, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
2545, d5lmkC1, 0.7585, 2.86, 0.242, 264, 244, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2546, d5jsmD1, 0.7585, 2.67, 0.331, 255, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2547, d4iz5A_, 0.7585, 2.84, 0.204, 347, 245, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2548, d4dgoA_, 0.7585, 3.14, 0.172, 325, 250, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
2549, d4cfvC1, 0.7585, 2.75, 0.244, 263, 242, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2550, d4bibB_, 0.7585, 2.72, 0.224, 258, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2551, d4b99A_, 0.7585, 3.00, 0.211, 335, 247, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
2552, d3socB1, 0.7585, 2.57, 0.254, 294, 240, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
2553, d3fknA_, 0.7585, 3.24, 0.239, 346, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
2554, d3a7hB_, 0.7585, 2.95, 0.256, 290, 250, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2555, d2uw6A_, 0.7585, 3.16, 0.231, 334, 251, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2556, d2uvyA_, 0.7585, 3.23, 0.230, 333, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
2557, d2uvxA_, 0.7585, 3.26, 0.233, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
2558, d2a2aA_, 0.7585, 3.44, 0.206, 304, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2559, d5d9kA_, 0.7584, 3.03, 0.238, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2560, d5cspA_, 0.7584, 2.97, 0.170, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2561, d4wsqA_, 0.7584, 2.88, 0.183, 317, 246, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2562, p4md8E_, 0.7584, 3.19, 0.167, 332, 251, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
2563, d4anmA1, 0.7584, 3.13, 0.172, 327, 250, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
2564, d3kq7A_, 0.7584, 3.38, 0.245, 348, 253, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
2565, d2w5bA1, 0.7584, 3.02, 0.216, 263, 250, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
2566, d2uw4A_, 0.7584, 3.22, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2567, d2iw8C2, 0.7584, 2.85, 0.234, 264, 244, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2568, d5n1vB_, 0.7583, 3.08, 0.169, 331, 249, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2569, d4j8nA_, 0.7583, 3.03, 0.242, 266, 252, AURORA A KINASE APO
2570, d3qd0A_, 0.7583, 3.17, 0.232, 274, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2571, d3orxF_, 0.7583, 3.05, 0.233, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2572, d3c13A_, 0.7583, 3.07, 0.169, 328, 248, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2573, d2a27E_, 0.7583, 3.49, 0.210, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2574, d1xh8A_, 0.7583, 3.28, 0.237, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2575, d4o0sA_, 0.7582, 2.93, 0.240, 265, 250, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2576, d3my0U1, 0.7582, 2.69, 0.252, 284, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2577, d3agmA_, 0.7582, 3.26, 0.241, 337, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
2578, d2pe1A_, 0.7582, 3.21, 0.231, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2579, d2a27A_, 0.7582, 3.50, 0.210, 304, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2580, d1bkxA_, 0.7582, 3.27, 0.245, 337, 253, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
2581, d3my0L1, 0.7581, 2.80, 0.251, 295, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2582, d3bqcA_, 0.7581, 3.07, 0.169, 328, 248, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2583, d1zzlA_, 0.7581, 3.20, 0.215, 351, 251, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
2584, d1zohA_, 0.7581, 3.15, 0.172, 326, 250, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2585, d1rekA_, 0.7581, 3.27, 0.241, 336, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
2586, d1gngA_, 0.7581, 3.81, 0.176, 348, 262, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
2587, p4nh1B_, 0.7580, 3.04, 0.173, 332, 249, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
2588, p4md8F_, 0.7580, 3.12, 0.168, 332, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
2589, d4l45A_, 0.7580, 3.21, 0.238, 317, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2590, d3l9lB_, 0.7580, 3.27, 0.241, 337, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2591, d3at2A_, 0.7580, 3.10, 0.165, 334, 249, CRYSTAL STRUCTURE OF CK2ALPHA
2592, d2jdtA_, 0.7580, 3.29, 0.233, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
2593, d2a2aB_, 0.7580, 3.40, 0.207, 303, 256, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2594, d1wzyA_, 0.7580, 2.89, 0.212, 350, 245, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
2595, d1q3dA_, 0.7580, 3.80, 0.172, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
2596, d6babB_, 0.7579, 2.86, 0.212, 285, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2597, p4lopB_, 0.7579, 3.14, 0.236, 350, 250, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
2598, d4l00A_, 0.7579, 3.25, 0.265, 277, 253, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
2599, d3orxH_, 0.7579, 3.06, 0.233, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2600, d2uw3A_, 0.7579, 3.26, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
2601, d4qyyA_, 0.7578, 2.70, 0.205, 337, 244, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
2602, p4md8H_, 0.7578, 3.13, 0.164, 331, 250, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
2603, d4iq6A_, 0.7578, 3.66, 0.178, 324, 258, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
2604, d4dgnA_, 0.7578, 3.15, 0.172, 325, 250, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
2605, d2vo0A_, 0.7578, 3.29, 0.233, 340, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2606, d1j91A_, 0.7578, 3.09, 0.169, 327, 249, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2607, d4tl0A_, 0.7577, 3.46, 0.211, 300, 256, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
2608, p4nh1A_, 0.7577, 3.04, 0.173, 330, 249, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
2609, p4loqD_, 0.7577, 3.17, 0.236, 351, 250, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
2610, d4ct1A_, 0.7577, 3.12, 0.225, 283, 249, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
2611, d3py3A1, 0.7577, 3.12, 0.224, 352, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
2612, d3ha6A1, 0.7577, 2.92, 0.241, 262, 249, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2613, d3dneA_, 0.7577, 3.29, 0.237, 336, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2614, p6g97A_, 0.7576, 2.93, 0.216, 344, 245, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2615, d5nhoA_, 0.7576, 2.85, 0.216, 343, 245, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2616, d5nhlA_, 0.7576, 2.75, 0.213, 345, 244, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2617, d5hd4A_, 0.7576, 2.72, 0.213, 347, 244, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
2618, d4uv0A_, 0.7576, 3.43, 0.215, 300, 256, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2619, d3erkA_, 0.7576, 2.81, 0.205, 350, 244, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
2620, p3be9A_, 0.7576, 3.14, 0.172, 327, 250, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
2621, d2xikA_, 0.7576, 3.13, 0.248, 288, 250, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
2622, d2uw0A_, 0.7576, 3.26, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
2623, d2oxdA_, 0.7576, 3.14, 0.172, 325, 250, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
2624, d2f7xE_, 0.7576, 3.42, 0.235, 336, 255, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
2625, d5m57A1, 0.7575, 2.51, 0.233, 253, 240, NEK2 BOUND TO ARYLAMINOPURINE 6
2626, p4ib5A_, 0.7575, 3.13, 0.164, 331, 250, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2627, d3hrcA_, 0.7575, 3.03, 0.234, 279, 248, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
2628, d2r0iA_, 0.7575, 2.72, 0.256, 300, 242, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
2629, d2oh0E_, 0.7575, 3.42, 0.235, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
2630, d2f57B1, 0.7575, 3.20, 0.194, 293, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2631, d2c6dA_, 0.7575, 2.88, 0.241, 254, 249, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
2632, d1smhA_, 0.7575, 3.20, 0.242, 348, 252, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
2633, d5fg8A_, 0.7574, 2.92, 0.227, 269, 247, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2634, d4ubaB_, 0.7574, 3.10, 0.169, 333, 249, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
2635, d4kd1A_, 0.7574, 3.20, 0.233, 298, 253, CDK2 IN COMPLEX WITH DINACICLIB
2636, d4bggA_, 0.7574, 2.59, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
2637, d3orxC_, 0.7574, 3.25, 0.235, 283, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2638, d3orxA_, 0.7574, 3.25, 0.235, 283, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2639, d2wmaC1, 0.7574, 2.87, 0.254, 264, 244, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2640, d1xh5A_, 0.7574, 3.30, 0.237, 335, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2641, d1lr4A_, 0.7574, 3.13, 0.172, 327, 250, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
2642, d4lg4F_, 0.7573, 3.11, 0.222, 276, 248, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2643, d4bggB_, 0.7573, 2.58, 0.279, 293, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
2644, d2r0iB_, 0.7573, 2.62, 0.257, 300, 241, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
2645, d2qc6A_, 0.7573, 3.09, 0.165, 326, 249, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
2646, d2ojfE_, 0.7573, 3.43, 0.235, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
2647, d5mohA_, 0.7572, 2.94, 0.171, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
2648, p4md9E_, 0.7572, 3.00, 0.169, 329, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2649, p4loqB_, 0.7572, 3.23, 0.235, 351, 251, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
2650, d3rpsA_, 0.7572, 3.19, 0.155, 334, 251, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2651, p6g9aA_, 0.7571, 2.76, 0.214, 341, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2652, d5deyA_, 0.7571, 3.29, 0.237, 295, 253, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2653, d4l01A_, 0.7571, 3.12, 0.266, 274, 252, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
2654, d5nhjA_, 0.7570, 2.85, 0.216, 345, 245, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2655, d4w9xA_, 0.7570, 2.77, 0.197, 300, 244, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2656, p4md9L_, 0.7570, 3.00, 0.165, 328, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2657, p4md9G_, 0.7570, 3.03, 0.169, 329, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2658, d4dgmA_, 0.7570, 3.16, 0.172, 326, 250, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
2659, d4cfmC1, 0.7570, 2.84, 0.251, 265, 243, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2660, d3zyaA1, 0.7570, 2.89, 0.224, 341, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
2661, p2pvmA_, 0.7570, 3.14, 0.172, 327, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2662, d5d9lA_, 0.7569, 3.13, 0.226, 299, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2663, d4ub7A_, 0.7569, 3.19, 0.159, 334, 251, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
2664, d4o0vA1, 0.7569, 3.35, 0.189, 289, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2665, d3a7jA_, 0.7569, 3.17, 0.254, 286, 252, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2666, d1wbnA_, 0.7569, 3.44, 0.244, 351, 254, FRAGMENT BASED P38 INHIBITORS
2667, d1i09A_, 0.7569, 3.67, 0.178, 338, 259, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
2668, d6babA_, 0.7568, 3.09, 0.212, 290, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2669, d5lvnA_, 0.7568, 3.13, 0.233, 283, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
2670, d5i3oB_, 0.7568, 2.91, 0.192, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2671, p4md9K_, 0.7568, 3.02, 0.173, 328, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2672, p4lopD_, 0.7568, 3.14, 0.221, 351, 249, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
2673, d3orxE_, 0.7568, 3.12, 0.233, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2674, d3mb6A_, 0.7568, 3.09, 0.169, 329, 248, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
2675, p6g93A_, 0.7567, 2.76, 0.214, 343, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2676, d5k3yA_, 0.7567, 2.78, 0.196, 267, 245, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2677, d4zsjA_, 0.7567, 2.81, 0.208, 344, 245, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
2678, d3my0R1, 0.7567, 2.64, 0.253, 293, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2679, d2vo3A_, 0.7567, 3.27, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2680, d2uztA_, 0.7567, 3.34, 0.236, 336, 254, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
2681, d2oxxA_, 0.7567, 3.17, 0.172, 325, 250, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2682, d1zoeA_, 0.7567, 3.16, 0.176, 325, 250, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2683, d1g3nE_, 0.7567, 3.05, 0.227, 293, 247, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
2684, d4u40A_, 0.7566, 3.36, 0.231, 295, 255, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
2685, p4loqC_, 0.7566, 3.15, 0.236, 337, 250, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
2686, d3q4tB1, 0.7566, 2.63, 0.258, 293, 240, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2687, d1svhA_, 0.7566, 3.31, 0.237, 335, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
2688, d1ol5A_, 0.7566, 2.95, 0.240, 263, 250, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2689, d5vedA_, 0.7565, 3.30, 0.190, 289, 253, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2690, d3my0G1, 0.7565, 2.66, 0.253, 293, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2691, d3my0A1, 0.7565, 2.83, 0.251, 295, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2692, d3kxmA_, 0.7565, 3.16, 0.172, 326, 250, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
2693, d3kxgA_, 0.7565, 3.15, 0.172, 326, 250, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
2694, d2vnwA_, 0.7565, 3.28, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
2695, d2uzuE_, 0.7565, 3.44, 0.235, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2696, d5lvmA_, 0.7564, 3.05, 0.234, 283, 248, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
2697, d4lg4C_, 0.7564, 3.16, 0.224, 288, 250, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2698, d4lg4A_, 0.7564, 3.28, 0.230, 289, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2699, d2yixA_, 0.7564, 3.19, 0.223, 351, 251, TRIAZOLOPYRIDINE INHIBITORS OF P38
2700, d2gnfA_, 0.7564, 3.27, 0.245, 339, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
2701, d5u94A_, 0.7563, 2.65, 0.218, 263, 243, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2702, p5owlA_, 0.7563, 3.09, 0.165, 331, 249, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2703, d5kwhA_, 0.7563, 3.12, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2
2704, d5ku8A_, 0.7563, 3.05, 0.169, 328, 248, CRYSTAL STRUCTURE OF CK2
2705, d4rllA_, 0.7563, 3.09, 0.173, 329, 248, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
2706, p4looA_, 0.7563, 3.03, 0.223, 349, 247, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
2707, d3rpsB_, 0.7563, 3.23, 0.155, 334, 251, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2708, d2uvzA_, 0.7563, 3.25, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
2709, d1zwsF_, 0.7563, 3.06, 0.204, 278, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2710, d1zwsB_, 0.7563, 3.14, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2711, d1j91B_, 0.7563, 3.11, 0.165, 327, 249, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2712, d1ctpE_, 0.7563, 3.32, 0.241, 332, 253, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2713, d5m51A1, 0.7562, 2.52, 0.233, 253, 240, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
2714, d4obqA_, 0.7562, 3.15, 0.222, 275, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
2715, p4md9F_, 0.7562, 3.04, 0.169, 327, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2716, d4l43A_, 0.7562, 3.32, 0.237, 316, 253, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
2717, d4c2wA_, 0.7562, 2.83, 0.215, 268, 246, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2718, d3oomA_, 0.7562, 2.70, 0.278, 297, 241, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
2719, d3mtfB_, 0.7562, 2.78, 0.277, 298, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
2720, d3ctqA_, 0.7562, 2.75, 0.226, 336, 243, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
2721, p2pvkA_, 0.7562, 3.15, 0.172, 327, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2722, d2c1aA_, 0.7562, 3.31, 0.237, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
2723, d1buhA_, 0.7562, 2.98, 0.230, 287, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
2724, d4qnyA_, 0.7561, 2.87, 0.211, 333, 246, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2725, p4h3qA_, 0.7561, 2.96, 0.211, 352, 246, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2726, p3u9cA_, 0.7561, 3.08, 0.165, 331, 249, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
2727, d3q4uD_, 0.7561, 2.75, 0.277, 299, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
2728, d3pe2A_, 0.7561, 3.06, 0.173, 327, 248, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
2729, d3my0W1, 0.7561, 2.67, 0.253, 280, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2730, d3kxnA_, 0.7561, 3.10, 0.165, 327, 249, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
2731, d3dlsD_, 0.7561, 2.92, 0.224, 284, 245, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2732, d2zoqA_, 0.7561, 2.81, 0.221, 351, 244, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
2733, d1pw2A_, 0.7561, 3.17, 0.226, 294, 252, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
2734, d5e8vA_, 0.7560, 2.72, 0.270, 296, 241, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
2735, d3rp0C_, 0.7560, 3.03, 0.169, 329, 248,  
2736, d3r0tA_, 0.7560, 3.01, 0.174, 327, 247, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
2737, d3pvgA_, 0.7560, 3.16, 0.172, 326, 250, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
2738, d2zmcA_, 0.7560, 2.85, 0.174, 260, 247, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
2739, d2fysA_, 0.7560, 2.99, 0.211, 348, 246, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
2740, d1g3nA_, 0.7560, 3.06, 0.227, 293, 247, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
2741, d1cmkE_, 0.7560, 3.23, 0.242, 348, 252, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
2742, d5l8kA_, 0.7559, 2.91, 0.241, 266, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2743, d4o0wA_, 0.7559, 2.89, 0.241, 259, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2744, d4ntsB_, 0.7559, 3.22, 0.242, 341, 252, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2745, p4loqA_, 0.7559, 3.26, 0.231, 352, 251, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
2746, d3u87A_, 0.7559, 3.02, 0.169, 329, 248, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
2747, d3orxD_, 0.7559, 3.23, 0.236, 282, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2748, d3kxjA_, 0.7559, 3.16, 0.172, 326, 250,  
2749, d2ya9B_, 0.7559, 3.45, 0.215, 299, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2750, d2w4kA_, 0.7559, 3.51, 0.215, 301, 256, X-RAY STRUCTURE OF A DAP-KINASE 2-302
2751, p2pvlA_, 0.7559, 3.17, 0.172, 327, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2752, d1lpuA_, 0.7559, 3.25, 0.171, 327, 251, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
2753, d1gngB_, 0.7559, 3.78, 0.176, 355, 261, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
2754, d1di9A_, 0.7559, 3.41, 0.245, 348, 253, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
2755, d5n9sA1, 0.7558, 2.85, 0.167, 256, 246, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
2756, d4izaA_, 0.7558, 2.90, 0.209, 346, 244, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
2757, d4deeA_, 0.7558, 3.05, 0.242, 271, 252, AURORA A IN COMPLEX WITH ADP
2758, p3u9cB_, 0.7558, 3.07, 0.165, 331, 249, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
2759, d2uw8A_, 0.7558, 3.27, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
2760, p4md9M_, 0.7557, 3.07, 0.169, 331, 249, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2761, d4j8nD_, 0.7557, 3.02, 0.239, 265, 251, AURORA A KINASE APO
2762, d4b6lA_, 0.7557, 3.12, 0.239, 281, 251, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
2763, d3warA_, 0.7557, 3.18, 0.172, 334, 250, CRYSTAL STRUCTURE OF HUMAN CK2A
2764, d3nayA_, 0.7557, 3.11, 0.225, 278, 249, PDK1 IN COMPLEX WITH INHIBITOR MP6
2765, d3ambA_, 0.7557, 3.30, 0.249, 340, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
2766, d1zwsD_, 0.7557, 3.16, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2767, d1m2rA_, 0.7557, 3.13, 0.165, 327, 249, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
2768, p5ooiA_, 0.7556, 3.11, 0.161, 329, 249, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2769, d5ehoA1, 0.7556, 2.82, 0.163, 255, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2770, d3otuA_, 0.7556, 3.06, 0.231, 276, 247, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2771, d3dlsA_, 0.7556, 2.92, 0.229, 285, 245, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2772, d2ya9A_, 0.7556, 3.47, 0.215, 299, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2773, d2f7eE_, 0.7556, 3.45, 0.235, 336, 255, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
2774, d2exmA_, 0.7556, 3.24, 0.237, 298, 253, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
2775, d1na7A_, 0.7556, 3.01, 0.170, 326, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
2776, d1f3mC_, 0.7556, 3.36, 0.219, 287, 256, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
2777, d5m56A_, 0.7555, 3.14, 0.164, 331, 250, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2778, d5k5nB_, 0.7555, 3.49, 0.181, 334, 254, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
2779, d5ap1A1, 0.7555, 2.95, 0.162, 264, 247, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2780, d4itiA_, 0.7555, 3.06, 0.283, 272, 247, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
2781, d4bhnB_, 0.7555, 2.64, 0.226, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2782, d4aw0A_, 0.7555, 3.14, 0.233, 283, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2783, d3qa0A_, 0.7555, 3.12, 0.169, 330, 249, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
2784, d3q9yA_, 0.7555, 3.05, 0.169, 327, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
2785, d3pe1A_, 0.7555, 3.01, 0.174, 327, 247, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
2786, d2yakA_, 0.7555, 3.16, 0.216, 277, 250, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2787, d2wqmA_, 0.7555, 2.82, 0.220, 258, 246, STRUCTURE OF APO HUMAN NEK7
2788, d2gngA_, 0.7555, 3.28, 0.245, 338, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
2789, d1zwsG_, 0.7555, 3.16, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2790, d1re8A_, 0.7555, 3.29, 0.241, 337, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
2791, p5n9nA_, 0.7554, 3.17, 0.177, 329, 249, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
2792, d5eykA_, 0.7554, 2.85, 0.199, 263, 246, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2793, d4qp8B_, 0.7554, 2.88, 0.212, 337, 245, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
2794, d4bicA_, 0.7554, 2.75, 0.220, 260, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2795, d3ngaA_, 0.7554, 3.11, 0.169, 331, 249, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
2796, d3fmmA_, 0.7554, 3.25, 0.228, 346, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
2797, d2vnyA_, 0.7554, 3.29, 0.230, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
2798, p2pvhA_, 0.7554, 3.17, 0.172, 327, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2799, d1jamA_, 0.7554, 3.26, 0.171, 327, 251, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
2800, d5t1hB_, 0.7553, 3.14, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2
2801, d5mrdA_, 0.7553, 2.98, 0.223, 283, 247, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
2802, d5i3rB_, 0.7553, 2.93, 0.192, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2803, p4lopA_, 0.7553, 3.15, 0.221, 351, 249, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
2804, d3rp0B_, 0.7553, 3.04, 0.169, 329, 248,  
2805, d2qvsE_, 0.7553, 3.16, 0.242, 323, 252, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2806, d2qluA1, 0.7553, 2.62, 0.243, 295, 239, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
2807, d5oy6B_, 0.7552, 2.61, 0.279, 292, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
2808, d5h8eB_, 0.7552, 3.14, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
2809, d5h8bB_, 0.7552, 3.14, 0.169, 331, 249, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
2810, d4bxbA_, 0.7552, 3.01, 0.170, 328, 247,  
2811, d3mptA_, 0.7552, 3.20, 0.232, 347, 250, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
2812, d2q0nA_, 0.7552, 3.15, 0.187, 293, 251, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
2813, d5nguA_, 0.7551, 2.82, 0.205, 339, 244, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2814, d5mmrA_, 0.7551, 2.95, 0.175, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
2815, d5cquA_, 0.7551, 3.01, 0.170, 328, 247, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2816, d4qp7A_, 0.7551, 2.73, 0.206, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
2817, d4bckA1, 0.7551, 3.01, 0.239, 296, 247, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2818, d3wyyA_, 0.7551, 2.97, 0.167, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
2819, d3wf7A_, 0.7551, 3.50, 0.228, 288, 259, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
2820, d3r8pA_, 0.7551, 3.19, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
2821, d3pzhA_, 0.7551, 3.18, 0.172, 327, 250, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
2822, d3l9nA_, 0.7551, 3.31, 0.241, 332, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
2823, d3d5uA_, 0.7551, 3.33, 0.226, 288, 252, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2824, d2uw5A_, 0.7551, 3.21, 0.231, 333, 251, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2825, d2f7zE_, 0.7551, 3.46, 0.235, 336, 255, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
2826, d4qnyB_, 0.7550, 2.89, 0.211, 339, 246, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2827, p4fmqA_, 0.7550, 2.87, 0.208, 350, 245, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2828, d4figB_, 0.7550, 3.36, 0.189, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
2829, d4dglC_, 0.7550, 3.19, 0.165, 334, 249, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
2830, d3wyxA_, 0.7550, 2.98, 0.167, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
2831, d3rm6A_, 0.7550, 3.08, 0.228, 293, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
2832, d3raiA_, 0.7550, 3.06, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
2833, d3q9zB_, 0.7550, 3.19, 0.164, 332, 250, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
2834, d3ds6C_, 0.7550, 3.25, 0.224, 349, 250, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
2835, d2zb0A_, 0.7550, 3.48, 0.244, 349, 254, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
2836, d2a0cX_, 0.7550, 3.16, 0.231, 294, 251, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
2837, d1q61A_, 0.7550, 3.32, 0.237, 335, 253, PKA TRIPLE MUTANT MODEL OF PKB
2838, d1m2pA_, 0.7550, 3.12, 0.165, 325, 249, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
2839, p5n9kA_, 0.7549, 3.03, 0.170, 329, 247, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
2840, d3w8lA_, 0.7549, 2.99, 0.170, 326, 247, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
2841, d3q4uB1, 0.7549, 2.74, 0.279, 298, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
2842, d3e93A_, 0.7549, 3.40, 0.238, 346, 252, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
2843, d3e8cD_, 0.7549, 3.30, 0.237, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2844, d2gnhA_, 0.7549, 3.29, 0.245, 338, 253, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
2845, d5oxgD_, 0.7548, 2.63, 0.279, 293, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2846, d5lqfA1, 0.7548, 2.81, 0.256, 284, 242, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2847, d5ax9B_, 0.7548, 3.31, 0.236, 274, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2848, d4bxaA_, 0.7548, 3.11, 0.169, 331, 249,  
2849, d3e8cF_, 0.7548, 3.30, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2850, d3e8cB_, 0.7548, 3.30, 0.237, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2851, d3e8cA_, 0.7548, 3.30, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2852, d2clxA_, 0.7548, 3.16, 0.227, 293, 251, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
2853, d1pjkA_, 0.7548, 3.09, 0.177, 331, 248, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2854, d1om1A_, 0.7548, 3.18, 0.172, 325, 250, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
2855, d1j3hB_, 0.7548, 3.17, 0.243, 327, 251, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2856, d5oxgB_, 0.7547, 2.63, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2857, d5kwhB_, 0.7547, 3.21, 0.172, 331, 250, CRYSTAL STRUCTURE OF CK2
2858, d5cu2A_, 0.7547, 3.05, 0.166, 328, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
2859, d5cqwA_, 0.7547, 3.11, 0.169, 331, 249, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2860, d4uynA_, 0.7547, 2.70, 0.246, 249, 244, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
2861, d4o22A1, 0.7547, 3.29, 0.238, 333, 252, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
2862, d3owjA_, 0.7547, 3.13, 0.173, 328, 248, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
2863, d3gc9B_, 0.7547, 2.82, 0.230, 339, 244, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
2864, d3e8cE_, 0.7547, 3.30, 0.237, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2865, d3e8cC_, 0.7547, 3.30, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2866, d3d5wA_, 0.7547, 3.28, 0.223, 284, 251, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2867, d2zoqB_, 0.7547, 2.91, 0.220, 351, 245, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
2868, d2w5aA1, 0.7547, 2.96, 0.222, 259, 248, HUMAN NEK2 KINASE ADP-BOUND
2869, d2pvrA_, 0.7547, 3.02, 0.166, 328, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
2870, d2bdwA_, 0.7547, 3.31, 0.204, 309, 255, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2871, p6g9hA_, 0.7546, 2.73, 0.214, 343, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2872, d5clpB_, 0.7546, 3.05, 0.170, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2873, d3wf5A_, 0.7546, 3.33, 0.229, 277, 253, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2874, d3u8wA_, 0.7546, 3.28, 0.211, 349, 251, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
2875, d3qqlA_, 0.7546, 3.19, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR L3
2876, d3ngaB_, 0.7546, 3.11, 0.169, 331, 249, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
2877, d3my0Q1, 0.7546, 2.70, 0.253, 293, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2878, p2pvjA_, 0.7546, 3.17, 0.172, 326, 250, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2879, d2ojgA_, 0.7546, 2.74, 0.209, 337, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
2880, d5dn3A_, 0.7545, 3.12, 0.238, 264, 252, AURORA A IN COMPLEX WITH ATP AND AA35.
2881, d5bmsA1, 0.7545, 3.32, 0.190, 289, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2882, d4kwpA_, 0.7545, 3.16, 0.177, 329, 249, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
2883, d4fv7A_, 0.7545, 2.86, 0.217, 342, 244, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
2884, d4erkA_, 0.7545, 2.79, 0.205, 350, 244, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
2885, d3q04A_, 0.7545, 3.11, 0.165, 328, 248, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
2886, d3my0S1, 0.7545, 2.70, 0.253, 293, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2887, d2xnbA_, 0.7545, 3.29, 0.245, 296, 253, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
2888, d2gnjA_, 0.7545, 3.32, 0.241, 335, 253, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
2889, d1xo2B_, 0.7545, 3.05, 0.235, 289, 247, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
2890, d5mrbA1, 0.7544, 2.78, 0.164, 259, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
2891, d4zsgA_, 0.7544, 2.98, 0.207, 347, 246, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
2892, p4md9H_, 0.7544, 3.05, 0.169, 328, 248, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2893, d4figA_, 0.7544, 3.33, 0.190, 292, 253, CATALYTIC DOMAIN OF HUMAN PAK4
2894, d3qziA_, 0.7544, 3.14, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
2895, d3owlA_, 0.7544, 3.12, 0.173, 330, 248, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2896, d3my0C1, 0.7544, 2.78, 0.252, 298, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2897, d3kmwA_, 0.7544, 3.18, 0.262, 268, 252, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
2898, d2xmyA_, 0.7544, 3.19, 0.230, 295, 252, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
2899, p6gdqA_, 0.7543, 2.79, 0.214, 339, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2900, d5xvuB_, 0.7543, 3.07, 0.182, 321, 247, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2901, d5oxgA_, 0.7543, 2.65, 0.279, 293, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2902, d5aneA_, 0.7543, 3.19, 0.226, 294, 252, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2903, d4usdA_, 0.7543, 3.08, 0.249, 268, 249, HUMAN STK10 (LOK) WITH SB-633825
2904, d4ixpA_, 0.7543, 3.10, 0.212, 334, 250, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
2905, d3aglB_, 0.7543, 3.31, 0.241, 335, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2906, d2xzsA_, 0.7543, 3.44, 0.212, 301, 255, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2907, d2vo6A_, 0.7543, 3.30, 0.230, 335, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
2908, d2uzvA_, 0.7543, 3.47, 0.235, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2909, d1xh9A_, 0.7543, 3.25, 0.246, 336, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2910, d1golA_, 0.7543, 2.81, 0.201, 357, 244, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
2911, d5xvuC_, 0.7542, 3.09, 0.174, 321, 247, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2912, d5ku8B_, 0.7542, 3.21, 0.180, 331, 250, CRYSTAL STRUCTURE OF CK2
2913, d5dewA_, 0.7542, 3.40, 0.232, 295, 254, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2914, d4zegA_, 0.7542, 2.94, 0.176, 260, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2915, d4ubaA_, 0.7542, 3.33, 0.175, 333, 252, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
2916, d3repA_, 0.7542, 3.18, 0.262, 268, 252, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
2917, d3q9xA_, 0.7542, 3.13, 0.169, 330, 249, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
2918, d3my0H1, 0.7542, 2.69, 0.253, 293, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2919, d3my0E1, 0.7542, 2.69, 0.253, 293, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2920, d3e8eI_, 0.7542, 3.32, 0.237, 345, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2921, d2ojiA_, 0.7542, 2.79, 0.205, 344, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
2922, d5xvuA_, 0.7541, 3.08, 0.178, 321, 247, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2923, d5n84A1, 0.7541, 2.88, 0.172, 253, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
2924, d5mo7B_, 0.7541, 3.01, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2925, d5m4uA_, 0.7541, 3.10, 0.153, 332, 248, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2926, d4qp4A_, 0.7541, 2.81, 0.217, 337, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
2927, d3u87B_, 0.7541, 3.04, 0.169, 329, 248, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
2928, d3qzhA_, 0.7541, 3.20, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
2929, d3orxB_, 0.7541, 3.21, 0.237, 280, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2930, d2vgpA_, 0.7541, 2.69, 0.214, 265, 243, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2931, d2gnlA_, 0.7541, 3.32, 0.241, 338, 253, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
2932, d1tvoA_, 0.7541, 2.78, 0.213, 350, 244, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2933, p5oulA_, 0.7540, 3.11, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
2934, d3wf6A_, 0.7540, 3.33, 0.229, 277, 253, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2935, d3my0F1, 0.7540, 2.71, 0.253, 293, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2936, d1zwsH_, 0.7540, 3.17, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2937, d5mo7A_, 0.7539, 3.07, 0.174, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2938, d5ct0A_, 0.7539, 3.05, 0.170, 326, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
2939, d3qx4A_, 0.7539, 3.15, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
2940, d2ojjA_, 0.7539, 2.77, 0.205, 344, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
2941, d1oveA_, 0.7539, 3.33, 0.222, 349, 252, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
2942, d5n7vA1, 0.7538, 2.92, 0.170, 257, 247, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
2943, d4ra4A_, 0.7538, 3.07, 0.245, 317, 249, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2944, d4ks8A_, 0.7538, 3.28, 0.198, 286, 252, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2945, d4asxB1, 0.7538, 2.63, 0.258, 296, 240, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
2946, d2f57A1, 0.7538, 3.21, 0.179, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2947, d1w84A_, 0.7538, 3.44, 0.233, 351, 253, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2948, d1pxjA_, 0.7538, 3.20, 0.226, 294, 252, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
2949, d1erkA_, 0.7538, 2.83, 0.205, 357, 244, STRUCTURE OF SIGNAL-REGULATED KINASE
2950, d3rpoA_, 0.7537, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
2951, d3royA_, 0.7537, 3.16, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
2952, d3r7yA_, 0.7537, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
2953, d3r6xA_, 0.7537, 3.20, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
2954, d3oxtA_, 0.7537, 3.28, 0.246, 335, 252, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2955, d3owkA_, 0.7537, 3.14, 0.169, 330, 248, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2956, d3mvjE_, 0.7537, 3.30, 0.241, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2957, d2z7lA_, 0.7537, 2.61, 0.199, 329, 241, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
2958, d2c1bA_, 0.7537, 3.34, 0.237, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
2959, d2b9iA_, 0.7537, 2.82, 0.262, 338, 244, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
2960, d1q62A_, 0.7537, 3.26, 0.234, 336, 252, PKA DOUBLE MUTANT MODEL OF PKB
2961, d1hckA_, 0.7537, 3.19, 0.226, 294, 252, HUMAN CYCLIN-DEPENDENT KINASE 2
2962, d5cu6A_, 0.7536, 3.11, 0.173, 327, 248, CRYSTAL STRUCTURE OF CK2ALPHA
2963, d3q4uC_, 0.7536, 2.64, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
2964, d3pwdA_, 0.7536, 3.20, 0.172, 327, 250, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
2965, d2b9jA_, 0.7536, 2.76, 0.251, 337, 243, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
2966, d1zwsC_, 0.7536, 3.17, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2967, d1mruB_, 0.7536, 2.84, 0.221, 271, 244, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2968, d5osdA_, 0.7535, 3.13, 0.238, 266, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2969, p5n9lA_, 0.7535, 3.20, 0.181, 329, 249, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
2970, d5k5nA_, 0.7535, 3.55, 0.177, 331, 254, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
2971, d5cu0A_, 0.7535, 3.05, 0.166, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2972, d4bxaB_, 0.7535, 3.11, 0.169, 331, 249,  
2973, d1wvxA_, 0.7535, 3.08, 0.222, 275, 248, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2974, d1j3hA_, 0.7535, 3.18, 0.240, 329, 250, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2975, d1hclA_, 0.7535, 3.18, 0.226, 294, 252, HUMAN CYCLIN-DEPENDENT KINASE 2
2976, p5v61A_, 0.7534, 2.68, 0.212, 348, 241, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
2977, p5omyA_, 0.7534, 3.23, 0.155, 332, 251, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2978, d5cx9A_, 0.7534, 3.07, 0.170, 328, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
2979, d4yxrA_, 0.7534, 3.34, 0.237, 334, 253, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
2980, d4qmlA_, 0.7534, 2.95, 0.262, 280, 248, MST3 IN COMPLEX WITH AMP-PNP
2981, d3r71A_, 0.7534, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
2982, d3ocbA_, 0.7534, 2.98, 0.251, 315, 247, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2983, d2gniA_, 0.7534, 3.33, 0.245, 338, 253, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
2984, d2gfcA_, 0.7534, 3.34, 0.237, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2985, d1vebA_, 0.7534, 3.33, 0.237, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
2986, d1m2qA_, 0.7534, 3.17, 0.169, 327, 249, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
2987, p5v62A_, 0.7533, 2.76, 0.212, 349, 241, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
2988, d5mmrB_, 0.7533, 3.00, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
2989, d5cqwB_, 0.7533, 3.12, 0.169, 331, 249, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2990, p4jqeA_, 0.7533, 3.22, 0.169, 369, 249, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
2991, d3r1sA_, 0.7533, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
2992, d3qrtA_, 0.7533, 3.17, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
2993, d3lauA1, 0.7533, 2.66, 0.243, 250, 243, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
2994, d1pxiA_, 0.7533, 3.19, 0.226, 294, 252, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
2995, d5cu4A_, 0.7532, 3.04, 0.174, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2996, d5ctpB_, 0.7532, 3.09, 0.166, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2997, d5ar8A_, 0.7532, 2.43, 0.242, 255, 236, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
2998, d4xrlA_, 0.7532, 2.68, 0.202, 337, 242, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2999, d4qp9A_, 0.7532, 2.84, 0.213, 335, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3000, d3q4uA_, 0.7532, 2.83, 0.277, 298, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3001, d3oogA_, 0.7532, 3.26, 0.242, 333, 252, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
3002, d3gp0A1, 0.7532, 2.72, 0.216, 332, 241, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
3003, d3amaA_, 0.7532, 3.26, 0.250, 342, 252, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
3004, d2vo7A_, 0.7532, 3.34, 0.237, 335, 253, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
3005, p5otyA_, 0.7531, 3.13, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
3006, p5os8A_, 0.7531, 3.11, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
3007, d5mmfA_, 0.7531, 3.01, 0.171, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
3008, d3qx2A_, 0.7531, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
3009, d3nrmA_, 0.7531, 3.11, 0.243, 263, 251, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
3010, d3f3zA_, 0.7531, 3.35, 0.209, 271, 253, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
3011, d3dndA_, 0.7531, 3.33, 0.237, 334, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
3012, d2f49A_, 0.7531, 2.78, 0.254, 335, 244, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3013, d2b9hA_, 0.7531, 2.85, 0.262, 337, 244, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
3014, p6g9mA_, 0.7530, 2.79, 0.210, 341, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3015, d5modA_, 0.7530, 3.01, 0.167, 327, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3016, d4uzhA1, 0.7530, 2.66, 0.243, 250, 243, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3017, d4rlkA_, 0.7530, 3.20, 0.172, 327, 250, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
3018, d4jajA_, 0.7530, 3.07, 0.239, 265, 251, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
3019, d3hv4A_, 0.7530, 3.13, 0.231, 339, 247, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
3020, d5dt3A_, 0.7529, 3.12, 0.235, 263, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3021, d3qwjA_, 0.7529, 3.21, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
3022, d3dlsF_, 0.7529, 2.86, 0.235, 281, 243, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3023, d2f2cB_, 0.7529, 2.81, 0.236, 280, 242, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
3024, d5m4iA_, 0.7528, 3.24, 0.159, 331, 251, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
3025, d4wbbB_, 0.7528, 3.29, 0.238, 334, 252, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
3026, d3flyA_, 0.7528, 3.39, 0.231, 347, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
3027, d3at4A_, 0.7528, 3.20, 0.177, 331, 249, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
3028, d1xh7A_, 0.7528, 3.32, 0.234, 337, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3029, d5umoA_, 0.7527, 2.73, 0.189, 347, 243, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
3030, d5mo8A_, 0.7527, 3.09, 0.170, 325, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3031, d4qo9B_, 0.7527, 3.07, 0.256, 285, 250, MST3 IN COMPLEX WITH DANUSERTIB
3032, d4ez7A1, 0.7527, 3.33, 0.246, 298, 252, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
3033, d3r73A_, 0.7527, 3.22, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
3034, p3e3bX_, 0.7527, 3.23, 0.168, 334, 250, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
3035, d3ckxA_, 0.7527, 2.91, 0.264, 276, 246, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
3036, d2y0aA_, 0.7527, 3.51, 0.207, 300, 256, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
3037, d1sveA_, 0.7527, 3.34, 0.237, 341, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
3038, d5cvhA_, 0.7526, 3.08, 0.174, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA
3039, d4qp3B_, 0.7526, 2.79, 0.210, 331, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
3040, d4jdiA_, 0.7526, 3.20, 0.191, 289, 251, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
3041, d4bn1A_, 0.7526, 3.04, 0.240, 261, 250, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
3042, d3qxoA_, 0.7526, 3.22, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
3043, d3my0D1, 0.7526, 2.76, 0.253, 297, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3044, d2jedA_, 0.7526, 3.10, 0.245, 324, 249, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
3045, p5otzA_, 0.7525, 3.12, 0.173, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
3046, d5byzA_, 0.7525, 2.81, 0.205, 348, 244, ERK5 IN COMPLEX WITH SMALL MOLECULE
3047, d4o0xA1, 0.7525, 3.36, 0.190, 289, 253, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3048, d3vquA_, 0.7525, 2.84, 0.164, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
3049, d3r1qA_, 0.7525, 3.18, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
3050, d3nx8A_, 0.7525, 3.36, 0.237, 333, 253, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
3051, d3my0I1, 0.7525, 2.67, 0.254, 292, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3052, d3mb7A_, 0.7525, 3.22, 0.177, 330, 249, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
3053, d3cohB_, 0.7525, 2.66, 0.239, 247, 243, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3054, d1svgA_, 0.7525, 3.35, 0.237, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
3055, d5os5A_, 0.7524, 3.14, 0.234, 267, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3056, d5mpjA_, 0.7524, 3.08, 0.170, 326, 247, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
3057, d5cu0B_, 0.7524, 3.08, 0.166, 325, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3058, d3at3A_, 0.7524, 3.19, 0.181, 332, 249, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
3059, d5n93A1, 0.7523, 2.84, 0.160, 256, 244, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
3060, d5lqfD1, 0.7523, 2.65, 0.251, 282, 239, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
3061, d4ditA_, 0.7523, 3.73, 0.180, 328, 256, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
3062, d4bggD_, 0.7523, 2.54, 0.283, 286, 237, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3063, d3pxzA1, 0.7523, 3.25, 0.239, 298, 251, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
3064, d1ydsE_, 0.7523, 3.34, 0.237, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
3065, d4usdB_, 0.7522, 3.10, 0.242, 267, 248, HUMAN STK10 (LOK) WITH SB-633825
3066, d4s33A_, 0.7522, 2.79, 0.201, 347, 244, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
3067, d4o0rA_, 0.7522, 3.43, 0.232, 293, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3068, d4iz7A_, 0.7522, 2.76, 0.206, 344, 243, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3069, d4c4eA1, 0.7522, 2.81, 0.160, 253, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3070, d3r28A_, 0.7522, 3.19, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
3071, d3pxfA1, 0.7522, 3.26, 0.239, 298, 251, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3072, d3pooA_, 0.7522, 3.36, 0.241, 331, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
3073, d2gfsA_, 0.7522, 3.21, 0.229, 344, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
3074, d2erzE_, 0.7522, 3.26, 0.242, 334, 252, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
3075, d1xh4A_, 0.7522, 3.32, 0.234, 334, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3076, d5h8gA_, 0.7521, 3.05, 0.183, 324, 246, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
3077, d5ehlA1, 0.7521, 2.82, 0.176, 254, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3078, d5dnrA_, 0.7521, 3.11, 0.239, 264, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
3079, d4nifE_, 0.7521, 2.91, 0.208, 348, 245, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3080, d4ks7A_, 0.7521, 3.24, 0.202, 286, 252, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
3081, d3rp0A_, 0.7521, 3.07, 0.169, 329, 248,  
3082, d3bv2A_, 0.7521, 2.83, 0.227, 337, 242, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
3083, d2zazA_, 0.7521, 3.17, 0.218, 345, 248, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
3084, d4utdA_, 0.7520, 2.99, 0.241, 266, 249, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
3085, d4txcA_, 0.7520, 3.11, 0.217, 276, 249, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3086, d3ds6B_, 0.7520, 3.14, 0.234, 343, 248, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
3087, d3dlsE_, 0.7520, 3.00, 0.224, 282, 245, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3088, d1ydrE_, 0.7520, 3.33, 0.237, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
3089, d1jwhB_, 0.7520, 3.28, 0.179, 335, 251, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
3090, d5mo6B_, 0.7519, 3.04, 0.167, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3091, d4s2zA_, 0.7519, 2.75, 0.193, 346, 243, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
3092, d4a07A_, 0.7519, 3.08, 0.239, 282, 247, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
3093, d3qruA_, 0.7519, 3.14, 0.231, 295, 251, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
3094, d3cohA_, 0.7519, 2.67, 0.239, 247, 243, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3095, d2i6lA_, 0.7519, 2.71, 0.200, 292, 240, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
3096, d5ct0B_, 0.7518, 3.04, 0.167, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
3097, d5b2lA_, 0.7518, 3.32, 0.237, 288, 253, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
3098, d4yffB_, 0.7518, 2.59, 0.274, 264, 237, TNNI3K COMPLEXED WITH INHIBITOR 2
3099, d4s34A_, 0.7518, 2.81, 0.205, 343, 244, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
3100, d3r7eA_, 0.7518, 3.18, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
3101, d3fmhA_, 0.7518, 3.29, 0.236, 347, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
3102, d5movA_, 0.7517, 3.01, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
3103, d5ho6A_, 0.7517, 2.23, 0.393, 240, 229, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.
3104, d5ei2A_, 0.7517, 2.94, 0.179, 256, 246, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3105, d4qp8A_, 0.7517, 2.72, 0.202, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3106, d4nifB_, 0.7517, 2.92, 0.208, 349, 245, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3107, d4fuxA_, 0.7517, 2.82, 0.210, 342, 243, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
3108, p3zuvC_, 0.7517, 2.75, 0.207, 357, 241, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
3109, d1q8wA_, 0.7517, 3.31, 0.234, 334, 252, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
3110, p6g9dA_, 0.7516, 2.79, 0.210, 345, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3111, d4bieB_, 0.7516, 2.59, 0.231, 257, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3112, d3r83A_, 0.7516, 3.23, 0.230, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
3113, d3db6A_, 0.7516, 3.37, 0.226, 287, 252, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
3114, d2x4zA1, 0.7516, 3.24, 0.183, 289, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
3115, d5moeA_, 0.7515, 3.03, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3116, d5mo5A_, 0.7515, 3.03, 0.175, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3117, d4ez3A_, 0.7515, 3.14, 0.232, 294, 250, CDK2 IN COMPLEX WITH NSC 134199
3118, d4ct2A_, 0.7515, 3.14, 0.227, 277, 247, HUMAN PDK1-PKCZETA KINASE CHIMERA
3119, p3zu7A_, 0.7515, 2.90, 0.201, 344, 244, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
3120, d3r7vA_, 0.7515, 3.19, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
3121, d2x6dA_, 0.7515, 2.96, 0.246, 255, 248, AURORA-A BOUND TO AN INHIBITOR
3122, p6g91A_, 0.7514, 2.82, 0.214, 344, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3123, d5mmfB_, 0.7514, 3.03, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
3124, d4zzoA_, 0.7514, 2.82, 0.206, 339, 243, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3125, d4s32A_, 0.7514, 2.83, 0.205, 346, 244, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
3126, p4lfiB_, 0.7514, 3.24, 0.180, 371, 250, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3127, d4i6hA_, 0.7514, 3.54, 0.220, 285, 255, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3128, d3qwkA_, 0.7514, 3.20, 0.235, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
3129, d3iphA_, 0.7514, 3.29, 0.237, 345, 249, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
3130, d1o6yA_, 0.7514, 2.59, 0.221, 260, 240, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3131, d1f0qA_, 0.7514, 3.26, 0.164, 329, 250, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
3132, d4i6bA_, 0.7513, 3.56, 0.224, 285, 255, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3133, d4i5pA_, 0.7513, 3.60, 0.220, 284, 255, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3134, d4fv3A_, 0.7513, 2.77, 0.206, 346, 243, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
3135, d4fv2A_, 0.7513, 2.80, 0.206, 344, 243, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
3136, d3gc9A_, 0.7513, 2.77, 0.231, 335, 242, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
3137, d3fl5A_, 0.7513, 3.23, 0.172, 324, 250, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
3138, d3fkoA_, 0.7513, 3.15, 0.231, 343, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
3139, d3e8eE_, 0.7513, 3.35, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3140, d3dlsC_, 0.7513, 2.97, 0.234, 281, 244, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3141, d2uzwE_, 0.7513, 3.40, 0.236, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
3142, d1wboA_, 0.7513, 3.52, 0.240, 351, 254, FRAGMENT BASED P38 INHIBITORS
3143, d5cx9B_, 0.7512, 3.04, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
3144, d4xp2A_, 0.7512, 2.76, 0.210, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3145, d4oa2A_, 0.7512, 3.15, 0.261, 280, 245,  
3146, p4lfiA_, 0.7512, 3.24, 0.180, 370, 250, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3147, d4fv1A_, 0.7512, 2.75, 0.206, 342, 243, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
3148, d3nszA_, 0.7512, 3.13, 0.170, 327, 247, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
3149, d3ds6A_, 0.7512, 3.15, 0.234, 343, 248, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
3150, d2xruA_, 0.7512, 2.89, 0.243, 253, 247, AURORA-A T288E COMPLEXED WITH PHA-828300
3151, d2qurA_, 0.7512, 3.35, 0.241, 338, 253, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
3152, d1xh6A_, 0.7512, 3.28, 0.238, 331, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
3153, d1mruA_, 0.7512, 2.74, 0.218, 269, 243, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3154, d5v60A_, 0.7511, 2.76, 0.212, 347, 241, PHOSPHO-ERK2 BOUND TO AMP-PCP
3155, d5mo8B_, 0.7511, 3.05, 0.171, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3156, d5cu2B_, 0.7511, 3.05, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
3157, d4qp1B_, 0.7511, 2.79, 0.210, 343, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3158, d2xzsB_, 0.7511, 3.39, 0.213, 293, 254, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3159, d2erkA_, 0.7511, 2.75, 0.207, 351, 241, PHOSPHORYLATED MAP KINASE ERK2
3160, d1zwsE_, 0.7511, 3.20, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3161, d1r39A_, 0.7511, 3.32, 0.224, 345, 250, THE STRUCTURE OF P38ALPHA
3162, d1pxpA_, 0.7511, 3.09, 0.216, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
3163, p5o7iA_, 0.7510, 2.70, 0.211, 340, 242, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
3164, d5lcjA_, 0.7510, 2.77, 0.210, 345, 243, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3165, d4zloA_, 0.7510, 3.20, 0.222, 277, 252, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3166, d4qp6B_, 0.7510, 2.80, 0.206, 334, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3167, d4o0tA_, 0.7510, 3.41, 0.236, 292, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3168, d3my0P_, 0.7510, 2.71, 0.254, 290, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3169, d1zwsA_, 0.7510, 3.22, 0.211, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3170, d1jbpE_, 0.7510, 3.35, 0.241, 339, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
3171, d4s30A_, 0.7509, 2.73, 0.193, 342, 243, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
3172, d4i6fA_, 0.7509, 3.55, 0.220, 285, 255, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3173, p4gubA_, 0.7509, 3.08, 0.174, 329, 247, CASEIN KINASE II BOUND TO INHIBITOR
3174, d4c4jA1, 0.7509, 2.77, 0.169, 258, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3175, d4bckC1, 0.7509, 2.94, 0.237, 291, 245, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3176, d3r21A_, 0.7509, 2.90, 0.247, 254, 247, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3177, d3cqwA_, 0.7509, 2.91, 0.252, 318, 246, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
3178, d2fysB_, 0.7509, 2.65, 0.195, 338, 241, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3179, p6ge0A_, 0.7508, 2.74, 0.211, 343, 242, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3180, d5mowA1, 0.7508, 3.07, 0.175, 326, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3181, d4zznA_, 0.7508, 2.79, 0.206, 338, 243, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
3182, d4usfA1, 0.7508, 3.53, 0.247, 275, 255, HUMAN SLK WITH SB-440719
3183, d3rp0D_, 0.7508, 3.09, 0.169, 329, 248,  
3184, d3flwA_, 0.7508, 3.39, 0.227, 345, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
3185, d5n87A1, 0.7507, 2.84, 0.173, 252, 243, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3186, d5mo5B_, 0.7507, 3.05, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3187, d5cvhB_, 0.7507, 3.05, 0.171, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA
3188, d4xneA_, 0.7507, 2.78, 0.202, 344, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3189, d4qp7B_, 0.7507, 2.74, 0.202, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3190, d3qtwA_, 0.7507, 3.22, 0.235, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
3191, d1zmuB_, 0.7507, 2.45, 0.249, 296, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3192, d1r3cA_, 0.7507, 3.63, 0.243, 349, 255, THE STRUCTURE OF P38ALPHA C162S MUTANT
3193, d1jluE_, 0.7507, 3.36, 0.241, 337, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
3194, d5jznA_, 0.7506, 2.95, 0.234, 268, 244, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3195, d5dh3B_, 0.7506, 3.26, 0.241, 283, 249, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
3196, d5cshA_, 0.7506, 3.06, 0.167, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
3197, d4zslA_, 0.7506, 2.81, 0.210, 341, 243, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3198, d4q9zB_, 0.7506, 3.25, 0.244, 308, 250, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
3199, d3u4uA_, 0.7506, 3.06, 0.163, 327, 246, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
3200, d3e8eP_, 0.7506, 3.35, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3201, d2w5hA1, 0.7506, 3.00, 0.219, 257, 247, HUMAN NEK2 KINASE APO
3202, d1h4lB_, 0.7506, 2.61, 0.232, 278, 237, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
3203, d4zzmA_, 0.7505, 2.86, 0.206, 344, 243, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3204, d4o0yA1, 0.7505, 3.38, 0.190, 289, 253, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3205, d4jbqA_, 0.7505, 2.81, 0.248, 257, 246, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3206, d4grbA_, 0.7505, 3.07, 0.171, 327, 246, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
3207, d3nizA1, 0.7505, 3.00, 0.226, 284, 243, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
3208, d3gcuA_, 0.7505, 3.00, 0.241, 339, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
3209, d5modB_, 0.7504, 3.07, 0.167, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3210, d5ajqB_, 0.7504, 3.29, 0.251, 267, 247, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3211, d4u44B_, 0.7504, 3.71, 0.203, 296, 261, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
3212, d4o6lA_, 0.7504, 2.89, 0.177, 257, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3213, d3rk9A_, 0.7504, 3.15, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
3214, d3r63A_, 0.7504, 2.77, 0.189, 347, 243, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
3215, d3qxpA_, 0.7504, 3.16, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3216, d3hmnA_, 0.7504, 2.87, 0.169, 255, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
3217, d5l8lA_, 0.7503, 2.98, 0.241, 263, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3218, d5hidB1, 0.7503, 2.46, 0.319, 252, 235, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
3219, d5ap7A1, 0.7503, 2.79, 0.165, 253, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3220, d4yc6E_, 0.7503, 3.09, 0.239, 285, 247, CDK1/CKS1
3221, d4xj0B_, 0.7503, 2.84, 0.214, 338, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3222, d4qp4B_, 0.7503, 2.74, 0.202, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3223, p4h3pA_, 0.7503, 2.81, 0.215, 342, 242, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3224, d4bcqC1, 0.7503, 2.93, 0.237, 291, 245, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3225, d3tnqB_, 0.7503, 3.33, 0.238, 331, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
3226, d3idbA_, 0.7503, 3.36, 0.241, 341, 253, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
3227, d3flzA_, 0.7503, 3.39, 0.231, 347, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
3228, d3e8eA_, 0.7503, 3.36, 0.237, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3229, d3a8xA1, 0.7503, 3.11, 0.218, 331, 248, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3230, d4wsqB_, 0.7502, 2.98, 0.180, 310, 245, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3231, d4wnpA_, 0.7502, 2.81, 0.267, 273, 243, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3232, d4gt3A_, 0.7502, 2.83, 0.206, 347, 243, ATP-BOUND FORM OF THE ERK2 KINASE
3233, d3mtfA_, 0.7502, 2.74, 0.279, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
3234, p6g8xA_, 0.7501, 2.90, 0.213, 338, 244, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3235, d4x6rA_, 0.7501, 3.31, 0.238, 347, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
3236, d4qpaA_, 0.7501, 2.76, 0.198, 331, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3237, d4qp2B_, 0.7501, 2.66, 0.199, 329, 241, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3238, d4ewqA_, 0.7501, 3.06, 0.224, 346, 246, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
3239, d3rk7A_, 0.7501, 3.14, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
3240, d5mp8A_, 0.7500, 3.06, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3241, d4yffA_, 0.7500, 2.58, 0.275, 264, 236, TNNI3K COMPLEXED WITH INHIBITOR 2
3242, d4bhnA_, 0.7500, 2.75, 0.218, 256, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3243, d3rkbA_, 0.7500, 3.16, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
3244, d3ow4A_, 0.7500, 2.93, 0.252, 317, 246, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
3245, d3my0T1, 0.7500, 2.67, 0.255, 291, 239, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3246, d3hv5A_, 0.7500, 3.00, 0.241, 339, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
3247, d2gu8A_, 0.7500, 3.38, 0.245, 335, 253, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
3248, d2fumB_, 0.7500, 2.74, 0.219, 262, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3249, d2fa2A_, 0.7500, 2.72, 0.259, 333, 243, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
3250, d2f49B_, 0.7500, 2.84, 0.258, 337, 244, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3251, d1q8uA_, 0.7500, 3.35, 0.237, 341, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
3252, d5cu3A_, 0.7499, 3.08, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
3253, d4lmnA1, 0.7499, 3.36, 0.220, 291, 255, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
3254, d4erwA_, 0.7499, 3.13, 0.237, 292, 249, CDK2 IN COMPLEX WITH STAUROSPORINE
3255, d4arkA1, 0.7499, 3.38, 0.220, 290, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3256, d3ow3A_, 0.7499, 3.38, 0.241, 334, 253, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
3257, d3my0O1, 0.7499, 2.74, 0.254, 296, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3258, d3gu5A1, 0.7499, 3.20, 0.217, 276, 249, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
3259, d2x39A_, 0.7499, 3.03, 0.227, 316, 247, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
3260, d2c5yA_, 0.7499, 3.13, 0.229, 290, 249, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3261, d1w7hA_, 0.7499, 3.46, 0.237, 351, 253, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3262, d1q24A_, 0.7499, 3.37, 0.233, 335, 253, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
3263, d5mo6A_, 0.7498, 3.06, 0.167, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3264, p4mwhA_, 0.7498, 3.21, 0.173, 371, 249, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
3265, d4jdhA_, 0.7498, 3.24, 0.191, 289, 251, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
3266, p4fi1A_, 0.7498, 3.20, 0.173, 371, 249, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
3267, d3e8eB_, 0.7498, 3.36, 0.237, 337, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3268, d3bx5A_, 0.7498, 2.96, 0.226, 338, 243, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
3269, d5ehyA1, 0.7497, 2.84, 0.169, 251, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3270, d5ctpA_, 0.7497, 3.08, 0.167, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3271, d4xrjA_, 0.7497, 2.80, 0.202, 344, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3272, d4xj0A_, 0.7497, 2.88, 0.206, 345, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3273, d4js8A_, 0.7497, 2.88, 0.168, 259, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
3274, d4g6oA_, 0.7497, 2.70, 0.203, 339, 241, CRYSTAL STRUCTURE OF THE ERK2
3275, d3qtqA_, 0.7497, 3.16, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
3276, d3ocbB_, 0.7497, 3.04, 0.251, 319, 247, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
3277, d3nnxA_, 0.7497, 2.93, 0.236, 336, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
3278, d2jdsA_, 0.7497, 3.35, 0.234, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
3279, d1bl6A_, 0.7497, 3.63, 0.243, 351, 255, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
3280, p6g9nA_, 0.7496, 2.83, 0.210, 344, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3281, d5mowB_, 0.7496, 3.08, 0.171, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3282, d4yfiC_, 0.7496, 2.78, 0.269, 269, 238, TNNI3K COMPLEXED WITH INHIBITOR 1
3283, d4yfiA_, 0.7496, 2.75, 0.261, 268, 238, TNNI3K COMPLEXED WITH INHIBITOR 1
3284, d4yffD_, 0.7496, 2.47, 0.269, 257, 234, TNNI3K COMPLEXED WITH INHIBITOR 2
3285, d4o21A_, 0.7496, 3.34, 0.238, 333, 252, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
3286, p3zuvA_, 0.7496, 2.75, 0.207, 357, 241, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
3287, d3pxqA1, 0.7496, 3.46, 0.249, 294, 253, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3288, d3p0mA_, 0.7496, 3.38, 0.241, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
3289, d3mv5A_, 0.7496, 3.12, 0.250, 315, 248, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
3290, d3e8nA1, 0.7496, 3.16, 0.228, 290, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
3291, d3e8eL_, 0.7496, 3.36, 0.237, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3292, d3bv3A_, 0.7496, 2.80, 0.231, 338, 242, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
3293, d2qg5A1, 0.7496, 3.16, 0.189, 268, 249, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3294, p2gmxA_, 0.7496, 2.84, 0.226, 357, 243, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
3295, d5oy6A_, 0.7495, 2.66, 0.280, 291, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3296, d5cwzC_, 0.7495, 3.20, 0.224, 271, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3297, d3mvhA_, 0.7495, 3.19, 0.250, 311, 248, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
3298, d2qg5B1, 0.7495, 3.17, 0.188, 275, 250, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3299, d5oy6C_, 0.7494, 2.68, 0.280, 291, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3300, d5objA_, 0.7494, 3.01, 0.242, 260, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
3301, d5nhfA_, 0.7494, 2.82, 0.202, 339, 243, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3302, d4zs0A_, 0.7494, 2.98, 0.243, 257, 247, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3303, d3qzfA_, 0.7494, 3.23, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
3304, d3flsA_, 0.7494, 3.26, 0.226, 343, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
3305, d1ydtE_, 0.7494, 3.29, 0.238, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
3306, d5oryA_, 0.7493, 3.10, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3307, d5mpjB_, 0.7493, 3.06, 0.171, 324, 246, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
3308, d4zthA_, 0.7493, 2.85, 0.235, 339, 243, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
3309, d4yc6C_, 0.7493, 3.06, 0.243, 285, 247, CDK1/CKS1
3310, d4xozA_, 0.7493, 2.80, 0.202, 341, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3311, d4wnpB_, 0.7493, 2.84, 0.270, 272, 244, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3312, d3socA1, 0.7493, 2.72, 0.258, 296, 240, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3313, d3hmoA_, 0.7493, 2.81, 0.165, 257, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
3314, d3d83A_, 0.7493, 3.40, 0.243, 347, 251, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
3315, p6g92A_, 0.7492, 2.84, 0.210, 343, 243, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3316, d5ikwA_, 0.7492, 2.94, 0.196, 297, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3317, d4wnoA_, 0.7492, 2.87, 0.270, 272, 244, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
3318, d4s31A_, 0.7492, 2.84, 0.205, 347, 244, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
3319, d3r9dA_, 0.7492, 3.18, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
3320, d2jdoA_, 0.7492, 3.04, 0.227, 314, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
3321, d1zmvB_, 0.7492, 2.58, 0.248, 296, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
3322, d1q8tA_, 0.7492, 3.37, 0.237, 338, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
3323, d4ae6A_, 0.7491, 3.28, 0.242, 319, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3324, d3mblA_, 0.7491, 3.43, 0.219, 290, 256, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
3325, d3eqfA_, 0.7491, 3.29, 0.226, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
3326, d4xp3A_, 0.7490, 2.83, 0.210, 339, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3327, d4jboA_, 0.7490, 3.19, 0.243, 266, 251, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3328, d3s3iA_, 0.7490, 3.44, 0.230, 349, 252, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3329, d2bujB1, 0.7490, 3.09, 0.206, 277, 248, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3330, d1jktA_, 0.7490, 3.26, 0.220, 276, 250, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3331, d5cvfA_, 0.7489, 3.08, 0.175, 325, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
3332, d3rniA_, 0.7489, 3.24, 0.231, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
3333, d3rm7A_, 0.7489, 3.28, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
3334, d3rk5A_, 0.7489, 3.18, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
3335, d3qamE_, 0.7489, 3.38, 0.237, 348, 253, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
3336, d2b52A_, 0.7489, 3.11, 0.227, 283, 247, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
3337, d1wvwA_, 0.7489, 3.17, 0.217, 275, 249, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3338, d5lpvA_, 0.7488, 2.96, 0.272, 282, 243, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
3339, d5jrqB1, 0.7488, 2.32, 0.323, 245, 235, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
3340, d4fa2A_, 0.7488, 2.88, 0.235, 339, 243, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
3341, d3qudA_, 0.7488, 3.09, 0.232, 345, 246, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
3342, p3nieA_, 0.7488, 2.96, 0.191, 369, 246, CRYSTAL STRUCTURE OF PF11_0147
3343, d2gtnA_, 0.7488, 2.85, 0.236, 337, 242, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
3344, d2ds1A_, 0.7488, 3.13, 0.226, 290, 248, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3345, d1mq4A_, 0.7488, 3.08, 0.240, 261, 250, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
3346, d4g6nA_, 0.7487, 2.84, 0.202, 341, 243, CRYSTAL STRUCTURE OF THE ERK2
3347, d2vu3A_, 0.7487, 3.06, 0.233, 285, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3348, d1rdqE_, 0.7487, 3.38, 0.241, 340, 253, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
3349, d5moeB_, 0.7486, 3.01, 0.171, 323, 245, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3350, d4yc6G_, 0.7486, 3.06, 0.243, 285, 247, CDK1/CKS1
3351, d4byiA_, 0.7486, 2.85, 0.244, 254, 246, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3352, d3queA_, 0.7486, 3.04, 0.233, 343, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
3353, d3qqfA_, 0.7486, 3.28, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR L1
3354, d3fklA_, 0.7486, 3.25, 0.245, 344, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
3355, d5oseA_, 0.7485, 3.12, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3356, d3r8uA_, 0.7485, 3.23, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
3357, d3pxrA_, 0.7485, 3.22, 0.227, 294, 251, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
3358, d3h9fA1, 0.7485, 2.95, 0.171, 256, 245, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
3359, d2v0dA_, 0.7485, 3.17, 0.233, 292, 249, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3360, d2gtmA_, 0.7485, 3.02, 0.225, 341, 244, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
3361, d2fumD_, 0.7485, 2.72, 0.223, 258, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3362, p6gdmA_, 0.7484, 2.75, 0.194, 341, 242, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3363, p5lw1B_, 0.7484, 2.86, 0.212, 355, 245, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3364, d5ih9A_, 0.7484, 2.72, 0.229, 308, 240, MELK IN COMPLEX WITH NVS-MELK8A
3365, d5c03B_, 0.7484, 2.92, 0.287, 260, 244, CRYSTAL STRUCTURE OF KINASE
3366, d4x6qC_, 0.7484, 3.30, 0.238, 334, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
3367, d4ntsA_, 0.7484, 3.22, 0.236, 341, 250, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3368, d3tnpF_, 0.7484, 3.31, 0.238, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
3369, d3tnpC_, 0.7484, 3.31, 0.238, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
3370, p3nieB_, 0.7484, 2.98, 0.191, 367, 246, CRYSTAL STRUCTURE OF PF11_0147
3371, d3fjqE_, 0.7484, 3.39, 0.241, 334, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
3372, d2w4jA_, 0.7484, 3.22, 0.221, 276, 249, X-RAY STRUCTURE OF A DAP-KINASE 2-277
3373, d1y8yA_, 0.7484, 3.13, 0.225, 292, 249, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3374, d1h07A_, 0.7484, 3.18, 0.229, 285, 249, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3375, d5orzA_, 0.7483, 3.12, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3376, d5obrA_, 0.7483, 2.91, 0.244, 255, 246, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3377, d5cu3B_, 0.7483, 3.09, 0.175, 324, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
3378, d4cvaA1, 0.7483, 2.86, 0.174, 250, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3379, d1yw2A_, 0.7483, 3.01, 0.224, 341, 245, MUTATED MUS MUSCULUS P38 KINASE (MP38)
3380, d1h4lA_, 0.7483, 2.66, 0.232, 278, 237, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
3381, d1h0uA_, 0.7483, 3.10, 0.226, 291, 248,  
3382, d5uorA_, 0.7482, 2.58, 0.234, 249, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3383, d5cvgA_, 0.7482, 2.94, 0.169, 326, 243, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
3384, d4yc6A_, 0.7482, 3.12, 0.243, 285, 247, CDK1/CKS1
3385, d3pp1A1, 0.7482, 3.25, 0.226, 290, 252, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
3386, d3gu6A1, 0.7482, 3.22, 0.221, 276, 249, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
3387, d3c9wB2, 0.7482, 2.72, 0.213, 335, 239, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3388, d3c9wA2, 0.7482, 2.70, 0.209, 335, 239, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3389, d5orrA_, 0.7481, 3.11, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3390, d4wnpD_, 0.7481, 2.77, 0.269, 272, 242, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3391, d4au8B_, 0.7481, 2.81, 0.246, 277, 240, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
3392, d4aguC_, 0.7481, 2.75, 0.251, 278, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3393, d3w8lB_, 0.7481, 3.09, 0.174, 326, 247, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
3394, d2r3oA_, 0.7481, 3.05, 0.227, 289, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3395, p2no3A_, 0.7481, 2.80, 0.219, 357, 242, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3396, d1apmE_, 0.7481, 3.38, 0.237, 338, 253, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
3397, p5o90A_, 0.7480, 2.89, 0.223, 330, 242, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
3398, d3ql8A_, 0.7480, 3.25, 0.231, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
3399, d3dgkA1, 0.7480, 3.21, 0.221, 276, 249, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
3400, d2ozaB_, 0.7480, 2.83, 0.226, 340, 243, STRUCTURE OF P38ALPHA COMPLEX
3401, d2i0hA_, 0.7480, 3.39, 0.222, 349, 252, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
3402, d2c69A_, 0.7480, 3.21, 0.228, 292, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3403, d1u7eA_, 0.7480, 3.38, 0.241, 338, 253,  
3404, d5osfA_, 0.7479, 3.12, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3405, d5os1A_, 0.7479, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3406, d4rvtB_, 0.7479, 3.77, 0.209, 297, 263, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3407, d4bi0A1, 0.7479, 2.75, 0.170, 251, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3408, d3rpvA_, 0.7479, 3.12, 0.221, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
3409, d3r8lA_, 0.7479, 3.15, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L3-4
3410, d3r1yA_, 0.7479, 3.23, 0.227, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
3411, d3qu0A_, 0.7479, 3.16, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
3412, d2c6iA_, 0.7479, 3.11, 0.230, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3413, d5orvA_, 0.7478, 3.12, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3414, d5orpA_, 0.7478, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3415, d4jdkA_, 0.7478, 3.32, 0.195, 288, 251, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
3416, d3s0oA_, 0.7478, 3.21, 0.227, 293, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
3417, d3qqkA_, 0.7478, 3.11, 0.225, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L4
3418, d3fhiA_, 0.7478, 3.38, 0.241, 336, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
3419, d5orsA_, 0.7477, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3420, d5nadA1, 0.7477, 2.72, 0.170, 253, 241, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
3421, d5ci7A_, 0.7477, 2.79, 0.273, 276, 242, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
3422, d4ztrA_, 0.7477, 2.85, 0.245, 249, 245, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3423, d4u40B_, 0.7477, 3.77, 0.217, 299, 263, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3424, d4eklA_, 0.7477, 2.95, 0.252, 329, 246, AKT1 WITH GDC0068
3425, d4dglD_, 0.7477, 3.16, 0.181, 328, 249, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
3426, d3fmkA_, 0.7477, 3.43, 0.227, 346, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
3427, d3a8xB1, 0.7477, 2.97, 0.220, 325, 246, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3428, d5os3A_, 0.7476, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3429, d5orwA_, 0.7476, 3.12, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3430, p5lw1H_, 0.7476, 2.89, 0.216, 355, 245, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3431, d4bggC_, 0.7476, 2.70, 0.282, 279, 238, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3432, d3sqqA_, 0.7476, 3.12, 0.221, 288, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
3433, d3o71A_, 0.7476, 2.90, 0.201, 340, 244, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
3434, p3lhjA_, 0.7476, 3.17, 0.228, 341, 246, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
3435, d3an0A_, 0.7476, 3.95, 0.228, 291, 263,  
3436, d2c6oA_, 0.7476, 3.14, 0.225, 290, 249, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3437, d2c6kA_, 0.7476, 3.21, 0.228, 292, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3438, d1jklA_, 0.7476, 3.22, 0.225, 280, 249, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
3439, d5ornA_, 0.7475, 3.11, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3440, d4bc6A_, 0.7475, 3.09, 0.243, 285, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3441, d3vw6A_, 0.7475, 2.75, 0.218, 255, 238, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3442, d3qywA_, 0.7475, 2.87, 0.206, 340, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3443, d3npcA_, 0.7475, 3.12, 0.211, 357, 246, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
3444, d2b9fA_, 0.7475, 3.00, 0.257, 337, 245, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
3445, d1fmoE_, 0.7475, 3.40, 0.241, 336, 253, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
3446, d1b38A_, 0.7475, 3.14, 0.234, 290, 248, HUMAN CYCLIN-DEPENDENT KINASE 2
3447, d6b4wA_, 0.7474, 3.04, 0.175, 259, 246, TTK IN COMPLEX WITH INHIBITOR
3448, d5ihcA_, 0.7474, 2.44, 0.224, 305, 237, MELK IN COMPLEX WITH NVS-MELK12B
3449, d4pf4A1, 0.7474, 3.21, 0.221, 277, 249, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
3450, d4bieA_, 0.7474, 2.75, 0.223, 257, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3451, d3rjcA_, 0.7474, 3.19, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L4-12
3452, d1gz8A_, 0.7474, 3.09, 0.226, 290, 248, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
3453, d5os0A_, 0.7473, 3.13, 0.240, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3454, d5a14A_, 0.7473, 3.19, 0.252, 284, 246, HUMAN CDK2 WITH TYPE II INHIBITOR
3455, d4l8mA_, 0.7473, 3.02, 0.230, 339, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
3456, d3w1fA_, 0.7473, 2.90, 0.164, 259, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
3457, d3vn9A_, 0.7473, 3.95, 0.228, 291, 263, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
3458, d3ti1A_, 0.7473, 3.17, 0.232, 294, 250, CDK2 IN COMPLEX WITH SUNITINIB
3459, d3qtzA_, 0.7473, 3.12, 0.225, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
3460, d2c6mA_, 0.7473, 3.13, 0.226, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3461, d1zz2A_, 0.7473, 3.07, 0.234, 337, 244, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
3462, d5vefA_, 0.7472, 3.28, 0.191, 289, 251, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
3463, d5orxA_, 0.7472, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3464, d5i3oA_, 0.7472, 2.97, 0.196, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3465, d4yo4A1, 0.7472, 3.22, 0.225, 276, 249, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
3466, d4o0uA_, 0.7472, 3.01, 0.237, 259, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3467, d4fijA_, 0.7472, 3.29, 0.195, 291, 251, CATALYTIC DOMAIN OF HUMAN PAK4
3468, d4fihA_, 0.7472, 3.29, 0.191, 291, 251, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
3469, d4b8lA_, 0.7472, 2.72, 0.215, 249, 242, AURORA B KINASE P353G MUTANT
3470, d3w55A_, 0.7472, 2.80, 0.216, 335, 241, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
3471, d3tiyA_, 0.7472, 3.19, 0.232, 293, 250, CDK2 IN COMPLEX WITH NSC 35676
3472, d3h0zC_, 0.7472, 2.68, 0.236, 246, 242, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3473, d3gu4A1, 0.7472, 3.24, 0.217, 276, 249, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
3474, d3cquA_, 0.7472, 3.04, 0.251, 318, 247, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
3475, d3bhhD1, 0.7472, 2.98, 0.208, 285, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3476, d2uzoA_, 0.7472, 3.10, 0.230, 290, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3477, d2e14A_, 0.7472, 2.80, 0.216, 335, 241,  
3478, d1e1vA_, 0.7472, 3.05, 0.227, 290, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
3479, d1blxA_, 0.7472, 3.61, 0.195, 305, 256, P19INK4D/CDK6 COMPLEX
3480, d5oroA_, 0.7471, 3.13, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3481, d5ci6B_, 0.7471, 2.68, 0.217, 350, 240, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
3482, d5anjA_, 0.7471, 3.20, 0.233, 291, 249, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3483, d4rj3A_, 0.7471, 3.14, 0.226, 287, 248, CDK2 WITH EGFR INHIBITOR COMPOUND 8
3484, d4qp1A_, 0.7471, 2.84, 0.206, 342, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3485, d4n4sA_, 0.7471, 2.90, 0.201, 342, 244, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
3486, d4aguB_, 0.7471, 2.76, 0.247, 276, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3487, d3r9hA_, 0.7471, 3.19, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
3488, d3flqA_, 0.7471, 3.34, 0.225, 345, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
3489, d2c6eB_, 0.7471, 2.73, 0.240, 246, 242, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3490, d5kbqA_, 0.7470, 3.46, 0.233, 289, 253, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3491, d5jzjA_, 0.7470, 2.84, 0.232, 271, 241, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3492, d5dr9A_, 0.7470, 2.90, 0.244, 257, 246, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3493, d5dr6A_, 0.7470, 2.91, 0.244, 257, 246, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3494, d5c03A_, 0.7470, 2.88, 0.288, 260, 243, CRYSTAL STRUCTURE OF KINASE
3495, d5ap4A1, 0.7470, 2.93, 0.169, 253, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3496, d4bcqA1, 0.7470, 2.85, 0.231, 289, 242, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3497, d3r8zA_, 0.7470, 3.21, 0.232, 290, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
3498, d3gu8A1, 0.7470, 3.22, 0.225, 276, 249, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
3499, d3gu7A1, 0.7470, 3.25, 0.221, 276, 249, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
3500, d2vtlA_, 0.7470, 3.14, 0.230, 290, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3501, d2qcsA_, 0.7470, 3.35, 0.238, 335, 252, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
3502, d2nryB_, 0.7470, 3.04, 0.273, 286, 242, CRYSTAL STRUCTURE OF IRAK-4
3503, d1pxoA_, 0.7470, 3.24, 0.223, 294, 251, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
3504, d3wzkA_, 0.7469, 2.86, 0.165, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
3505, d3lfnA_, 0.7469, 3.20, 0.230, 285, 248, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
3506, d3h0zA_, 0.7469, 2.79, 0.246, 248, 244, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3507, d3gc0A_, 0.7469, 2.75, 0.203, 278, 241, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
3508, d2hakD_, 0.7469, 2.93, 0.261, 309, 245, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3509, d3qtuA_, 0.7468, 3.14, 0.225, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
3510, d3qalE_, 0.7468, 3.40, 0.237, 339, 253, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
3511, d3dfcB1, 0.7468, 3.24, 0.217, 276, 249, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
3512, d1pmeA_, 0.7468, 2.71, 0.204, 333, 240, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
3513, d5ap0A1, 0.7467, 2.61, 0.167, 250, 239, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3514, d4ehvA_, 0.7467, 2.93, 0.222, 337, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
3515, d4eh3A_, 0.7467, 2.82, 0.227, 339, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
3516, d3q9zA_, 0.7467, 3.37, 0.175, 332, 251, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
3517, p2no3B_, 0.7467, 2.98, 0.230, 357, 244, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3518, d1ol7A_, 0.7467, 3.07, 0.237, 261, 249, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
3519, d5v19A_, 0.7466, 2.65, 0.247, 250, 235, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3520, d5jznB_, 0.7466, 2.90, 0.223, 266, 242, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3521, d4bi2A1, 0.7466, 2.83, 0.174, 250, 242, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3522, d3q4tA1, 0.7466, 2.63, 0.261, 294, 238, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3523, d3ow4B_, 0.7466, 2.98, 0.252, 317, 246, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
3524, d3o7lB_, 0.7466, 3.30, 0.240, 326, 250, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
3525, d2vtrA_, 0.7466, 3.16, 0.230, 290, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3526, p2h96B_, 0.7466, 2.95, 0.230, 357, 244, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
3527, d1zmuA_, 0.7466, 2.37, 0.251, 293, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3528, d1wfcA_, 0.7466, 3.16, 0.220, 340, 246, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
3529, d1ig1A_, 0.7466, 3.24, 0.221, 280, 249, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
3530, p5lw1E_, 0.7465, 2.90, 0.216, 355, 245, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3531, d3cekA1, 0.7465, 2.98, 0.173, 252, 243, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
3532, d2vtmA_, 0.7465, 3.15, 0.230, 290, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3533, d2jdrA_, 0.7465, 2.95, 0.228, 316, 246, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
3534, d2fumA_, 0.7465, 2.76, 0.220, 263, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3535, d1f3mD_, 0.7465, 3.35, 0.221, 285, 253, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3536, d5dr2A1, 0.7464, 3.01, 0.246, 263, 248, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
3537, d4ypdA1, 0.7464, 3.24, 0.225, 276, 249, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
3538, d3o8uA_, 0.7464, 2.74, 0.222, 332, 239, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
3539, d3flnC_, 0.7464, 3.40, 0.225, 343, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
3540, d2uw9A_, 0.7464, 3.07, 0.227, 316, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
3541, d1bmkA_, 0.7464, 3.56, 0.237, 351, 253, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
3542, d5na0A1, 0.7463, 2.79, 0.174, 250, 241, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
3543, d5lckA_, 0.7463, 2.78, 0.215, 345, 242, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3544, d5dosA_, 0.7463, 3.02, 0.243, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3545, d5av2A_, 0.7463, 3.19, 0.226, 275, 248, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
3546, d4oa6A_, 0.7463, 3.17, 0.262, 279, 244,  
3547, d4o6lB_, 0.7463, 2.59, 0.162, 256, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3548, d4c4fA1, 0.7463, 2.81, 0.170, 250, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3549, d3s00A_, 0.7463, 3.30, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR L4-14
3550, d3qklA_, 0.7463, 3.08, 0.251, 317, 247, SPIROCHROMANE AKT INHIBITORS
3551, d3iggA_, 0.7463, 3.02, 0.220, 290, 246, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
3552, d3eqdA_, 0.7463, 3.31, 0.226, 315, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
3553, d1pxlA_, 0.7463, 3.04, 0.224, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
3554, d1bl7A_, 0.7463, 3.62, 0.241, 351, 253, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
3555, d1atpE_, 0.7463, 3.32, 0.242, 334, 252, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
3556, d5cs6A_, 0.7462, 3.17, 0.170, 327, 247, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
3557, d5av3A_, 0.7462, 3.20, 0.222, 275, 248, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
3558, d5av1A_, 0.7462, 3.19, 0.226, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
3559, d4oa9A_, 0.7462, 3.11, 0.262, 280, 244,  
3560, d4jdjA_, 0.7462, 3.24, 0.196, 288, 250, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
3561, d3qyzA_, 0.7462, 2.89, 0.206, 339, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3562, d1jksA_, 0.7462, 3.25, 0.221, 280, 249, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3563, d5dpvA_, 0.7461, 2.92, 0.244, 257, 246, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3564, d4u7zA1, 0.7461, 3.22, 0.228, 290, 250, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
3565, d4prjA_, 0.7461, 2.83, 0.245, 251, 245, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3566, d3p7aA_, 0.7461, 2.72, 0.222, 332, 239, P38 INHIBITOR-BOUND
3567, d3eqiA_, 0.7461, 3.31, 0.226, 315, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
3568, d3dv3A_, 0.7461, 3.29, 0.232, 288, 250, MEK1 WITH PF-04622664 BOUND
3569, d1jkkA_, 0.7461, 3.25, 0.221, 277, 249, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
3570, d5lpzA_, 0.7460, 3.11, 0.263, 283, 243, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
3571, d4u43B_, 0.7460, 3.79, 0.221, 302, 262, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3572, d4ae9A_, 0.7460, 3.29, 0.239, 321, 251, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
3573, d3mvjA_, 0.7460, 3.39, 0.241, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
3574, d1h0vA_, 0.7460, 3.14, 0.226, 288, 248, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
3575, d1b39A_, 0.7460, 3.15, 0.234, 290, 248, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
3576, d5i3rA_, 0.7459, 2.99, 0.196, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3577, d5dt4A_, 0.7459, 3.02, 0.243, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3578, d4ek3A_, 0.7459, 3.11, 0.231, 287, 247, CRYSTAL STRUCTURE OF APO CDK2
3579, d4dhfA_, 0.7459, 3.05, 0.243, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3580, d4aguA_, 0.7459, 2.78, 0.251, 277, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3581, d3dlsB_, 0.7459, 3.00, 0.227, 280, 242, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3582, d3a7gA_, 0.7459, 3.12, 0.256, 289, 250, HUMAN MST3 KINASE
3583, d5os6A_, 0.7458, 3.15, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3584, d4l67A_, 0.7458, 3.39, 0.190, 289, 252, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
3585, d3py1A1, 0.7458, 3.49, 0.244, 298, 254, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3586, d3npcB_, 0.7458, 3.06, 0.212, 356, 245, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
3587, d2r3pA_, 0.7458, 3.08, 0.227, 289, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3588, d2cpkE_, 0.7458, 3.30, 0.239, 333, 251, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
3589, d2cdzA_, 0.7458, 3.28, 0.192, 289, 250, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
3590, d2c6lA_, 0.7458, 3.19, 0.229, 291, 249, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3591, d5os4A_, 0.7457, 3.15, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3592, d5c01B_, 0.7457, 2.91, 0.296, 260, 243, CRYSTAL STRUCTURE OF KINASE
3593, d5ap3A1, 0.7457, 2.83, 0.170, 250, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3594, d4zp5B_, 0.7457, 3.81, 0.218, 300, 262, MAP4K4 IN COMPLEX WITH INHIBITOR
3595, d4yo6C_, 0.7457, 3.10, 0.262, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
3596, d4fklA_, 0.7457, 3.15, 0.234, 290, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3597, d4bi1A1, 0.7457, 2.65, 0.172, 249, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3598, d3qtxA_, 0.7457, 3.21, 0.232, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
3599, p5oo0A_, 0.7456, 3.15, 0.230, 288, 248, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
3600, d4qpaB_, 0.7456, 2.86, 0.206, 345, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3601, d3fmjA_, 0.7456, 3.32, 0.233, 344, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
3602, d2w1eA1, 0.7456, 2.96, 0.244, 252, 246, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3603, d2r3fA_, 0.7456, 3.16, 0.230, 290, 248, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3604, d1e1xA_, 0.7456, 3.04, 0.228, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
3605, p6g9jA_, 0.7455, 2.75, 0.195, 347, 241, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3606, d4zjjA_, 0.7455, 3.11, 0.230, 280, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3607, d2vz6A1, 0.7455, 2.97, 0.233, 285, 245, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3608, d2r3rA_, 0.7455, 3.08, 0.227, 290, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3609, d1f5qC_, 0.7455, 3.04, 0.239, 288, 243, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
3610, p5w5qB_, 0.7454, 3.74, 0.214, 297, 262, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
3611, d4yffC_, 0.7454, 2.36, 0.272, 258, 232, TNNI3K COMPLEXED WITH INHIBITOR 2
3612, d4ek5A_, 0.7454, 3.14, 0.231, 289, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3613, p2h96A_, 0.7454, 2.90, 0.222, 358, 243, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
3614, d1w8cA_, 0.7454, 3.20, 0.229, 290, 249, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
3615, d1l3rE_, 0.7454, 3.40, 0.238, 338, 252, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3616, d5uoxB_, 0.7453, 2.73, 0.224, 252, 237, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3617, d5t1tC_, 0.7453, 3.11, 0.280, 286, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3618, d3vw6B_, 0.7453, 2.67, 0.229, 253, 236, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3619, d3gfwA1, 0.7453, 2.84, 0.178, 249, 241, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
3620, d2w1gA1, 0.7453, 2.88, 0.245, 254, 245, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3621, d1y91A_, 0.7453, 3.15, 0.227, 286, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3622, d5j95B_, 0.7452, 3.76, 0.218, 300, 261, MAP4K4 IN COMPLEX WITH INHIBITOR
3623, d4fkuA_, 0.7452, 3.17, 0.218, 293, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3624, d4ek4A_, 0.7452, 3.12, 0.231, 287, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3625, d4cegA_, 0.7452, 3.26, 0.243, 264, 251, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
3626, d3fl4A_, 0.7452, 3.13, 0.237, 339, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
3627, d3ehaA1, 0.7452, 3.22, 0.222, 275, 248, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
3628, d1zmvA_, 0.7452, 2.52, 0.250, 293, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
3629, d5av0A_, 0.7451, 3.20, 0.226, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
3630, d4gvaA_, 0.7451, 2.87, 0.202, 345, 243, ADP-BOUND FORM OF THE ERK2 KINASE
3631, d4eh7A_, 0.7451, 2.76, 0.229, 337, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
3632, d3o8pA_, 0.7451, 2.86, 0.231, 336, 242, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
3633, d3bwjA_, 0.7451, 3.38, 0.234, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
3634, d2c68A_, 0.7451, 3.24, 0.228, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3635, d1cdkB_, 0.7451, 3.41, 0.241, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
3636, d4fv0A_, 0.7450, 2.80, 0.186, 341, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
3637, d3d2iA_, 0.7450, 2.93, 0.248, 255, 246, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3638, d3bhhC1, 0.7450, 2.97, 0.205, 284, 244, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3639, d5f9eB_, 0.7449, 3.18, 0.246, 293, 248, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
3640, d5auyA_, 0.7449, 3.21, 0.222, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
3641, d5aafA_, 0.7449, 2.92, 0.244, 254, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3642, d4njdA1, 0.7449, 3.30, 0.191, 289, 251, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
3643, d2qg5D1, 0.7449, 3.19, 0.190, 267, 248, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3644, d2pk9A_, 0.7449, 2.88, 0.246, 287, 240, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
3645, d3f5gA1, 0.7448, 3.22, 0.222, 275, 248, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
3646, d2balA_, 0.7448, 2.97, 0.224, 337, 241, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
3647, d1pxnA_, 0.7448, 3.21, 0.224, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
3648, d5t1sC_, 0.7447, 3.09, 0.254, 284, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3649, d5ortA_, 0.7447, 3.15, 0.236, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3650, d5jt2B1, 0.7447, 2.73, 0.318, 250, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3651, d5di1B_, 0.7447, 3.81, 0.218, 300, 262, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3652, d5dh3A_, 0.7447, 3.28, 0.242, 287, 248, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
3653, d4oacA_, 0.7447, 3.15, 0.262, 280, 244,  
3654, d4gv1A1, 0.7447, 3.11, 0.251, 328, 247, PKB ALPHA IN COMPLEX WITH AZD5363
3655, d4dhfB_, 0.7447, 3.00, 0.244, 258, 246, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3656, d1pf8A_, 0.7447, 3.60, 0.231, 298, 255, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
3657, d5ap2A1, 0.7446, 3.00, 0.172, 253, 244, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3658, d4ztsA_, 0.7446, 2.77, 0.247, 249, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3659, d4eh8A_, 0.7446, 2.72, 0.226, 336, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
3660, d4dymA_, 0.7446, 2.70, 0.278, 293, 237, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
3661, d4cv9A1, 0.7446, 2.99, 0.169, 250, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3662, d3gcqA_, 0.7446, 2.77, 0.225, 337, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
3663, p2y4iC_, 0.7446, 3.48, 0.220, 313, 255, KSR2-MEK1 HETERODIMER
3664, d2dwbA_, 0.7446, 3.01, 0.239, 259, 247, AURORA-A KINASE COMPLEXED WITH AMPPNP
3665, d1v0bA_, 0.7446, 3.19, 0.214, 286, 248, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
3666, p5ax3A_, 0.7445, 2.89, 0.212, 329, 241, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
3667, d5auvA_, 0.7445, 3.22, 0.222, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
3668, d4q9zA1, 0.7445, 3.23, 0.245, 330, 249, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
3669, d4p90B_, 0.7445, 2.87, 0.219, 262, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3670, d4mygA_, 0.7445, 2.77, 0.221, 335, 240, MAPK13 ACTIVE FORM
3671, d4fkiA_, 0.7445, 3.25, 0.230, 287, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3672, d3o8tA_, 0.7445, 2.74, 0.226, 332, 239, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
3673, d2p55A2, 0.7445, 3.42, 0.225, 288, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3674, d2onlB1, 0.7445, 3.07, 0.246, 339, 244, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
3675, d6eimB_, 0.7444, 3.20, 0.241, 295, 245, HUMAN STK10 BOUND TO GW683134A
3676, d4eh4A_, 0.7444, 2.70, 0.230, 337, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
3677, p3vuiA_, 0.7444, 2.97, 0.230, 355, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3678, d3p7bA_, 0.7444, 2.75, 0.222, 332, 239, P38 INHIBITOR-BOUND
3679, d3k5uA_, 0.7444, 2.89, 0.244, 260, 246, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3680, d2j50B_, 0.7444, 2.77, 0.248, 249, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3681, d2j50A_, 0.7444, 2.77, 0.248, 249, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3682, d2fa2B_, 0.7444, 2.81, 0.255, 332, 243, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
3683, d5o21B_, 0.7443, 3.30, 0.257, 273, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3684, d5hu3A_, 0.7443, 3.01, 0.225, 266, 244, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
3685, d4cv8A1, 0.7443, 2.99, 0.177, 252, 243, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3686, p3vugA_, 0.7443, 2.96, 0.235, 356, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3687, p3teiA_, 0.7443, 2.76, 0.212, 339, 240, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3688, d3m11A_, 0.7443, 2.93, 0.240, 256, 246, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3689, d2r3hA_, 0.7443, 3.15, 0.235, 289, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3690, d5uyjA1, 0.7442, 3.15, 0.253, 279, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3691, d3d14A1, 0.7442, 2.99, 0.247, 257, 247, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3692, d3amyA_, 0.7442, 2.77, 0.159, 318, 239, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
3693, d5i0bA_, 0.7441, 3.15, 0.198, 288, 248, STRUCTURE OF PAK4
3694, d5auwA_, 0.7441, 3.17, 0.227, 274, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
3695, d5aaeA_, 0.7441, 2.91, 0.244, 252, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3696, d4ztnC_, 0.7441, 3.07, 0.267, 284, 243, IRAK4-INHIBITOR CO-STRUCTURE
3697, d3pj8A1, 0.7441, 3.37, 0.237, 287, 249, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
3698, d3p78A_, 0.7441, 2.73, 0.226, 332, 239, P38 INHIBITOR-BOUND
3699, d3hv3A_, 0.7441, 2.78, 0.225, 335, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
3700, d1ol6A_, 0.7441, 2.69, 0.242, 245, 240, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3701, d4zk5B_, 0.7440, 3.67, 0.208, 294, 259, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3702, d4appA1, 0.7440, 3.31, 0.191, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
3703, d3lfsA_, 0.7440, 3.19, 0.230, 290, 248, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
3704, d3hp2A_, 0.7440, 2.88, 0.236, 341, 242, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
3705, d1y8gA_, 0.7440, 2.72, 0.244, 292, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
3706, d1p38A_, 0.7440, 3.63, 0.237, 351, 253, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
3707, d6babC_, 0.7439, 3.11, 0.216, 284, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3708, d4zy4A_, 0.7439, 3.33, 0.229, 288, 249, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3709, d4xp0A_, 0.7439, 2.77, 0.191, 336, 241, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3710, d4u80A_, 0.7439, 3.32, 0.232, 286, 250, MEK 1 KINASE BOUND TO G799
3711, d4bidA_, 0.7439, 2.83, 0.218, 254, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3712, d3r22A_, 0.7439, 2.99, 0.244, 255, 246, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3713, d2r3iA_, 0.7439, 3.10, 0.227, 289, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3714, d1unhA_, 0.7439, 2.63, 0.234, 276, 235, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3715, d5auxA_, 0.7438, 3.23, 0.222, 275, 248, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
3716, p3v3vA_, 0.7438, 2.94, 0.235, 351, 243, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
3717, d3p7cA_, 0.7438, 2.70, 0.227, 332, 238, P38 INHIBITOR-BOUND
3718, d3p5kA_, 0.7438, 2.78, 0.222, 332, 239, P38 INHIBITOR-BOUND
3719, d3o2mB_, 0.7438, 3.02, 0.230, 358, 244, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
3720, d2phkA_, 0.7438, 3.19, 0.219, 277, 247, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
3721, d5o21A_, 0.7437, 3.32, 0.257, 272, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3722, d5av4A_, 0.7437, 3.18, 0.227, 274, 247, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
3723, p3vuhA_, 0.7437, 2.97, 0.230, 355, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
3724, d3o2mA_, 0.7437, 2.95, 0.226, 358, 243, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
3725, d3eh9A1, 0.7437, 3.25, 0.222, 274, 248, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
3726, d1unhB_, 0.7437, 2.63, 0.234, 276, 235, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3727, d5mp8B_, 0.7436, 3.07, 0.176, 323, 244, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3728, d5f9eA1, 0.7436, 3.28, 0.249, 331, 249, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
3729, d4lynA_, 0.7436, 3.12, 0.237, 287, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
3730, d3ns9A_, 0.7436, 3.16, 0.231, 289, 247, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
3731, d3a7hA_, 0.7436, 3.17, 0.256, 289, 250, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3732, d1s9jA1, 0.7436, 3.34, 0.232, 288, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3733, d1lezA_, 0.7436, 3.11, 0.244, 343, 246, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
3734, d4ka3A_, 0.7435, 3.10, 0.238, 340, 244, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
3735, d3a8wB1, 0.7435, 3.14, 0.215, 324, 246, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3736, d2okrA_, 0.7435, 3.09, 0.238, 339, 244, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
3737, d5ih8A_, 0.7434, 2.69, 0.231, 306, 238, MELK IN COMPLEX WITH NVS-MELK1
3738, d3eqhA_, 0.7434, 3.45, 0.220, 314, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
3739, d2xh5A_, 0.7434, 3.03, 0.228, 316, 246, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
3740, d4zjiA_, 0.7433, 2.92, 0.229, 278, 245, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3741, d4qtaA_, 0.7433, 2.78, 0.209, 335, 239, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3742, d3r8vA_, 0.7433, 3.35, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
3743, p3n9xB_, 0.7433, 3.10, 0.191, 362, 246, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
3744, d3lfqA_, 0.7433, 3.17, 0.231, 289, 247, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
3745, p6ehuA_, 0.7432, 3.28, 0.169, 327, 248, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
3746, d4ztlA_, 0.7432, 3.14, 0.267, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
3747, d3wzjA_, 0.7432, 2.82, 0.169, 257, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
3748, d3qqjA_, 0.7432, 3.23, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2
3749, d3ag9A_, 0.7432, 3.30, 0.224, 323, 250, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
3750, d4u81A1, 0.7431, 3.29, 0.233, 288, 249, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
3751, d3o50B_, 0.7431, 2.94, 0.241, 249, 245, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
3752, d3d15A_, 0.7431, 2.95, 0.248, 256, 246, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3753, d3aglA_, 0.7431, 3.33, 0.242, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
3754, d2w1fA1, 0.7431, 2.90, 0.245, 253, 245, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3755, d1lewA_, 0.7431, 2.93, 0.236, 341, 242, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
3756, d4zjiB_, 0.7430, 3.15, 0.222, 276, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3757, p4jr7A_, 0.7430, 3.15, 0.164, 367, 244, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3758, d4iz7C_, 0.7430, 2.87, 0.202, 340, 242, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3759, p3vudA_, 0.7430, 2.97, 0.230, 355, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
3760, d3tizA_, 0.7430, 3.26, 0.220, 293, 250, CDK2 IN COMPLEX WITH NSC 111848
3761, d3eqbA1, 0.7430, 3.30, 0.233, 288, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3762, d2vz6B1, 0.7430, 3.11, 0.235, 288, 247, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3763, d1oirA_, 0.7430, 3.13, 0.224, 286, 246, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
3764, d5kx8C_, 0.7429, 3.17, 0.270, 287, 244, IRAK4-INHIBITOR CO-STRUCTURE
3765, d4gsbA_, 0.7429, 2.73, 0.200, 343, 240, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
3766, d4b9dB1, 0.7429, 3.32, 0.197, 291, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3767, d3zhpC1, 0.7429, 3.32, 0.243, 267, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3768, p3vukA_, 0.7429, 2.98, 0.235, 355, 243, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
3769, d3ma6B_, 0.7429, 3.32, 0.246, 266, 252, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
3770, d4fkgA_, 0.7428, 3.22, 0.231, 286, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3771, d4eh6A_, 0.7428, 2.70, 0.223, 335, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
3772, d4c4iA1, 0.7428, 2.91, 0.178, 250, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3773, d3sa0A_, 0.7428, 2.76, 0.178, 354, 241, COMPLEX OF ERK2 WITH NORATHYRIOL
3774, p3o17A_, 0.7428, 3.00, 0.230, 357, 244, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
3775, d3hllA_, 0.7428, 2.89, 0.228, 337, 241, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
3776, d3hegA_, 0.7428, 2.65, 0.223, 333, 238, P38 IN COMPLEX WITH SORAFENIB
3777, d4xs2A_, 0.7427, 3.12, 0.267, 283, 243, IRAK4-INHIBITOR CO-STRUCTURE
3778, d4o6eA_, 0.7427, 2.73, 0.206, 328, 238, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
3779, p4h3bA_, 0.7427, 3.12, 0.207, 351, 246, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
3780, d4apcB1, 0.7427, 3.34, 0.201, 291, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3781, d5auuA_, 0.7426, 3.20, 0.227, 274, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
3782, d4zjiD_, 0.7426, 3.48, 0.221, 280, 253, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3783, d3dj7A_, 0.7426, 3.02, 0.247, 257, 247, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3784, d5autA_, 0.7425, 3.20, 0.223, 274, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
3785, d4kinB_, 0.7425, 3.19, 0.233, 341, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
3786, p4h3bC_, 0.7425, 3.13, 0.207, 351, 246, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
3787, d3v01A1, 0.7425, 3.29, 0.229, 288, 249, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3788, d3mh1A_, 0.7425, 2.75, 0.217, 337, 240, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
3789, d3gubA1, 0.7425, 3.29, 0.225, 276, 249, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
3790, d1pxkA_, 0.7425, 3.13, 0.227, 290, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
3791, d4xv9A1, 0.7424, 2.19, 0.316, 244, 231, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
3792, d4jvgB1, 0.7424, 2.23, 0.322, 242, 230, B-RAF KINASE IN COMPLEX WITH BIRB796
3793, d4eh2A_, 0.7424, 2.83, 0.229, 337, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
3794, d3qzgA_, 0.7424, 3.25, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
3795, d3oz6A_, 0.7424, 2.65, 0.248, 343, 238, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
3796, d1y8gB_, 0.7424, 2.86, 0.243, 292, 239, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
3797, d4oabA_, 0.7423, 3.14, 0.263, 279, 243,  
3798, d3f5uA1, 0.7423, 3.28, 0.222, 275, 248, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
3799, d3rocA_, 0.7422, 3.06, 0.230, 337, 243, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
3800, d3gc7A_, 0.7422, 3.47, 0.219, 349, 251, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
3801, d5n66A_, 0.7421, 2.53, 0.225, 332, 236, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
3802, d4ztlD_, 0.7421, 3.12, 0.272, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
3803, p4ux9C_, 0.7421, 2.70, 0.222, 333, 239, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3804, d3fdnA_, 0.7421, 2.94, 0.248, 261, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3805, d2ghmA_, 0.7421, 2.99, 0.223, 336, 242, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
3806, d4wnpC_, 0.7420, 2.89, 0.269, 271, 242, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3807, d3zonA_, 0.7420, 2.98, 0.292, 261, 243, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
3808, d3zlyA_, 0.7420, 3.31, 0.224, 310, 250, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
3809, d3p79A_, 0.7420, 2.76, 0.222, 332, 239, P38 INHIBITOR-BOUND
3810, d3fmlA_, 0.7420, 3.38, 0.218, 342, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
3811, d5w5jB_, 0.7419, 2.78, 0.229, 257, 240, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
3812, p4ux9B_, 0.7419, 2.60, 0.219, 327, 237, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3813, d4qo9A_, 0.7419, 3.17, 0.262, 280, 248, MST3 IN COMPLEX WITH DANUSERTIB
3814, d3uliA_, 0.7419, 3.19, 0.228, 286, 246, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
3815, p3n9xA_, 0.7419, 3.06, 0.192, 374, 245, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
3816, d3fz1A_, 0.7419, 3.19, 0.228, 284, 246, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
3817, d3c5uA_, 0.7419, 2.81, 0.232, 338, 241, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
3818, d2r3gA_, 0.7419, 3.10, 0.233, 287, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3819, d5orlA_, 0.7418, 3.21, 0.244, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3820, d4yp8C_, 0.7418, 3.12, 0.280, 287, 243, IRAK4-INHIBITOR CO-STRUCTURE
3821, d4y73C_, 0.7418, 3.18, 0.270, 290, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3822, d4fkvA_, 0.7418, 3.12, 0.229, 282, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3823, d3le6A_, 0.7418, 3.11, 0.229, 283, 245, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
3824, d2f9gA_, 0.7418, 2.76, 0.264, 332, 239, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
3825, p6ehuB_, 0.7417, 3.23, 0.170, 327, 247, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
3826, d5lpwA_, 0.7417, 2.82, 0.264, 280, 239, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
3827, d4ztmA_, 0.7417, 3.10, 0.267, 287, 243, IRAK4-INHIBITOR CO-STRUCTURE
3828, d4ra5B_, 0.7417, 3.19, 0.246, 310, 248, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
3829, d3qqgA_, 0.7417, 3.26, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2-5
3830, d3qkkA_, 0.7417, 3.05, 0.252, 326, 246, SPIROCHROMANE AKT INHIBITORS
3831, d2pv8A_, 0.7417, 2.82, 0.220, 337, 241,  
3832, d2onlA1, 0.7417, 3.09, 0.243, 338, 243, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
3833, d2i0eA_, 0.7417, 2.98, 0.262, 326, 244, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
3834, d1xr1A_, 0.7417, 3.20, 0.224, 277, 245, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
3835, p4ux9A_, 0.7416, 2.77, 0.221, 343, 240, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3836, d4ithA_, 0.7416, 2.45, 0.305, 247, 233, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
3837, d4bhzA1, 0.7416, 2.67, 0.168, 248, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3838, d4b0gA_, 0.7416, 2.70, 0.242, 247, 240, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3839, d1h01A_, 0.7416, 3.13, 0.224, 286, 246, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3840, d1a9uA_, 0.7416, 3.48, 0.225, 351, 249, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
3841, d5dt0A_, 0.7415, 2.99, 0.244, 259, 246, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3842, d5drdA_, 0.7415, 2.98, 0.244, 259, 246, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3843, d5buiA_, 0.7415, 2.80, 0.222, 338, 239, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
3844, d4useA_, 0.7415, 3.15, 0.243, 286, 243, HUMAN STK10 (LOK) WITH SB-633825
3845, d3qqhA_, 0.7415, 3.25, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2-2
3846, d3fmnA_, 0.7415, 3.35, 0.238, 341, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
3847, d5k4iA_, 0.7414, 2.84, 0.218, 336, 239, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
3848, d5bx0A_, 0.7414, 3.40, 0.225, 315, 253, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
3849, d3nwwA_, 0.7414, 3.05, 0.227, 339, 242, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
3850, d3fskA_, 0.7414, 3.30, 0.242, 342, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
3851, d2nruB_, 0.7414, 3.09, 0.281, 294, 242, CRYSTAL STRUCTURE OF IRAK-4
3852, d1cdkA_, 0.7414, 3.45, 0.241, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
3853, d5uiqC_, 0.7413, 2.83, 0.283, 280, 237, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3854, d5cshB_, 0.7413, 3.07, 0.169, 323, 243, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
3855, d5c01A_, 0.7413, 2.91, 0.302, 258, 242, CRYSTAL STRUCTURE OF KINASE
3856, d5auzA_, 0.7413, 3.22, 0.223, 274, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
3857, d5aagA_, 0.7413, 2.92, 0.245, 253, 245, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3858, d4bf2B_, 0.7413, 2.62, 0.231, 252, 234, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3859, d3zhpD_, 0.7413, 3.30, 0.255, 264, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3860, d3v04A1, 0.7413, 3.48, 0.217, 288, 254, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3861, d3krwA2, 0.7413, 3.34, 0.192, 349, 250, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
3862, d2oibB_, 0.7413, 2.94, 0.276, 278, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3863, p6gihA_, 0.7412, 3.12, 0.180, 324, 245, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
3864, d5vc5A_, 0.7412, 2.98, 0.181, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
3865, d5os2A_, 0.7412, 3.13, 0.246, 261, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3866, d4ra5A1, 0.7412, 3.30, 0.245, 331, 249, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
3867, d4bibA_, 0.7412, 2.81, 0.224, 254, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3868, d3t9iA_, 0.7412, 3.20, 0.225, 273, 244, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3869, d3qkmA_, 0.7412, 3.04, 0.252, 329, 246, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
3870, d3ha8A_, 0.7412, 3.30, 0.230, 342, 248, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
3871, d4ztmD_, 0.7411, 3.19, 0.267, 282, 243, IRAK4-INHIBITOR CO-STRUCTURE
3872, d4zjiC_, 0.7411, 3.44, 0.222, 281, 252, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3873, d4u41B_, 0.7411, 3.84, 0.202, 297, 262, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3874, d3pvuA2, 0.7411, 3.28, 0.193, 340, 249, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
3875, d3hl7A_, 0.7411, 2.94, 0.237, 336, 241, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
3876, d3eqgA_, 0.7411, 3.29, 0.215, 314, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
3877, d1o6lA_, 0.7411, 3.13, 0.227, 316, 247, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
3878, d1jsvA_, 0.7411, 3.11, 0.233, 287, 245, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
3879, d5jq5A_, 0.7410, 3.13, 0.233, 287, 245, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
3880, d4oboB_, 0.7410, 3.78, 0.203, 297, 261, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3881, d4n0sA_, 0.7410, 2.88, 0.190, 348, 242, COMPLEX OF ERK2 WITH CAFFEIC ACID
3882, d3vvhA1, 0.7410, 3.50, 0.230, 286, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3883, d3tl8D_, 0.7410, 3.29, 0.279, 306, 247, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
3884, d3gcvA_, 0.7410, 3.05, 0.230, 338, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
3885, d3c4eB_, 0.7410, 3.36, 0.223, 273, 247, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3886, d5clpA_, 0.7409, 3.05, 0.169, 322, 242, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
3887, d4zxtA_, 0.7409, 2.86, 0.186, 348, 242, COMPLEX OF ERK2 WITH CATECHOL
3888, d4u45B_, 0.7409, 3.79, 0.208, 295, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
3889, d4jvgC1, 0.7409, 2.19, 0.328, 241, 229, B-RAF KINASE IN COMPLEX WITH BIRB796
3890, d3jy0A_, 0.7409, 3.19, 0.225, 275, 244, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3891, d3a8wA1, 0.7409, 3.19, 0.215, 323, 246, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3892, d5uy6A1, 0.7408, 3.15, 0.254, 280, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3893, d3uc3A_, 0.7408, 2.88, 0.219, 272, 242, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
3894, d5jzjB_, 0.7407, 2.85, 0.230, 261, 239, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3895, d4f9wA_, 0.7407, 2.90, 0.237, 336, 241, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
3896, d3pvwA2, 0.7407, 3.42, 0.203, 343, 251, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
3897, d3objA_, 0.7407, 2.67, 0.227, 332, 238, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
3898, p3o17B_, 0.7407, 3.03, 0.230, 357, 244, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
3899, d3i60A_, 0.7407, 2.80, 0.218, 335, 238, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
3900, d2w1dA1, 0.7407, 3.00, 0.245, 251, 245, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3901, d2a4lA_, 0.7407, 3.06, 0.238, 286, 244, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
3902, d5jt2A1, 0.7406, 2.78, 0.319, 253, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3903, d5hidA1, 0.7406, 2.36, 0.325, 240, 231, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
3904, d5ap5A1, 0.7406, 2.94, 0.174, 248, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3905, d4jt3A_, 0.7406, 2.84, 0.170, 254, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
3906, d3idcA_, 0.7406, 3.47, 0.241, 341, 253, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
3907, p2g01A_, 0.7406, 3.02, 0.230, 355, 244, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3908, d6b16A_, 0.7405, 3.23, 0.239, 285, 247, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3909, d5v24A_, 0.7405, 2.75, 0.225, 249, 236, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3910, d3ocgA_, 0.7405, 3.04, 0.241, 336, 241, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
3911, d3d0eB_, 0.7405, 3.32, 0.225, 322, 249, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
3912, d2x9eA_, 0.7405, 2.84, 0.175, 253, 240, HUMAN MPS1 IN COMPLEX WITH NMS-P715
3913, d2i0eB_, 0.7405, 2.98, 0.254, 300, 244, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
3914, p2gmxB_, 0.7405, 2.97, 0.226, 357, 243, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
3915, d3zlwA_, 0.7404, 3.30, 0.228, 312, 250, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
3916, d3mygA_, 0.7404, 2.97, 0.245, 252, 245, AURORA A KINASE COMPLEXED WITH SCH 1473759
3917, d3hv4B_, 0.7404, 3.09, 0.238, 338, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
3918, d3d0eA_, 0.7404, 3.32, 0.225, 322, 249, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
3919, d4fk3B1, 0.7403, 2.20, 0.341, 241, 229, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
3920, d3hv5B_, 0.7403, 3.14, 0.237, 339, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
3921, d2xngA_, 0.7403, 2.94, 0.250, 253, 244, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3922, d2vtoA_, 0.7403, 3.06, 0.230, 283, 244, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3923, d1yrpA_, 0.7403, 3.32, 0.221, 275, 249, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
3924, d1o6kA_, 0.7403, 3.04, 0.228, 317, 246, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
3925, d2fvdA_, 0.7402, 3.05, 0.236, 284, 242, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
3926, d1yrpB_, 0.7402, 3.32, 0.221, 275, 249, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
3927, d5ieyA_, 0.7401, 3.24, 0.227, 286, 247, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
3928, p4h3pD_, 0.7401, 2.75, 0.218, 338, 238, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3929, d3zlsA_, 0.7401, 3.34, 0.223, 315, 251, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
3930, d3c4eA_, 0.7401, 3.37, 0.223, 273, 247, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3931, d2r3qA_, 0.7401, 3.12, 0.233, 286, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3932, d5t1tA_, 0.7400, 3.17, 0.276, 283, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3933, d3mvlA_, 0.7400, 3.09, 0.231, 339, 242, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
3934, d3e88B_, 0.7400, 3.24, 0.226, 319, 248, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3935, d3e88A_, 0.7400, 3.24, 0.226, 319, 248, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3936, d2vtsA_, 0.7400, 3.05, 0.230, 282, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3937, d1ywrA_, 0.7400, 3.07, 0.231, 338, 242, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
3938, d4ztmC_, 0.7399, 3.00, 0.276, 282, 239, IRAK4-INHIBITOR CO-STRUCTURE
3939, d3qc4A_, 0.7399, 3.30, 0.222, 276, 248, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3940, d2r7iB_, 0.7399, 2.97, 0.160, 322, 243, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3941, d4jvgD1, 0.7398, 2.30, 0.322, 245, 230, B-RAF KINASE IN COMPLEX WITH BIRB796
3942, d3krxA2, 0.7398, 3.36, 0.192, 349, 250, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
3943, d2r7iA_, 0.7398, 3.00, 0.156, 322, 243, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3944, d4kipB_, 0.7397, 3.20, 0.234, 338, 244, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
3945, d5k76B_, 0.7396, 3.11, 0.278, 281, 241, IRAK4 IN COMPLEX WITH COMPOUND 28
3946, d4zy6A_, 0.7396, 3.20, 0.232, 284, 246, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3947, d4h36A_, 0.7396, 3.15, 0.203, 353, 246, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
3948, d4f9yA_, 0.7396, 3.11, 0.235, 339, 243, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
3949, d3h0yA_, 0.7396, 2.92, 0.246, 250, 244, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3950, d3e8dB_, 0.7396, 3.34, 0.225, 317, 249, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3951, d3e8dA_, 0.7396, 3.34, 0.225, 315, 249, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
3952, d3dajA_, 0.7396, 2.67, 0.251, 245, 239, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
3953, d2ptjA_, 0.7396, 2.78, 0.230, 334, 239,  
3954, d5kx7B_, 0.7395, 3.18, 0.272, 286, 243, IRAK4-INHIBITOR CO-STRUCTURE
3955, d4ztnA_, 0.7395, 3.09, 0.273, 286, 242, IRAK4-INHIBITOR CO-STRUCTURE
3956, d4c3rA_, 0.7395, 2.93, 0.246, 252, 244, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3957, d3kf7A_, 0.7395, 2.96, 0.228, 337, 241, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
3958, d2r7iD_, 0.7395, 2.98, 0.160, 322, 243, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3959, d2puuA_, 0.7395, 2.57, 0.213, 330, 235, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
3960, d5dgzA_, 0.7394, 3.33, 0.224, 273, 246, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
3961, d4u3yB_, 0.7394, 3.95, 0.223, 300, 264, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
3962, d4mygB_, 0.7394, 2.92, 0.228, 335, 241, MAPK13 ACTIVE FORM
3963, d3zz2A_, 0.7394, 3.08, 0.246, 281, 240,  
3964, d3vvhB1, 0.7394, 3.34, 0.231, 289, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3965, d3d5xA_, 0.7394, 3.18, 0.230, 279, 244, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
3966, d1zrzA_, 0.7394, 3.27, 0.219, 310, 247, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
3967, d1wccA_, 0.7394, 3.07, 0.234, 283, 244, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
3968, d4wovA_, 0.7393, 2.91, 0.298, 258, 242, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
3969, d4fv6A_, 0.7393, 2.75, 0.215, 332, 237, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
3970, d4crsA1, 0.7393, 2.94, 0.248, 329, 242, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
3971, d3vvhC1, 0.7393, 3.37, 0.222, 282, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3972, d3uvrA_, 0.7393, 3.02, 0.240, 331, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
3973, d3lffA_, 0.7393, 3.08, 0.231, 335, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
3974, d3comB_, 0.7393, 3.32, 0.220, 279, 250, CRYSTAL STRUCTURE OF MST1 KINASE
3975, d1vzoA_, 0.7393, 3.62, 0.214, 319, 252, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
3976, d5k4jA1, 0.7392, 3.14, 0.238, 281, 244, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
3977, d4jbpA_, 0.7392, 3.02, 0.244, 255, 246, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3978, d4eh9A_, 0.7392, 2.80, 0.231, 334, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
3979, d2j7tA_, 0.7392, 3.33, 0.247, 285, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
3980, d1yxuB_, 0.7392, 3.47, 0.226, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3981, d1yxuA_, 0.7392, 3.46, 0.222, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3982, d5vc4A_, 0.7391, 3.02, 0.181, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3983, d5mhqA1, 0.7391, 3.16, 0.228, 288, 246, CCT068127 IN COMPLEX WITH CDK2
3984, d4ztnD_, 0.7391, 3.16, 0.272, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
3985, d4u3zB_, 0.7391, 3.67, 0.201, 294, 259, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
3986, d4jvgA1, 0.7391, 2.30, 0.330, 245, 230, B-RAF KINASE IN COMPLEX WITH BIRB796
3987, d3unkA_, 0.7391, 3.43, 0.234, 295, 252, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
3988, d2nruA_, 0.7391, 3.13, 0.281, 293, 242, CRYSTAL STRUCTURE OF IRAK-4
3989, p6cpwA_, 0.7390, 2.68, 0.202, 328, 238, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
3990, d4b9dA1, 0.7390, 3.34, 0.198, 286, 248, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3991, d3pxyA_, 0.7390, 3.29, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS648
3992, d2w17A_, 0.7390, 3.11, 0.230, 278, 243, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
3993, d1s9iB_, 0.7390, 3.34, 0.236, 291, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3994, d5he0A2, 0.7389, 3.45, 0.195, 346, 251, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
3995, d5ew9A_, 0.7389, 3.19, 0.232, 257, 250, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
3996, d4k18A_, 0.7389, 3.26, 0.224, 277, 246, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3997, d4fv8A_, 0.7389, 2.84, 0.218, 333, 238, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
3998, d4equB_, 0.7389, 3.10, 0.241, 282, 241, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3999, d4c4gA1, 0.7389, 2.81, 0.176, 247, 239, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4000, d2jc6C_, 0.7389, 2.95, 0.207, 277, 242, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4001, d1xwsA_, 0.7389, 3.36, 0.223, 273, 247, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
4002, d6bkuA1, 0.7388, 3.09, 0.255, 264, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
4003, d4u42B_, 0.7388, 3.02, 0.231, 265, 242, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4004, d1eh4B_, 0.7388, 3.50, 0.169, 293, 254, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
4005, d1aq1A_, 0.7388, 3.01, 0.244, 277, 242, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
4006, d5t1tD_, 0.7387, 3.20, 0.276, 283, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4007, d5lpbA_, 0.7387, 2.99, 0.271, 280, 240, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4008, d4mbiA_, 0.7387, 3.40, 0.227, 274, 247, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
4009, d3mh3A_, 0.7387, 2.80, 0.230, 334, 239, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4010, d3hrbA_, 0.7387, 3.38, 0.211, 344, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4011, d3eqcA_, 0.7387, 3.42, 0.225, 312, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
4012, d5lpyA_, 0.7386, 3.06, 0.261, 282, 241, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
4013, d5he2A2, 0.7386, 3.32, 0.185, 353, 249, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
4014, d3zlxA_, 0.7386, 3.43, 0.225, 312, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
4015, d3e87B_, 0.7386, 3.27, 0.226, 321, 248, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
4016, d3e87A_, 0.7386, 3.27, 0.226, 321, 248, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
4017, d5t1sA_, 0.7385, 3.09, 0.269, 280, 242, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4018, d4zy5A_, 0.7385, 3.21, 0.237, 283, 245, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
4019, d3oc1A_, 0.7385, 2.58, 0.221, 330, 235, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4020, d3mw1A_, 0.7385, 3.31, 0.215, 342, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4021, d3hv6A_, 0.7385, 2.66, 0.225, 331, 236, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
4022, d2oi4X_, 0.7385, 3.33, 0.232, 275, 246, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
4023, d4pnkA2, 0.7384, 3.40, 0.192, 350, 250, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
4024, p4f9bA_, 0.7384, 3.07, 0.172, 318, 244, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
4025, p4d28C_, 0.7384, 3.16, 0.235, 279, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4026, d3mvjB_, 0.7384, 3.39, 0.235, 320, 251, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
4027, d1pxmA_, 0.7384, 3.20, 0.227, 290, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
4028, d4jx3A_, 0.7383, 3.33, 0.224, 274, 246, CRYSTAL STRUCTURE OF PIM1 KINASE
4029, d2np8A_, 0.7383, 3.00, 0.249, 256, 245, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
4030, d1sykA_, 0.7383, 3.33, 0.232, 348, 250, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4031, d1oz1A_, 0.7383, 3.33, 0.239, 344, 247, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
4032, d1yxsA_, 0.7382, 3.46, 0.226, 274, 248, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
4033, d5c1qB_, 0.7381, 3.46, 0.226, 273, 248, SERINE/THREONINE-PROTEIN KINASE PIM-1
4034, d4zjjB_, 0.7381, 3.22, 0.222, 277, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4035, d2jc6A_, 0.7381, 2.89, 0.211, 278, 242, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4036, d2c30A_, 0.7381, 3.30, 0.193, 289, 249, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
4037, d1ywvA_, 0.7381, 3.34, 0.220, 274, 246, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
4038, d5l8jA_, 0.7380, 2.87, 0.235, 253, 243, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
4039, d2vv9A_, 0.7380, 3.14, 0.238, 279, 244, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
4040, d2bzhB_, 0.7380, 3.28, 0.229, 275, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4041, d3c4eC_, 0.7379, 3.36, 0.224, 272, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4042, d2o3pA_, 0.7379, 3.41, 0.227, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
4043, d5w84A_, 0.7378, 3.04, 0.280, 279, 239, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4044, d3r01A_, 0.7378, 3.29, 0.220, 274, 245, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4045, d3o50A_, 0.7378, 2.79, 0.249, 246, 241, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4046, d3hecA_, 0.7378, 2.62, 0.213, 329, 235, P38 IN COMPLEX WITH IMATINIB
4047, d3a99A_, 0.7378, 3.18, 0.225, 273, 244, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
4048, d2o64A_, 0.7378, 3.42, 0.227, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
4049, d2j2iB_, 0.7378, 3.27, 0.229, 273, 245, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
4050, d2j0iA_, 0.7378, 3.31, 0.198, 289, 248, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4051, d1sykB_, 0.7378, 3.34, 0.232, 323, 250, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4052, d5m44A_, 0.7377, 3.21, 0.163, 329, 246, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
4053, d4tyhB_, 0.7377, 2.85, 0.242, 335, 240, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
4054, d4r3cA_, 0.7377, 2.88, 0.229, 335, 240, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
4055, d4obqB_, 0.7377, 3.67, 0.206, 293, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4056, d4dfyE_, 0.7377, 3.30, 0.245, 312, 249, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4057, d3pg3A_, 0.7377, 2.92, 0.240, 337, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
4058, d3fc1X_, 0.7377, 2.76, 0.207, 330, 237, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
4059, d4wt6A_, 0.7376, 3.28, 0.224, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
4060, d2fumC_, 0.7376, 2.67, 0.218, 254, 238, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4061, d5ihaA_, 0.7375, 2.70, 0.225, 303, 236, MELK IN COMPLEX WITH NVS-MELK8F
4062, d4yo6A_, 0.7375, 3.16, 0.267, 286, 243, IRAK4-INHIBITOR CO-STRUCTURE
4063, d4kiqC_, 0.7375, 3.07, 0.236, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4064, d4kiqA_, 0.7375, 3.06, 0.236, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4065, d3uzpA_, 0.7375, 3.50, 0.217, 292, 253, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4066, d4ztlC_, 0.7374, 3.04, 0.276, 282, 239, IRAK4-INHIBITOR CO-STRUCTURE
4067, d3vapA_, 0.7374, 3.04, 0.245, 249, 245, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
4068, d2vtpA_, 0.7374, 3.01, 0.231, 281, 242, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4069, d2oicD_, 0.7374, 2.93, 0.278, 284, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4070, d2o63A_, 0.7374, 3.48, 0.222, 274, 248, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
4071, d5telA_, 0.7373, 3.42, 0.223, 273, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4072, p5nzzE_, 0.7373, 2.92, 0.213, 343, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4073, d4mblA_, 0.7373, 3.29, 0.224, 274, 245, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
4074, d4kipA_, 0.7373, 3.05, 0.237, 337, 241, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4075, d4fkwA_, 0.7373, 3.16, 0.230, 280, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4076, d4apcA1, 0.7373, 3.30, 0.202, 289, 247, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
4077, d3vc4A_, 0.7373, 3.28, 0.220, 274, 245, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4078, d2oibD_, 0.7373, 3.13, 0.269, 288, 242, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4079, d2o65A_, 0.7373, 3.47, 0.222, 274, 248, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
4080, p5oatF_, 0.7372, 3.12, 0.198, 359, 243, PINK1 STRUCTURE
4081, d4wovB_, 0.7372, 2.94, 0.307, 256, 241, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
4082, d4ll5A_, 0.7372, 3.24, 0.225, 268, 244, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4083, d3gi3A_, 0.7372, 2.69, 0.212, 330, 236, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
4084, d2rg6A_, 0.7372, 2.99, 0.234, 335, 239, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
4085, d5v5yA_, 0.7371, 2.98, 0.183, 259, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
4086, d4wsyA_, 0.7371, 3.29, 0.224, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
4087, d4k1bA_, 0.7371, 3.28, 0.229, 273, 245, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4088, d3dtcA_, 0.7371, 2.41, 0.371, 245, 232, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
4089, d1s9iA_, 0.7371, 3.51, 0.233, 303, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4090, d3uytB_, 0.7370, 3.44, 0.220, 286, 250, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4091, d3jxwA_, 0.7370, 3.29, 0.224, 274, 245, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4092, d3c4eD_, 0.7370, 3.37, 0.224, 273, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4093, d2nruC_, 0.7370, 3.10, 0.274, 293, 241, CRYSTAL STRUCTURE OF IRAK-4
4094, d5t1sD_, 0.7369, 3.07, 0.270, 281, 241, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4095, d5li1A1, 0.7369, 3.13, 0.224, 329, 246, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
4096, d5kx8D_, 0.7369, 3.20, 0.267, 283, 243, IRAK4-INHIBITOR CO-STRUCTURE
4097, d4wrsA_, 0.7369, 3.41, 0.223, 273, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
4098, d4kinD_, 0.7369, 3.07, 0.241, 339, 241, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4099, d2r7iC_, 0.7369, 3.00, 0.157, 321, 242, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
4100, d1zysA_, 0.7369, 3.58, 0.230, 271, 248, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
4101, d1yxxA_, 0.7369, 3.29, 0.224, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
4102, d1cm8B_, 0.7369, 2.67, 0.195, 327, 236, PHOSPHORYLATED MAP KINASE P38-GAMMA
4103, d4rpvA_, 0.7368, 3.29, 0.224, 273, 245, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
4104, d4bbmA1, 0.7368, 3.56, 0.262, 306, 252, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
4105, d3e3pA_, 0.7368, 3.62, 0.192, 337, 250, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
4106, d3cr0A_, 0.7368, 2.89, 0.180, 257, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
4107, d1yxuC_, 0.7368, 3.45, 0.227, 272, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4108, d1cm8A_, 0.7368, 2.67, 0.195, 327, 236, PHOSPHORYLATED MAP KINASE P38-GAMMA
4109, d5kx8A_, 0.7367, 3.18, 0.267, 285, 243, IRAK4-INHIBITOR CO-STRUCTURE
4110, d5kgdA_, 0.7367, 3.28, 0.224, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
4111, d4fuyA_, 0.7367, 2.80, 0.193, 329, 238, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
4112, d4bf2A_, 0.7367, 2.72, 0.222, 253, 234, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4113, d4alvA_, 0.7367, 3.36, 0.224, 274, 246, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4114, d3mpaA_, 0.7367, 2.67, 0.225, 331, 236, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4115, d3lfbA_, 0.7367, 2.81, 0.231, 333, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
4116, p2g01B_, 0.7367, 3.02, 0.226, 356, 243, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
4117, d1yxvA_, 0.7367, 3.42, 0.227, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
4118, d1h08A_, 0.7367, 3.21, 0.229, 283, 245, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4119, d5diaA_, 0.7366, 3.36, 0.220, 273, 246, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
4120, d5dhjA_, 0.7366, 3.28, 0.229, 273, 245, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
4121, d4xh6A_, 0.7366, 3.29, 0.224, 273, 245, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
4122, d4kiqB_, 0.7366, 3.09, 0.236, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4123, d3py0A_, 0.7366, 3.29, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR SU9516
4124, d4fkoA_, 0.7365, 3.42, 0.229, 291, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4125, d2bcjA3, 0.7365, 3.38, 0.193, 348, 249, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
4126, d1xqzA_, 0.7365, 3.24, 0.229, 277, 245, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
4127, d5uojA_, 0.7364, 3.31, 0.239, 343, 247, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
4128, d5kgeA_, 0.7364, 3.40, 0.223, 273, 247, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
4129, d4xs2D_, 0.7364, 3.10, 0.270, 277, 241, IRAK4-INHIBITOR CO-STRUCTURE
4130, d4m68A_, 0.7364, 3.29, 0.252, 268, 246, CRYSTAL STRUCTURE OF THE MOUSE MLKL KINASE-LIKE DOMAIN
4131, d3r00A_, 0.7364, 3.29, 0.220, 274, 245, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4132, d3fsfA_, 0.7364, 3.24, 0.224, 340, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4133, d1eh4A_, 0.7364, 3.50, 0.166, 293, 253, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
4134, d5kbrB_, 0.7363, 2.79, 0.218, 260, 238, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4135, d3gcuB_, 0.7363, 3.11, 0.239, 337, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4136, d2r3mA_, 0.7363, 3.21, 0.242, 278, 244, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4137, d1xjdA_, 0.7363, 3.23, 0.253, 280, 245, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
4138, d5w5jA_, 0.7362, 2.49, 0.233, 251, 232, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4139, d5aadA_, 0.7362, 2.96, 0.242, 252, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
4140, d4n6yA_, 0.7362, 3.33, 0.229, 273, 245, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
4141, d4dljA_, 0.7362, 3.04, 0.216, 336, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
4142, d4as0A_, 0.7362, 3.29, 0.229, 273, 245, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
4143, d4aluA_, 0.7362, 3.30, 0.224, 274, 245, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4144, d3jpvA_, 0.7362, 3.30, 0.229, 273, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
4145, d5w4wB_, 0.7361, 3.59, 0.217, 291, 254, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4146, d5jt2C1, 0.7361, 2.74, 0.319, 247, 235, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4147, d5he1A2, 0.7361, 3.39, 0.192, 342, 250, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
4148, d4aa4A_, 0.7361, 3.04, 0.225, 347, 240, P38ALPHA MAP KINASE BOUND TO CMPD 22
4149, d3wblA_, 0.7361, 3.08, 0.230, 283, 243, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
4150, d3hv7A_, 0.7361, 2.73, 0.229, 330, 236, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
4151, d2z2wA_, 0.7361, 3.02, 0.183, 260, 241, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
4152, d2ydiA_, 0.7361, 3.65, 0.229, 279, 249, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4153, d2pkjA_, 0.7361, 2.99, 0.230, 332, 239,  
4154, d2okrD_, 0.7361, 3.00, 0.242, 339, 240, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4155, d5vc6A_, 0.7360, 3.01, 0.182, 259, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
4156, d5owrA_, 0.7360, 3.05, 0.247, 282, 239, HUMAN STK10 BOUND TO DASATINIB
4157, d5k7gC_, 0.7360, 3.09, 0.283, 283, 240, IRAK4 IN COMPLEX WITH AZ3862
4158, d4mtaA_, 0.7360, 3.32, 0.224, 273, 245, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
4159, d4jx7A_, 0.7360, 3.31, 0.224, 274, 245, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
4160, d4fg8B_, 0.7360, 3.20, 0.233, 268, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4161, d3jyaA_, 0.7360, 3.44, 0.227, 274, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4162, d3ezvA_, 0.7360, 3.06, 0.240, 277, 242, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
4163, d1zyjA_, 0.7360, 2.92, 0.239, 331, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
4164, d5kgkA_, 0.7359, 3.46, 0.222, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
4165, d5k75B_, 0.7359, 3.01, 0.272, 274, 239, IRAK4 IN COMPLEX WITH COMPOUND 1
4166, d4lg4E_, 0.7359, 3.17, 0.226, 275, 243, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4167, d4au8A1, 0.7359, 2.83, 0.250, 274, 236, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
4168, d2bzjA_, 0.7359, 3.41, 0.223, 273, 247, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
4169, d5ievA_, 0.7358, 3.12, 0.234, 284, 244, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
4170, d5w4wA_, 0.7357, 3.59, 0.217, 291, 254, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4171, d4n70A_, 0.7357, 3.33, 0.224, 274, 245, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
4172, d2nryC_, 0.7356, 3.01, 0.273, 280, 238, CRYSTAL STRUCTURE OF IRAK-4
4173, d5iisA_, 0.7355, 3.27, 0.230, 273, 244, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
4174, d5he3A2, 0.7355, 3.48, 0.195, 346, 251, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
4175, d4y73A_, 0.7355, 3.21, 0.272, 289, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4176, d4qp3A_, 0.7355, 2.78, 0.206, 339, 238, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
4177, d3mvlB_, 0.7355, 3.17, 0.226, 339, 243, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4178, d2nryD_, 0.7355, 3.13, 0.271, 282, 240, CRYSTAL STRUCTURE OF IRAK-4
4179, d4c4hA1, 0.7354, 2.86, 0.176, 245, 238, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4180, d3i5zA_, 0.7354, 2.78, 0.216, 331, 236, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
4181, d3gbzA_, 0.7354, 2.62, 0.208, 274, 236, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
4182, d3bi6A_, 0.7354, 3.03, 0.183, 258, 241, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
4183, d5kgiA_, 0.7353, 3.29, 0.224, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
4184, d5bveA_, 0.7353, 2.80, 0.220, 330, 236, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4185, d3mh0A_, 0.7353, 2.92, 0.231, 332, 238, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4186, d3k3iA_, 0.7353, 2.83, 0.232, 332, 237, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
4187, d2x8dA_, 0.7353, 3.67, 0.237, 279, 249, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4188, d2w05A_, 0.7353, 2.96, 0.237, 276, 240, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
4189, d1a06A_, 0.7353, 2.59, 0.224, 279, 237, CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT
4190, d6brcA1, 0.7352, 3.22, 0.254, 263, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
4191, d5bujA_, 0.7352, 2.77, 0.220, 331, 236, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
4192, d4twcB_, 0.7352, 3.61, 0.217, 292, 254, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
4193, d2bikB_, 0.7352, 3.36, 0.224, 272, 246, HUMAN PIM1 PHOSPHORYLATED ON SER261
4194, d5ipjA_, 0.7351, 3.31, 0.224, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
4195, d2xj0A_, 0.7351, 3.33, 0.229, 274, 245, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4196, d2dylA_, 0.7351, 2.95, 0.227, 272, 242, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
4197, d5w85A_, 0.7350, 3.02, 0.277, 278, 238, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4198, d4dliA_, 0.7350, 2.85, 0.218, 334, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
4199, d2w06A_, 0.7350, 3.11, 0.230, 282, 243, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
4200, d2nruD_, 0.7350, 3.11, 0.274, 293, 241, CRYSTAL STRUCTURE OF IRAK-4
4201, d4xs2C_, 0.7349, 3.01, 0.277, 281, 238, IRAK4-INHIBITOR CO-STRUCTURE
4202, d4xhkB_, 0.7349, 3.34, 0.229, 269, 245, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
4203, d4mneE_, 0.7349, 3.40, 0.222, 286, 252, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4204, d2oibA_, 0.7349, 3.18, 0.261, 280, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4205, d1x8bA_, 0.7349, 2.99, 0.183, 259, 240, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
4206, d1ia8A_, 0.7349, 3.69, 0.241, 272, 249, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
4207, d3vbtA_, 0.7348, 3.27, 0.226, 267, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4208, d3e7oA_, 0.7348, 3.19, 0.216, 342, 245, CRYSTAL STRUCTURE OF JNK2
4209, d1fotA_, 0.7348, 3.20, 0.244, 299, 246, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
4210, d4ic8B_, 0.7347, 3.22, 0.208, 336, 245, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
4211, d4a7cA_, 0.7347, 3.39, 0.228, 273, 246, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
4212, d5hzeA_, 0.7346, 3.30, 0.208, 305, 250, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
4213, d5fp6A_, 0.7346, 3.08, 0.246, 278, 244, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
4214, d4nj3A_, 0.7346, 3.16, 0.243, 277, 243, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
4215, d4medA_, 0.7346, 3.46, 0.223, 272, 247, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
4216, d4dtkA_, 0.7346, 3.31, 0.224, 273, 245, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
4217, d3r8mA_, 0.7346, 3.39, 0.226, 286, 248, CDK2 IN COMPLEX WITH INHIBITOR L3-3
4218, d3bwfA_, 0.7346, 3.32, 0.224, 273, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
4219, d6bqqA1, 0.7345, 3.20, 0.254, 269, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
4220, d1kv1A_, 0.7345, 2.78, 0.237, 331, 236, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
4221, d5w85B_, 0.7344, 2.99, 0.277, 279, 238, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4222, p5nzzG_, 0.7344, 2.78, 0.224, 342, 237, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4223, d4x7nA_, 0.7344, 3.29, 0.233, 259, 245, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4224, d4kiqD_, 0.7344, 3.15, 0.236, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4225, d3we8A_, 0.7344, 3.45, 0.227, 273, 247, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
4226, p5xyxA_, 0.7343, 3.07, 0.212, 337, 240, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
4227, d4yo6D_, 0.7343, 3.17, 0.273, 285, 242, IRAK4-INHIBITOR CO-STRUCTURE
4228, d3tl8G_, 0.7343, 3.10, 0.280, 301, 243, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4229, d3slsA1, 0.7343, 3.47, 0.232, 289, 250, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4230, d3bgpA_, 0.7343, 3.36, 0.224, 272, 245, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
4231, d1yxuD_, 0.7343, 3.24, 0.221, 273, 244, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4232, d5w4wC_, 0.7342, 3.45, 0.218, 284, 252, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4233, d5v82A_, 0.7342, 3.27, 0.225, 273, 244, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
4234, d4ty1A_, 0.7342, 3.30, 0.225, 273, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
4235, d4tw9B_, 0.7342, 3.63, 0.217, 289, 254, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
4236, d4k0yA_, 0.7342, 3.33, 0.224, 274, 245, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4237, d3vbyA_, 0.7342, 3.27, 0.226, 267, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4238, d3p4kA_, 0.7342, 3.12, 0.243, 338, 243, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
4239, d2bhhA_, 0.7342, 2.88, 0.248, 274, 238, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
4240, d5turA_, 0.7341, 3.30, 0.225, 270, 244, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4241, d5k7gD_, 0.7341, 3.16, 0.282, 283, 241, IRAK4 IN COMPLEX WITH AZ3862
4242, d5bvdA_, 0.7341, 2.83, 0.220, 330, 236, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4243, d4eyjA_, 0.7341, 2.89, 0.213, 338, 239, MAPK13 COMPLEX WITH INHIBITOR
4244, d3zm4A_, 0.7341, 3.43, 0.231, 309, 251, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
4245, d3zduA_, 0.7341, 3.26, 0.263, 297, 243, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
4246, d3cqeA_, 0.7341, 3.05, 0.183, 258, 241, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
4247, d2weiA1, 0.7341, 3.40, 0.238, 269, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
4248, d1yxtA_, 0.7341, 3.34, 0.229, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
4249, d5uitB_, 0.7339, 3.19, 0.269, 283, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4250, d5texA_, 0.7339, 3.47, 0.227, 274, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4251, d5eolA_, 0.7339, 3.33, 0.229, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
4252, d4n4sB_, 0.7339, 2.90, 0.204, 337, 240, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
4253, d3ckwA_, 0.7339, 2.70, 0.253, 255, 237, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4254, d4bzdA_, 0.7338, 3.11, 0.236, 277, 242, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
4255, d3oefX_, 0.7338, 3.20, 0.243, 334, 243, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
4256, d2xnmA1, 0.7338, 3.03, 0.231, 250, 242, STRUCTURE OF NEK2 BOUND TO CCT
4257, d1jktB_, 0.7338, 3.46, 0.212, 276, 250, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
4258, d4ztqA_, 0.7337, 2.78, 0.250, 247, 240, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4259, d4x7lA_, 0.7337, 3.43, 0.232, 260, 246, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4260, d4rmzB_, 0.7337, 3.13, 0.283, 282, 240, CRYSTAL STRUCTURE OF IRAK-4
4261, d4i41A_, 0.7337, 3.29, 0.225, 272, 244, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
4262, d4bznA_, 0.7337, 3.31, 0.225, 272, 244, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
4263, d3iw6A_, 0.7337, 3.04, 0.240, 337, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
4264, d3cikA2, 0.7337, 3.38, 0.189, 347, 249, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
4265, d2xizA_, 0.7337, 3.28, 0.225, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4266, d2w1hA_, 0.7337, 3.09, 0.226, 283, 243, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
4267, d5up3B_, 0.7336, 2.60, 0.235, 243, 230, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4268, d5k72A_, 0.7336, 3.01, 0.282, 277, 238, IRAK4 IN COMPLEX WITH COMPOUND 21
4269, p5etaB_, 0.7336, 2.91, 0.238, 335, 239, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
4270, d4tn6B_, 0.7336, 3.54, 0.213, 285, 253, CK1D IN COMPLEX WITH INHIBITOR
4271, d3vbxA_, 0.7336, 3.28, 0.226, 268, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4272, d3pscA2, 0.7336, 3.39, 0.189, 344, 249, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
4273, d3mvmA_, 0.7336, 3.13, 0.229, 335, 240, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4274, d3fi4A_, 0.7336, 3.22, 0.243, 339, 243, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
4275, p5nzzF_, 0.7335, 2.75, 0.212, 341, 236, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4276, d4yp8A_, 0.7335, 3.21, 0.267, 284, 243, IRAK4-INHIBITOR CO-STRUCTURE
4277, d4ynoA_, 0.7335, 3.13, 0.218, 342, 243, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
4278, d4x7kA_, 0.7335, 3.43, 0.232, 260, 246, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4279, d4qp6A_, 0.7335, 2.80, 0.206, 339, 238, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
4280, d4iaaA_, 0.7335, 3.46, 0.227, 272, 247, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
4281, d4fv9A_, 0.7335, 2.83, 0.220, 331, 236, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
4282, d4ae6B_, 0.7335, 3.34, 0.218, 321, 248, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
4283, d4aacA_, 0.7335, 3.06, 0.230, 350, 239, P38ALPHA MAP KINASE BOUND TO CMPD 29
4284, d3uysC_, 0.7335, 3.50, 0.217, 286, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4285, d3dcvA_, 0.7335, 3.28, 0.230, 273, 244, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
4286, d1wvyA_, 0.7335, 3.32, 0.214, 273, 248, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
4287, d5o8uA_, 0.7334, 2.68, 0.216, 331, 236, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
4288, d4y73B_, 0.7334, 3.21, 0.273, 289, 242, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4289, d4hnfB_, 0.7334, 3.42, 0.218, 290, 252, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4290, d3f69B_, 0.7334, 3.11, 0.220, 282, 245, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4291, d2b55A_, 0.7334, 2.96, 0.229, 276, 240, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
4292, d5m53A1, 0.7333, 2.59, 0.235, 248, 234, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4293, d5li9A1, 0.7333, 3.18, 0.220, 328, 245, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
4294, d5kggA_, 0.7333, 3.35, 0.229, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
4295, d2r3jA_, 0.7333, 3.17, 0.239, 278, 243, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4296, d3tg1A_, 0.7332, 2.90, 0.230, 334, 239, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
4297, d2z7rA_, 0.7332, 2.91, 0.252, 265, 238, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
4298, d1di8A_, 0.7332, 3.27, 0.237, 283, 245, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
4299, d5o23B1, 0.7331, 3.28, 0.264, 276, 250, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4300, d5dwrA_, 0.7331, 3.29, 0.225, 273, 244, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
4301, d3od6X_, 0.7331, 3.06, 0.231, 344, 242, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
4302, d3efwB_, 0.7331, 2.76, 0.248, 242, 238, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4303, d2x7fE_, 0.7331, 2.65, 0.236, 251, 233, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4304, d1h00A_, 0.7331, 3.17, 0.240, 278, 242, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4305, d1g5sA_, 0.7331, 3.05, 0.242, 275, 240, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
4306, d5kcxA_, 0.7330, 3.36, 0.229, 272, 245, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
4307, d3vbvA_, 0.7330, 3.29, 0.226, 268, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4308, d2hxqA_, 0.7330, 3.64, 0.238, 272, 248, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
4309, d4nfmA_, 0.7329, 3.66, 0.227, 293, 255, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
4310, d4awiA_, 0.7329, 3.18, 0.221, 352, 244, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
4311, d2xkdA1, 0.7329, 2.61, 0.221, 243, 235, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4312, d2cgxA_, 0.7329, 3.49, 0.236, 265, 246, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4313, d2bziB_, 0.7329, 3.42, 0.224, 272, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
4314, d1jowB_, 0.7329, 2.77, 0.243, 277, 235, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
4315, d5ukmA2, 0.7328, 3.51, 0.188, 353, 250, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
4316, d4kinC_, 0.7328, 3.26, 0.248, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4317, d4aa5A_, 0.7328, 2.95, 0.227, 340, 238, P38ALPHA MAP KINASE BOUND TO CMPD 33
4318, d3unjA_, 0.7328, 3.50, 0.226, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
4319, d2vtqA_, 0.7328, 2.94, 0.243, 274, 239, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4320, d2j9mA_, 0.7328, 3.02, 0.254, 275, 240, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
4321, d1fvtA_, 0.7328, 3.15, 0.235, 282, 243, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
4322, d1ckpA_, 0.7328, 3.00, 0.242, 279, 240, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
4323, d4ek8A_, 0.7327, 3.14, 0.236, 280, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4324, d3bgzA_, 0.7327, 3.30, 0.225, 267, 244, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
4325, d5iexA_, 0.7326, 3.34, 0.236, 285, 246, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
4326, d4un0D_, 0.7326, 2.80, 0.236, 276, 237, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4327, d4rc4A_, 0.7326, 3.21, 0.226, 272, 243, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4328, d4qp2A_, 0.7326, 2.82, 0.206, 336, 238, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
4329, d5kziA_, 0.7325, 3.34, 0.229, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
4330, d5k75C_, 0.7325, 3.13, 0.257, 282, 241, IRAK4 IN COMPLEX WITH COMPOUND 1
4331, d3hp5A_, 0.7325, 2.64, 0.226, 330, 235, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
4332, d4ek6A_, 0.7324, 3.20, 0.248, 278, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4333, d4aaaA1, 0.7324, 3.31, 0.285, 290, 246, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
4334, d3uvpA_, 0.7324, 2.93, 0.230, 334, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
4335, d3obgA_, 0.7324, 2.88, 0.224, 332, 237, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
4336, d3naxA_, 0.7324, 3.08, 0.227, 278, 242, PDK1 IN COMPLEX WITH INHIBITOR MP7
4337, d1ym7D3, 0.7324, 3.45, 0.184, 340, 250, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4338, d4rblA_, 0.7323, 3.45, 0.220, 271, 246, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4339, d4kbkB_, 0.7323, 3.49, 0.218, 289, 252, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4340, d4fkrA_, 0.7323, 3.05, 0.224, 282, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4341, d3ggfA_, 0.7323, 3.34, 0.264, 275, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4342, d2xiyA_, 0.7323, 3.32, 0.225, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4343, d2hakC_, 0.7323, 3.14, 0.257, 310, 245, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4344, d1ym7A3, 0.7323, 3.45, 0.184, 347, 250, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4345, d1ua2D_, 0.7323, 3.04, 0.223, 286, 242, CRYSTAL STRUCTURE OF HUMAN CDK7
4346, d5toeA_, 0.7322, 3.37, 0.233, 272, 245, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4347, d4kinA_, 0.7322, 3.10, 0.232, 338, 241, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4348, d4fktA_, 0.7322, 3.13, 0.236, 278, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4349, d3r7iA_, 0.7322, 3.05, 0.232, 282, 241, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
4350, d3r04A_, 0.7322, 3.28, 0.222, 271, 243, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4351, d3newA_, 0.7322, 2.99, 0.234, 334, 239, P38-ALPHA COMPLEXED WITH COMPOUND 10
4352, d2r64A_, 0.7322, 3.01, 0.237, 279, 240, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
4353, d2cgvA_, 0.7322, 3.42, 0.237, 264, 245, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4354, d4rc3A_, 0.7321, 3.18, 0.219, 271, 242, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4355, d4izaC_, 0.7321, 2.93, 0.205, 335, 239, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4356, d4a9yA_, 0.7321, 2.94, 0.231, 334, 238, P38ALPHA MAP KINASE BOUND TO CMPD 8
4357, d2zdtA_, 0.7321, 3.27, 0.220, 342, 245, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4358, d2bakA_, 0.7321, 2.94, 0.231, 334, 238, P38ALPHA MAP KINASE BOUND TO MPAQ
4359, d1zltA_, 0.7321, 3.76, 0.241, 272, 249, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
4360, d1ym7B3, 0.7321, 3.45, 0.184, 347, 250, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4361, d3f2aA_, 0.7320, 3.22, 0.226, 276, 243, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
4362, d2objA_, 0.7320, 3.33, 0.225, 272, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
4363, d1v0oA_, 0.7320, 2.99, 0.241, 276, 237, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
4364, d5t1sB_, 0.7319, 3.13, 0.280, 282, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4365, d3oz6B_, 0.7319, 2.83, 0.256, 341, 238, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
4366, d3g9nA_, 0.7319, 3.25, 0.217, 346, 244, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
4367, d2vtiA_, 0.7319, 3.15, 0.240, 280, 242, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4368, d2uznA_, 0.7319, 3.21, 0.244, 279, 242, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4369, d2in6A_, 0.7319, 3.05, 0.183, 256, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
4370, d5ci6A_, 0.7318, 2.54, 0.202, 335, 233, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4371, p4d28B_, 0.7318, 3.28, 0.231, 277, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4372, d4byjA_, 0.7318, 2.87, 0.240, 246, 242, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4373, d3tl8H_, 0.7318, 3.08, 0.281, 303, 242, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4374, d3tl8A_, 0.7318, 3.10, 0.280, 300, 243, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4375, d3e3pB_, 0.7318, 3.54, 0.194, 337, 248, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
4376, d3bgqA_, 0.7318, 3.32, 0.225, 272, 244, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
4377, d2xneA_, 0.7318, 2.90, 0.245, 246, 241, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4378, d2brbA_, 0.7318, 3.72, 0.241, 272, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4379, d5k75D_, 0.7317, 3.16, 0.271, 280, 240, IRAK4 IN COMPLEX WITH COMPOUND 1
4380, d3iw7A_, 0.7317, 3.03, 0.237, 335, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
4381, d3is5A1, 0.7317, 3.33, 0.235, 254, 247, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4382, d1ym7C3, 0.7317, 3.45, 0.180, 346, 250, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4383, d1yi4A_, 0.7317, 3.17, 0.223, 267, 242, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
4384, d6bleA1, 0.7316, 3.26, 0.254, 263, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
4385, d4rc2A_, 0.7316, 3.43, 0.224, 272, 246, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4386, d3a62A_, 0.7316, 3.08, 0.237, 263, 241, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
4387, d2xj2A_, 0.7316, 3.31, 0.230, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4388, d2r3kA_, 0.7316, 3.16, 0.240, 277, 242, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4389, d4qtdA_, 0.7315, 3.18, 0.225, 355, 244, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
4390, d4fv4A_, 0.7315, 2.60, 0.210, 329, 233, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
4391, d3uytC_, 0.7315, 3.43, 0.219, 286, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4392, d3slsB1, 0.7315, 3.43, 0.233, 291, 249, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4393, d1h0wA_, 0.7315, 3.29, 0.234, 283, 244, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
4394, d1dm2A_, 0.7315, 3.01, 0.255, 274, 239, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
4395, d4obpB_, 0.7314, 3.71, 0.200, 290, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4396, d4fv5A_, 0.7314, 2.79, 0.217, 330, 235, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
4397, d3v5wA2, 0.7314, 3.44, 0.177, 355, 249, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
4398, d2oibC_, 0.7314, 3.08, 0.268, 278, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4399, d2e9oA_, 0.7314, 3.50, 0.241, 269, 245, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
4400, d5bueA_, 0.7313, 2.87, 0.220, 329, 236, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
4401, d4tw9A_, 0.7313, 3.57, 0.217, 290, 253, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
4402, d3r02A_, 0.7313, 3.30, 0.222, 271, 243, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4403, d2aypA_, 0.7313, 3.41, 0.242, 268, 244, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
4404, d1ke7A_, 0.7313, 3.21, 0.239, 281, 243, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
4405, d5uitA_, 0.7312, 3.24, 0.269, 284, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4406, d4hyiA_, 0.7312, 3.62, 0.239, 269, 247, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
4407, d3ig7A_, 0.7312, 3.08, 0.246, 278, 240, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
4408, d2gdoA_, 0.7312, 3.58, 0.240, 269, 246, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
4409, d2btrA_, 0.7312, 3.09, 0.242, 275, 240, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
4410, d3qc4B1, 0.7311, 3.17, 0.222, 268, 243, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
4411, d4kbkC_, 0.7310, 3.43, 0.216, 280, 250, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4412, d2ywpA_, 0.7310, 3.54, 0.240, 269, 246, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
4413, d2fgaA_, 0.7310, 3.54, 0.240, 269, 246,  
4414, d1yi3A_, 0.7310, 3.30, 0.230, 267, 243, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
4415, d1yhsA_, 0.7310, 3.20, 0.227, 267, 242, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
4416, d5uisB_, 0.7309, 2.87, 0.275, 274, 236, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4417, d4x7hA_, 0.7309, 3.39, 0.238, 256, 244, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4418, d4n6zA_, 0.7309, 3.34, 0.230, 272, 244, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
4419, d3lfeA_, 0.7309, 2.92, 0.230, 334, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
4420, d2ghlA_, 0.7309, 2.97, 0.236, 334, 237, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
4421, d2cguA_, 0.7309, 3.39, 0.234, 263, 244, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4422, d4bzoA_, 0.7308, 3.24, 0.222, 272, 243, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
4423, d3r7uA_, 0.7308, 3.23, 0.230, 282, 243, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
4424, d2xj1A_, 0.7308, 3.34, 0.225, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
4425, d2vtnA_, 0.7308, 2.97, 0.243, 274, 239, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4426, d1ua2C_, 0.7308, 3.05, 0.224, 286, 241, CRYSTAL STRUCTURE OF HUMAN CDK7
4427, d5cs6B_, 0.7307, 2.99, 0.172, 316, 238, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
4428, d4xs2B_, 0.7307, 3.06, 0.273, 278, 238, IRAK4-INHIBITOR CO-STRUCTURE
4429, d3w18B_, 0.7307, 2.63, 0.255, 236, 235, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4430, d6bqpA1, 0.7306, 3.26, 0.254, 262, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
4431, d4alwA_, 0.7306, 3.35, 0.225, 273, 244, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4432, d3uvqA_, 0.7306, 2.78, 0.234, 333, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
4433, d3s2pA_, 0.7306, 3.12, 0.241, 279, 241, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
4434, d1ke8A_, 0.7306, 3.04, 0.228, 282, 241, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
4435, d6brcB_, 0.7305, 3.29, 0.255, 260, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
4436, d5mtxA_, 0.7305, 3.07, 0.243, 331, 239, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
4437, d5aniA_, 0.7305, 3.23, 0.231, 280, 242, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4438, d4ztmB_, 0.7305, 3.02, 0.274, 280, 237, IRAK4-INHIBITOR CO-STRUCTURE
4439, d4fkjA_, 0.7305, 3.21, 0.244, 278, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4440, d4dfyA_, 0.7305, 3.16, 0.249, 310, 245, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4441, d3mvmB_, 0.7305, 3.01, 0.241, 332, 237, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4442, d1ua2A_, 0.7305, 3.01, 0.216, 286, 241, CRYSTAL STRUCTURE OF HUMAN CDK7
4443, d3vbqA_, 0.7304, 3.30, 0.222, 271, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4444, d3r9oA_, 0.7304, 3.26, 0.239, 282, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
4445, d3qtrA_, 0.7304, 3.26, 0.230, 282, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
4446, d2r3nA_, 0.7304, 3.18, 0.240, 275, 242, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4447, d1ke5A_, 0.7304, 3.15, 0.236, 281, 242, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
4448, d4y73D_, 0.7303, 3.17, 0.274, 288, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4449, d2hxlA_, 0.7303, 3.60, 0.243, 272, 247, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
4450, d1ua2B_, 0.7303, 3.05, 0.216, 286, 241, CRYSTAL STRUCTURE OF HUMAN CDK7
4451, d4mneA_, 0.7302, 3.43, 0.219, 286, 251, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4452, d2brnA_, 0.7302, 3.61, 0.239, 268, 247, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4453, d4x7jA_, 0.7301, 3.29, 0.230, 257, 243, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4454, d4nfnA_, 0.7301, 3.75, 0.227, 293, 256, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
4455, d2x81A_, 0.7301, 2.76, 0.235, 242, 238, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4456, d3w16A_, 0.7300, 2.91, 0.248, 249, 242, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4457, d2ptoA_, 0.7300, 2.74, 0.221, 330, 235,  
4458, d4lmuA_, 0.7299, 3.17, 0.224, 265, 241, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
4459, d4fksA_, 0.7299, 3.19, 0.237, 275, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4460, d3is5F1, 0.7299, 3.33, 0.227, 259, 247, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4461, d3cgfA_, 0.7299, 3.33, 0.224, 346, 245, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4462, d2xixA_, 0.7299, 3.30, 0.226, 272, 243, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4463, d2rg5A_, 0.7299, 3.03, 0.239, 333, 238, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
4464, d1v0pA_, 0.7299, 3.07, 0.225, 277, 240, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
4465, d3p9jA_, 0.7298, 2.92, 0.248, 249, 242, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4466, d3my0X_, 0.7298, 2.69, 0.262, 257, 233, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4467, d3g90X_, 0.7298, 3.21, 0.218, 345, 243, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
4468, d4xoyA_, 0.7297, 2.84, 0.191, 326, 236, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4469, d4hnfA_, 0.7297, 3.52, 0.219, 289, 251, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4470, d3pzeA_, 0.7297, 3.20, 0.231, 347, 242, JNK1 IN COMPLEX WITH INHIBITOR
4471, d2p33A_, 0.7297, 3.30, 0.220, 332, 245, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4472, d2oicC_, 0.7297, 3.06, 0.270, 277, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4473, d3is5B1, 0.7296, 3.13, 0.230, 255, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4474, d1omwA3, 0.7296, 3.44, 0.189, 344, 249, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
4475, d4y46A_, 0.7295, 3.25, 0.213, 340, 244, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4476, d4fkqA_, 0.7295, 3.04, 0.233, 283, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4477, d5k7gA_, 0.7294, 3.09, 0.282, 277, 238, IRAK4 IN COMPLEX WITH AZ3862
4478, d5uklA2, 0.7293, 3.48, 0.181, 353, 249, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
4479, d5k7gB_, 0.7293, 3.02, 0.288, 275, 236, IRAK4 IN COMPLEX WITH AZ3862
4480, d5ih5A_, 0.7293, 3.55, 0.217, 286, 253, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
4481, d3zshA_, 0.7293, 2.95, 0.233, 331, 240, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
4482, d3ptgA_, 0.7293, 3.03, 0.225, 340, 240, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
4483, d3dy7A_, 0.7293, 3.24, 0.229, 260, 245, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4484, d3cgoA_, 0.7293, 3.32, 0.220, 332, 245, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4485, d2rioA_, 0.7293, 3.01, 0.230, 396, 235, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4486, d5vuaB_, 0.7292, 3.37, 0.222, 270, 243, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4487, d4lm5A_, 0.7292, 3.19, 0.220, 264, 241, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
4488, d4kbaC_, 0.7292, 3.58, 0.219, 277, 251, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4489, d4kb8C_, 0.7292, 3.50, 0.212, 277, 250, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4490, d4btkA_, 0.7292, 3.54, 0.226, 287, 252, TTBK1 IN COMPLEX WITH INHIBITOR
4491, d3wzuA_, 0.7292, 3.27, 0.229, 270, 245, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4492, d3mh2A_, 0.7292, 2.75, 0.221, 330, 235, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4493, d1ke9A_, 0.7292, 3.18, 0.236, 281, 242, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
4494, d4kbcA_, 0.7291, 3.50, 0.208, 288, 250, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4495, d4g16A1, 0.7291, 3.62, 0.198, 301, 253, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
4496, d2csnA_, 0.7291, 3.61, 0.166, 293, 253, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
4497, d4w4yA_, 0.7290, 3.35, 0.220, 350, 245, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4498, d4g17A1, 0.7290, 3.64, 0.201, 301, 254, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
4499, d4fkpA_, 0.7290, 3.18, 0.237, 279, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4500, d2bheA_, 0.7290, 3.02, 0.247, 274, 239, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
4501, d5vdkA_, 0.7289, 3.10, 0.200, 260, 240, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
4502, d5o13A_, 0.7289, 3.20, 0.224, 270, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4503, d5hi2A1, 0.7289, 2.15, 0.329, 231, 225, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH SORAFENIB
4504, d4ztnB_, 0.7289, 3.09, 0.273, 282, 238, IRAK4-INHIBITOR CO-STRUCTURE
4505, d3v6sA_, 0.7289, 3.12, 0.219, 349, 242, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4506, d3sw7A_, 0.7289, 3.10, 0.224, 278, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4507, d3rzbA_, 0.7289, 3.25, 0.239, 282, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
4508, d3eljA_, 0.7289, 3.30, 0.233, 347, 245, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
4509, d4u97A_, 0.7288, 2.88, 0.280, 272, 232, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4510, d4kkgA_, 0.7288, 3.21, 0.209, 353, 244, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
4511, d2pv5A_, 0.7288, 2.77, 0.226, 329, 235,  
4512, d2br1A_, 0.7288, 3.77, 0.241, 272, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4513, d5jq8A_, 0.7287, 3.02, 0.234, 278, 239, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
4514, d4rmzA_, 0.7287, 3.16, 0.275, 284, 240, CRYSTAL STRUCTURE OF IRAK-4
4515, d3efwA_, 0.7287, 2.66, 0.250, 240, 236, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4516, d2vthA_, 0.7287, 3.11, 0.242, 278, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
4517, d5l4qB_, 0.7286, 2.73, 0.188, 287, 234, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4518, d5anoA_, 0.7286, 3.19, 0.245, 277, 241, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4519, d4zjjC_, 0.7286, 3.44, 0.214, 276, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4520, d4ae9B_, 0.7286, 3.37, 0.219, 321, 247, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
4521, d4acmA_, 0.7286, 3.08, 0.234, 277, 239, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
4522, d1jnkA_, 0.7286, 3.32, 0.224, 346, 245, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
4523, d5o11A_, 0.7285, 3.22, 0.229, 268, 240, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4524, d4u9aA_, 0.7285, 2.90, 0.280, 272, 232, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4525, d4twcA_, 0.7285, 3.62, 0.217, 293, 253, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
4526, d3mgyA_, 0.7285, 2.75, 0.226, 329, 235, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4527, d6bqlA1, 0.7284, 3.30, 0.254, 276, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
4528, d5ih6A_, 0.7284, 3.57, 0.217, 286, 253, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
4529, d4l7fA1, 0.7284, 3.01, 0.229, 343, 240, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
4530, d3w18A_, 0.7284, 2.66, 0.235, 234, 234, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4531, d3rmfA_, 0.7284, 3.17, 0.240, 278, 242, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
4532, d3f69A_, 0.7284, 2.96, 0.228, 270, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4533, d2xkfA1, 0.7284, 2.67, 0.214, 242, 234, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
4534, d5uiuB_, 0.7283, 3.26, 0.274, 287, 241, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4535, d4y5hA_, 0.7283, 3.24, 0.209, 349, 244, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4536, d2pmiC_, 0.7283, 2.64, 0.237, 285, 232, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4537, d1ke6A_, 0.7283, 3.13, 0.232, 280, 241, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
4538, d4hgsA1, 0.7282, 3.55, 0.198, 301, 253, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
4539, d3oriB_, 0.7282, 2.88, 0.230, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4540, d4tn6A_, 0.7280, 3.70, 0.217, 292, 254, CK1D IN COMPLEX WITH INHIBITOR
4541, d3zsiA_, 0.7280, 2.78, 0.243, 326, 235, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
4542, d3zh8C_, 0.7280, 3.41, 0.214, 312, 248, A NOVEL SMALL MOLECULE APKC INHIBITOR
4543, d3rpyA_, 0.7280, 3.13, 0.241, 277, 241, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
4544, d2e9nA_, 0.7280, 3.54, 0.241, 269, 245, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
4545, d1ob3A_, 0.7280, 3.09, 0.225, 277, 240, STRUCTURE OF P. FALCIPARUM PFPK5
4546, d5drbA_, 0.7279, 3.47, 0.265, 273, 249, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
4547, d4yp8D_, 0.7279, 3.31, 0.281, 285, 242, IRAK4-INHIBITOR CO-STRUCTURE
4548, d1vyzA_, 0.7279, 3.11, 0.237, 279, 240, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
4549, d4kkeA_, 0.7278, 3.44, 0.224, 354, 246, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
4550, d2btsA_, 0.7278, 3.13, 0.254, 274, 240, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
4551, d1h06A_, 0.7278, 3.10, 0.237, 277, 240,  
4552, d4w4xA_, 0.7277, 3.33, 0.220, 342, 245, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4553, d4fk3A1, 0.7277, 2.30, 0.329, 238, 228, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4554, d3d2kA_, 0.7277, 2.85, 0.256, 245, 238, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4555, d2e9vA_, 0.7277, 3.49, 0.238, 268, 244, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4556, d5x18A_, 0.7276, 3.65, 0.173, 294, 254, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4557, d3zh8A_, 0.7276, 3.37, 0.210, 318, 248, A NOVEL SMALL MOLECULE APKC INHIBITOR
4558, d2vtjA_, 0.7276, 3.14, 0.246, 276, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4559, d3uytA_, 0.7275, 3.57, 0.211, 287, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4560, d3rakA_, 0.7275, 3.12, 0.241, 277, 241, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
4561, d5vd2A_, 0.7274, 3.00, 0.183, 258, 240, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
4562, d5ekoA_, 0.7274, 3.20, 0.219, 341, 242, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
4563, d4w4vA_, 0.7274, 3.35, 0.220, 342, 245, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4564, d4kkhA_, 0.7274, 3.32, 0.220, 351, 245, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
4565, d3lfcA_, 0.7274, 2.98, 0.230, 334, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
4566, d2e9uA_, 0.7274, 3.55, 0.241, 269, 245, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
4567, d5eknA_, 0.7273, 2.90, 0.207, 336, 237, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
4568, d4eqmF_, 0.7273, 3.22, 0.184, 268, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4569, d4eqmD_, 0.7273, 3.22, 0.184, 268, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4570, p3vumA_, 0.7273, 2.78, 0.237, 347, 236, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
4571, d1pmuA_, 0.7273, 3.14, 0.219, 342, 242, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
4572, d1p4fA_, 0.7273, 3.20, 0.223, 269, 242, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
4573, d3oriA_, 0.7272, 2.89, 0.226, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4574, p3hdmA_, 0.7272, 3.64, 0.212, 285, 250, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4575, d3ezrA_, 0.7272, 3.00, 0.235, 273, 238, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
4576, d1szmB_, 0.7272, 3.31, 0.211, 320, 246, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
4577, d5uiqD_, 0.7271, 2.87, 0.278, 271, 234, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4578, d3my0K_, 0.7271, 2.71, 0.259, 261, 232, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4579, d2vtaA_, 0.7271, 3.05, 0.238, 278, 239, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4580, d2broA_, 0.7271, 3.56, 0.240, 272, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4581, d5uiqB_, 0.7270, 2.88, 0.277, 272, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4582, d5k72C_, 0.7270, 3.04, 0.284, 277, 236, IRAK4 IN COMPLEX WITH COMPOUND 21
4583, d4yr8A_, 0.7270, 2.85, 0.230, 320, 235, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4584, d2vttA_, 0.7270, 2.98, 0.249, 272, 237, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4585, d2c3kA_, 0.7270, 3.42, 0.235, 262, 243, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4586, d3pg1A_, 0.7269, 2.90, 0.202, 341, 238, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
4587, d3l8sA_, 0.7268, 2.97, 0.230, 334, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
4588, d3hubA_, 0.7268, 3.06, 0.245, 335, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
4589, d3ggfB_, 0.7268, 3.25, 0.262, 270, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4590, d3daeB_, 0.7268, 2.81, 0.232, 246, 237, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4591, d2cgwA_, 0.7268, 3.41, 0.235, 262, 243, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4592, d5mqvC_, 0.7267, 3.50, 0.223, 288, 251, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4593, d3my0J_, 0.7267, 2.52, 0.271, 252, 229, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4594, d3k3jA_, 0.7267, 2.72, 0.226, 329, 234, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
4595, d3hucA_, 0.7267, 3.27, 0.230, 337, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
4596, d2bajA2, 0.7267, 2.92, 0.260, 334, 235, P38ALPHA BOUND TO PYRAZOLOUREA
4597, d1r78A_, 0.7267, 2.95, 0.236, 273, 237, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
4598, d5vc3A_, 0.7266, 3.07, 0.183, 260, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4599, d5bvfA_, 0.7266, 2.71, 0.220, 327, 232, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4600, d4zjjD_, 0.7266, 3.57, 0.216, 274, 250, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4601, d4fg9B_, 0.7266, 3.06, 0.224, 279, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4602, d3s1hA_, 0.7266, 3.15, 0.241, 277, 241, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
4603, d2ewaA_, 0.7266, 2.82, 0.239, 330, 234, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
4604, d2cl1A_, 0.7266, 3.15, 0.232, 250, 241,  
4605, d1w0xC_, 0.7266, 3.21, 0.240, 280, 242, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
4606, p5nzzH_, 0.7265, 2.81, 0.217, 335, 235, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4607, d4hyhA_, 0.7265, 3.40, 0.235, 263, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
4608, d4eqmE_, 0.7265, 3.25, 0.184, 268, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4609, d3ttiA_, 0.7265, 3.34, 0.224, 341, 245, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
4610, d2ghgA1, 0.7265, 3.61, 0.232, 269, 246, H-CHK1 COMPLEXED WITH A431994
4611, p3vulA_, 0.7264, 2.89, 0.236, 344, 237, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
4612, d2r3lA_, 0.7264, 3.20, 0.245, 275, 241, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4613, d1csnA_, 0.7264, 3.69, 0.177, 293, 254, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
4614, d5oq5A_, 0.7263, 3.47, 0.234, 265, 244, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4615, d4eymA_, 0.7263, 3.14, 0.216, 340, 241, MAPK13 COMPLEX WITH INHIBITOR
4616, d3fmeA1, 0.7263, 3.37, 0.247, 267, 243, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4617, p6f5eB_, 0.7261, 2.96, 0.211, 346, 237, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4618, d5tcoA_, 0.7261, 2.92, 0.242, 327, 236, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
4619, p5lenB_, 0.7261, 2.96, 0.211, 346, 237, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
4620, d5k75A_, 0.7261, 2.94, 0.278, 271, 234, IRAK4 IN COMPLEX WITH COMPOUND 1
4621, d5k72D_, 0.7261, 3.01, 0.285, 276, 235, IRAK4 IN COMPLEX WITH COMPOUND 21
4622, d5ih4A_, 0.7261, 3.59, 0.213, 286, 253, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
4623, d4btjB_, 0.7261, 3.65, 0.227, 293, 255, TTBK1 IN COMPLEX WITH ATP
4624, d3qtsA_, 0.7261, 3.17, 0.228, 282, 241, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
4625, d3is5C1, 0.7261, 3.16, 0.226, 254, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4626, d2wajA_, 0.7261, 3.28, 0.222, 348, 243, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
4627, d1pmnA_, 0.7261, 3.28, 0.213, 344, 244, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
4628, d5awmA_, 0.7260, 3.15, 0.221, 345, 240, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
4629, d3iw5A_, 0.7260, 3.08, 0.241, 336, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
4630, d2w99B_, 0.7260, 3.31, 0.217, 291, 244, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4631, d4hglA1, 0.7259, 3.57, 0.198, 301, 253, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
4632, d2xnnA1, 0.7259, 2.71, 0.230, 243, 235, STRUCTURE OF NEK2 BOUND TO CCT242430
4633, d2izsA_, 0.7259, 3.57, 0.194, 298, 253, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4634, d1gihA_, 0.7259, 3.22, 0.241, 276, 241, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4635, d3zh8B_, 0.7258, 3.39, 0.210, 317, 248, A NOVEL SMALL MOLECULE APKC INHIBITOR
4636, d2bvaB_, 0.7258, 3.12, 0.178, 274, 241, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4637, d5ukkA2, 0.7257, 3.60, 0.179, 348, 251, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
4638, d5oopA_, 0.7257, 3.39, 0.227, 261, 242, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
4639, d5n68A_, 0.7257, 2.80, 0.231, 328, 234, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
4640, d5andA_, 0.7257, 3.09, 0.243, 273, 239, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4641, d4w4wA_, 0.7257, 3.34, 0.220, 349, 245, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
4642, d4hokI_, 0.7257, 3.59, 0.215, 291, 251, CRYSTAL STRUCTURE OF APO CK1E
4643, d4enxA_, 0.7257, 3.28, 0.228, 266, 241, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
4644, d3v6sB_, 0.7257, 2.98, 0.223, 340, 238, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4645, d2brmA_, 0.7257, 3.42, 0.243, 263, 243, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4646, d1ckiA_, 0.7257, 3.64, 0.217, 292, 253, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
4647, d4xv1B1, 0.7256, 1.90, 0.335, 233, 221, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4648, d4bgqA_, 0.7256, 2.92, 0.224, 276, 237, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
4649, d3vbwA_, 0.7256, 3.24, 0.226, 264, 239, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4650, d3hvcA_, 0.7256, 2.76, 0.227, 327, 233, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
4651, d3dakB_, 0.7256, 3.48, 0.229, 278, 245, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4652, d2p5aA_, 0.7256, 2.76, 0.227, 327, 233,  
4653, d2i6lB_, 0.7256, 2.65, 0.206, 269, 233, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
4654, d5w4wD_, 0.7255, 3.60, 0.216, 287, 250, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4655, d4cjyD_, 0.7255, 2.78, 0.235, 272, 234,  
4656, d5hnvA1, 0.7254, 2.95, 0.194, 278, 237, CRYSTAL STRUCTURE OF PPKA
4657, d4kb8A_, 0.7254, 3.39, 0.211, 265, 246, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4658, d3rahA_, 0.7254, 3.17, 0.228, 282, 241, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
4659, d4fg7A_, 0.7253, 2.79, 0.243, 250, 235, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4660, d4afeA1, 0.7253, 2.84, 0.232, 245, 237, NEK2 BOUND TO HYBRID COMPOUND 21
4661, d3ulzA_, 0.7253, 3.09, 0.291, 291, 237, CRYSTAL STRUCTURE OF APO BAK1
4662, d5vubB_, 0.7252, 3.22, 0.221, 269, 240, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4663, d4enyA_, 0.7252, 3.15, 0.226, 261, 239, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
4664, d3uytD_, 0.7252, 3.63, 0.216, 268, 250, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4665, d3uixA_, 0.7252, 3.28, 0.228, 266, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4666, d1pmvA_, 0.7252, 3.34, 0.216, 347, 245, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
4667, d3v6rA_, 0.7251, 3.21, 0.215, 349, 242, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4668, d2baqA_, 0.7251, 2.98, 0.233, 329, 236, P38ALPHA BOUND TO RO3201195
4669, d6eimA_, 0.7250, 3.26, 0.235, 286, 238, HUMAN STK10 BOUND TO GW683134A
4670, d4btmB_, 0.7250, 3.65, 0.227, 293, 255, TTBK1 IN COMPLEX WITH INHIBITOR
4671, d1giiA_, 0.7250, 3.19, 0.237, 279, 241, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4672, d5uisA_, 0.7249, 2.91, 0.277, 269, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4673, d5l4qA_, 0.7249, 2.86, 0.191, 293, 235, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4674, d4u9aB_, 0.7249, 3.02, 0.265, 270, 234, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4675, d4hokM_, 0.7249, 3.71, 0.217, 291, 254, CRYSTAL STRUCTURE OF APO CK1E
4676, d3bizA_, 0.7249, 2.92, 0.179, 250, 235, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
4677, d2e9vB_, 0.7249, 3.57, 0.241, 268, 245, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4678, d1ianA_, 0.7249, 2.76, 0.232, 328, 233, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
4679, d5x17B_, 0.7248, 3.70, 0.217, 289, 254, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
4680, p2xs0A_, 0.7248, 2.93, 0.228, 346, 237, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4681, d1v1kA_, 0.7248, 3.21, 0.237, 277, 241, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4682, d5vucB_, 0.7247, 3.32, 0.224, 269, 241, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4683, d3rprA_, 0.7247, 3.24, 0.236, 282, 242, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
4684, d3ralA_, 0.7247, 3.18, 0.241, 277, 241, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
4685, d3oroA_, 0.7247, 3.11, 0.211, 272, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4686, d2xnpA1, 0.7247, 2.86, 0.232, 245, 237, STRUCTURE OF NEK2 BOUND TO CCT244858
4687, d5x17A_, 0.7246, 3.59, 0.222, 290, 252, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
4688, p4ux9D_, 0.7246, 3.03, 0.218, 344, 238, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4689, d4u97B_, 0.7246, 3.01, 0.265, 270, 234, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4690, d4feqA_, 0.7246, 2.08, 0.439, 224, 223, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
4691, d1ckjA_, 0.7246, 3.68, 0.217, 296, 253, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
4692, d5t1tB_, 0.7245, 3.16, 0.283, 280, 237, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4693, d4d2sA_, 0.7245, 2.71, 0.188, 249, 234, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
4694, d2io6A_, 0.7245, 2.92, 0.179, 252, 235, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
4695, p4btfA2, 0.7244, 3.33, 0.246, 297, 244, STRUCTURE OF MLKL
4696, d1ukiA_, 0.7244, 2.87, 0.228, 328, 237, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
4697, d1gzoA_, 0.7244, 3.01, 0.209, 271, 239, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4698, d4tthB_, 0.7243, 2.86, 0.218, 256, 234, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
4699, d3umwA_, 0.7242, 3.23, 0.221, 264, 240, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
4700, d5uisC_, 0.7241, 2.88, 0.278, 270, 234, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4701, d3uysD_, 0.7241, 3.48, 0.211, 284, 247, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4702, d2oidB_, 0.7241, 3.22, 0.256, 272, 238, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4703, p4d28A_, 0.7240, 3.14, 0.235, 274, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4704, d3r9nA_, 0.7240, 3.25, 0.236, 282, 242, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
4705, d3ormA_, 0.7240, 3.04, 0.221, 266, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4706, d3dj6A_, 0.7240, 2.88, 0.257, 252, 237, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4707, d3daeA_, 0.7240, 2.87, 0.228, 248, 237, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4708, d5uiuA_, 0.7239, 3.30, 0.274, 286, 241, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4709, p4whzA_, 0.7239, 3.39, 0.220, 342, 245, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
4710, d2o0uA_, 0.7239, 3.39, 0.220, 331, 245, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
4711, d1gzkA_, 0.7239, 3.01, 0.209, 271, 239, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4712, d3v6rB_, 0.7238, 3.23, 0.220, 346, 241, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4713, d2rioB_, 0.7238, 2.93, 0.227, 395, 233, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4714, d5fqdF_, 0.7237, 3.71, 0.193, 294, 254, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
4715, d4yomB1, 0.7237, 3.41, 0.228, 320, 250, STRUCTURE OF SAD KINASE
4716, d1p2aA_, 0.7237, 2.92, 0.243, 271, 235, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
4717, d4p41B_, 0.7236, 2.87, 0.218, 256, 234,  
4718, d4hokU_, 0.7236, 3.55, 0.208, 289, 250, CRYSTAL STRUCTURE OF APO CK1E
4719, d2izrA_, 0.7236, 3.65, 0.190, 298, 252, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4720, d2hy0A_, 0.7236, 3.84, 0.235, 272, 247, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
4721, d5oorA_, 0.7235, 3.54, 0.222, 273, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
4722, d3sw4A_, 0.7235, 3.03, 0.231, 279, 238, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4723, d5tbeA_, 0.7234, 3.03, 0.236, 332, 237, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
4724, d5n65A_, 0.7234, 3.13, 0.234, 333, 239, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
4725, d3q4zA1, 0.7234, 3.26, 0.212, 281, 241, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4726, d5mqvF_, 0.7233, 3.50, 0.224, 286, 250, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4727, d4a4xA1, 0.7233, 2.87, 0.232, 245, 237, NEK2-EDE BOUND TO CCT248662
4728, d2zduA_, 0.7233, 3.05, 0.222, 330, 239, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4729, d2chlA_, 0.7233, 3.61, 0.194, 298, 253, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
4730, d1ckiB_, 0.7233, 3.64, 0.217, 286, 253, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
4731, d4equA_, 0.7232, 3.04, 0.244, 274, 234, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4732, d2iztA_, 0.7232, 3.54, 0.191, 296, 251, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4733, d5k76A_, 0.7231, 3.22, 0.267, 270, 236, IRAK4 IN COMPLEX WITH COMPOUND 28
4734, d4qyeA_, 0.7231, 3.80, 0.236, 271, 246, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
4735, d5o8vA_, 0.7230, 2.64, 0.221, 328, 231, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
4736, d4mneD_, 0.7230, 3.42, 0.218, 285, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4737, d5tkdB_, 0.7228, 3.08, 0.300, 247, 237, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4738, d5n67A_, 0.7228, 2.65, 0.221, 327, 231, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
4739, d4eqmA_, 0.7228, 3.30, 0.189, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4740, d3g33A_, 0.7228, 3.16, 0.228, 291, 241, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4741, d3dj5A_, 0.7228, 2.89, 0.257, 252, 237, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 290.
4742, d5n64A_, 0.7227, 2.68, 0.228, 329, 232, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
4743, d5fqdC_, 0.7227, 3.73, 0.193, 294, 254, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
4744, d4bghA_, 0.7227, 3.21, 0.246, 275, 240, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
4745, d2xnoA1, 0.7227, 2.78, 0.221, 243, 235, STRUCTURE OF NEK2 BOUND TO CCT243779
4746, d4eqmB_, 0.7226, 3.30, 0.189, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4747, d3uimA_, 0.7226, 3.16, 0.280, 291, 239, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
4748, d3dakD_, 0.7226, 3.86, 0.242, 284, 252, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4749, d4fsnA_, 0.7225, 3.67, 0.234, 270, 244, CRYSTAL STRUCTURE OF THE CHK1
4750, d4fg8A_, 0.7225, 2.95, 0.227, 263, 238, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4751, d5mtyA_, 0.7224, 2.87, 0.231, 328, 234, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
4752, d3dakA_, 0.7224, 3.61, 0.230, 279, 248, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4753, d2p4iA_, 0.7224, 2.22, 0.445, 252, 218, EVOLUTION OF A HIGHLY SELECTIVE AND POTENT 2-(PYRIDIN-2-YL)- 135-TRIAZINE TIE-2 KINASE INHIBITOR
4754, d4xv2B1, 0.7223, 2.18, 0.333, 234, 225, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
4755, d4eqmC_, 0.7223, 3.30, 0.189, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4756, d1gznA_, 0.7223, 3.03, 0.209, 271, 239, STRUCTURE OF PKB KINASE DOMAIN
4757, d2yzaA_, 0.7222, 3.13, 0.237, 258, 241, CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D)
4758, d2wtkC1, 0.7222, 3.10, 0.234, 261, 239, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4759, d2jboA_, 0.7222, 2.94, 0.190, 295, 237, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4760, d4x21A_, 0.7221, 2.99, 0.218, 336, 238, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
4761, d2javA1, 0.7221, 2.94, 0.231, 245, 238, HUMAN KINASE WITH PYRROLE-INDOLINONE LIGAND
4762, d1ckjB_, 0.7221, 3.68, 0.220, 293, 254, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
4763, d5y8uA_, 0.7220, 3.20, 0.232, 267, 241, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4764, d5o12A_, 0.7220, 3.13, 0.224, 264, 237, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4765, d5k7iA_, 0.7220, 2.97, 0.288, 272, 233, IRAK4 IN COMPLEX WITH AZ3864
4766, d3e7oB_, 0.7220, 2.67, 0.219, 326, 233, CRYSTAL STRUCTURE OF JNK2
4767, d2yiwA_, 0.7220, 2.62, 0.230, 325, 230, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
4768, p4h39A_, 0.7219, 3.19, 0.207, 340, 241, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
4769, p4d28D_, 0.7219, 3.22, 0.232, 271, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4770, d3zuuA_, 0.7219, 3.01, 0.199, 281, 241, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4771, d3zutA_, 0.7219, 3.05, 0.202, 281, 242, THE STRUCTURE OF OST1 (D160A) KINASE
4772, d3lfaA_, 0.7219, 3.12, 0.230, 333, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
4773, d3comA_, 0.7219, 3.08, 0.243, 264, 239, CRYSTAL STRUCTURE OF MST1 KINASE
4774, d2xk4A1, 0.7219, 2.85, 0.226, 244, 235, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 17
4775, d4kbaB_, 0.7217, 3.61, 0.218, 285, 248, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4776, d5op7A_, 0.7216, 3.40, 0.228, 261, 241, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
4777, d4eh5A_, 0.7216, 2.76, 0.224, 329, 232, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
4778, d3iw8A_, 0.7216, 3.10, 0.237, 334, 240, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
4779, d4rvkA_, 0.7215, 3.58, 0.235, 264, 243, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
4780, d3zutB_, 0.7215, 3.21, 0.204, 282, 245, THE STRUCTURE OF OST1 (D160A) KINASE
4781, d3tkiA_, 0.7215, 3.82, 0.232, 272, 246, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
4782, d3cg2A_, 0.7215, 2.93, 0.231, 327, 234,  
4783, d2wqeA_, 0.7215, 2.83, 0.245, 241, 237, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4784, d4yr8E_, 0.7214, 2.90, 0.231, 317, 234, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4785, d4mneH_, 0.7214, 3.45, 0.218, 275, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4786, d3dxnA_, 0.7214, 3.43, 0.269, 258, 245, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
4787, d2c47D1, 0.7214, 3.35, 0.198, 289, 247, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4788, d4hokO_, 0.7213, 3.60, 0.212, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4789, d4kb8B_, 0.7212, 3.60, 0.218, 285, 248, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4790, d2duvA_, 0.7212, 3.09, 0.258, 272, 236, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
4791, d1nvsA_, 0.7212, 3.60, 0.235, 264, 243, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
4792, d3kc3E_, 0.7211, 3.05, 0.189, 287, 238, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4793, d2w9zB_, 0.7211, 3.38, 0.221, 287, 244, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4794, d4ftiA_, 0.7210, 3.66, 0.234, 270, 244, CRYSTAL STRUCTURE OF THE CHK1
4795, d4btmA_, 0.7210, 3.80, 0.227, 292, 256, TTBK1 IN COMPLEX WITH INHIBITOR
4796, d3sv0A_, 0.7210, 3.72, 0.189, 294, 254, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
4797, d3ma3A_, 0.7210, 3.24, 0.227, 266, 238, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
4798, d3l8xA_, 0.7210, 2.89, 0.224, 326, 232, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
4799, d4x21B_, 0.7209, 3.13, 0.226, 336, 239, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
4800, d3zuuB_, 0.7209, 3.23, 0.208, 282, 245, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4801, d1v0oB_, 0.7209, 3.08, 0.243, 274, 235, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
4802, d5uirA_, 0.7208, 3.00, 0.285, 270, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
4803, d5x18B_, 0.7207, 3.70, 0.170, 294, 253, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4804, d1nvqA_, 0.7207, 3.61, 0.235, 264, 243, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
4805, d5k72B_, 0.7206, 2.82, 0.287, 267, 230, IRAK4 IN COMPLEX WITH COMPOUND 21
4806, d4kbaA_, 0.7205, 3.48, 0.224, 263, 246, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4807, d3h0zB_, 0.7205, 2.84, 0.237, 240, 236, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4808, d1mryA_, 0.7205, 3.22, 0.221, 270, 240, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4809, d4ft9A_, 0.7204, 3.61, 0.236, 270, 242, CRYSTAL STRUCTURE OF THE CHK1
4810, d1nvrA_, 0.7203, 3.61, 0.235, 264, 243, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
4811, d4useB_, 0.7202, 3.10, 0.251, 278, 235, HUMAN STK10 (LOK) WITH SB-633825
4812, d5op2A_, 0.7201, 3.55, 0.225, 263, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4813, d5imeA1, 0.7201, 3.15, 0.239, 279, 238, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4814, d3ttjA_, 0.7201, 3.38, 0.222, 333, 243, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
4815, d2yisA_, 0.7201, 2.64, 0.230, 325, 230, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
4816, d4z9lA_, 0.7200, 3.27, 0.219, 333, 242, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
4817, d4nt4A1, 0.7200, 3.64, 0.194, 299, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
4818, d2izuA_, 0.7200, 3.57, 0.191, 297, 251, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4819, d2hogA_, 0.7200, 3.75, 0.233, 272, 245, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
4820, d1urwA_, 0.7200, 3.19, 0.244, 274, 238, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
4821, d5fd2B_, 0.7198, 2.24, 0.329, 234, 225, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
4822, d4ftuA_, 0.7198, 3.80, 0.237, 270, 245, CRYSTAL STRUCTURE OF THE CHK1
4823, d3dfaA1, 0.7198, 3.42, 0.229, 262, 249, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
4824, d2xk8A1, 0.7198, 2.57, 0.222, 238, 230, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 15
4825, d5ootA_, 0.7197, 3.40, 0.229, 260, 240, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4826, d5mqvB_, 0.7197, 3.52, 0.225, 287, 249, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4827, d4jjrB_, 0.7197, 3.46, 0.213, 283, 249, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4828, d4ic8A_, 0.7197, 3.04, 0.198, 325, 237, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
4829, d4btjA_, 0.7197, 3.76, 0.227, 292, 255, TTBK1 IN COMPLEX WITH ATP
4830, d5o1vA_, 0.7196, 3.30, 0.262, 278, 240, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4831, d4rvmA_, 0.7196, 3.61, 0.230, 264, 243, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
4832, d4qyfA_, 0.7196, 3.56, 0.236, 269, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
4833, d4ft7A_, 0.7196, 3.65, 0.230, 270, 243, CRYSTAL STRUCTURE OF THE CHK1
4834, d3nlbA_, 0.7196, 3.55, 0.244, 261, 242, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
4835, d3dakC_, 0.7196, 3.60, 0.228, 281, 246, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4836, d5mqvA_, 0.7195, 3.43, 0.222, 286, 248, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4837, d4af3A_, 0.7195, 2.56, 0.255, 253, 231, HUMAN AURORA B KINASE IN COMPLEX WITH INCENP AND VX-680
4838, d3oxiA_, 0.7194, 2.90, 0.219, 322, 237, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
4839, d5o23A_, 0.7193, 3.30, 0.263, 269, 247, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4840, d5mqvD_, 0.7193, 3.54, 0.225, 287, 249, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4841, d4yr8C_, 0.7193, 2.80, 0.232, 318, 233, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4842, d4qygA_, 0.7193, 3.62, 0.239, 264, 243, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4843, d4hokW_, 0.7193, 3.64, 0.212, 289, 250, CRYSTAL STRUCTURE OF APO CK1E
4844, d5ml5A_, 0.7192, 3.04, 0.235, 326, 238, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
4845, d4yp8B_, 0.7192, 3.18, 0.284, 278, 236, IRAK4-INHIBITOR CO-STRUCTURE
4846, d4e5aX_, 0.7192, 3.03, 0.233, 332, 236, THE W197A MUTANT OF P38A MAP KINASE
4847, d2qd9A_, 0.7192, 3.08, 0.238, 330, 235, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
4848, d1pyeA_, 0.7192, 2.76, 0.238, 266, 231, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
4849, d3zs5A1, 0.7191, 3.39, 0.239, 339, 243, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
4850, d3ot3A_, 0.7191, 3.46, 0.233, 259, 240, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
4851, d2c3lA_, 0.7191, 3.63, 0.235, 265, 243, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4852, d4p90A_, 0.7190, 3.25, 0.234, 272, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4853, d4geoA_, 0.7190, 2.71, 0.238, 326, 231, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
4854, d4ft3A_, 0.7190, 3.36, 0.243, 269, 239, CRYSTAL STRUCTURE OF THE CHK1
4855, d4e6cA_, 0.7190, 3.07, 0.228, 330, 237, P38A-PERIFOSINE COMPLEX
4856, d1gijA_, 0.7190, 3.21, 0.239, 273, 238, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4857, d4qyhB_, 0.7189, 3.69, 0.238, 264, 244, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4858, d4qygB_, 0.7189, 3.58, 0.231, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4859, d5o2bA1, 0.7188, 3.29, 0.257, 268, 241, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN A COMPLEX WITH THE INHIBITOR PP-121
4860, d3aqvA_, 0.7188, 3.33, 0.217, 267, 244, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
4861, d5lohB_, 0.7186, 2.84, 0.223, 250, 233, KINASE DOMAIN OF HUMAN GREATWALL
4862, d5n63A_, 0.7185, 2.64, 0.223, 325, 229, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
4863, d5mqvE_, 0.7185, 3.54, 0.225, 287, 249, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4864, d3da6A_, 0.7185, 3.10, 0.227, 328, 238, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
4865, d4kbkA_, 0.7184, 3.51, 0.215, 283, 246, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4866, d4czuD1, 0.7184, 3.50, 0.229, 296, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4867, d3oriD_, 0.7184, 3.19, 0.220, 267, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4868, d3ma6A_, 0.7184, 3.56, 0.230, 267, 252, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4869, d4xv3A1, 0.7183, 2.31, 0.324, 232, 225, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7922
4870, d3umxA_, 0.7183, 3.22, 0.227, 261, 238, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
4871, d5uirB_, 0.7182, 3.12, 0.275, 273, 236, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
4872, d4hokA_, 0.7182, 3.65, 0.212, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4873, d3s4qA_, 0.7182, 2.89, 0.241, 326, 232, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
4874, d4qyhA_, 0.7181, 3.64, 0.239, 264, 243, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4875, d3famB_, 0.7181, 2.78, 0.232, 239, 233,  
4876, d2oidD_, 0.7181, 3.02, 0.275, 274, 233, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4877, d2eueB_, 0.7181, 2.78, 0.227, 239, 233,  
4878, d2e9pA_, 0.7181, 3.70, 0.237, 269, 245, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
4879, d4kbcB_, 0.7180, 3.56, 0.214, 277, 248, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4880, d4hokE_, 0.7180, 3.68, 0.211, 291, 251, CRYSTAL STRUCTURE OF APO CK1E
4881, d3fv8A_, 0.7179, 2.99, 0.229, 331, 236, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
4882, d2o2uA_, 0.7178, 2.94, 0.212, 319, 236, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
4883, d2hakA_, 0.7178, 3.43, 0.243, 309, 247, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4884, d2yexA_, 0.7177, 3.74, 0.239, 269, 247, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
4885, d2qkrA1, 0.7177, 2.79, 0.245, 269, 229, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
4886, d5uiqA_, 0.7176, 3.06, 0.279, 268, 233, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4887, d4aa0A_, 0.7176, 2.96, 0.226, 328, 234, P38ALPHA MAP KINASE BOUND TO CMPD 2
4888, d2j51A_, 0.7175, 3.27, 0.244, 288, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4889, d2c47B_, 0.7175, 3.36, 0.199, 289, 246, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4890, d5opbA_, 0.7174, 3.53, 0.210, 262, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
4891, d4fg9A_, 0.7174, 3.09, 0.234, 278, 239, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4892, d5kx8B_, 0.7173, 3.13, 0.277, 278, 235, IRAK4-INHIBITOR CO-STRUCTURE
4893, d3oriC_, 0.7173, 3.20, 0.220, 267, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4894, d2bmcB_, 0.7173, 3.00, 0.244, 258, 238, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4895, d4qd6A1, 0.7172, 2.15, 0.424, 242, 217, ITK KINASE DOMAIN IN COMPLEX WITH INHIBITOR COMPOUND
4896, d3kc3L_, 0.7172, 3.07, 0.198, 291, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4897, d2jflA_, 0.7172, 3.27, 0.244, 286, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
4898, d1ukhA_, 0.7172, 2.94, 0.221, 321, 235, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
4899, d1oitA_, 0.7172, 3.20, 0.249, 273, 237, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4900, d1kv2A_, 0.7172, 2.76, 0.239, 325, 230, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
4901, d5dbxA_, 0.7171, 3.38, 0.261, 284, 241, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4902, d4fsrA_, 0.7171, 3.70, 0.230, 269, 243, CRYSTAL STRUCTURE OF THE CHK1
4903, d2pmiA_, 0.7171, 2.62, 0.246, 284, 228, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4904, d2hw7A1, 0.7171, 2.89, 0.207, 269, 232, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4905, d2c3jA_, 0.7171, 3.32, 0.235, 257, 238, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4906, d1ungB_, 0.7171, 2.66, 0.238, 268, 227, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4907, d5opvA_, 0.7170, 3.49, 0.233, 261, 240, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4908, d3nuxA_, 0.7170, 2.85, 0.238, 261, 231, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
4909, d2xk3A1, 0.7170, 2.64, 0.221, 239, 231, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 35
4910, d2jfmA_, 0.7170, 3.25, 0.244, 287, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4911, d4jjrA_, 0.7169, 3.56, 0.219, 284, 247, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4912, d3kc3H_, 0.7169, 2.85, 0.191, 290, 235, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4913, d4hokG_, 0.7168, 3.66, 0.212, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4914, d3gcpA_, 0.7168, 3.39, 0.243, 337, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
4915, d4ynzB1, 0.7166, 3.32, 0.237, 316, 245, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4916, d3hyhA_, 0.7166, 2.73, 0.241, 238, 232, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
4917, d3gcsA_, 0.7166, 2.96, 0.246, 331, 236, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
4918, d3coiA1, 0.7166, 3.34, 0.227, 342, 242, CRYSTAL STRUCTURE OF P38DELTA KINASE
4919, d2x8eA_, 0.7166, 3.39, 0.237, 259, 240, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4920, d2vwiD_, 0.7166, 3.63, 0.233, 284, 245, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4921, d4yo6B_, 0.7165, 3.17, 0.285, 277, 235, IRAK4-INHIBITOR CO-STRUCTURE
4922, d4hokS_, 0.7165, 3.61, 0.213, 286, 249, CRYSTAL STRUCTURE OF APO CK1E
4923, d3zsgA_, 0.7165, 3.35, 0.236, 337, 242, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
4924, d5opuA_, 0.7164, 3.44, 0.225, 261, 240, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4925, d5l2sA_, 0.7164, 2.85, 0.251, 263, 231, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
4926, d2bmcC_, 0.7164, 3.12, 0.247, 257, 239, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4927, d4czuC_, 0.7163, 3.42, 0.243, 281, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4928, d2fslX_, 0.7163, 3.09, 0.228, 332, 237, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
4929, d4u79A_, 0.7162, 3.11, 0.219, 337, 237, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
4930, d2a19B1, 0.7162, 3.28, 0.218, 261, 238, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
4931, d3wi6F_, 0.7161, 2.99, 0.192, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4932, d5b2kA_, 0.7159, 3.07, 0.235, 264, 238, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4933, d5ankA_, 0.7159, 3.20, 0.254, 273, 236, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4934, d3wi6E_, 0.7159, 2.99, 0.192, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4935, d3wi6C_, 0.7159, 2.99, 0.192, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4936, d3wi6B_, 0.7159, 2.99, 0.192, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4937, d2xrwA1, 0.7159, 3.16, 0.235, 346, 238, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4938, d5op5A_, 0.7158, 3.42, 0.226, 259, 239, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
4939, d4hokQ_, 0.7158, 3.66, 0.212, 290, 250, CRYSTAL STRUCTURE OF APO CK1E
4940, d4cztA1, 0.7158, 3.40, 0.227, 289, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4941, d6bu6A_, 0.7157, 3.79, 0.145, 322, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4942, d4fszA_, 0.7157, 3.56, 0.229, 268, 240, CRYSTAL STRUCTURE OF THE CHK1
4943, d5vt1A1, 0.7156, 3.42, 0.255, 264, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
4944, d5dbxB_, 0.7156, 3.38, 0.245, 282, 241, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4945, d2excX_, 0.7155, 3.04, 0.225, 335, 236, INHIBITOR COMPLEX OF JNK3
4946, d3kc3I_, 0.7154, 3.01, 0.190, 295, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4947, d2iwiB_, 0.7154, 2.85, 0.230, 249, 230, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4948, d2h6dA_, 0.7154, 3.12, 0.238, 256, 239, PROTEIN KINASE DOMAIN OF THE HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (AMPK ALPHA-2 CHAIN)
4949, d4czuB1, 0.7153, 3.43, 0.239, 283, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4950, d3u9nA_, 0.7153, 3.34, 0.244, 257, 238, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4951, d2c47A_, 0.7153, 3.35, 0.196, 288, 245, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4952, d5oprA_, 0.7152, 3.36, 0.227, 258, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
4953, d4xv2A1, 0.7152, 2.29, 0.326, 232, 224, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
4954, d4qd6B1, 0.7151, 2.09, 0.417, 241, 216, ITK KINASE DOMAIN IN COMPLEX WITH INHIBITOR COMPOUND
4955, d4kbkD_, 0.7151, 3.49, 0.213, 281, 244, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4956, d4kbaD_, 0.7151, 3.42, 0.217, 274, 244, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4957, d3rtpA_, 0.7151, 2.99, 0.221, 331, 235, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
4958, d3fpqA_, 0.7151, 3.22, 0.267, 262, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4959, d2yerA_, 0.7151, 3.68, 0.241, 268, 245, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
4960, d5k7iB_, 0.7150, 2.98, 0.280, 271, 232, IRAK4 IN COMPLEX WITH AZ3864
4961, d4xv1A1, 0.7150, 2.24, 0.341, 228, 223, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4962, d4fsyA_, 0.7150, 3.75, 0.236, 267, 242, CRYSTAL STRUCTURE OF THE CHK1
4963, d3kmuA_, 0.7150, 3.22, 0.250, 253, 240, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (APO)
4964, d2zv2A_, 0.7150, 3.18, 0.256, 256, 238, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
4965, d5ukfA_, 0.7149, 3.81, 0.145, 322, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4966, d4kb8D_, 0.7149, 3.39, 0.214, 278, 243, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4967, d4hokC_, 0.7149, 3.68, 0.215, 289, 251, CRYSTAL STRUCTURE OF APO CK1E
4968, d4cztD1, 0.7148, 3.48, 0.234, 296, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4969, d3kvxA_, 0.7147, 3.02, 0.229, 327, 236, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
4970, d5angA_, 0.7146, 3.04, 0.239, 268, 234, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4971, d3oy1A_, 0.7146, 3.04, 0.225, 329, 236, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
4972, d2z7sA_, 0.7146, 2.79, 0.248, 256, 230, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4973, d4othA_, 0.7144, 3.15, 0.256, 305, 234, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
4974, d3g33C_, 0.7144, 3.28, 0.226, 291, 239, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4975, p3lfdA_, 0.7143, 2.94, 0.226, 331, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
4976, d2r0uA_, 0.7143, 3.79, 0.230, 269, 243, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
4977, d4fsuA_, 0.7141, 3.53, 0.242, 260, 240, CRYSTAL STRUCTURE OF THE CHK1
4978, d5oq8A_, 0.7140, 3.57, 0.223, 261, 242, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4979, d3wi6D_, 0.7140, 2.98, 0.193, 282, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4980, d2ac3A1, 0.7140, 2.96, 0.197, 275, 233, STRUCTURE OF HUMAN MNK2 KINASE DOMAIN
4981, d5we8A_, 0.7139, 3.15, 0.254, 270, 236, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4982, d2ok1A_, 0.7139, 3.00, 0.212, 333, 236, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4983, d2b1pA_, 0.7139, 3.04, 0.220, 331, 236, INHIBITOR COMPLEX OF JNK3
4984, d3wi6A_, 0.7138, 2.98, 0.193, 282, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4985, d3uibA_, 0.7138, 2.69, 0.206, 309, 228, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
4986, d3kc3A_, 0.7138, 3.02, 0.187, 288, 235, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4987, p5hoaA_, 0.7137, 2.05, 0.409, 225, 215, CRYSTAL STRUCTURE OF C-MET L1195V IN COMPLEX WITH SAR125844
4988, d4ft0A_, 0.7137, 3.55, 0.237, 266, 240, CRYSTAL STRUCTURE OF THE CHK1
4989, d4cztC_, 0.7137, 3.41, 0.240, 286, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4990, d3uysA_, 0.7137, 3.39, 0.214, 281, 243, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4991, d3kc3B_, 0.7137, 3.00, 0.191, 290, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4992, d3uc4A_, 0.7136, 3.31, 0.188, 295, 245, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
4993, d2qhmA_, 0.7136, 3.62, 0.233, 268, 240, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
4994, d5oq7B_, 0.7135, 3.31, 0.228, 256, 237, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4995, d2bvaA_, 0.7135, 3.25, 0.180, 272, 239, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4996, d5tkdA_, 0.7133, 3.10, 0.298, 248, 235, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4997, d3g9lX_, 0.7133, 3.22, 0.214, 336, 238, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
4998, d2bmcD_, 0.7133, 3.00, 0.246, 256, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4999, d5tf9A_, 0.7131, 3.01, 0.268, 262, 235, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
5000, d5d1jA_, 0.7131, 2.93, 0.247, 265, 231, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
